VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 18 (1-11 agosto / 2022)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Resumen de la información publicada por la OMS sobre vacunas en desarrollo contra la COVID-19 a nivel mundial.
- El legado de Fidel en la Ciencia Cubana. Breves apuntes.
- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.
- Patentes más recientes en USPTO sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

Resumen de la información publicada por la OMS sobre los candidatos vacunales contra la COVID-19 en desarrollo a nivel mundial

Última actualización por la OMS: 9 de agosto de 2022.

Fuente de información utilizada: World Health Organization | R&DBlueprint Powering research to prevent epidemics

170 Vacunas en evaluación clínica y 198 en evaluación preclínica



Candidatos vacunales en evaluación clínica por plataforma

Platform		Candidate vaccines (no. and %)	
PS	Protein subunit	54	32%
VVnr	Viral Vector (non-replicating)	21	12%
DNA	DNA	16	9%
IV	Inactivated Virus	22	13%
RNA	RNA	41	24%
VVr	Viral Vector (replicating)	4	2%
VLP	Virus Like Particle	6	4%
VVr + APC	VVr + Antigen Presenting Cell	2	1%
LAV	Live Attenuated Virus	2	1%
VVnr + APC	VVnr + Antigen Presenting Cell	1	1%
BacAg-SpV	Bacterial antigen-spore expression vector	1	1%
		170	

Candidatos vacunales mucosales en evaluación clínica

Desarrollador de la vacuna/fabricante/país	Plataforma de la vacuna	Vía de administración	Fase
University of Oxford/Reino Unido	Vector viral no replicativo	Intranasal	1
CanSino Biological Inc./Beijing Institute of Biotechnology/China	Vector viral no replicativo	Inhalación	4
Vaxart/Estados Unidos	Vector viral no replicativo	Oral	2
Univ. Hong Kong, Xiamen Univ./Beiging Wantai Biol. Pharm./China	Vector viral replicativo	Intranasal	3
Symvivo/Canadá	ADN	Oral	1
ImmunityBio, Inc./Estados Unidos	Vector viral no replicativo	Oral o SL	1/2
Codagenix/Serum Institute of India	Virus vivo atenuado	Intranasal	3
Center for Genetic Engineering and Biotechnology (CIGB)/Cuba	Subunidad proteica	Intranasal	1/2
Razi Vaccine and Serum Research Institute/India	Subunidad proteica	IM e IN	3
Bharat Biotech International Limited/India	Vector viral no replicativo	Intranasal	3
Meissa Vaccines, Inc./Estados Unidos	Virus vivo atenuado	Intranasal	1
Laboratorio Avi-Mex/México	Virus inactivado	IM o IN	2/3
USSF + VaxForm/Estados Unidos	Subunidad proteica	Oral	1
CyanVac LLC/Estados Unidos	Vector viral no replicativo	Intranasal	1
DreamTec Research Limited/Hong Kong	BacAg-SpV	Oral	NA
Sean Liu, Icahn School of Medicine at Mount Sinai	Vector viral replicativo	IN/IM	2/3
Hannover Medical School/Alemania	Vector viral no replicativo	Inhalación	1
ACM Biolabs/Singapur	Subunidad proteica	IN/IM	1

Candidatos vacunales más avanzados a nivel global

Desarrollador de la vacuna/fabricante/país	Plataforma de la vacuna	Fase
Sinovac/China	Virus Inactivado	4
Sinopharm/Wuhan Institute of Biological Products/China	Virus Inactivado	4
Sinopharm/Beijing Institute of Biological Products/China	Virus Inactivado	4
University of Oxford/AstraZeneca/Reino Unido	Vector viral no replicativo	4
CanSino Biological Inc./Beijing Institute Biotechnology/China	Vector viral no replicativo	4
CanSino Biological Inc./Beijing Institute Biotechnology/China	Vector viral no replicativo (IH)	4
Gamaleya Research Institute/Rusia	Vector viral no replicativo	3
Janssen Pharmaceutical Companies/Estados Unidos	Vector viral no replicativo	4
Novavax/Estados Unidos	Subunidad proteica	3
Moderna/NIAID/Estados Unidos	ARN	4
Pfizer/BioNTech Fosun Pharma/Estados Unidos	ARN	4
Anhui Zhifei Longcom Biopharmac./Inst. Microbiol, Chin Acad Sci/China	Subunidad proteica	3
CureVac AG/Alemania	ARN	3
Institute of Medical Biology/Chinese Academy of Medical Sciences	Virus inactivado	3
Research Institute for Biological Safety Problems, Kazakhstan	Virus inactivado	3
Inovio Pharmac. + Intern. Vacc Inst. + Advaccine Biopharm Co., Ltd	ADN	3
Zydus Cadila Healthcare Ltd./India	ADN	3
Bharat Biotech International Limited/India	Virus Inactivado	3
Sanofi Pasteur + GSK/Francia/Gran Bretaña	Subunidad proteica	3
Shenzhen Kangtai Biological Products Co., Ltd./China	Virus Inactivado	3
Clover Biopharmaceuticals Inc./GSK/Dynavax/China/Reino Unido/EE.UU	Subunidad proteica	3
Vaxine Pty Ltd. + CinnaGen Co./Australia, Irán	Subunidad proteica	3
Medigen Vaccine Biol./Dynavax/NIAID/Taiwán/EE.UU	Subunidad proteica	4
Instituto Finlay de Vacunas/Cuba	Subunidad proteica	3
Federal Budget Res Inst State Res Cent Virol Biotechnol "Vector"/Rusia	Subunidad proteica	3
West China Hospital + Sichuan University/China	Subunidad proteica	3
Vaxxinity/EE.UU	Subunidad proteica	3
Univ. Hong Kong, Xiamen Univ. & Beijing Wantai Biological Pharm./China	Vector viral replicativo	3
Acad Milit Sci (AMS) Walvax Biotechnol, Suzhou Abogen Biosci/China	ARN	3
Medicago Inc./Canadá	Particula similar a virus	3
Codagenix/Serum Institute of India	Virus vivo atenuado	3
Center for Genetic Engineering and Biotechnology (CIGB)/Cuba	Subunidad proteica	3
Valneva, National Institute for Health Research, Reino Unido	Virus inactivado	3
Biological E. Limited/India	Subunidad proteica	3
Nanogen Pharmaceutical Biotechnology/Vietnam	Subunidad proteica	3
Shionogi/Japón	Subunidad proteica	3
Erciyes University/Turquia	Virus inactivado	3
SK Bioscience Co., Ltd./CEPI/Corea del Sur/Noruega	Subunidad proteica	3
Razi Vaccine and Serum Research Institute/Irán, India	Subunidad proteica	3
Bharat Biotech International Limited/India	Vector viral no replicativo (IN)	3
Jiangsu Rec-Biotechnology/China	Subunidad proteica	3
Radboud University/Holanda	Particula similar a virus	3
Livzon Pharmaceutical/China	Subunidad proteica	3
KM Biologics Co., Ltd./Japón	Virus inactivado	2
Bagheiat-allah University of Medical Sciences/AmitisGen/Irán	Subunidad proteica	3
Laboratorios Hipra, S.A.	Subunidad proteica	3
Arcturus Therapeutics, Inc./Estados Unidos	ARN	3
Sinocelltech Ltd./China	Subunidad proteica	3
Chumakov Federal Scientific Center for Research/Rusia	Virus Inactivado	3
PT Biofarma/Indonesia	Subunidad proteica	3
AIM Vaccine and LiveRNA Therapeutics/China	ARN	3
CanSino Biologics Inc./China	ARN	3
Moderna TX/Estados Unidos	ARN	3
China National Biotec Group Company Limited	Virus inactivado	3

Fidel Por Siempre

El legado de Fidel en la Ciencia Cubana. Breves apuntes

Desde que comenzó la pandemia en el mundo, provocada por el impacto del nuevo coronavirus, y su enfrentamiento en nuestro país, han sido reiteradas las expresiones de reconocimiento a la visión de largo alcance presente en las concepciones del líder histórico de la Revolución Cubana, Fidel Castro Ruz, sobre el papel de la ciencia en la solución de los principales problemas que habría de enfrentar la nación en el complejo camino hacia un desarrollo económico y social que garantizara el bienestar del pueblo.

El punto de referencia hoy para tales expresiones, lo constituye, evidentemente, la encomiable labor de nuestros científicos en la búsqueda primero, y en la materialización después, de cinco candidatos vacunales, cien por ciento cubanos, de los cuales dos ya han alcanzado la categoría de vacunas, como solución clínica ante la nueva enfermedad, con un probado impacto positivo, reconocido, incluso, a nivel internacional.

Y no nos falta razón a quienes afirmamos que en dichos resultados se transparenta la impronta de Fidel. Ello es innegable. El valor de sus concepciones, y de la obra que forjó, han sido decisivas para el enfrentamiento a la pandemia en Cuba.

Y es, precisamente, esa obra la que es indispensable develar y divulgar, esencialmente en las actuales y futuras generaciones, pues, aunque en la conciencia cotidiana, la vacuna sea, como ya se ha expresado, el punto referencial del justo reconocimiento, lo cierto es que las concepciones de Fidel Castro acerca de la ciencia, no se limitan al campo de la medicina, ni solo al aspecto técnico-material del desarrollo científico. Es una concepción multifacética e integral, fraguada desde los mismos albores de la Revolución.

No es posible, en tan poco espacio, reseñar el legado de Fidel en el campo de la ciencia, forjado en medio de enormes dificultades por las que ha atravesado el proceso revolucionario cubano, en condiciones de economía subdesarrollada y bajo un asedio sin precedentes por parte de sucesivos gobiernos de Estados Unidos.

En tales circunstancias, uno de los grandes méritos de Fidel Castro fue, desde un inicio, jerarquizar el valor del conocimiento para garantizar el futuro. De ahí su empeño en lograr el acceso masivo del pueblo a la educación y a la cultura, concebidos no solo como derechos humanos fundamentales, sino además como componentes esenciales de una concepción integral de la sociedad, en la que educación, cultura y ciencia conforman un todo único e interrelacionado y base para nuestra

Fidel Por Siempre

soberanía, independencia y desarrollo económico y social. A ello se suman su capacidad para analizar los contextos históricos, su voluntad para plantearse audaces metas y para trabajar en su consecución, así como su confianza ilimitada en las potencialidades intelectuales y éticas de los cubanos. Todo ello condicionó una inédita hazaña: lograr que un pequeño país subdesarrollado, bloqueado y amenazado por la principal potencia imperialista mundial, a solo 90 millas de sus costas, se adentrara con solidez por los complejos caminos de la ciencia.

Una de las primeras pautas trazadas por Fidel Castro, respecto a la definición de la política científica de la Revolución, - con un alcance hasta el presente y para el futuro-, fue su intervención el 15 de enero de 1960, en la Sociedad Espeleológica de Cuba, ocasión en la que se le otorgó el título de Socio de Honor de esa entidad científica, una de las pocas que existían en el país.

Esto tuvo lugar, en momentos en que la radicalización de la Revolución ya era palpable, lo que provocaba las acciones del enemigo, incluyendo la incitación al éxodo masivo de profesionales, además del inicio de la cruenta guerra económica impuesta por Estados Unidos. En este contexto, Fidel proyectó su concepción estratégica e integral sobre el rol de la ciencia, el pensamiento y la inteligencia para el desarrollo del país. Sentenciaba entonces el Comandante en Jefe: “El futuro de nuestra patria tiene que ser necesariamente un futuro de hombres de ciencia, tiene que ser un futuro de hombres de pensamiento, porque precisamente es lo que más estamos sembrando; lo que más estamos sembrando son oportunidades a la inteligencia; ya que una parte considerabilísima de nuestro pueblo no tenía acceso a la cultura, ni a la ciencia".



Fidel Por Siempre

Resulta interesante el hecho de que este discurso tiene lugar con anterioridad a sus célebres Palabras a los Intelectuales y al despliegue de la Campaña de Alfabetización en 1961, que convirtió a Cuba en el primer país de América Latina libre de analfabetismo.

Así mismo, con su extraordinaria sensibilidad humanista, desde entonces se comprometió a revertir el olvido al que estaba sometida la ciencia en la república neocolonial, y reconoció que lograr el desarrollo científico formaba parte de los objetivos priorizados de la Revolución, no solo desde el punto de vista socioeconómico, sino en materia de justicia social. A la vez, hizo patente su compromiso de promover políticas para el cultivo de las inteligencias y para el desarrollo de la ciencia y del pensamiento: A tal efecto, afirmaba: "¡Cuántas inteligencias se habrán desperdiciado en ese olvido! ¡Cuántas inteligencias se habrán perdido! Inteligencias que hoy se incorporarán a la vida de su país; inteligencias que hoy se incorporarán a la cultura y a la ciencia, porque para eso estamos convirtiendo las fortalezas en escuelas; para eso estamos construyendo ciudades escolares; para eso estamos llenando la isla de maestros, para que en el futuro la patria pueda contar con una pléyade brillante de hombres de pensamiento, de investigadores y de científicos".

Esos fueron los inicios de un largo y complejo camino que llega hasta el presente y se enrumba con optimismo hacia el futuro, pues en consecuencia con dicha estrategia, a lo largo de todo el proceso revolucionario, se han dedicado múltiples esfuerzos y recursos al desarrollo de la ciencia en Cuba y su implementación en la práctica social, en cuyo empeño es preciso –y justo– reconocer la titánica labor realizada por los miles de hombres de ciencia, y de muchos otros que, sin serlo, han contribuido significativamente en dicha obra, formados todos, precisamente, en los principios de la política científica nacional, fundada por Fidel Castro.

No es fácil sintetizar el legado de Fidel en el campo de la ciencia y en el despliegue de proyectos tecnológicos y de innovación en las diversas ramas de la economía y del desarrollo social en general. Pero sin lugar a dudas sus aportes y logros son palpables en los altos índices de desarrollo científico que hoy Cuba puede exhibir.

Vale la pena, por tanto, recordar algunos hitos que dan fe de su invaluable obra a favor del desarrollo simultáneo e integral de la cultura, la educación y la ciencia en la Cuba revolucionaria.

Es una obra sembrada durante el primer lustro de la Revolución, en las propias raíces de la construcción del socialismo en Cuba. No es casual que bajo su guía e impulso, desde 1959, se iniciara una profunda revolución educacional y que en 1961 se desplegara la inédita Campaña de Alfabetización a partir de sus convicciones sobre el importante rol de la participación popular y de los jóvenes en el proceso de transformación revolucionaria de la sociedad cubana.

Su visión de futuro también fue decisiva cuando la nueva institucionalidad creada para el desarrollo de la ciencia se concibió con un sentido inclusivo de la tecnología, la innovación y la protección de los recursos naturales. Un hito en ese empeño fue la creación de la Academia de Ciencias de Cuba en 1962, bajo una concepción integradora de todas las esferas y disciplinas de la ciencia, a lo que se unió el despliegue de la reforma universitaria y la creación del Centro Nacional de Investigaciones Científicas (CENIC) en 1965, matriz de otras instituciones que posteriormente fueron desarrollándose hasta conformar toda una potente y eficaz infraestructura para el desarrollo de la ciencia en el país.

Fidel Por Siempre

Desde esos pilares, levantados por Fidel, la ciencia dejó de constituir una actividad de élites o de científicos aislados, para convertirse en patrimonio del pueblo a partir de la universalización de la educación. Ello se hizo patente, con singular fuerza, a lo largo de los años 70 y 80, en los que, junto con la creación de universidades y de múltiples centros de investigación, surgieron entidades como el Fórum de Ciencia y Técnica, las Brigadas Técnicas Juveniles, el Movimiento de Innovadores y Racionalizadores y otras, vinculadas con el movimiento obrero y sindical, que habrían de desempeñar un papel protagónico en la ardua tarea de contrarrestar las nefastas consecuencias derivadas del subdesarrollo y del bloqueo económico impuesto por los Estados Unidos.

Mención especial merece el impulso, diseño estratégico y presencia fundacional de Fidel en el surgimiento de diversas entidades de investigación en el campo de las ciencias biomédicas y agropecuarias, entre otras, con una proyección interdisciplinaria y colosal visión de futuro. En ese marco sobresale la creación del Sector Biotecnológico a partir de 1981, cuando su despliegue era monopolizado por países del llamado primer mundo. Ahí radica uno de los más importantes antecedentes de la fortaleza científica cubana que ha permitido hoy el enfrentamiento exitoso al nuevo coronavirus.

Lo que Fidel generó no se limita al rescate de inteligencias, ni a la creación de instituciones científicas, aunque esto solo ya sería un gran mérito. Su gran aporte en este campo ha sido generar una política de desarrollo de la ciencia y la tecnología impregnada de valores éticos, con un sentido humanista y de trabajo colectivo, de colaboración interinstitucional, de solidaridad internacional y de promoción de los diversos campos de la investigación científica, incluyendo las ciencias básicas, las ciencias técnicas y nucleares, así como la no menos importante esfera de las ciencias sociales y humanísticas.

Esa concepción tuvo su prueba de fuego en la década de los años 90 del pasado siglo, ante la necesidad de potenciar una economía basada en las ciencias para enfrentar los negativos impactos del derrumbe del socialismo en Europa del Este y la URSS y del recrudecimiento del bloqueo económico de Estados Unidos contra Cuba. A la vez, para garantizar la independencia y soberanía del país, la supervivencia de la Revolución y las bases para el desarrollo económico en nuevas y más complejas condiciones nacionales e internacionales.

En aquel contexto la capacidad de previsión de Fidel resultó decisiva al proclamar que la independencia del país dependía del desarrollo de la ciencia y la tecnología. Ante la escasez de recursos de todo tipo, sobre todo los energéticos, estimuló y potenció la producción de la inteligencia y el conocimiento, consciente de que estos factores habrían de desempeñar un rol estratégico en el desarrollo y futuro de la nación.

Fidel Por Siempre

Esta concepción fue validada por acciones concretas que elevaron el nivel de desarrollo científico de la nación, particularmente la organización de los polos científicos a partir de 1991, cuya integración generó capacidades para potenciar los recursos científicos, tecnológicos y organizativos con que contaba el país y atender programas priorizados que dieran solución a múltiples problemas de la sociedad.

De igual forma, y como expresión de la materialización de esta línea de pensamiento de Fidel, se crea, en 1994, el Ministerio de Ciencia, Tecnología y Medio Ambiente, como herramienta institucional para la proyección y concreción de la política científico-tecnológica nacional y la protección del medio ambiente, en sintonía con las ideas expuestas por él en la Conferencia de Naciones Unidas Sobre Medio Ambiente y Desarrollo, celebrada en Río de Janeiro en 1992, y que tanto impacto tuvieron en la comunidad internacional.

Desde entonces diversos programas continuaron enriqueciendo el quehacer científico nacional, varios de ellos asociados a la Batalla de Ideas que, bajo la concepción y dirección de Fidel, se desplegó en los primeros años del actual siglo.

Sus esfuerzos en defensa del papel de la ciencia en el desarrollo del país y de la solución de los problemas que afectan a la sociedad, fueron palpables hasta los últimos años de su vida, particularmente en el impulso de alternativas, con la aplicación del conocimiento científico, para enfrentar las dificultades en los ámbitos de la salud y la alimentación del pueblo.

Resumiendo todo lo anterior, que apenas constituye una apretada síntesis de las concepciones y la obra de Fidel Castro acerca de la ciencia y su papel en la vida social, se puede afirmar que ésta tiene un singular significado, muchas veces protagónico y decisivo, para la actividad y desarrollo de la comunidad científica cubana de nuestros días, no solo por lo que hizo, sino por lo que su legado aporta al presente y al futuro de nuestro país.

Los que de una u otra forma trabajamos en esa comunidad, independientemente de la rama de la ciencia de que se trate, somos parte de los agradecidos por su obra, y frutos de la promoción y siembra de inteligencias que proyectó desde los mismos albores del proceso revolucionario cubano.

Hoy, en Cuba, la ciencia constituye un arma poderosa, porque está en manos de miles de profesionales y trabajadores integrados a nuestro pueblo, plagado de hombres y mujeres de vasta experiencia, formando equipo con jóvenes educados y talentosos capaces de llevar adelante la Revolución como proceso integral de liberación nacional, antiimperialista y socialista.

Fidel Por Siempre

De ahí que, en el actual contexto de enfrentamiento a la pandemia del coronavirus, el reconocimiento de la impronta y de la huella del pensamiento y la obra de Fidel Castro, con un profundo sentido ético, a favor de una ciencia para el mejoramiento humano, para la paz y no para la guerra, para y con el pueblo, y con nobles compromisos para el despliegue de solidaridad e internacionalismo, brote de manera espontánea en los hijos de este pueblo.

Fuente: CUBAHORA. Disponible en https://bit.ly/3dwyx8o

Noticias en la Web

La vacuna de Medigen supera a la AstraZeneca en estudio de fase 3 en Paraguay

1 ago. El estudio de fase 3 de la vacuna contra la COVID-19 del laboratorio taiwanés Medigen, desarrollado en Paraguay, demostró que es "segura, tolerable y que funciona", dijo a Efe el investigador principal, Julio Torrales, sobre los resultados de este trabajo divulgados este lunes en Asunción.

El estudio, que duró 8 meses, comparó el biológico MVC-COV1901 elaborado por Medigen Vaccine Biologics Corporation (MVC) con la vacuna AZD1222 del laboratorio AstraZeneca.

"Lo que buscábamos era determinar la seguridad en términos de efectos adversos, la tolerabilidad de nuestra vacuna y su inmunogenicidad, que quiere decir la capacidad de generar anticuerpos", explicó el también catedrático.

La investigación mostró que la vacuna candidata causó "menos" efectos adversos locales y sistémicos, como cefalea, dolor en el sitio de la inyección y mialgia, que la AstraZeneca.

Fuente de la imagen: Sitio web www.medigenvac.com

En total, participaron 1.030 personas divididas en dos grupos que recibieron uno de los biológicos. Ni los participantes, los investigadores o patrocinadores fueron informados sobre cuál fue el biológico administrado durante la evaluación.

El experto detalló que el grupo que recibió la vacuna candidata desarrolló 2,6 veces más anticuerpos específicos (o antiespiga) que los inmunizados con AstraZeneca.

"Lo que nosotros estamos informando al Gobierno paraguayo es que tenemos otra opción: tenemos una vacuna segura, tolerable, muy inmunogénica que podría formar parte del bagaje de la lucha contra la covid-19", agregó Torrales.

Señaló que el estudio tuvo lugar en las localidades de San Lorenzo (a unos 15 kilómetros de Asunción) y Ciudad del Este (sureste), en la frontera con Brasil y Argentina.

En febrero pasado, la Dirección Nacional de Vigilancia Sanitaria (Dinavisa) de Paraguay concedió la autorización para el uso de emergencia de la vacuna de Medigen en personas mayores de 18 años.

Se recomienda la aplicación intramuscular de dos dosis, con un intervalo de 4 semanas entre cada una.

Las vacunas, desarrolladas con la colaboración del Instituto Nacional de Salud de Estados Unidos (NIH, por su sigla en inglés), requieren una temperatura de conservación de entre 2 y 8 grados centígrados.

En julio del año pasado, la Administración de Alimentos y Medicamentos de Taiwán otorgó la autorización de emergencia a esta vacuna.

Fuente: SWI swissinfo.ch. Disponible en https://bit.ly/3AoOkzv

Bruselas comprará 250 millones de vacunas para la COVID-19 a la española Hipra

2 ago. "Dado el nuevo aumento de casos en Europa, este acuerdo pondrá la vacuna de Hipra a disposición de los países participantes, tan pronto como la vacuna haya recibido una evaluación positiva por parte de la Agencia Europea de Medicamentos", ha señalado este martes la Comisión Europea para anunciar la adquisición de vacunas a la farmacéutica española Hipra.

La firma del contrato recoge la compra para el próximo otoño de 250 millones de dosis de la vacuna contra la covid-19 desarrollada por esta empresa, cuyo fármaco está aún pendiente de aprobación por la Agencia Europea de Medicamentos (EMA). Asimismo, según informó la CE en un comunicado recogido por Efe, en la adquisición participan catorce Estados miembros y países, que pueden solicitar hasta 250 millones de dosis.

El Ejecutivo comunitario valora que la vacuna proteica de Hipra añade "una opción más" que complementa la cartera de vacunas comunitaria, declaró la comisaria de Salud y Seguridad Alimentaria, Stella Kyriakides.

El contrato de adquisición con Hipra, con sede en Girona, se suma a los firmados por Bruselas con las farmacéuticas AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica, BioNtech-Pfizer, Moderna, Novavax y Valneva.

En esta línea, se han conseguido unos 4.200 millones de dosis en el marco de la Estrategia de Vacunas de la UE y los países participantes podrían decidir donar las vacunas a países de renta baja y media o redirigirlas a otros países europeos. "Ante el aumento de las infecciones por la covid-19 en Europa, tenemos que garantizar la máxima preparación para los meses de otoño e invierno", añadió Kyriakides.

Sánchez aplaude el acuerdo de Hipra con UE

Al respecto se ha pronunciado el presidente del Gobierno, Pedro Sánchez, que ha celebrado el contrato de compra conjunta porque demuestra la fortaleza de la innovación en la industria farmacéutica en España. "Por fin hemos logrado esta vacuna", se ha felicitado Sánchez en una rueda de prensa en el palacio de La Almudaina (Palma) tras despachar con el rey.

Para el Gobierno español, en palabras del líder del Ejecutivo, el contrato supone una "prueba magnífica de lo bien que puede funcionar la colaboración público-privada en una nueva política industrial", que hace que hoy España "sea referente" a nivel de vacunación y también por esta aportación "frente a nuevas variantes". De ahí que haya querido trasladar la satisfacción y compromiso del Ejecutivo con esta industria. "Es una muy buena noticia", ha concluido.

La vacuna de Hipra contra la covid-19 está basada en dos proteínas recombinantes estructuralmente similares, una correspondiente a la variante alfa y otra a la variante beta, que se unen formando una estructura única llamada dímero, y que está acompañada de un adyuvante que incrementa la respuesta inmunológica. Una de sus ventajas es que se puede adaptar a las variantes, según la farmacéutica.

La profilaxis, que actualmente está siendo objeto de revisión por parte de la EMA, se está desarrollando como dosis de refuerzo en personas previamente inmunizadas de 16 años o más y si recibe la autorización de comercialización, los países participantes podrán adquirirla a través del contrato vigente.

Fuente: Público. Disponible en https://bit.ly/3AfjsRK

Padecer COVID-19 en múltiples oportunidades incrementa el riesgo de sufrir COVID-19 prolongada, indica estudio

3 ago. La reinfección de COVID-19 es un tema de conversación no solo en medios. Entre nuestro círculo social hemos escuchado de alguien que ha padecido la enfermedad hasta 3 o 4 veces.

El Dr. Elmer Huerta analiza dos estudios en donde se indican los efectos de esas reinfecciones y uno de esos tienen que ver con los síntomas persistentes de la enfermedad, conocido como COVID-19 prolongada.

Anteriormente, escuchamos lo que se llama COVID-19 persistente o *long-covid*, y como esa condición —al igual que muchas otras en la historia de la medicina— tuvo que luchar por ser reconocida por los profesionales de la salud.

No hay duda que con la llegada de la variante Ómicron y sus diferentes sublinajes, la pandemia ha cambiado drásticamente.

Ómicron, la variante que cambió el curso de la pandemia

Si antes de Ómicron se esgrimía el concepto de inmunidad de rebaño como una de las armas de control de la pandemia, la llegada de esa familia del SARS-CoV-2 cambió completamente las reglas del juego.

Eso es porque una de las características más importantes de la familia Ómicron es que es capaz de evadir los anticuerpos neutralizantes que se producen como consecuencia de la infección previa y de la vacunación.

Eso hace que una persona pueda infectarse dos, tres y hasta cuatro veces, con lo que el concepto de inmunidad de rebaño ya no es posible.

Recordemos que la inmunidad de rebaño se define como la protección que adquiere una comunidad como consecuencia de que una cierta proporción de la población se infecte con determinado virus. Dicha definición tiene su fundamento en que una persona no puede reinfectarse con el virus en cuestión.

Al ocurrir millones de reinfecciones, el concepto de inmunidad de rebaño se convierte entonces en una situación relativamente irrelevante.

¿Múltiples infecciones de COVID-19, mayor protección?

Si se acepta entonces que una persona puede infectarse más de una vez, una pregunta muy pertinente es la que se refiere al significado de esa, o de esas reinfecciones: ¿le brinda algún beneficio, o al revés, lo predispone a complicaciones?

Dos recientes estudios, hechos por investigadores de la Universidad Washington en St. Louis, así como del sistema de Atención de Veteranos en St. Louis y la Universidad de St. Louis, en Missouri, Estados Unidos, brindan respuestas a esas preguntas.

En el primero, publicado en Nature Medicine del 25 de mayo, los investigadores compararon lo que sucedió con la salud de casi 34.000 personas que tuvieron por lo menos una reinfección después de haber sido vacunadas contra COVID-19, con la de tres grupos de personas, llamados grupos de control.

El primero, llamado contemporáneo, compuesto de casi 5 millones de personas que vivieron durante la pandemia, pero sin historia de infección por el SARS-CoV-2.

El segundo, un grupo de casi 5 millones y medio de personas que vivieron antes de la pandemia y el tercero, de casi 3 millones de personas vacunadas contra COVID-19.

Los resultados muestran que a pesar de que los síntomas de COVID-19 prolongada, incluyendo un mayor riesgo de muerte, pueden presentarse también en personas vacunadas que se reinfectan, su frecuencia es menor en este último grupo.

Los autores concluyen que, aunque la vacunación puede reducir parcialmente los riesgos de muerte y COVID-19 prolongada, se requiere que las políticas de salud pública sigan alentando la prevención primaria de la infección con el uso de mascarillas, distancia social y ventilación de espacios cerrados.

La COVID-19 prolongada tras una reinfección

En el segundo estudio, aún una prepublicación no revisada por pares, los autores amplían su estudio para saber si el tener dos o más infecciones aumenta el riesgo de sufrir de síntomas de COVID-19 prolongada.

Para eso, comparan tres grupos:

El primero de más de 257.000 personas que tuvieron una sola infección del SARS-CoV-2,

El segundo, de casi 39.000 personas que tuvieron dos, tres o cuatro infecciones por SARS-CoV-2,

El tercero, de más de 5 millones y medio de personas sin historia de infección.

Como dato interesante, en el grupo de casi 39.000 reinfecciones se vio que:

- Más de 36.000 lo tuvieron dos veces,
- Más de 2.200 lo tuvieron tres veces y
- 246 se infectaron cuatro veces.

Con respecto al tiempo entre infección e infección, se vio que la media entre la primera y la segunda infección fue de 79 días (con un intervalo entre 48 y 119 días), y entre la segunda y tercera infección fue de 65.

Los resultados del estudio indican que, al contrario de lo que la gente cree, tener dos o más infecciones no brinda mayor protección o resistencia a desarrollar síntomas, sino que, al revés, aumenta la posibilidad de presentar síntomas persistentes.

En ese sentido, se vio que el riesgo de presentar nuevos síntomas fue mayor cuando la persona se reinfectaba, viéndose que los síntomas duraban por lo menos seis meses. Ese mayor riesgo de desarrollar síntomas fue observado independientemente de si alguien había sido vacunado o no, y fue directamente proporcional al número de infecciones, observándose que aumentaba con cada infección posterior.

Síntomas más comunes que se presentan en una reinfección

Los síntomas más comunes después de las reinfecciones incluyeron:

⇒ Dolor de pecho

⇒ Ritmos cardíacos anormales

⇒ Ataques cardíacos

⇒ Inflamación del músculo cardíaco o del saco que rodea el corazón

⇒ Insuficiencia cardíaca y coágulos sanguíneos

Los problemas pulmonares comunes incluyeron:

⇒ Dificultad para respirar

⇒ Bajo nivel de oxígeno en la sangre

⇒ Enfermedad pulmonar

Acumulación de líquido alrededor de los pulmones

En resumen, la aparición de la variante Ómicron cambió completamente el panorama de la pandemia, haciendo que las reinfecciones sean mucho más frecuentes que antes, las que —al contrario de lo que uno pudiera creer— no es que refuerzan el sistema de defensa causando enfermedades más leves, sino que nos ponen en un mayor riesgo de desarrollar síntomas de COVID-19 persistente.

Si bien es cierto que la vacunación puede proteger en parte contra esas complicaciones, esa protección no sería completa, por lo que es importante que —mientras persista la pandemia— hagamos todo el esfuerzo para evitar la infección.

Fuente: CNN en español. Disponible en https://cnn.it/3bJB8eZ

Over 6.42m Belarusians now fully vaccinated against COVID-19

Aug 4. Over 6.512 million people in Belarus have got the first shot of a COVID-19 vaccine, of them over 6.424 million have completed the vaccination process, BelTA learned from the press service of the Belarusian Healthcare Ministry.

Over 892,300 people completed the full vaccination series in Brest Oblast, over 789,900 in Vitebsk Oblast, over 973,800 in Gomel Oblast, over 693,500 in Grodno Oblast, over 691,000 in Mogilev Oblast, over 983,700 in Minsk Oblast, and over 1.28 million in the city of Minsk.

Over 111,000 employees of organizations and institutions have completed the vaccination process.

Over 150,700 teenagers aged 12-17 have received one shot of the vaccine, of them more than 145,500 children have been fully vaccinated.

Thus, 70.4% of the country's population have received one dose of the vaccine, 69.4% have been fully vaccinated.

Belarusians are also getting booster shots of the vaccine, with 26.1% of the population having completed it so far.

Fuente: BELTA. Disponible en https://bit.ly/3SMayCk

Tinnitus, nuevo efecto secundario de la vacuna de AstraZeneca contra la COVID-19: qué es y cómo tratarlo

5 ago. A medida que va pasando el tiempo, se van conociendo cada vez más cosas sobre la COVID-19, algo en lo que también ha influido la llegada de las nuevas variantes, cuyos cambios en los tiempos de incubación, síntomas o duración del virus, han dado un giro de 180º a todo lo que ya sabíamos de la enfermedad.

Aunque esté menos presente, el virus sigue estando ahí y siguen existiendo contagios e ingresos hospitalarios.

Hasta mediados de julio, las nuevas variantes BA.4 y BA.5 de Ómicron supusieron más del 75% de las nuevas infecciones, tal y como reflejó el último informe de la situación epidemiológica hecho público por el Ministerio de Sanidad este martes.

Nuevos efectos secundarios

¿Y qué hacer ante la permanente presencia de un virus que va mutando y del que surgen más variantes? Vacunarse continúa siendo la mejor opción para prevenir tanto la enfermedad como su gravedad en caso de contagiarnos.

Los nuevos conocimientos del virus que mencionábamos anteriormente también se aplican a las vacunas, ya que a medida que va pasando el tiempo y cada vez más población está inoculada, se van descubriendo nuevos efectos adversos de las mismas. Uno de ellos es el Tinnitus, un viejo conocido para muchos que han padecido la COVID-19.

¿Por qué? Porque según el último informe de Farmacovigilancia sobre las vacunas frente a la COVID-19 publicado por la Agencia Española de Medicamento y Productos Sanitarios (AEMPS) se han detectado nuevos efectos secundarios de las vacunas, tanto de las más como de las menos utilizadas.

El dossier revela que en Moderna se ha identificado la inflamación extrema de la extremidad vacunada; en AstraZeneca, el Tinnitus, la parestesia o la hipoestesia; y en Nuvaxovid, la anafilaxia, la parestesia y la hipoestesia. Sin embargo, aún se está evaluando si los sangrados menstruales abundantes son un posible efecto adverso con Pfizer y Moderna.

¿Qué es el Tinnitus?

Según la Clínica Mayo, se conoce como Tinnitus a aquella sensación de pitido u otros ruidos en uno o ambos oídos. No es un sonido externo, por lo que otras personas no pueden escucharlo. Afecta a entre un 15% y un 20% de la población, sobre todo en adultos mayores.

Este zumbido es un problema de salud muy frecuente en nuestra sociedad y puede empeorar notablemente la calidad de vida de quienes lo padecen.

Las infecciones virales pueden generar síntomas relacionados con la audición. Esto se debe a que las membranas mucosas tienden a congestionarse y acumulan líquido detrás de los tímpanos. Por eso, estos virus pueden dañar las células sensoriales del oído interno. No es de extrañar entonces que la enfermedad infecciosa causada por el virus SARS-COV-2 está relacionada con el Tinnitus.

Principales síntomas

El especialista del Hospital Universitario Central de Asturias, Faustino Núñez Batalla, precisa que se define como 'persistente' aquel tinnitus que dura más de 6 meses, al tiempo que remarca que puede ocurrir en uno o ambos lados de la cabeza y ser notado como proveniente de dentro o de fuera de la misma.

"Más frecuentemente ocurre en el lado donde coexista con una sordera, en particular en aquellos pacientes que describen una sensación más intensa", aprecia el especialista.

Por otro lado explica que se califica como 'tinnitus primario' aquel que no tiene una causa clara (idiopático) y que se puede asociar o no con una sordera; mientras que se define como 'tinnitus secundario' aquel que se asocia con una causa subyacente, con una enfermedad orgánica.

¿Cómo tratarlo?

En algunos casos, podrá ser tratado si la causa es una afección de salud subyacente. En este caso, el médico podrá reducir los síntomas tratando la causa. Por ejemplo:

⇒ Eliminar la cera de los oídos.

⇒ Tratamiento de una afección de los vasos sanguíneos.

⇒ Audífonos.

⇒ Cambios de medicamentos.

Según explica la Clínica Mayo, en muchos casos el Tinnitus no tiene cura, pero se pueden realizar tratamientos para hacer que los síntomas sean menos perceptibles, como por ejemplo, un dispositivo electrónico para inhibir el ruido:

⇒ Máquinas de ruido blanco: reproducen sonidos similares a los ambientales como la caída de la lluvia o las olas del mar. También, ventiladores, humidificadores y aire acondicionado pueden ayudar.

⇒ Dispositivos de enmascaramiento: se colocan en el oído y son similares a los audífonos.

Cuando nada de esto sirve, sólo queda el asesoramiento psicológico a través del tratamiento conductora para ayudar al paciente a vivir con el Tinnitus.

Fuente: ONDA CERO. Disponible en https://bit.ly/3QiVkTQ

Las vacunas anti-Covid-19 de Cuba, más allá de sus fronteras

5 ago. Además de Soberana Plus, ha llegado al Viejo Continente otra de las vacunas cubanas, Soberana 02.

Soberana 02, diseñada en el Instituto Finlay de Vacunas (IFV) de la isla caribeña, al igual que Soberana Plus; recibió luz verde en abril para ser producido parcialmente en Italia gracias a un acuerdo entre dicha entidad y la empresa ADIENNE Pharma & Biotech y la Agencia de Intercambios Económicos y Culturales con Cuba (AICEC) -ambas italianas-.

El memorándum suscrito en el congreso BioHabana 2022 permitirá formular y envasar en el país europeo el inmunógeno de la isla.

En esa ocasión, el director general del IFV, Vicente Verez, indicó que el acuerdo estaba cerrado pensando en un potencial momento de entrada de esta vacuna en Europa o, incluso, en América del Norte. Ello necesita de alianzas para compartir la ciencia".

Verez también ha explicado que la intención es, en una segunda fase, poder valorar si se podrían producir íntegramente en esta empresa italiana las vacunas Soberana 02 y otras de IFV.

Con Italia, los hilos que unen los productos anti-Covid-19 de IFV son más fuertes. En noviembre de 2021, alrededor de 30 personas de entre 19 y 59 años viajaron desde este país a Cuba para participar como voluntarias en el estudio clínico Soberana Plus Turín.

El objetivo del ensayo fue evaluar el inmunógeno en convalecientes de COVID-19 y sujetos sin antecedentes de la enfermedad, pero inmunizados con otras vacunas.

En el marco de este análisis colaborativo, en el hospital "Amadeo di Savoia" de la ciudad de Turín, se evalúan sueros de voluntarios cubanos vacunados con Soberana Plus desde julio del año pasado.

Los resultados demostraron la capacidad de Soberana Plus para inducir anticuerpos neutralizantes contra las variantes alfa, beta y delta del coronavirus SARS-CoV-2 que causa la enfermedad.

Primera en el mundo, especialmente diseñada para repotenciar la inmunidad previamente inducida por otras vacunas anti-Covid-19 o por infección natural, Soberana Plus también ha sido utilizada en Cuba como dosis de refuerzo en el régimen de vacunación anti-Covid-19, diseñado por IFV a partir de dos dosis de su otro producto Soberana 02.

La combinación de ambos ha demostrado en ensayos clínicos una eficacia del 92,4 % frente a la enfermedad sintomática, según el informe de resultados finales del estudio de fase III de Soberana 02.

Este fue el cronograma utilizado para la vacunación contra la COVID-19 en niños de 2 a 18 años en el país, la primera campaña en el mundo que llegó a más de 1,7 millones de infantes.

Las autoridades cubanas calificaron de "éxito total" la vacunación en la edad pediátrica; Pues se han prevenido alrededor de 70 000 casos y desde 2021 no ha muerto ningún niño por la COVID-19 en Cuba.

No es sólo en Europa donde se conocen los "soberanos". Soberana 02 llegó a Irán a principios de 2021 cuando aún era solo un candidato vacunal, con el objetivo de completar la fase III de sus ensayos clínicos.

"Como parte de la colaboración con otros países en el desarrollo de vacunas contra la COVID-19, se han enviado al Instituto Pasteur de Irán 100.000 dosis de Soberana02, que serán utilizadas en ensayos clínicos en este país", anunció el grupo de empresas BioCubaFarma.

A fines de junio del mismo año, Soberana 02 recibió la autorización de uso de emergencia en la República Islámica de Irán. La autorización fue concedida al Instituto Pasteur de Irán (IPI), que comercializará la vacuna en territorio iraní, en el marco de un acuerdo de colaboración suscrito con el Instituto Finlay de Vacunas.

De esta forma, el país persa se convierte en el primero del mundo en producir vacunas cubanas contra la COVID-19.

En este país se inauguró un centro de producción masiva de la inyección de la vacuna PastoCorona, resultado de la transferencia, al Instituto Pasteur, de la tecnología de la vacuna cubana Soberana 02.

De este lado del mundo, en Nicaragua y Venezuela; Soberana 02 y Soberana Plus están autorizados para uso de emergencia.

Soberana 02 se encuentra entre las vacunas aprobadas por las autoridades sanitarias venezolanas para su uso en niños mayores de dos años y a principios de 2022 llegó al país bolivariano un envío de un millón de dosis de Soberana Plus.

Las autoridades sanitarias han aclarado que utilizarán este último medicamento para brindar protección contra la reinfección con la variante Ómicron.

Por su parte, la Autoridad Reguladora de Nicaragua ha indicado desde octubre de 2021 que Soberana 02 se ofrece como una herramienta terapéutica de acceso seguro para reducir la transmisibilidad del COVID-19; particularmente en la población pediátrica de dos a 17 años de edad.

Soberana 02 también ha llegado a los brazos de los niños de la República Árabe Saharaui Democrática. En febrero, Cuba donó a ese país un lote de 458 000 dosis de esta vacuna para uso pediátrico.

Abdala también protege fuera de Cuba

Aunque los vacunas de la línea de Soberana ya son conocidos en varias naciones, lo mismo sucede con Abdala, vacuna diseñada en el Centro de Ingeniería Genética y Biotecnología de Cuba y la primera en este país y en América Latina diseñada contra el virus SARS-Cov-2.

A Vietnam, México, Venezuela y Nicaragua han llegado millones de dosis de esta vacuna que, aplicada en un esquema de tres dosis cada 14 días, ha demostrado una efectividad del 92,28% contra enfermedades sintomáticas. Además, ha demostrado una eficacia del 100% en la prevención de enfermedades sistémicas graves y muertes por COVID-19.

En septiembre de 2021, a pedido del Centro de Investigación y Producción de Vacunas y Productos Biológicos Médicos, el Ministerio de Salud de Vietnam aprobó la importación y uso de la vacuna Abdala en esta nación indochina.

Durante ese mismo mes llegó a ese país el primer lote de la vacuna cubana, compuesto por 900 000 dosis compradas por Vietnam y otras 150 000 donadas por la nación caribeña.

Durante el recibimiento de ese primer envío, el viceministro de Relaciones Exteriores Dang Hoang Giang agradeció a Cuba las dosis, de un total de 10 millones acordadas con la mayor de las Antillas y desde donde también se transferirá a Vietnam la tecnología para producir la vacuna en Ese pais.

En Nicaragua, Abdala está aprobado para uso de emergencia desde octubre de 2021; mientras que Venezuela firmó un contrato para suministrar 12 millones de unidades del inmunógeno con la isla caribeña el mismo año.

A finales de 2021, la Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) del gobierno mexicano se pronunció sobre la autorización de uso de emergencia de Abdala.

Como autoridad reguladora nacional de referencia, calificada por la Organización Panamericana de la Salud; Las decisiones de la Cofepris son reconocidas por varios países de la región, por lo que es probable que las vacunas aprobadas se utilicen en otros países.

Como miembro de la Conferencia Internacional sobre Armonización de Requisitos Técnicos para el Registro de Productos Farmacéuticos de Uso Humano, todas las decisiones de esta autoridad se toman sobre la base de la evidencia técnico-científica presentada.

En diciembre del mismo año, el Ministerio de Salud de San Vicente y las Granadinas anunció en su cuenta de redes sociales de Facebook que Abdala estaba disponible en los puntos de vacunación de ese país.

Con este anuncio, esta nación se convierte en la primera de la Comunidad del Caribe (Caricom) en autorizar una de las vacunas de Cuba contra la Covid-19.

¿Y la certificación de la OMS?

A pesar de toda la evidencia presentada anteriormente, muchos escépticos dirán que las vacunas cubanas aún no son reconocidas por la Organización Mundial de la Salud (OMS); y no son sin razón; solo aclara eso; Aunque el problema ha durado más de lo esperado, cada país puede autorizar el uso de una vacuna, esté o no aprobada por este organismo internacional.

Sin embargo, esto no significa que Cuba esté detenida en el proceso.

Así lo confirmó recientemente el director general de la OMS, Tedros Adhanom, quien aseguró en mayo pasado que el organismo estaba siguiendo el proceso de certificación de las vacunas anti-Covid-19 creadas y desarrolladas en Cuba.

Desde marzo, el Grupo de las Industrias Biotecnológica y Farmacéutica de la Nación Caribeña (BioCubaFarma) ha detallado en su cuenta de Twitter que la OMS ha sido informada del documento finalizado para ser revisado por expertos e iniciar el proceso de reconocimiento internacional de la vacuna Abdala.

La entidad señaló en esta misma red social que el Centro de Ingeniería Genética y Biotecnología (CIGB) a cargo de esta vacuna inició durante este mes el intercambio formal con la entidad de salud.

A mediados de febrero de este año, el director de BioCubaFarma, Eduardo Martínez, explicó que la empresa estaba trabajando en el texto, compuesto por varios capítulos con resultados sobre la investigación clínica y preclínica, el desarrollo farmacéutico, así como todo lo referente a las instalaciones de producción, un aspecto al que se han hecho adaptaciones.

Sobre los procesos seguidos con Abdala para esta evaluación, Martínez señaló que se tomó la decisión de trasladar el sitio de producción a la recién inaugurada fábrica de Mariel, ubicada en este polo industrial, al oeste de La Habana.

En funcionamiento desde noviembre de 2021, el Parque Tecnológico Industrial CIGB-Mariel es considerado el más moderno de Cuba y uno de los más avanzados de América Latina y el Caribe con laboratorios de control de calidad y almacenes de materias primas y productos terminados.

También cuenta con fábricas para obtener el principio activo de vacunas e inmunógenos completos en formulaciones líquidas, en polvo y spray.

El objetivo es que los representantes de la OMS visiten también las plantas productivas de esta entidad donde realizarán la inspección necesaria para posteriormente obtener el permiso y su inclusión en la lista de productos reconocidos por el organismo de las Naciones Unidas, subrayó Martínez.

"Cuba siempre mantiene intercambios con la representación de la OMS/OPS sobre todo lo relacionado con la precalificación de vacunas anti-Covid-19", dijo.

Y la afirmación no es menos cierta, desde septiembre del año pasado, el representante de la Organización Panamericana y Mundial de la Salud (OPS/OMS) en la isla caribeña, José Moya, informó a la agencia AP un encuentro virtual entre especialistas en La Habana. , Ginebra y Washington para compartir información, coordinar documentación y establecer cronogramas.

La solidaridad de Cuba no sólo ha llenado de batas blancas al mundo; También llega a varios países en ampollas que pueden salvar millones de vidas. Las vacunas desarrolladas en esta isla cuentan con el compromiso, esfuerzo y capacidad de científicos con más de tres décadas de experiencia produciendo sus propios inmunógenos.

Fuente: Cuba ES Euro. Disponible en https://bit.ly/3SQ6LE2

Prestigiosa revista científica de oncología publica resultados de investigación entre el CIM y el Roswell Park con la vacuna cubana CIMAvax-EGF

5 ago. La prestigiosa revista científica *Frontiers in Oncology* publicó este 3 de agosto resultados de la investigación entre el CIM y el Instituto Roswell Park, de Nueva York, en Estados Unidos, con la vacuna terapéutica cubana contra el cáncer de pulmón CIMAvax-EGF.

Así dio a conocer en su cuenta de Twitter el Centro de Inmunología Molecular (CIM).

Se trata de un estudio en curso por la institución científica radicada en Nueva York, en el escenario más avanzado de los pacientes en la segunda línea del cáncer de pulmón de células no pequeñas.

"En este estudio no se usa la vacuna solamente, sino que es una combinación de CIMAvax-EGF® con Nivolumab, una droga inmunomoduladora. En este caso también demostramos que la combinación fue muy segura e incrementó la inmunogenicidad.

"Al mismo tiempo tenemos un conjunto de pacientes que está obteniendo una supervivencia muy larga. Ello nos brinda la posibilidad de identificar nuevos biomarcadores que nos permitan anticipar poblaciones que reciban un beneficio de la combinación de ambas drogas", explicó recientemente a Cubadebate la doctora Tania Crombet, directora de Investigaciones Clínicas del CIM.

Más de 10 000 pacientes cubanos han sido beneficiados con esta vacuna en los diferentes escenarios de atención médica (primaria, hospitales e institutos) del sistema nacional de Salud.

Los datos del mundo real de uso de CIMAvax-EGF® —como se le denomina a la investigación clínica una vez que se concluye el registro del producto—, confirman los datos de seguridad y efectividad que se habían generado en las investigaciones cubanas previas. De igual modo, los datos obtenidos por el Instituto Roswell Park.

Frontiers in Oncology es la tercera revista más citada en su campo con más de 155 000 citas y 60 millones de visitas en 17 000 artículos. La publicación de esta investigación confirma los resultados obtenidos en los estudios que se están conduciendo en Cuba actualmente con el fármaco y constituye un importante paso en la visibilización de la ciencia cubana.

Fuente: Cubadebate. Disponible en https://bit.ly/3QHvfxD

Cuarta dosis y nuevas vacunas



7 ago. Hemos evidenciado el gran triunfo de la ciencia con las vacunas frente a la COVID-19; se han aprobado varias vacunas en Europa, dos de ellas basadas en una nueva tecnología de ARN, de las empresas Moderna y Pfizer-BioNTech, dos empleando adenovirus (AstraZeneca-Oxford y Janssen-Cilag), una con virus inactivado (Valneva Austria) y otra con proteína recombinante (Novavax). Actualmente están en fase de estudio por la Agencia Europea del Medicamento, vacunas de las empresas Sanofi-GSK, Hipra (vacuna española que emplea dos proteínas recombinantes de las variantes alfa y beta), Moderna y Pfizer (que incluyen a la nueva variante Ómicron), así como muchas más en investigación.

► https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised

Actualmente la pandemia en España ha pasado a una fase de estabilización, con una disminución de los casos activos y de personas hospitalizadas, y con una alta tasa de vacunación. Ante esta situación actual cabe preguntarse qué hacer en los próximos meses en relación a las vacunas. Los estudios científicos han demostrado que tanto la vacunación como haber pasado la infección inducen una respuesta inmunitaria que genera memoria, y que ésta puede ser duradera (no sabemos cuánto tiempo). Incluso la combinación infección-vacunación, ha mostrado generar mejor respuesta, al ver nuestra inmunidad al virus completo, actuando una diversidad de «soldados inmunitarios» y no solo los que ven la proteína S (presente en las vacunas disponibles). Esto también se observa al combinar vacunas distintas.

La memoria inmunitaria (tanto celular como humoral) se mantiene durante tiempo, pero los anticuerpos, esas proteínas tan específicas que pueden bloquear y neutralizar al virus, decaen tras varios meses. En una persona sana y joven que se vacunó y/o infectó previamente, si se contagia con una nueva variante, es previsible que tenga síntomas durante unos días, pero rápidamente resolverá la infección. Por el contrario, una persona vulnerable (mayor, con patologías, trasplantados, etcétera), si se contagia puede desarrollar

una enfermedad grave. La estrategia futura de vacunación debe por tanto centrarse en aquellos más vulnerables (ancianos y con alto riesgo de sufrir una enfermedad grave), pero no en la población general, como aseguran el Centro Europeo para el Control y Prevención de Enfermedades y la Agencia Europea del Medicamento.

► https://www.ema.europa.eu/en/news/ecdc-ema-issue-advice-fourth-doses-mrna-covid-19-vaccines

La pregunta que surge es si las personas con mayor riesgo, deben recibir una cuarta dosis de la misma vacuna, combinar vacunas ya autorizadas, o esperar a la aprobación otras nuevas, como las que incluyen ya a la variante ómicron. Los estudios realizados en Israel con cuatro dosis de Pfizer indican que se incrementa la protección frente a enfermedad grave/fallecimientos, pero que los anticuerpos vuelven a decaer pasados unos 4 meses, por lo que no parece ser la mejor estrategia a largo plazo. Los ensayos llevados a cabo combinando vacunas autorizadas han mostrado buenos resultados, así como también los de las nuevas vacunas, aún en fase de aprobación.

El contagio con el virus moviliza también a la inmunidad, por lo que una persona inoculada con 3 dosis y que ha sufrido la infección, su sistema inmunitario se ha activado ya 4 veces. Otro elemento importante: no cansar siempre a los mismos soldados inmunitarios y esperar 5-6 meses tras una infección para recibir una dosis de vacuna.

Fuente: La Voz de Galicia. Disponible en https://bit.ly/3bNd2jz

El ensayo clínico PANCOVID liderado por el Hospital La Paz de Madrid ha sido publicado en la revista Clinical Infectious Diseases

9 ago. Los resultados del ensayo clínico español PANCOVID, diseñado para evaluar la eficacia de diversas alternativas farmacológicas, y estrategias en el tratamiento de SARS-CoV-2 sintomático, han sido publicados en la revista Clinical Infectious Diseases, una de las más importantes de su campo. Se trata de uno de los ensayos académicos sobre estrategias de tratamiento de COVID-19 más grande realizado en España.

Los resultados del ensayo clínico español PANCOVID, diseñado por el Hospital Universitario La Paz - IdiPAZ para evaluar la eficacia de diversas alternativas farmacológicas, y estrategias en el tratamiento de SARS-CoV-2 sintomático, han sido publicados en la revista Clinical Infectious Diseases, una de las más importantes de su campo.

El ensayo ha sido liderado por los doctores José Ramón Arribas, jefe de Sección de Medicina Interna y enfermedades infecciosas, Alberto Borobia, coordinador de la Unidad de Ensayos Clínicos y Antonio Carcas del servicio de Farmacología Clínica, todos ellos pertenecen al CIBERINFEC. El objetivo principal del ensayo clínico PANCOVID ha sido proporcionar estimaciones fiables sobre los efectos de diferentes estrategias de tratamiento de COVID-19 sintomático.

En el estudio se investigó la eficacia de Emtricitabina/Tenofovir disoproxil fumarato (TDF/FTC) y de Baricitinib en pacientes, principalmente hospitalizados, con alto riesgo de COVID-19 grave durante un año. La investigación ha sido impulsada y promovida por el CIBER de Enfermedades Infecciosas y ha sido financiado por el Instituto de Salud Carlos III, en la convocatoria extraordinaria de ayudas para la investigación de la COVID-19.

Se incluyó a un total de 355 participantes, donde el criterio de valoración principal fue la mortalidad a los 28 días, que era del 3,1%. El riesgo relativo de mortalidad a los 28 días para los participantes tratados con TDF/FTC fue de 1,76% y del 0,42% para los tratados con Baricitinib. Estos resultados no sugirieren un efecto beneficioso de TDF/FTC en pacientes con COVID hospitalizados; sin embargo, son compatibles con el efecto beneficioso de Baricitinib ya establecido por otros ensayos clínicos. Los resultados del ensayo han servido para afianzar el papel de Baricitinib como terapia antiinflamatoria en pacientes con COVID grave.

Fuente: Comunidad de Madrid. Disponible en https://bit.ly/3AkHRoX

Prestigiosa revista europea publica artículo del desarrollo de la vacuna Abdala

9 ago. El Dr. Gerardo Enrique Guillén, director de Investigaciones Biomédicas del Centro de Ingeniería Genética y Biotecnología (CIGB) informó a través de su cuenta en Twitter que se publicó en revista de la Sociedad Europea de Biotecnología el artículo del desarrollo de la vacuna Abdala que comprende desde la construcción genética hasta la evaluación en modelos animales.

La publicación de este artículo en una revista de alto impacto constituye un reconocimiento a la calidad del desarrollo de la ciencia cubana, en tanto, estos resultados fueron arbitrados por expertos internacionales para su publicación, un proceso que se realiza a ciegas para los autores.

La revista *New Biotechnology* tiene un alto factor de impacto dentro de las publicaciones científicas, con un estimado de 6.49 en el 2021.

Abdala es un inmunógeno desarrollado por el CIGB, siendo una de las tres vacunas creadas por Cuba ante la pandemia.

La misma se ha aplicado como parte de la campaña de vacunación masiva anti COVID impulsada por la nación caribeña.

Fuente: Cubadebate. Disponible en https://bit.ly/3JZN3lp

OMS: Muertes por COVID-19 a nivel mundial disminuyeron nueve por ciento durante la última semana

10 ago. De acuerdo con el último reporte semanal de la OMS, publicado este miércoles, la cifra de fallecimientos como consecuencia del coronavirus disminuyó un 9 % durante la última semana. Asimismo, el número de nuevos casos se mantuvo estable.

La agencia de Naciones Unidas informó que en la última semana se produjeron más de 14 000 decesos por COVID-19 y casi siete millones de contagios.

Los casos aumentaron un 30 % en el Pacífico occidental y disminuyeron un 46 % en África.

En América y el Medio Oriente, la cifra de contagios se redujo en más del 20 %.

Los decesos aumentaron 19 % en Oriente Medio, pero cayeron más del 70 % en el continente africano, 15% en Europa y 10% en África.

La subvariante Ómicron BA.5 sigue predominando en el mundo y representa casi el 70 % de las secuencias de virus reportadas, según la OMS. Los datos indican que otras subvariantes de Ómicron parecen disminuir.

La Organización Mundial de la Salud aclaró que su evaluación de las tendencias de la COVID-19 continúa con limitaciones por el abandono de los países de una parte de los esfuerzos de vigilancia, pruebas y secuenciación, como consecuencia de la relajación de los controles de la pandemia.

Fuente: Cubadebate. Disponible en https://bit.ly/3JRvl3o

USS realiza estudios clínicos para el desarrollo de nuevas vacunas

10 ago. USS participa en 5 estudios clínicos para el desarrollo de nuevas vacunas. Se trata de nuevas vacunas contra la COVID-19, Influenza y Neumococo. A su vez, la institución trabaja en la conformación de un centro de estudios clínicos de referencia.

El avance de las enfermedades, la aparición de nuevos agentes infecciosos o la resistencia de algunos virus o bacterias a las terapias actuales, obliga al mundo de la ciencia a buscar nuevas alternativas de tratamiento.

En ese contexto, son muy importantes los estudios clínicos. Se trata de investigaciones que buscan probar la eficacia y seguridad de nuevos medicamentos, vacunas, dispositivos u otras fórmulas que se desarrollan con el fin de encontrar mejores formas de prevenir, diagnosticar o tratar una enfermedad.

Cada estudio clínico tiene diferentes etapas y un protocolo muy riguroso que se debe cumplir. En el caso de Chile, es el Instituto de Salud Pública (ISP) el organismo encargado de autorizar la realización de estos ensayos con el fin de proteger los derechos y el bienestar de los participantes y asegurar la calidad de los datos obtenidos en la investigación. Se requiere también de la aprobación por Comités de Ética Científica independientes, que aseguran que los estudios cumplan con todas las normas internacionales de buenas prácticas clínicas de investigación.

Centro USS

La Universidad San Sebastián participa en cinco estudios clínicos multicéntricos para probar nuevas vacunas. Se trata de vacunas contra el SARS-CoV-2, Influenza y Neumococo, tres microorganismos respiratorios que causan gran carga de morbilidad en el país.

“Aspiramos a ser un centro de referencia a nivel nacional para el desarrollo de estudios clínicos que impacten en resultados de pacientes, en la práctica clínica y la salud pública”, explica Pilar Espinoza, directora de investigación, postgrado y vinculación internacional de la Facultad de Ciencias de Ciencias para el Cuidado de la Salud.

La docente comenta que actualmente se está trabajando en la conformación de un Centro de Estudios Clínicos USS, de la mano de la Facultad de Medicina y Ciencia.

Estudios

La primera experiencia en esta área fue la participación de la USS en el estudio multicéntrico para evaluar la eficacia, seguridad e inmunogenicidad de la vacuna contra el virus SARS-CoV-2 (CoronaVac), liderado en Chile por la Pontificia Universidad Católica y el laboratorio Sinovac Biotech, donde se invitó a la Universidad a participar junto a otras instituciones.

Según explicó Espinoza, esto "nos permitió darnos cuenta de que contamos con el know how necesario para convertirnos en un centro de referencia, al mismo tiempo que empezamos a ser requeridos por parte de otras instituciones para hacer este trabajo".

Actualmente la Universidad participa en otros cuatro Ensayos Clínicos Fase III, es decir buscan responder si la nueva intervención bajo estudio es no inferior o superior a la convencional, explica el Dr. Carlos Pérez, Decano de la Facultad de Medicina y Ciencia e investigador responsable de estos estudios junto con la profesora Espinoza.

Uno de ellos es el estudio de una nueva vacuna tetravalente contra la Influenza de Sinovac Biotech que pretende evaluar la inmunogenicidad y seguridad del producto farmacéutico en comparación con otra vacuna tetravalente, disponible en el mercado, para ser usada por personas mayores de tres años y que es patrocinado por la PUC y Sinovac Biotech (Chile).

Otros dos estudios son para evaluar la seguridad, la tolerancia e inmunogenicidad de una nueva vacuna contra el neumococo, en diferentes grupos de la población.

Espinoza agrega que se está en conversaciones con Sinovac Biotech (Chile) para comenzar próximamente el estudio de una nueva vacuna contra el SARS-CoV-2, variante Ómicron.

"Nuestro objetivo es generar conocimiento científico que responda a las problemáticas de salud relevantes de la población, de manera de socializar estos resultados con la comunidad académica y científica a nivel local e internacional. Estamos capacitados para entregar guía experta, soporte metodológico, logístico y estructural para el desenvolvimiento de estudios clínicos", concluye Pilar Espinoza.

Fuente: IPSUSS. Disponible en https://bit.ly/3PqIsd0

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

Síganos en redes sociales

@vaccimonitor

@finlayediciones

@finlayediciones

Artículos científicos publicados en Medline

Filters activated: Publication date from 2022/08/01 to 2022/08/11. "Vaccine" (Title/Abstract) 957 records.

Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper.
Barbaud A, Garvey LH, Arcolaci A, Brockow K, Mori F, Mayorga C, Bonadonna P, Atanaskovic-Markovic M, Moral L, Zanoni G, Pagani M, Soria A, Jošt M, Caubet JC, Carmo A, Mona AA, Alvarez-Perea A, Bavbek S, Benedetta B, Bilo MB, Blanca-López N, Bogas HG, Buonomo A, Calogiuri G, Carli G, Cernadas J, Cortellini G, Celik G, Demir S, Doña I, Dursun AB, Eberlein B, Faria E, Fernandes B, Garcez T, Garcia-Nunez I, Gawlik R, Gelincik A, Gomes E, Gooi JHC, Grosber M, Gülen T, Hacard F, Hoarau C, Janson C, Johnston SL, Joerg L, Kepil Özdemir S, Klimek L, Košnik M, Kowalski ML, Kuyucu S, Kvedariene V, Laguna JJ, Lombardo C, Marinho S, Merk H, Meucci E, Morisset M, Munoz-Cano R, Murzilli F, Nakonechna A, Popescu FD, Porebski G, Radice A, Regateiro FS, Röckmann H, Romano A, Sargur R, Sastre J, Scherer Hofmeier K, Sedláčková L, Sobotkova M, Terreehorst I, Treudler R, Walusiak-Skorupa J, Wedi B, Wöhrl S, Zidarn M, Zuberbier T, Agache I, Torres MJ. Allergy. 2022 Aug;77(8):2292-2312. doi: 10.1111/all.15241. Epub 2022 Mar 5. PMID: 35112371

Viral vector vaccines.
McCann N, O'Connor D, Lambe T, Pollard AJ. Curr Opin Immunol. 2022 Aug;77:102210. doi: 10.1016/j.coi.2022.102210. Epub 2022 May 25. PMID: 35643023

The demand for a COVID-19 **vaccine**.
Sun S. Econ Hum Biol. 2022 Aug;46:101135. doi: 10.1016/j.ehb.2022.101135. Epub 2022 Mar 17. PMID: 35338910

Vaccine literacy: A concept analysis.
Badua AR, Caraquel KJ, Cruz M, Narvaez RA. Int J Ment Health Nurs. 2022 Aug;31(4):857-867. doi: 10.1111/inm.12988. Epub 2022 Mar 14. PMID: 35289065

Predicting COVID-19 booster **vaccine** intentions.
Hagger MS, Hamilton K. Appl Psychol Health Well Being. 2022 Aug;14(3):819-841. doi: 10.1111/aphw.12349. Epub 2022 Feb 22. PMID: 35193171

Is COVID-19 really a geriatric syndrome?
Akbarzadeh MA, Hosseini MS. Ageing Res Rev. 2022 Aug;79:101657. doi: 10.1016/j.arr.2022.101657. Epub 2022 May 29. PMID: 35640838

COVID-19 **vaccine** uptake and intention during pregnancy in Canada.
Reifferscheid L, Marfo E, Assi A, Dubé E, MacDonald NE, Meyer SB, Bettinger JA, Driedger SM, Robinson J, Sadarangani M, Wilson SE, Benzies K, Lemaire-Paquette S, Gagneur A, MacDonald SE. Can J Public Health. 2022 Aug;113(4):547-558. doi: 10.17269/s41997-022-00641-9. Epub 2022 Apr 27. PMID: 35476258

COVID-19 vaccination in pregnancy.
Kalafat E, Heath P, Prasad S, O Brien P, Khalil A. Am J Obstet Gynecol. 2022 Aug;227(2):136-147. doi: 10.1016/j.ajog.2022.05.020. Epub 2022 May 11. PMID: 35568189

The politics of **vaccine** hesitancy in Europe.
Stoeckel F, Carter C, Lyons BA, Reifler J. Eur J Public Health. 2022 Aug 1;32(4):636-642. doi: 10.1093/eurpub/ckac041. PMID: 35522721

COVID-19 **vaccine**: missed opportunities and hospital **vaccine** implementation.
Martinot M, Mohseni-Zadeh M, Marion L, Roncalez D. Clin Microbiol Infect. 2022 Aug;28(8):1174-1175. doi: 10.1016/j.cmi.2022.03.036. Epub 2022 Apr 1. PMID: 35378268

Parental COVID-19 **Vaccine** Hesitancy in the United States.
Ruiz JB, Bell RA. Public Health Rep. 2022 Aug 2:333549221114346. doi: 10.1177/00333549221114346. Online ahead of print. PMID: 35915993

COVID-19 **vaccine** hesitancy and intent in California registered nurses.
Vuong L, Bidwell JT, Apesoa-Varano EC, Cothran FA, Catz SL. Vaccine X. 2022 Aug;11:100162. doi: 10.1016/j.jvacx.2022.100162. Epub 2022 Apr 23. PMID: 35492506

Attributing public ignorance in vaccination narratives.
Vanderslott S, Enria L, Bowmer A, Kamara A, Lees S. Soc Sci Med. 2022 Aug;307:115152. doi: 10.1016/j.socscimed.2022.115152. Epub 2022 Jun 20. PMID: 35840479

Associations Between Social Media Engagement and **Vaccine** Hesitancy.
Al-Uqdah L, Franklin FA, Chiu CC, Boyd BN. J Community Health. 2022 Aug;47(4):577-587. doi: 10.1007/s10900-022-01081-9. Epub 2022 Mar 25. PMID: 35332393

The potential cost-effectiveness of HPV vaccination among girls in Mongolia.
Luvsan ME, Vodicka E, Jugder U, Tudev U, Clark A, Groman D, Otgonbayar D, Demberelsuren S, LaMongtagne DS, Pecenka C. Vaccine X. 2022 Apr 8;11:100161. doi: 10.1016/j.jvacx.2022.100161. eCollection 2022 Aug. PMID: 35509519

Myocarditis Following COVID-19 Vaccination.
Marschner CA, Shaw KE, Tijmes FS, Fronza M, Khullar S, Seidman MA, Thavendiranathan P, Udell JA, Wald RM, Hanneman K. Cardiol Clin. 2022 Aug;40(3):375-388. doi: 10.1016/j.ccl.2022.05.002. Epub 2022 May 6. PMID: 35851461

Update on COVID-19 vaccination in pediatric solid organ transplant recipients.
Dulek DE, Ardura MI, Green M, Michaels MG, Chaudhuri A, Vasquez L, Danziger-Isakov L, Posfay-Barbe KM, McCulloch MI, L'Huillier AG, Benden C. Pediatr Transplant. 2022 Aug;26(5):e14235. doi: 10.1111/petr.14235. Epub 2022 Jan 20. PMID: 35060251

Childhood COVID-19 **vaccine** acceptance and preference from caregivers and healthcare workers in China: A survey experiment.
Hou Z, Song K, Wang Q, Zang S, Tu S, Chantler T, Larson HJ. Prev Med. 2022 Aug;161:107138. doi: 10.1016/j.ypmed.2022.107138. Epub 2022 Jul 7. PMID: 35809825

[Vaccination and Vaccination Response in Immunodeficiency].
Rohner GB, Jandus P. Ther Umsch. 2022 Aug;79(6):307-311. doi: 10.1024/0040-5930/a001366. PMID: 35903827

In silico based multi-epitope **vaccine** design against norovirus.
Shanthappa PM, Suravajhala R, Suravajhala P, Kumar G, Melethadathil N. J Biomol Struct Dyn. 2022 Aug 2:1-11. doi: 10.1080/07391102.2022.2105400. Online ahead of print. PMID: 35916029

Oral organic nanovaccines against bacterial and viral diseases.
Angulo C, Sanchez V, Delgado K, Monreal-Escalante E, Hernández-Adame L, Angulo M, Tello-Olea M, Reyes-Becerril M. Microb Pathog. 2022 Aug;169:105648. doi: 10.1016/j.micpath.2022.105648. Epub 2022 Jun 18. PMID: 35728750

Lymphohistiocytic Myocarditis and Moderna mRNA-1273 **Vaccine**.
Sookaromdee P, Wiwanitkit V. Am J Clin Pathol. 2022 Aug 4;158(2):311. doi: 10.1093/ajcp/aqac050. PMID: 35460221

Vaccine hesitancy and COVID-19 immunization among rural young adults.
Mann S, Christini K, Chai Y, Chang CP, Hashibe M, Kepka D. Prev Med Rep. 2022 Aug;28:101845. doi: 10.1016/j.pmedr.2022.101845. Epub 2022 Jun 2. PMID: 35669235

Narrative Review: Addressing Covid-19 **Vaccine** Concerns in Special and Vulnerable Populations.
Owusu KA, Effendi MK, Thompson Bastin ML, Tirmizi S, Lat I, Ammar MA. Hosp Pharm. 2022 Aug;57(4):575-587. doi: 10.1177/00185787211066463. Epub 2022 Jan 19. PMID: 35898240

In silico design of a multi-epitope **vaccine** against HPV16/18.
Sanami S, Rafieian-Kopaei M, Dehkordi KA, Pazoki-Toroudi H, Azadegan-Dehkordi F, Mobini GR, Alizadeh M, Nezhad MS, Ghasemi-Dehnoo M, Bagheri N. BMC Bioinformatics. 2022 Aug 2;23(1):311. doi: 10.1186/s12859-022-04784-x. PMID: 35918631

Safety and immunogenicity of synchronous COVID19 and influenza vaccination.
Baj A, Gasperina DD, Focosi D, Forlani G, Ferrante FD, Novazzi F, Azzi L, Maggi F. J Clin Virol Plus. 2022 Aug;2(3):100082. doi: 10.1016/j.jcvp.2022.100082. Epub 2022 May 7. PMID: 35571072

Frequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination.
Horvat JV, Sevilimedu V, Becker AS, Perez-Johnston R, Yeh R, Feigin KN. Eur Radiol. 2022 Aug;32(8):5752-5758. doi: 10.1007/s00330-022-08655-0. Epub 2022 Mar 5. PMID: 35247087

Principles and practical applications of structure-based **vaccine** design.
Byrne PO, McLellan JS. Curr Opin Immunol. 2022 Aug;77:102209. doi: 10.1016/j.coi.2022.102209. Epub 2022 May 19. PMID: 35598506

COVID-19 **vaccine** hesitancy and influential factors among Thai parents and guardians to vaccinate their children.
Kitro A, Sirikul W, Dilokkhamaruk E, Sumitmoh G, Pasirayut S, Wongcharoen A, Panumasvivat J, Ongprasert K, Sapbamrer R. Vaccine X. 2022 Aug;11:100182. doi: 10.1016/j.jvacx.2022.100182. Epub 2022 Jun 13. PMID: 35722523

Immunogenicity and safety studies of an inactivated **vaccine** against Rift Valley fever.
Ronchi GF, Testa L, Iorio M, Pinoni C, Bortone G, Dondona AC, Rossi E, Capista S, Mercante MT, Morelli D, Di Ventura M, Monaco F. Acta Trop. 2022 Aug;232:106498. doi: 10.1016/j.actatropica.2022.106498. Epub 2022 May 2. PMID: 35513072

Communicating about COVID-19 **vaccine** development and safety.
Thorpe A, Fagerlin A, Butler J, Stevens V, Drews FA, Shoemaker H, Riddoch MS, Scherer LD. PLoS One. 2022 Aug 5;17(8):e0272426. doi: 10.1371/journal.pone.0272426. eCollection 2022. PMID: 35930557

A Virion-Based Combination **Vaccine** Protects against Influenza and SARS-CoV-2 Disease in Mice.
Chaparian RR, Harding AT, Hamele CE, Riebe K, Karlsson A, Sempowski GD, Heaton NS, Heaton BE. J Virol. 2022 Aug 10;96(15):e0068922. doi: 10.1128/jvi.00689-22. Epub 2022 Jul 12. PMID: 35862698

Predicting COVID-19 **vaccine** hesitancy in Hong Kong: **Vaccine** knowledge, risks from coronavirus, and risks and benefits of vaccination.
Tsang SJ. Vaccine X. 2022 Aug;11:100164. doi: 10.1016/j.jvacx.2022.100164. Epub 2022 Apr 29. PMID: 35573268

Vaccine hesitancy and health care providers: Using the preferred cognitive styles and decision- making model and empathy tool to make progress.
Poland CM, Ratishvili T. Vaccine X. 2022 Jun 6;11:100174. doi: 10.1016/j.jvacx.2022.100174. eCollection 2022 Aug. PMID: 35782719

Comment to "Pregnancy and COVID-19, focus on **vaccine** and pharmacological treatment".
Ceulemans M, Sillis L, Foulon V, Panchaud A, Winterfeld U, Pomar L, Cleary B, O'Shaughnessy F, Passier A, Richardson JL, Nordeng H. J Reprod Immunol. 2022 Aug;152:103639. doi: 10.1016/j.jri.2022.103639. Epub 2022 May 10. PMID: 35569346

Measuring **vaccine** acceptance and knowledge within health professions education.
Singh H, Chase AJ. Vaccine. 2022 Aug 3:S0264-410X(22)00926-4. doi: 10.1016/j.vaccine.2022.07.039. Online ahead of print. PMID: 35933277

COVID-19 vaccination and the right to take risks.
Huang PH. J Med Ethics. 2022 Aug;48(8):534-537. doi: 10.1136/medethics-2021-107545. Epub 2021 Jul 12. PMID: 34253621

In silico SARS-CoV-2 **vaccine** development for Omicron strain using reverse vaccinology.
Li V, Lee C, Yoo D, Cho S, Kim H. Genes Genomics. 2022 Aug;44(8):937-944. doi: 10.1007/s13258-022-01255-8. Epub 2022 Jun 4. PMID: 35665465

Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy.
Syversen SW, Jyssum I, Tveter AT, Tran TT, Sexton J, Provan SA, Mjaaland S, Warren DJ, Kvien TK, Grødeland G, Nissen-Meyer LSH, Ricanek P, Chopra A, Andersson AM, Kro GB, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Lund-Johansen F, Jørgensen KK, Goll GL. Arthritis Rheumatol. 2022 Aug;74(8):1321-1332. doi: 10.1002/art.42153. Epub 2022 Jun 29. PMID: 35507355

mRNA vaccines induce rapid antibody responses in mice.
Gebre MS, Rauch S, Roth N, Gergen J, Yu J, Liu X, Cole AC, Mueller SO, Petsch B, Barouch DH. NPJ Vaccines. 2022 Aug 1;7(1):88. doi: 10.1038/s41541-022-00511-y. PMID: 35915094

Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T **vaccine** versus separate DTwP-HB-PRP∼T and IPV vaccines at 12-24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in India.
Mangarule S, Palkar S, Mitra M, Ravi MD, Singh R, Moureau A, Jayanth MV, Patel DM, Ravinuthala S, Patnaik BN, Jordanov E, Noriega F. Vaccine X. 2022 Jul 2;11:100190. doi: 10.1016/j.jvacx.2022.100190. eCollection 2022 Aug. PMID: 35899104

Will anti-**vaccine** activism in the USA reverse global goals?
Hotez PJ. Nat Rev Immunol. 2022 Aug 1:1-2. doi: 10.1038/s41577-022-00770-9. Online ahead of print. PMID: 35915141

Resolving adjuvant mode of action to enhance **vaccine** efficacy.
Turley JL, Lavelle EC. Curr Opin Immunol. 2022 Aug;77:102229. doi: 10.1016/j.coi.2022.102229. Epub 2022 Jun 29. PMID: 35779364

Sociopolitical and psychological correlates of COVID-19 **vaccine** hesitancy in the United States during summer 2021.
Stoler J, Klofstad CA, Enders AM, Uscinski JE. Soc Sci Med. 2022 Aug;306:115112. doi: 10.1016/j.socscimed.2022.115112. Epub 2022 Jun 6. PMID: 35700550

A **vaccine** for human babesiosis: prospects and feasibility.
Al-Nazal H, Low L, Kumar S, Good MF, Stanisic DI. Trends Parasitol. 2022 Aug 3:S1471-4922(22)00157-X. doi: 10.1016/j.pt.2022.07.005. Online ahead of print. PMID: 35933301

Development of virus-like particles-based vaccines against coronaviruses.
Yong CY, Liew WPP, Ong HK, Poh CL. Biotechnol Prog. 2022 Aug 5:e3292. doi: 10.1002/btpr.3292. Online ahead of print. PMID: 35932092

The Conflict of Public Health Law and Civil Liberties Part II: The **Vaccine** Mandates and What the Supreme Court Decided.
Harris CE. Am J Med. 2022 Aug;135(8):931-932. doi: 10.1016/j.amjmed.2022.02.030. Epub 2022 Mar 17. PMID: 35307356

Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.
Molica S, Tam C, Polliack A. Hematol Oncol. 2022 Aug;40(3):313-319. doi: 10.1002/hon.2990. Epub 2022 Mar 23. PMID: 35304771

Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults.
Loong D, Pham B, Amiri M, Saunders H, Mishra S, Radhakrishnan A, Rodrigues M, Yeung MW, Muller MP, Straus SE, Tricco AC, Isaranuwatchai W. Value Health. 2022 Aug;25(8):1439-1458. doi: 10.1016/j.jval.2022.03.011. Epub 2022 Jun 2. PMID: 35659487

Epigenetic adjuvants: durable reprogramming of the innate immune system with adjuvants.
Lee A, Wimmers F, Pulendran B. Curr Opin Immunol. 2022 Aug;77:102189. doi: 10.1016/j.coi.2022.102189. Epub 2022 May 16. PMID: 35588691

Trends in reporting embolic and thrombotic events after COVID-19 vaccination: A retrospective, pharmacovigilance study.
Kan Y, Asada M, Uesawa Y. PLoS One. 2022 Aug 1;17(8):e0269268. doi: 10.1371/journal.pone.0269268. eCollection 2022. PMID: 35913955

Exploring COVID-19 **Vaccine** Confidence with People from Black and Asian Backgrounds in England.
Eberhardt J, Ling J, Horsley L, Cunnett J, Fryer-Smith E, Lant J, Edwards S, Ross E. J Racial Ethn Health Disparities. 2022 Aug 1:1-11. doi: 10.1007/s40615-022-01372-w. Online ahead of print. PMID: 35913541
Hypertensive Crisis Following COVID-19 Vaccination.
Khani E, Entezari-Maleki T. J Clin Pharmacol. 2022 Aug;62(8):1047-1048. doi: 10.1002/jcph.2037. Epub 2022 Feb 27. PMID: 35147213

Vaccine pragmatism in the 21st century.
Keddy KH. Lancet Infect Dis. 2022 Aug;22(8):1097-1098. doi: 10.1016/S1473-3099(22)00181-5. Epub 2022 May 16. PMID: 35588756
Awareness of human papillomavirus and reported human papillomavirus **vaccine** uptake in a high-risk population.
Amboree TL, Montealegre JR, Padgett Wermuth P, Mgbere O, Fujimoto K, Darkoh C. Prev Med Rep. 2022 Jun 10;28:101853. doi: 10.1016/j.pmedr.2022.101853. eCollection 2022 Aug. PMID: 35733608

Evaluation of the Acceptance Rate of Covid-19 **Vaccine** and its Associated Factors: A Systematic Review and Meta-analysis.
Kazeminia M, Afshar ZM, Rajati M, Saeedi A, Rajati F. J Prev (2022). 2022 Aug;43(4):421-467. doi: 10.1007/s10935-022-00684-1. Epub 2022 Jun 10. PMID: 35687259

Adverse events following COVID-19 vaccination: A systematic review and meta-analysis.
Kouhpayeh H, Ansari H. Int Immunopharmacol. 2022 Aug;109:108906. doi: 10.1016/j.intimp.2022.108906. Epub 2022 May 30. PMID: 35671640

Vaccination Hesitancy and Conspiracy Beliefs in the UK During the SARS-COV-2 (COVID-19) Pandemic.
Bacon AM, Taylor S. Int J Behav Med. 2022 Aug;29(4):448-455. doi: 10.1007/s12529-021-10029-7. Epub 2021 Oct 1. PMID: 34599463

COVID **Vaccine** Information Sources Utilized by Female Healthcare Workers.
Paul MR, Raghuraman N, Carter EB, Odibo AO, Kelly JC, Foeller ME, Perez MJ. Am J Obstet Gynecol MFM. 2022 Aug 2:100704. doi: 10.1016/j.ajogmf.2022.100704. Online ahead of print. PMID: 35931368

The Genetic Basis of Sudden Death after Covid-19 Vaccination in Thailand.
Ittiwut C, Mahasirimongkol S, Srisont S, Ittiwut R, Chockjamsai M, Durongkadech P, Sawaengdee W, Khunphon A, Larpadisorn K, Wattanapokayakit S, Wetchaphanphesat S, Arunotong S, Srimahachota S, Pittayawonganon C, Thammawijaya P, Sutdan D, Doungngern P, Khongphatthanayothin A, Kerr SJ, Shotelersuk V. Heart Rhythm. 2022 Aug 4:S1547-5271(22)02266-4. doi: 10.1016/j.hrthm.2022.07.019. Online ahead of print. PMID: 35934244

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.
Tallantyre EC, Scurr MJ, Vickaryous N, Richards A, Anderson V, Baker D, Chance R, Evangelou N, George K, Giovannoni G, Harding KE, Hibbert A, Ingram G, Jolles S, Jones M, Kang AS, Loveless S, Moat SJ, Robertson NP, Rios F, Schmierer K, Willis M, Godkin A, Dobson R. Mult Scler Relat Disord. 2022 Aug;64:103937. doi: 10.1016/j.msard.2022.103937. Epub 2022 Jun 4. PMID: 35700625

Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya.
Orangi S, Ojal J, Brand SP, Orlendo C, Kairu A, Aziza R, Ogero M, Agweyu A, Warimwe GM, Uyoga S, Otieno E, Ochola-Oyier LI, Agoti CN, Kasera K, Amoth P, Mwangangi M, Aman R, Ng'ang'a W, Adetifa IM, Scott JAG, Bejon P, Keeling MJ, Flasche S, Nokes DJ, Barasa E. BMJ Glob Health. 2022 Aug;7(8):e009430. doi: 10.1136/bmjgh-2022-009430. PMID: 35914832

Effects of Covid-19 vaccination on different semen parameters.
Abd ZH, Muter SA, Saeed RAM, Ammar O. Basic Clin Androl. 2022 Aug 2;32(1):13. doi: 10.1186/s12610-022-00163-x. PMID: 35915409

National rates and disparities in childhood vaccination and **vaccine**-preventable disease during the COVID-19 pandemic: English sentinel network retrospective database study.
Hoang U, de Lusignan S, Joy M, Sherlock J, Williams J, Bankhead C, Howsam G, Thomas M, Snape MD, Hobbs FDR, Pollard AJ. Arch Dis Child. 2022 Aug;107(8):733-739. doi: 10.1136/archdischild-2021-323630. Epub 2022 Mar 31. PMID: 35361613

Vaccination policies for healthcare personnel: Current challenges and future perspectives.
Maltezou HC, Dounias G, Rapisarda V, Ledda C. Vaccine X. 2022 May 31;11:100172. doi: 10.1016/j.jvacx.2022.100172. eCollection 2022 Aug. PMID: 35719325

Determinants of seasonal influenza vaccination hesitancy among healthcare personnel: An integrative review.
Hall CM, Northam H, Webster A, Strickland K. J Clin Nurs. 2022 Aug;31(15-16):2112-2124. doi: 10.1111/jocn.16103. Epub 2021 Oct 29. PMID: 34716635

"Intention to receive COVID-19 **vaccine** among healthcare workers: a comparison between two surveys".
Meysamie A, Ghasemi E, Moshksar S, Askarian M. BMC Health Serv Res. 2022 Aug 1;22(1):982. doi: 10.1186/s12913-022-08379-3. PMID: 35915483

Global Epidemiology of **Vaccine**-preventable Bacterial Meningitis.
Syrogiannopoulos GA, Michoula AN, Grivea IN. Pediatr Infect Dis J. 2022 Aug 5. doi: 10.1097/INF.0000000000003629. Online ahead of print. PMID: 35895889

Antibody responses and correlates after two and three doses of BNT162b2 COVID-19 **vaccine**.
Yamamoto S, Tanaka A, Oshiro Y, Inamura N, Mizoue T, Ohmagari N; for SARS-CoV-2 Seroepidemiological Study among NCGM staff. Infection. 2022 Aug 4:1-3. doi: 10.1007/s15010-022-01898-5. Online ahead of print. PMID: 35925506

Adolescents with ADHD are at increased risk for COVID-19 **vaccine** hesitancy.
Dvorsky MR, Breaux R, Langberg JM, Becker SP. J Psychiatr Res. 2022 Aug;152:25-30. doi: 10.1016/j.jpsychires.2022.06.005. Epub 2022 Jun 9. PMID: 35714550

Association of caregiver attitudes with adolescent HPV vaccination in 13 southern US states.
Vasudevan L, Ostermann J, Wang Y, Harrison SE, Yelverton V, Fish LJ, Williams C, Walter EB. Vaccine X. 2022 Jun 15;11:100181. doi: 10.1016/j.jvacx.2022.100181. eCollection 2022 Aug. PMID: 35789674

Knowledge, Attitudes and Behaviors of Women who have or have not had human papillomavirus **vaccine** in Turkey about the Virus and the **vaccine**.
Agadayi E, Karademir D, Karahan S. J Community Health. 2022 Aug;47(4):650-657. doi: 10.1007/s10900-022-01089-1. Epub 2022 Apr 27. PMID: 35476168

Stakeholders' perspectives on system-level barriers to and facilitators of HPV vaccination among Hispanic migrant farmworkers.
Vamos CA, Kline N, Vázquez-Otero C, Lockhart EA, Lake PW, Wells KJ, Proctor S, Meade CD, Daley EM. Ethn Health. 2022 Aug;27(6):1442-1464. doi: 10.1080/13557858.2021.1887820. Epub 2021 Mar 18. PMID: 33733962

COVID-19 Vaccination Intent and Belief that Vaccination Will End the Pandemic.
de Vries M, Claassen L, Lambooij M, Leung KY, Boersma K, Timen A. Emerg Infect Dis. 2022 Aug;28(8):1642-1649. doi: 10.3201/eid2808.212556. Epub 2022 Jul 7. PMID: 35797995

Persistence of **Vaccine** Hesitancy and Acceptance of the EU Covid Certificate Among French Students.
Chamon Q, Govindin Ramassamy K, Rahis AC, Guignot L, Tzourio C, Montagni I. J Community Health. 2022 Aug;47(4):666-673. doi: 10.1007/s10900-022-01092-6. Epub 2022 May 5. PMID: 35513757 Free PMC article.

Efficacy and safety of mRNA SARS-CoV-2 vaccines in lung transplant recipients.
Hirama T, Akiba M, Shundo Y, Watanabe T, Watanabe Y, Oishi H, Niikawa H, Okada Y. J Infect Chemother. 2022 Aug;28(8):1153-1158. doi: 10.1016/j.jiac.2022.04.019. Epub 2022 May 17. PMID: 35599079

Racial/ethnic and nativity disparities in U.S. Covid-19 vaccination hesitancy during **vaccine** rollout and factors that explain them.
Frisco ML, Van Hook J, Thomas KJA. Soc Sci Med. 2022 Aug;307:115183. doi: 10.1016/j.socscimed.2022.115183. Epub 2022 Jun 30. PMID: 35843179

The impact of pausing the Oxford-AstraZeneca COVID-19 **vaccine** on uptake in Europe: a difference-in-differences analysis.
Jain V, Lorgelly P. Eur J Public Health. 2022 Aug 1;32(4):648-654. doi: 10.1093/eurpub/ckac039. PMID: 35394507

Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review.
Napuri NI, Curcio D, Swerdlow DL, Srivastava A. Infect Dis Ther. 2022 Aug;11(4):1391-1414. doi: 10.1007/s40121-022-00648-2. Epub 2022 May 25. PMID: 35614299

Predictors of seroconversion after coronavirus disease 2019 vaccination.
Chiarella SE, Jenkins SM, Smith CY, Prasad V, Shakuntulla F, Ahluwalia V, Iyer VN, Theel ES, Joshi AY. Ann Allergy Asthma Immunol. 2022 Aug;129(2):189-193. doi: 10.1016/j.anai.2022.05.026. Epub 2022 May 28. PMID: 35640775

A Cohort Study on Influenza **Vaccine** and All-Cause Mortality in Older Adults: Methodological Concerns and Public Health Implications.
Lapi F, Marconi E, Gualano MR, Vetrano DL, Grattagliano I, Rossi A, Cricelli C. Drugs Aging. 2022 Aug;39(8):645-656. doi: 10.1007/s40266-022-00958-7. Epub 2022 Jul 21. PMID: 35867212

COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations.
Jutel M, Torres MJ, Palomares O, Akdis CA, Eiwegger T, Untersmayr E, Barber D, Zemelka-Wiacek M, Kosowska A, Palmer E, Vieths S, Mahler V, Canonica WG, Nadeau K, Shamji MH, Agache I. Allergy. 2022 Aug;77(8):2313-2336. doi: 10.1111/all.15252. Epub 2022 Mar 18. PMID: 35147230

How to best handle **vaccine** decliners: scientific facts and psychological approach.
Xantus GZ, Burke D, Kanizsai P. Postgrad Med J. 2022 Aug;98(1162):626-632. doi: 10.1136/postgradmedj-2021-139835. Epub 2021 Apr 9. PMID: 33837130

Politics of COVID-19 **vaccine** mandates: Left/right-wing authoritarianism, social dominance orientation, and libertarianism.
Peng Y. Pers Individ Dif. 2022 Aug;194:111661. doi: 10.1016/j.paid.2022.111661. Epub 2022 Apr 11. PMID: 35431382

Parents' perceptions on COVID-19 vaccination as the new routine for their children ≤ 11 years old.
Humble RM, Sell H, Wilson S, Sadarangani M, Bettinger JA, Meyer SB, Dubé È, Lemaire-Paquette S, Gagneur A, MacDonald SE. Prev Med. 2022 Aug;161:107125. doi: 10.1016/j.ypmed.2022.107125. Epub 2022 Jul 2. PMID: 35792197

Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial.
Li J, Hui AM, Zhang X, Ge L, Qiu Y, Tang R, Ye H, Wang X, Lin M, Zhu Z, Zheng J, Qiu J, Lagkadinou E, Shpyro S, Ozhelvaci O, Türeci Ö, Khondker Z, Yin W, Shishkova Y, Jia S, Pan H, Peng F, Ma Z, Wu Z, Guo X, Shi Y, Muik A, Şahin U, Zhu L, Zhu F. Adv Ther. 2022 Aug;39(8):3789-3798. doi: 10.1007/s12325-022-02206-1. Epub 2022 Jun 30. PMID: 35771353

Phylogenetic analysis of porcine reproductive and respiratory syndrome virus in Vietnam, 2021.
Nguyen NH, Tran HAT, Nguyen TQ, Nguyen PBT, Le THT, Lai DC, Nguyen MN. Virus Genes. 2022 Aug;58(4):361-366. doi: 10.1007/s11262-022-01912-w. Epub 2022 May 19. PMID: 35589912

COVID-19 Vaccines in Older Adults: Challenges in **Vaccine** Development and Policy Making.
Liang CK, Lee WJ, Peng LN, Meng LC, Hsiao FY, Chen LK. Clin Geriatr Med. 2022 Aug;38(3):605-620. doi: 10.1016/j.cger.2022.03.006. Epub 2022 Mar 21. PMID: 35868676

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA **vaccine**.
Zeng G. Lancet Microbe. 2022 Aug;3(8):e561. doi: 10.1016/S2666-5247(22)00150-1. Epub 2022 May 31. PMID: 35659883

Safety and immunogenicity of a trivalent virus-like particle **vaccine** against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.
Coates EE, Edupuganti S, Chen GL, Happe M, Strom L, Widge A, Florez MB, Cox JH, Gordon I, Plummer S, Ola A, Yamshchikov G, Andrews C, Curate-Ingram S, Morgan P, Nagar S, Collins MH, Bray A, Nguyen T, Stein J, Case CL, Kaltovich F, Wycuff D, Liang CJ, Carlton K, Vazquez S, Mascola JR, Ledgerwood JE; VRC 313 Study Team. Lancet Infect Dis. 2022 Aug;22(8):1210-1220. doi: 10.1016/S1473-3099(22)00052-4. Epub 2022 May 11. PMID: 35568049

Recent advances to accelerate purification process development: A review with a focus on vaccines.
Keulen D, Geldhof G, Bussy OL, Pabst M, Ottens M. J Chromatogr A. 2022 Aug 2;1676:463195. doi: 10.1016/j.chroma.2022.463195. Epub 2022 Jun 2. PMID: 35749985

COVID-19 infection, and reinfection, and **vaccine** effectiveness against symptomatic infection among health care workers in the setting of omicron variant transmission in New Delhi, India.
Malhotra S, Mani K, Lodha R, Bakhshi S, Mathur VP, Gupta P, Kedia S, Sankar MJ, Kumar P, Kumar A, H V, Ahuja V, Sinha S, Guleria R, Dua A, Ahmad S, Upadhyay AD, Sati HC, Mani K, Lokade AK, Devi KP, Johnson RM, Gowthaman K, Kumari M, Singh R, Kalra D, Swetambri, Vasudha, Sharma S, Singh A, Sharma V, Kanswal S, Sharma R, Giri T, Rajput S, Mehra G, Sharma A, Madan D, Singh M, Gupta A, Sharma S, Sachdeva S, Kumar M, Sachin, Singh AK, Gohar N, Kumar R, Kanojia N, Singhania J, Dubey R, Shukla S, G A, Sarkar S, Gupta I, Rai S, Tummala S, Reddy T, Vadodaria V, Sharma A, Gupta A, Vats M, Deori TJ, Jaiswal A, Pandit S. Lancet Reg Health Southeast Asia. 2022 Aug;3:100023. doi: 10.1016/j.lansea.2022.100023. Epub 2022 Jun 6. PMID: 35769163

The Omicron wave and the waning of COVID-19 **vaccine** effectiveness. Influence of **vaccine** booster and age on confirmed infection incidence.
Corral-Gudino L, Del-Amo-Merino MP, Eiros-Bouza JM, García-Cruces-Méndez JF, Domínguez-Gil González M. Eur J Intern Med. 2022 Aug;102:122-124. doi: 10.1016/j.ejim.2022.05.025. Epub 2022 May 26. PMID: 35641361

Evaluation of the Attitude of Parents in Pediatric Oncology Towards COVID-19 **Vaccine**.
Kilci C, Fettah A, Çapkinoğlu E, Kurucu B, Ünüvar Gök Ş, Yeşil Ş, Berber Hamamci M, Şahin G. J Pediatr Hematol Oncol. 2022 Aug 3. doi: 10.1097/MPH.0000000000002516. Online ahead of print. PMID: 35917148

Time of day of vaccination does not relate to antibody response to thymus-independent vaccinations.
Whittaker AC, Gallagher S, Drayson M. Vaccine X. 2022 Jun 13;11:100178. doi: 10.1016/j.jvacx.2022.100178. eCollection 2022 Aug. PMID: 35719326

COVID-19 booster **vaccine** attitudes and behaviors among university students and staff in the United States: The USC Trojan pandemic research Initiative.
Lee RC, Hu H, Kawaguchi ES, Kim AE, Soto DW, Shanker K, Klausner JD, Van Orman S, Unger JB. Prev Med Rep. 2022 Aug;28:101866. doi: 10.1016/j.pmedr.2022.101866. Epub 2022 Jun 27. PMID: 35785408

Microtiter Plate-Based Differential Scanning Fluorimetry: A High-Throughput Method for Efficient Formulation Development.
Nie M, Liu Y, Huang X, Zhang Z, Zhao Q. J Pharm Sci. 2022 Aug;111(8):2397-2403. doi: 10.1016/j.xphs.2022.05.015. Epub 2022 May 20. PMID: 35605687

A century of attempts to develop an effective tuberculosis **vaccine**: Why they failed?
Soleimanpour S, Yaghoubi A, Sadat Seddighinia F, Rezaee SAR. Int Immunopharmacol. 2022 Aug;109:108791. doi: 10.1016/j.intimp.2022.108791. Epub 2022 Apr 26. PMID: 35487086

Signaling differences in peripheral blood mononuclear cells of high and low **vaccine** responders prior to, and following, vaccination in piglets.
Lipsit S, Facciuolo A, Scruten E, Wilkinson J, Plastow G, Kusalik A, Napper S. Vaccine X. 2022 May 9;11:100167. doi: 10.1016/j.jvacx.2022.100167. eCollection 2022 Aug. PMID: 35692279

Stabilizing vaccines via drying: Quality by design considerations.
Ghaemmaghamian Z, Zarghami R, Walker G, O'Reilly E, Ziaee A. Adv Drug Deliv Rev. 2022 Aug;187:114313. doi: 10.1016/j.addr.2022.114313. Epub 2022 May 19. PMID: 35597307

Coping with COVID-19: Survey data assessing psychological distress to COVID-19 and **vaccine** hesitancy with measures of theory of planned behavior, mindfulness, compassion, cultural orientation, and pandemic fatigue.
Mueller EA, Suvanbenjakule P, Lim CX, O'Brien WH, Chavanovanich J, Jarukasemthawee S, Pisitsungkagarn K, Suavansri P. Data Brief. 2022 Aug;43:108390. doi: 10.1016/j.dib.2022.108390. Epub 2022 Jun 14. PMID: 35721375

The durability of natural infection and **vaccine**-induced immunity against future infection by SARS-CoV-2.
Townsend JP, Hassler HB, Sah P, Galvani AP, Dornburg A. Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2204336119. doi: 10.1073/pnas.2204336119. Epub 2022 Jul 15. PMID: 35858382 Free

Assessing COVID-19 **Vaccine**'s Acceptability Amongst Health Care Workers in Oman: A cross-sectional study.
Awaidy STA, Al Siyabi H, Khatiwada M, Al Siyabi A, Al Mukhaini S, Dochez C, Giron DM, Langrial SU, Mahomed O. J Infect Public Health. 2022 Aug;15(8):906-914. doi: 10.1016/j.jiph.2022.06.005. Epub 2022 Jun 16. PMID: 35870324

Vaccines for healthcare associated infections without **vaccine** prevention to date.
Amandine GB, Gagnaire J, Pelissier C, Philippe B, Elisabeth BN. Vaccine X. 2022 May 5;11:100168. doi: 10.1016/j.jvacx.2022.100168. eCollection 2022 Aug. PMID: 35600984

Adjuvanted recombinant zoster **vaccine** in solid organ transplant and hematopoietic stem-cell transplant recipients.
Provost-Olewczynska JX, Eberhardt CS. Curr Opin Infect Dis. 2022 Aug 1;35(4):312-320. doi: 10.1097/QCO.0000000000000845. Epub 2022 Jul 5. PMID: 35849521

Brief Motivational Interviewing: Evaluation of a skills-based education program.
Arnett MC, Evans MD, Stull CL. J Dent Hyg. 2022 Aug;96(4):46-56. PMID: 35906078

COVID-19 **vaccine** hesitancy amongst healthcare workers: An assessment of its magnitude and determinants during the initial phase of national **vaccine** deployment in Nigeria.
Nomhwange T, Wariri O, Nkereuwem E, Olanrewaju S, Nwosu N, Adamu U, Danjuma E, Onuaguluchi N, Enegela J, Nomhwange E, Jean Baptiste AE, Mulombo WK. EClinicalMedicine. 2022 Jun 25;50:101499. doi: 10.1016/j.eclinm.2022.101499. eCollection 2022 Aug. PMID: 35770256

Interventions to increase COVID-19 **vaccine** uptake: a scoping review.
Andreas M, Iannizzi C, Bohndorf E, Monsef I, Piechotta V, Meerpohl JJ, Skoetz N. Cochrane Database Syst Rev. 2022 Aug 3;8(8):CD015270. doi: 10.1002/14651858.CD015270. PMID: 35920693

Effects of exposure to per- and polyfluoroalkyl substances on **vaccine** antibodies: A systematic review and meta-analysis based on epidemiological studies.
Zhang X, Xue L, Deji Z, Wang X, Liu P, Lu J, Zhou R, Huang Z. Environ Pollut. 2022 Aug 1;306:119442. doi: 10.1016/j.envpol.2022.119442. Epub 2022 May 11. PMID: 35568291

New onset of psoriasis following COVID-19 vaccination.
Tran TNA, Nguyen TTP, Pham NN, Pham NTU, Vu TTP, Nguyen HT. Dermatol Ther. 2022 Aug;35(8):e15590. doi: 10.1111/dth.15590. Epub 2022 May 26. PMID: 35583958

Humoral immune response of BBIBP COVID-19 vaccination before and after the booster immunization.
Cheng ZJ, Huang H, Zheng P, Xue M, Ma J, Zhan Z, Gan H, Zeng Y, Lin R, Li S, Zhong R, Li S, Wang H, Sun B. Allergy. 2022 Aug;77(8):2404-2414. doi: 10.1111/all.15271. Epub 2022 Mar 16. PMID: 35255171

HPV **vaccine** recommendation practices of current and future physicians in North Carolina: an exploratory study.
Richman AR, Torres E, Wu Q, Eldridge D, Lawson L. Health Educ Res. 2022 Aug 1;37(4):213-226. doi: 10.1093/her/cyac016. PMID: 35788319

Exploring chitosan-shelled nanobubbles to improve HER2 + immunotherapy via dendritic cell targeting.
Argenziano M, Occhipinti S, Scomparin A, Angelini C, Novelli F, Soster M, Giovarelli M, Cavalli R. Drug Deliv Transl Res. 2022 Aug;12(8):2007-2018. doi: 10.1007/s13346-022-01185-8. Epub 2022 Jun 7. PMID: 35672651

Development and evaluation of temperature-sensitive *Mycoplasma anserisalpingitidis* clones as **vaccine** candidates.
Bekő K, Grózner D, Mitter A, Udvari L, Földi D, Wehmann E, Kovács ÁB, Domán M, Bali K, Bányai K, Gyuris É, Thuma Á, Kreizinger Z, Gyuranecz M. Avian Pathol. 2022 Aug 9:1-15. doi: 10.1080/03079457.2022.2102967. Online ahead of print. PMID: 35866306

Heterologous prime-boost vaccination programs against Newcastle disease virus genotype VII in chickens.
Sedeik ME, Awad AM, El-Shall NA. Comp Immunol Microbiol Infect Dis. 2022 Aug;87:101836. doi: 10.1016/j.cimid.2022.101836. Epub 2022 Jun 1. PMID: 35700555

Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey.
Ellul P, Revés J, Abreu B, Chaparro M, Gisbert JP, Allocca M, Fiorino G, Barberio B, Zingone F, Pisani A, Cassar D, Michalopoulos G, Mantzaris G, Koutroubakis I, Karmiris K, Katsanos K, Ďuricova D, Burisch J,

Madsen GR, Maaser C, Naila A, Orfanoudaki E, Milivojevic V, Buisson A, Avedano L, Leone S, Torres J. J Crohns Colitis. 2022 Aug 4;16(7):1070-1078. doi: 10.1093/ecco-jcc/jjac010. PMID: 35037033

Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein.
Lim H, Kim SE, Lee YH, Hwang YH, Kim SH, Kim MY, Chung GT, Kim YJ, Kim D, Lee JA. Virology. 2022 Aug;573:118-123. doi: 10.1016/j.virol.2022.06.006. Epub 2022 Jun 10. PMID: 35751974

New-onset Graves' disease following SARS-CoV-2 vaccination: a case report.
Manta R, Martin C, Muls V, Poppe KG. Eur Thyroid J. 2022 Jul 19;11(4):e220049. doi: 10.1530/ETJ-22-0049. Print 2022 Aug 1. PMID: 35900872

Pneumonia Frequency and Severity in Patients With Symptomatic COVID-19: Impact of mRNA and Adenovirus Vector Vaccines.
Vicini S, Bellini D, Iannarelli A, Rengo M, Pelle G, Ruggiero S, Fusco M, Ambrogi C, Carbone I. AJR Am J Roentgenol. 2022 Aug 10:1-10. doi: 10.2214/AJR.22.27843. Online ahead of print. PMID: 35642761

Antibody response after a booster dose of BNT162B2mRNA and inactivated COVID-19 **vaccine**.
Yigit M, Ozkaya-Parlakay A, Cosgun Y, Ince YE, Kalayci F, Yilmaz N, Senel E. J Clin Virol Plus. 2022 Aug;2(3):100094. doi: 10.1016/j.jcvp.2022.100094. Epub 2022 Jun 30. PMID: 35789553

Applying high throughput and comprehensive immunoinformatics approaches to design a trivalent subunit **vaccine** for induction of immune response against emerging human coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2.
Rahmani A, Baee M, Saleki K, Moradi S, Nouri HR. J Biomol Struct Dyn. 2022 Aug;40(13):6097-6113. doi: 10.1080/07391102.2021.1876774. Epub 2021 Jan 29. PMID: 33509045

COVID-19 **vaccine** side effects among nursing home residents and staff.
Bhatnagar S, Jones K, Montoya A. J Med Virol. 2022 Aug;94(8):3491-3493. doi: 10.1002/jmv.27756. Epub 2022 Apr 12. PMID: 35365909

COVID-19 **vaccine** hesitancy among low-income, racially and ethnically diverse US parents.
Schilling S, Orr CJ, Delamater AM, Flower KB, Heerman WJ, Perrin EM, Rothman RL, Yin HS, Sanders L. Patient Educ Couns. 2022 Aug;105(8):2771-2777. doi: 10.1016/j.pec.2022.03.023. Epub 2022 Mar 30. PMID: 35393230

Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
Nam M, Yun SG, Kim SW, Kim CG, Cha JH, Lee C, Kang S, Park SG, Kim SB, Lee KB, Chung YS, Nam MH, Lee CK, Cho Y. Microbiol Spectr. 2022 Aug 10:e0249521. doi: 10.1128/spectrum.02495-21. Online ahead of print. PMID: 35946811

Knowledge about COVID-19 and **vaccine** acceptability among priority groups defined for vaccination: A cross-sectional study in Araba/Alava, Spain, before the vaccination against SARS-CoV-2.
Parraza-Diez N, Bermudez-Ampudia C, Cobos-Campos R, Garmendia I, Orruño E, Ojeda E, Garitano I, Robledo M, Portu JJ, Apiñaniz A. Vaccine X. 2022 Aug;11:100176. doi: 10.1016/j.jvacx.2022.100176. Epub 2022 Jun 6. PMID: 35692459

Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species.
Peng L, Fang Z, Renauer PA, McNamara A, Park JJ, Lin Q, Zhou X, Dong MB, Zhu B, Zhao H, Wilen CB, Chen S. Cell Rep. 2022 Aug 2;40(5):111160. doi: 10.1016/j.celrep.2022.111160. Epub 2022 Jul 19. PMID: 35921835

The impact of politics, religion, and rurality on COVID-19 **vaccine** hesitancy in Oregon: a cross-sectional study.
Morrison T. Rural Remote Health. 2022 Aug;22(3):7140. doi: 10.22605/RRH7140. Epub 2022 Aug 1. PMID: 35909220

Medical Mistrust, Perceived Discrimination, and Race: a Longitudinal Analysis of Predictors of COVID-19 **Vaccine** Hesitancy in US Adults.
Morgan KM, Maglalang DD, Monnig MA, Ahluwalia JS, Avila JC, Sokolovsky AW. J Racial Ethn Health Disparities. 2022 Aug 1:1-10. doi: 10.1007/s40615-022-01368-6. Online ahead of print. PMID: 35913543

Characteristics associated with serological COVID-19 **vaccine** response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study.
Søgaard OS, Reekie J, Johansen IS, Nielsen H, Benfield T, Wiese L, Stærke NB, Iversen K, Fogh K, Bodilsen J, Iversen M, Knudsen LS, Klastrup V, Larsen FD, Andersen SD, Hvidt AK, Andreasen SR, Madsen LW, Lindvig SO, Øvrehus A, Ostrowski SR, Abildgaard C, Matthews C, Jensen TO, Raben D, Erikstrup C, Fischer TK, Tolstrup M, Østergaard L, Lundgren J; ENFORCE Writing Group. Clin Microbiol Infect. 2022 Aug;28(8):1126-1133. doi: 10.1016/j.cmi.2022.03.003. Epub 2022 Mar 11. PMID: 35283313

Efficacy, safety and immunogenicity of hexavalent rotavirus **vaccine** in Chinese infants.
Wu Z, Li Q, Liu Y, Lv H, Mo Z, Li F, Yu Q, Jin F, Chen W, Zhang Y, Huang T, Hu X, Xia W, Gao J, Zhou H, Bai X, Liu Y, Liang Z, Jiang Z, Chen Y, Zhang J, Du J, Yang B, Xing B, Xing Y, Dong B, Yang Q, Shi C, Yan T, Ruan B, Shi H, Fan X, Feng D, Lv W, Zhang D, Kong X, Zhou L, Que D, Chen H, Chen Z, Guo X, Zhou W, Wu C, Zhou Q, Liu Y, Qiao J, Wang Y, Li X, Duan K, Zhao Y, Yang X, Xu G. Virol Sin. 2022 Aug 1:S1995-820X(22)00135-3. doi: 10.1016/j.virs.2022.07.011. Online ahead of print. PMID: 35926726

Factors associated with human papillomavirus and meningococcal vaccination among adolescents living in rural and urban areas.
Boyce TG, Christianson B, Hanson KE, Dunn D, Polter E, VanWormer JJ, Williams CL, Belongia EA, McLean HQ. Vaccine X. 2022 Jun 11;11:100180. doi: 10.1016/j.jvacx.2022.100180. eCollection 2022 Aug. PMID: 35755142

Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years.
Hause AM, Shay DK, Klein NP, Abara WE, Baggs J, Cortese MM, Fireman B, Gee J, Glanz JM, Goddard K, Hanson KE, Hugueley B, Kenigsberg T, Kharbanda EO, Lewin B, Lewis N, Marquez P, Myers T, Naleway A, Nelson JC, Su JR, Thompson D, Olubajo B, Oster ME, Weintraub ES, Williams JTB, Yousaf AR, Zerbo O, Zhang B, Shimabukuro TT. Pediatrics. 2022 Aug 1;150(2):e2022057313. doi: 10.1542/peds.2022-057313. PMID: 35581698

Forming and updating vaccination beliefs: does the continued effect of misinformation depend on what we think we know?
Pluviano S, Watt C, Pompéia S, Ekuni R, Della Sala S. Cogn Process. 2022 Aug;23(3):367-378. doi: 10.1007/s10339-022-01093-2. Epub 2022 May 18. PMID: 35583578

Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages.
Huang WC, Mabrouk MT, Zhou L, Baba M, Tachibana M, Torii M, Takashima E, Locke E, Plieskatt J, King CR, Coelho CH, Duffy PE, Long C, Tsuboi T, Miura K, Wu Y, Ishino T, Lovell JF. Commun Biol. 2022 Aug 1;5(1):773. doi: 10.1038/s42003-022-03688-z. PMID: 35915227

Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and **vaccine** recipients.
Hagemann K, Riecken K, Jung JM, Hildebrandt H, Menzel S, Bunders MJ, Fehse B, Koch-Nolte F, Heinrich F, Peine S, Schulze Zur Wiesch J, Brehm TT, Addo MM, Lütgehetmann M, Altfeld M. Eur J Immunol. 2022 Aug;52(8):1297-1307. doi: 10.1002/eji.202149470. Epub 2022 Apr 22. PMID: 35416291

Critical success factors for routine immunization performance: A case study of Zambia 2000 to 2018.
Micek K, Hester KA, Chanda C, Darwar R, Dounebaine B, Ellis AS, Keskinocak P, Leslie A, Manyando M, Sililo Manyando M, Nazzal D, Awino Ogutu E, Sakas Z, Castillo-Zunino F, Kilembe W, Bednarczyk RA, Freeman MC; Vaccine Exemplars Research Consortium. Vaccine X. 2022 Apr 30;11:100166. doi: 10.1016/j.jvacx.2022.100166. eCollection 2022 Aug. PMID: 35707220

Associations of BMI with COVID-19 **vaccine** uptake, **vaccine** effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study.
Piernas C, Patone M, Astbury NM, Gao M, Sheikh A, Khunti K, Shankar-Hari M, Dixon S, Coupland C, Aveyard P, Hippisley-Cox J, Jebb SA. Lancet Diabetes Endocrinol. 2022 Aug;10(8):571-580. doi: 10.1016/S2213-8587(22)00158-9. Epub 2022 Jul 1. PMID: 35780805

Contributions of Trustworthiness, Health Literacy, and Self-Efficacy in Communicating With COVID-19 **Vaccine**-Hesitant Audiences: Web-Based Survey Study.
Weerakoon SM, Henson-Garcia M, Valerio-Shewmaker MA, Messiah SE, Knell G. JMIR Form Res. 2022 Aug 1;6(8):e38076. doi: 10.2196/38076. PMID: 35878123

Learning from maternal voices on COVID-19 **vaccine** uptake: Perspectives from pregnant women living in the Midwest on the COVID-19 pandemic and **vaccine**.
Redmond ML, Mayes P, Morris K, Ramaswamy M, Ault KA, Smith SA. J Community Psychol. 2022 Aug;50(6):2630-2643. doi: 10.1002/jcop.22851. Epub 2022 Apr 13. PMID: 35419848

Repeated-Dose Toxicity, Biodistribution, and Shedding Assessments With a ChAd155 Respiratory Syncytial Virus **Vaccine** Candidate Evaluated in Rabbits and Rats.
Stokes AH, Planty C, Pion J, Ancian P, Rogue A, Bansard C, Silvano J, Papineau D, Ben Abdeljelil N, Maruggi G, Song H, Spickler C, Blouin K, Dubois G, Rodriguez LA, Baumeister J, Steff AM, Destexhe E. Int J Toxicol. 2022 Aug;41(4):263-275. doi: 10.1177/10915818221101788. Epub 2022 Jun 2. PMID: 35653115

Why we should not 'just use age' for COVID-19 **vaccine** prioritisation.
Smith MJ. J Med Ethics. 2022 Aug;48(8):538-541. doi: 10.1136/medethics-2021-107443. Epub 2021 Jul 9. PMID: 34244345

Determinants of COVID-19 **vaccine** acceptability among older adults living with HIV.
Davtyan M, Frederick T, Taylor J, Christensen C, Brown BJ, Nguyen AL. Medicine (Baltimore). 2022 Aug 5;101(31):e29907. doi: 10.1097/MD.0000000000029907. PMID: 35945741

COVID-19 Pandemic and Im/migrants' Elevated Health Concerns in Canada: **Vaccine** Hesitancy, Anticipated Stigma, and Risk Perception of Accessing Care.
Lin S. J Immigr Minor Health. 2022 Aug;24(4):896-908. doi: 10.1007/s10903-022-01337-5. Epub 2022 Feb 25. PMID: 35212825

Induction of T- and NK-cell Activity Improves Cancer **Vaccine** Efficacy.
[No authors listed] Cancer Discov. 2022 Aug 5;12(8):OF9. doi: 10.1158/2159-8290.CD-RW2022-102. PMID: 35657607

Development and Validation of a Performance Assessment Checklist Scale for **Vaccine** Administration.
Fujikawa H, Mitsuyama T, Son D, Izumiya M, Eto M. Intern Med. 2022 Aug 1;61(15):2295-2300. doi: 10.2169/internalmedicine.9268-21. Epub 2022 May 21. PMID: 35598994

Long-term clinical course and prognosis of **vaccine**-related persistent itching nodules (1997-2019): An observational study.
Lidholm AG, Inerot A, Gillstedt M, Bergfors E, Trollfors B. Vaccine X. 2022 Apr 29;11:100163. doi: 10.1016/j.jvacx.2022.100163. eCollection 2022 Aug. PMID: 35600985

Human Adenovirus Type 26 Infection Mediated by αvβ3 Integrin Is Caveolin-1-Dependent.
Nestić D, Custers J, Švec D, Majhen D. Microbiol Spectr. 2022 Aug 4:e0109722. doi: 10.1128/spectrum.01097-22. Online ahead of print. PMID: 35924932

Engineering a novel immunogenic chimera protein utilizing bacterial infections associated with atherosclerosis to induce a deviation in adaptive immune responses via Immunoinformatics approaches.
Saleki K, Alijanizade P, Moradi S, Rahmani A, Banazadeh M, Mohamadi MH, Shahabi F, Nouri HR. Infect Genet Evol. 2022 Aug;102:105290. doi: 10.1016/j.meegid.2022.105290. Epub 2022 May 12. PMID: 35568333

CoronaVac or BNT162b2 **Vaccine** as a Third Dose.
Mungmunpuntipantip R, Wiwanitkit V. Am J Respir Crit Care Med. 2022 Aug 1;206(3):360-361. doi: 10.1164/rccm.202201-0077LE. PMID: 35561336

Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S **vaccine** in humans.
Cho A, Muecksch F, Wang Z, Ben Tanfous T, DaSilva J, Raspe R, Johnson B, Bednarski E, Ramos V, Schaefer-Babajew D, Shimeliovich I, Dizon JP, Yao KH, Schmidt F, Millard KG, Turroja M, Jankovic M, Oliveira TY, Gazumyan A, Gaebler C, Caskey M, Hatziioannou T, Bieniasz PD, Nussenzweig MC. J Exp Med. 2022 Aug 1;219(8):e20220732. doi: 10.1084/jem.20220732. Epub 2022 Jul 1. PMID: 35776090

Symmetrical drug-related intertriginous and flexural exanthema-like eruption after COVID-19 **vaccine**.
Lahouel I, Ben Salah N, Ben Fadhel N, Chahed F, Ouni N, Belhadjali H, Aouam K, Zili J. J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e597-e599. doi: 10.1111/jdv.18108. Epub 2022 Apr 1. PMID: 35344627

COVID-19: Perceived Infection Risk and Barriers to Uptake of Pfizer-BioNTech and Moderna Vaccines Among Community Healthcare Workers.
Famuyiro TB, Ogunwale A, des Bordes J, Raji M. J Racial Ethn Health Disparities. 2022 Aug;9(4):1543-1549. doi: 10.1007/s40615-021-01093-6. Epub 2021 Jul 15. PMID: 34264506

Network methods and design of randomized trials: Application to investigation of COVID-19 vaccination boosters.
DeGruttola V, Goyal R, Martin NK, Wang R. Clin Trials. 2022 Aug;19(4):363-374. doi: 10.1177/17407745221111818. Epub 2022 Jul 27. PMID: 35894099

Fielding vaccines-challenges and opportunities in outbreaks, complex emergencies, and mass gatherings.
Fischer LJ, Rains RC, Brett-Major SM, Senga M, Holden D, Brett-Major DM. Hum Vaccin Immunother. 2022 Aug 5:2104500. doi: 10.1080/21645515.2022.2104500. Online ahead of print. PMID: 35930505

In-silico design of an immunoinformatics based multi-epitope **vaccine** against Leishmania donovani.
Saha S, Vashishtha S, Kundu B, Ghosh M. BMC Bioinformatics. 2022 Aug 5;23(1):319. doi: 10.1186/s12859-022-04816-6. PMID: 35931960

Vaccination strategies for Korean patients with inflammatory bowel disease.
Lee YJ, Kim ES. Korean J Intern Med. 2022 Aug 8. doi: 10.3904/kjim.2022.149. Online ahead of print. PMID: 35934888

Bacterial meningitis: Aetiology, risk factors, disease trends and severe sequelae during 50 years in Sweden.
Block N, Naucler P, Wagner P, Morfeldt E, Henriques-Normark B. J Intern Med. 2022 Aug;292(2):350-364. doi: 10.1111/joim.13488. Epub 2022 Apr 3. PMID: 35340067

Effectiveness of COVID-19 vaccines against Omicron variant.
de Oliveira Campos DM, da Silva MK, Silva de Oliveira CB, Fulco UL, Nobre Oliveira JI. Immunotherapy. 2022 Aug;14(12):903-904. doi: 10.2217/imt-2022-0077. Epub 2022 Jul 5. PMID: 35787018

Immunization of healthcare personnel: A continuing issue.
Maltezou HC, Poland GA, Poland CM. Vaccine X. 2022 Aug;11:100169. doi: 10.1016/j.jvacx.2022.100169. Epub 2022 May 10. PMID: 35574172

Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 **vaccine** in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Zhu F, Zhuang C, Chu K, Zhang L, Zhao H, Huang S, Su Y, Lin H, Yang C, Jiang H, Zang X, Liu D, Pan H, Hu Y, Liu X, Chen Q, Song Q, Quan J, Huang Z, Zhong G, Chen J, Han J, Sun H, Cui L, Li J, Chen Y, Zhang T, Ye X, Li C, Wu T, Zhang J, Xia NS. Lancet Respir Med. 2022 Aug;10(8):749-760. doi: 10.1016/S2213-2600(22)00131-X. Epub 2022 May 26. PMID: 35644168

Reply to Mungmunpuntipantip and Wiwanitkit: CoronaVac or BNT162b2 **Vaccine** as a Third Dose.
Mok CKP, Hui DS, Peiris M. Am J Respir Crit Care Med. 2022 Aug 1;206(3):361-362. doi: 10.1164/rccm.202201-0221LE. PMID: 35561327

Prevaccination Glycan Markers of Response to an Influenza **Vaccine** Implicate the Complement Pathway.
Qin R, Meng G, Pushalkar S, Carlock MA, Ross TM, Vogel C, Mahal LK. J Proteome Res. 2022 Aug 5;21(8):1974-1985. doi: 10.1021/acs.jproteome.2c00251. Epub 2022 Jun 27. PMID: 35757850

Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.
Giannoccaro MP, Vacchiano V, Leone M, Camilli F, Zenesini C, Panzera I, Balboni A, Tappatà M, Borghi A, Salvi F, Lugaresi A, Rinaldi R, Di Felice G, Lodi V, Lazzarotto T, Liguori R; ANCOVAX study group. J Neurol. 2022 Aug;269(8):4000-4012. doi: 10.1007/s00415-022-11142-7. Epub 2022 May 3. PMID: 35503375

Understanding hesitancy with revealed preferences across COVID-19 **vaccine** types.
Kutasi K, Koltai J, Szabó-Morvai Á, Röst G, Karsai M, Biró P, Lengyel B. Sci Rep. 2022 Aug 2;12(1):13293. doi: 10.1038/s41598-022-15633-5. PMID: 35918372

Cost-effectiveness of rotavirus vaccination in Mozambique.
Lourenço Guimarães E, Chissaque A, Pecenka C, Clark A, Vaz B, Banze A, Canana N, Romão C, do Rosário Oliveira Martins M, de Deus N, Debellut F. Vaccine. 2022 Aug 3:S0264-410X(22)00940-9. doi: 10.1016/j.vaccine.2022.07.044. Online ahead of print. PMID: 35933279

Effects of COVID-19 **vaccine** on semen parameters.
Masone MC. Nat Rev Urol. 2022 Aug;19(8):454. doi: 10.1038/s41585-022-00632-y. PMID: 35831542

SARS-CoV-2 mRNA booster **vaccine**-associated lichenoid drug eruption.
Mintoff D, Pisani D, Livori N, Said-Huntingford I, Baldacchino G. J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e617-e619. doi: 10.1111/jdv.18149. Epub 2022 Apr 25. PMID: 35429052

Correspondence on 'BNT162b2 **vaccine**-associated myo/pericarditis in adolescents'.
Sookaromdee P, Wiwanitkit V. Eur J Clin Invest. 2022 Aug;52(8):e13780. doi: 10.1111/eci.13780. Epub 2022 Apr 2. PMID: 35342934

Do Side Effects to the Primary COVID-19 **Vaccine** Reduce Intentions for a COVID-19 **Vaccine** Booster?
Geers AL, Clemens KS, Colagiuri B, Jason E, Colloca L, Webster R, Vase L, Seig M, Faasse K. Ann Behav Med. 2022 Aug 2;56(8):761-768. doi: 10.1093/abm/kaac027. PMID: 35640203

Clinical and Microbiological effects in High-risk Beef Calves Administered Intranasal or Parenteral Modified-live Virus Vaccines.
Powledge SA, McAtee TB, Woolums AR, Falkner TR, Groves JT, Thoresen M, Valeris-Chacin R, Richeson JT. J Anim Sci. 2022 Aug 4:skac249. doi: 10.1093/jas/skac249. Online ahead of print. PMID: 35926833

Impact of BMI on COVID-19 **vaccine** effectiveness.
Wilder-Smith A, Frahsa A. Lancet Diabetes Endocrinol. 2022 Aug;10(8):551-552. doi: 10.1016/S2213-8587(22)00170-X. Epub 2022 Jul 1. PMID: 35780806

Three cases of thyroiditis after COVID-19 RNA-**vaccine**.
Brès F, Joyeux MA, Delemer B, Vitellius G, Barraud S. Ann Endocrinol (Paris). 2022 Aug;83(4):262-264. doi: 10.1016/j.ando.2022.04.014. Epub 2022 May 1. PMID: 35760593

Acute pericarditis in patients receiving coronavirus disease 2019 vaccines: a case series from the community.

Dini FL, Franzoni F, Scarfò G, Pugliese NR, Imazio M. J Cardiovasc Med (Hagerstown). 2022 Aug 1;23(8):551-558. doi: 10.2459/JCM.0000000000001342. PMID: 35904995

Hesitancy and reactogenicity to mRNA-based COVID-19 vaccines-Early experience with **vaccine** rollout in a multi-site healthcare system.
Al-Obaydi S, Hennrikus E, Mohammad N, Lehman EB, Thakur A, Al-Shaikhly T. PLoS One. 2022 Aug 5;17(8):e0272691. doi: 10.1371/journal.pone.0272691. eCollection 2022. PMID: 35930586

The status of refrigeration solutions for last mile **vaccine** delivery in low-income settings.
Cattin M, Jonnalagedda S, Makohliso S, Schönenberger K. Vaccine X. 2022 Jun 18;11:100184. doi: 10.1016/j.jvacx.2022.100184. eCollection 2022 Aug. PMID: 35800134

Assessing the Impact of **Vaccine** Lotteries on COVID-19 Vaccination Rates in the United States in 2021.
Sload J, Bechtolsheim B, Gifford D. Am J Public Health. 2022 Aug;112(8):1130-1133. doi: 10.2105/AJPH.2022.306863. Epub 2022 Jun 23. PMID: 35737921

Vaccines against SARS-CoV-2 variants and future pandemics.
Park T, Hwang H, Moon S, Kang SG, Song S, Kim YH, Kim H, Ko EJ, Yoon SD, Kang SM, Hwang HS. Expert Rev Vaccines. 2022 Aug 4. doi: 10.1080/14760584.2022.2110075. Online ahead of print. PMID: 35924678

Differential Recognition of Computationally Optimized H3 Hemagglutinin Influenza **Vaccine** Candidates by Human Antibodies.
Abbadi N, Nagashima K, Pena-Briseno A, Ross TM, Mousa JJ. J Virol. 2022 Aug 2:e0089622. doi: 10.1128/jvi.00896-22. Online ahead of print. PMID: 35916534

Public Preferences for Policies to Promote COVID-19 Vaccination Uptake: A Discrete Choice Experiment in The Netherlands.
Mouter N, Boxebeld S, Kessels R, van Wijhe M, de Wit A, Lambooij M, van Exel J. Value Health. 2022 Aug;25(8):1290-1297. doi: 10.1016/j.jval.2022.03.013. Epub 2022 May 5. PMID: 35527162

Effect of vibration associated with cryotherapy on **vaccine**-related pain and anxiety levels in adults: study protocol for a randomized clinical trial.
da Cunha Lima EA, Toledo LV, Correia MDL, de Almeida Pereira D, Caetano RO, Faria TB, Braga LM. Trials. 2022 Aug 1;23(1):620. doi: 10.1186/s13063-022-06564-7. PMID: 35915477

An (un)healthy social dilemma: a normative messaging field experiment with flu vaccinations.
Mussio I, de Oliveira ACM. Health Econ Rev. 2022 Aug 2;12(1):41. doi: 10.1186/s13561-022-00385-9. PMID: 35917007

Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study.
Yegorov S, Kadyrova I, Negmetzhanov B, Kolesnikova Y, Kolesnichenko S, Korshukov I, Baiken Y, Matkarimov B, Miller MS, Hortelano GH, Babenko D. Sci Rep. 2022 Aug 1;12(1):13207. doi: 10.1038/s41598-022-17514-3. PMID: 35915123

Reverse vaccinology approach to design a multi-epitope **vaccine** construct based on the Mycobacterium tuberculosis biomarker PE_PGRS17.

Moodley A, Fatoba A, Okpeku M, Emmanuel Chiliza T, Blessing Cedric Simelane M, Pooe OJ. Immunol Res. 2022 Aug;70(4):501-517. doi: 10.1007/s12026-022-09284-x. Epub 2022 May 12. PMID: 35554858

COVID-19 mRNA Vaccines May Cause False Reactivity in Some Serologic Laboratory Tests, Including Rapid Plasma Reagin Tests.
Korentzelos D, Baloda V, Jung Y, Wheeler B, Shurin MR, Wheeler SE. Am J Clin Pathol. 2022 Aug 4;158(2):162-166. doi: 10.1093/ajcp/aqac025. PMID: 35353142

Effectiveness of Naturally Acquired and **Vaccine**-Induced Immune Responses to SARS-CoV-2 Mu Variant.
de Oliveira-Filho EF, Rincon-Orozco B, Jones-Cifuentes N, Peña-López B, Mühlemann B, Drosten C, Moreira-Soto A, Drexler JF. Emerg Infect Dis. 2022 Aug;28(8):1708-1712. doi: 10.3201/eid2808.220584. Epub 2022 Jul 13. PMID: 35830278

Six-month BNT162b2 **vaccine** efficacy in adolescents and young adults with cancer.
Donze C, Ninove L, de Lamballerie X, Saultier P, Andre N. Pediatr Blood Cancer. 2022 Aug;69(8):e29547. doi: 10.1002/pbc.29547. Epub 2021 Dec 26. PMID: 34957669

Impact of a Multi-Level, Multi-Component, System Intervention on HPV Vaccination in a Federally Qualified Health Center.
Glenn BA, Nonzee NJ, Herrmann AK, Crespi CM, Haroutunian GG, Sundin P, Chang LC, Singhal R, Taylor VM, Bastani R. Cancer Epidemiol Biomarkers Prev. 2022 Aug 1:EPI-22-0156. doi: 10.1158/1055-9965.EPI-22-0156. Online ahead of print. PMID: 35914738

Possible COVID-19 MRNA **Vaccine**-Induced Case of Unilateral Central Retinal Vein Occlusion.
Takacs A, Ecsedy M, Nagy ZZ. Ocul Immunol Inflamm. 2022 Aug 1:1-6. doi: 10.1080/09273948.2022.2094811. Online ahead of print. PMID: 35914296

Durability of Heterologous and Homologous COVID-19 **Vaccine** Boosts.
Tan CS, Collier AY, Yu J, Liu J, Chandrashekar A, McMahan K, Jacob-Dolan C, He X, Roy V, Hauser BM, Munt JE, Mallory ML, Mattocks M, Powers JM, Meganck RM, Rowe M, Hemond R, Bondzie EA, Jaegle KH, Baric RS, Schmidt AG, Alter G, Le Gars M, Sadoff J, Barouch DH. JAMA Netw Open. 2022 Aug 1;5(8):e2226335. doi: 10.1001/jamanetworkopen.2022.26335. PMID: 35947380

SOLVx therapeutics **vaccine** - Activate T-cell immunity using broad surveillance epitope strategy against mutant strains SARS-COV2.
Khan MSS, Catanzaro JA. Biomed Pharmacother. 2022 Aug;152:113212. doi: 10.1016/j.biopha.2022.113212. Epub 2022 May 30. PMID: 35653885

Association of Receiving a Fourth Dose of the BNT162b **Vaccine** With SARS-CoV-2 Infection Among Health Care Workers in Israel.
Cohen MJ, Oster Y, Moses AE, Spitzer A, Benenson S; Israeli-Hospitals 4th Vaccine Working Group. JAMA Netw Open. 2022 Aug 1;5(8):e2224657. doi: 10.1001/jamanetworkopen.2022.24657. PMID: 35917125

Serious Mental Illness Diagnosis and COVID-19 **Vaccine** Uptake in the Veterans Health Administration.
Haderlein TP, Steers WN, Dobalian A. Psychiatr Serv. 2022 Aug 1;73(8):918-921. doi: 10.1176/appi.ps.202100499. Epub 2022 Jan 18. PMID: 35042373

Cost-Benefit Analysis of Human Papillomavirus **Vaccine** in Iran.
Sargazi N, Takian A, Daroudi R, Nahvijou A, Yaseri M, Ghanbari Motlagh A, Zendehdel K. J Prev (2022). 2022 Aug 2. doi: 10.1007/s10935-022-00697-w. Online ahead of print. PMID: 35916995

Executive orders prohibiting **vaccine** mandates: Implications for transplant patients and physicians.
Testa G, Wall A, Lee SH, Fine R. Am J Transplant. 2022 Aug;22(8):2116. doi: 10.1111/ajt.17016. Epub 2022 Mar 15. PMID: 35247024

Post-Marketing Surveillance of Tetravalent Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus (DTaP-IPV) **Vaccine** in South Korea, 2009 to 2015.
Choe YJ, Vidor E, Manson C. Infect Dis Ther. 2022 Aug;11(4):1479-1492. doi: 10.1007/s40121-022-00650-8. Epub 2022 May 14. PMID: 35575974

Chrysin enhances antitumour immunity response through the IL-12-STAT4 signal pathway in the B16F10 melanoma mouse model.
Lu R, Wang S, Jiang S, Li C, Wang Y, Li L, Wang Y, Ma G, Qiao H, Leng Z, Niu J, Tian Z, Wang B. Scand J Immunol. 2022 Aug;96(2):e13177. doi: 10.1111/sji.13177. Epub 2022 May 13. PMID: 35484925

Adherence to and early adverse events of COVID-19 **vaccine** in a cohort of 600 Italian breastfeeding and pregnant physicians.
Montalti M, Guaraldi F, Di Valerio Z, Ragghianti B, Tedesco D, Mannucci E, Monami M, Gori D. Hum Vaccin Immunother. 2022 Aug 9:2106747. doi: 10.1080/21645515.2022.2106747. Online ahead of print. PMID: 35944074

Impact of COVID-19 **vaccine** on epilepsy in adult subjects: an Italian multicentric experience.
Romozzi M, Rollo E, Quintieri P, Dono F, Evangelista G, Consoli S, Veleno L, Anzellotti F, Calvello C, Costa C, Servidei S, Calabresi P, Vollono C. Neurol Sci. 2022 Aug;43(8):4627-4634. doi: 10.1007/s10072-022-06100-0. Epub 2022 May 2. PMID: 35501537

Moving targets: COVID-19 **vaccine** efficacy against Omicron subvariants.
da Silva MK, Fulco UL, Júnior EDDS, Oliveira JIN. Mol Ther. 2022 Aug 3;30(8):2644-2645. doi: 10.1016/j.ymthe.2022.07.004. Epub 2022 Jul 31. PMID: 35914527

Transparency of COVID-19 **vaccine** trials: decisions without data.
Tanveer S, Rowhani-Farid A, Hong K, Jefferson T, Doshi P. BMJ Evid Based Med. 2022 Aug;27(4):199-205. doi: 10.1136/bmjebm-2021-111735. Epub 2021 Aug 9. PMID: 34373256

Transparency of COVID-19 **vaccine** trials: decisions without data.
Tanveer S, Rowhani-Farid A, Hong K, Jefferson T, Doshi P. BMJ Evid Based Med. 2022 Aug;27(4):199-205. doi: 10.1136/bmjebm-2021-111735. Epub 2021 Aug 9. PMID: 34373256

Should COVID-19 vaccines be mandated in schools? - an international caregiver perspective.
Baumer-Mouradian SH, Hart RJ, Bone JN, Seiler M, Olson P, Keitel K, Manzano S, Gualco G, Krupik D, Schroter S, Weigert RM, Chung S, Thompson GC, Muhammad N, Shah P, Gaucher NO, Lunoe MM, Evers M, Pharisa Rochat C, Nelson CE, Shefler Gal M, Doucas A, Goldman RD; International COVID-19 Parental Attitude Study (COVIPAS) Group*. Vaccine. 2022 Aug 1:S0264-410X(22)00921-5. doi: 10.1016/j.vaccine.2022.07.038. Online ahead of print. PMID: 35945047

Changing characteristics over time of individuals receiving COVID-19 vaccines in Denmark: A population-based descriptive study of **vaccine** uptake.
Reilev M, Olesen M, Kildegaard H, Støvring H, Andersen JH, Hallas J, Lund LC, Ladebo L, Ernst MT, Damkier P, Jensen PB, Pottegård A, Rasmussen L. Scand J Public Health. 2022 Aug;50(6):686-692. doi: 10.1177/14034948221108246. Epub 2022 Jul 7. PMID: 35799465

The interface between U.S. primary care clinics and pharmacies for HPV vaccination delivery: A scoping literature review.
Carney PA, Bumatay S, Kuo GM, Darden PM, Hamilton A, Fagnan LJ, Hatch B. Prev Med Rep. 2022 Jul 4;28:101893. doi: 10.1016/j.pmedr.2022.101893. eCollection 2022 Aug. PMID: 35855918

Characterization of Functional B-Cell Epitopes at the Amino Terminus of *Shigella* Invasion Plasmid Antigen B (IpaB).
Li S, Han X, Upadhyay I, Zhang W. Appl Environ Microbiol. 2022 Aug 9;88(15):e0038422. doi: 10.1128/aem.00384-22. Epub 2022 Jul 20. PMID: 35856689

Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant.
Murray SM, Barbanti M, Campbell C, Brown A, Chen L, Dhanapal J, Tseu B, Pervaiz O, Peters L, Springett S, Danby R, Adele S, Phillips E, Malone T, Amini A, Stafford L, Deeks AS, Dunachie S, Klenerman P, Peniket A, Barnes E, Kesavan M. Br J Haematol. 2022 Aug;198(4):668-679. doi: 10.1111/bjh.18312. Epub 2022 Jun 22. PMID: 35655410

Curbing COVID-19 **Vaccine** Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the **Vaccine** Adverse Event Reporting System (VAERS) Database.
Falotico JM, Desai AD, Shah A, Ricardo JW, Lipner SR. Am J Clin Dermatol. 2022 Aug 5:1-9. doi: 10.1007/s40257-022-00715-x. Online ahead of print. PMID: 35931925

Secreted heat shock protein gp96-Ig and OX40L-Fc combination **vaccine** enhances SARS-CoV-2 Spike (S) protein-specific B and T cell immune responses.
Padula L, Fisher E, Rivas K, Podack K, Frasca D, Kupritz J, Seavey MM, Jayaraman P, Dixon E, Jasuja R, Strbo N. Vaccine X. 2022 Aug 3;12:100202. doi: 10.1016/j.jvacx.2022.100202. Online ahead of print. PMID: 35936992

Possible Association between Vogt-Koyanagi-Harada Disease and Coronavirus Disease **Vaccine**: A Report of Four Cases.
de Queiroz Tavares Ferreira F, Araújo DC, de Albuquerque LM, Bianchini PM, Holanda EC, Pugliesi A. Ocul Immunol Inflamm. 2022 Aug 1:1-7. doi: 10.1080/09273948.2022.2093756. Online ahead of print. PMID: 35914285

Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA.
Smith KJ, Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK. Infect Dis Ther. 2022 Aug;11(4):1683-1693. doi: 10.1007/s40121-022-00669-x. Epub 2022 Jul 13. PMID: 35831685

Shell disorder and the HIV **vaccine** mystery: lessons from the legendary Oswald Avery.
Goh GK, Uversky VN. J Biomol Struct Dyn. 2022 Aug;40(12):5702-5711. doi: 10.1080/07391102.2020.1870562. Epub 2021 Jan 7. PMID: 33410379

Knowledge, Attitude, Practices, and **Vaccine** Hesitancy Among the Latinx Community in Southern California Early in the COVID-19 Pandemic: Cross-sectional Survey.
Mehta SN, Burger ZC, Meyers-Pantele SA, Garfein RS, Ortiz DO, Mudhar PK, Kothari SB, Kothari J, Meka M, Rodwell T. JMIR Form Res. 2022 Aug 4;6(8):e38351. doi: 10.2196/38351. PMID: 35925649

Single-injection COVID-19 subunit **vaccine** elicits potent immune responses.
Zhou X, Wang H, Luo Y, Cui L, Guan Y, Zhang Y. Acta Biomater. 2022 Aug 7:S1742-7061(22)00475-5. doi: 10.1016/j.actbio.2022.08.006. Online ahead of print. PMID: 35948176

A Possible Case of COVID-19 Booster **Vaccine**-Associated Rhabdomyolysis and Acute Kidney Injury.
Unger K, Ponte CD, Anderson D. J Pharm Technol. 2022 Aug;38(4):247-250. doi: 10.1177/87551225221093944. Epub 2022 May 3. PMID: 35832563

Comparative Profiles of SARS-CoV-2 Spike-Specific Human Milk Antibodies Elicited by mRNA- and Adenovirus-Based COVID-19 Vaccines.
Yang X, Fox A, DeCarlo C, Norris C, Griffin S, Wedekind S, Flanagan JM, Shenker N, Powell RL. Breastfeed Med. 2022 Aug;17(8):638-646. doi: 10.1089/bfm.2022.0019. Epub 2022 Jun 8. PMID: 35675683

Evaluating clinical effectiveness of SARS-CoV-2 **vaccine** in solid organ transplant recipients: A propensity score matched analysis.
Tucker M, Azar MM, Cohen E, Gan G, Deng Y, Foppiano Palacios C, Malinis M. Transpl Infect Dis. 2022 Aug;24(4):e13876. doi: 10.1111/tid.13876. Epub 2022 Jun 27. PMID: 35684932

Analyzing COVID-19 **vaccine** efficacy in vulnerable communities: efforts beyond addressing **vaccine** inequity.
Sendi P, Tande AJ. Clin Microbiol Infect. 2022 Aug;28(8):1053-1054. doi: 10.1016/j.cmi.2022.04.012. Epub 2022 May 6. PMID: 35526690

Human Milk Antibody Response After Combining Two Different COVID-19 Vaccines: Mix-and-Match.
Mulleners SJ, Juncker HG, van Gils MJ, van Goudoever JB, van Keulen BJ. J Hum Lact. 2022 Aug;38(3):401-406. doi: 10.1177/08903344221103260. Epub 2022 Jun 21. PMID: 35726498

rVSV-ΔG-SARS-CoV-2-S **vaccine**: repeated intramuscular (IM) toxicity, local tolerance, immunogenicity and biodistribution study in NZW rabbits.
Rosner A, Steiner M, Melamed S, Politi B, Vitner E, Tamir H, Achdout H, Cherry L, Avraham R, Yahalom-Ronen Y, Levy H, Beth-Din A, Stein D, Mechaly A, Fisher M, Fatelevich E, Weiss S, Kronfeld N, Madar-Shapiro L, Nyska A, Yitzhaki S, Paran N, Israely T, Marcus H, Madar-Balakirski N. Arch Toxicol. 2022 Aug;96(8):2329-2339. doi: 10.1007/s00204-022-03302-5. Epub 2022 May 17. PMID: 35577986

Dendritic cell-based **vaccine**: the state-of-the-art **vaccine** platform for COVID-19 management.
Chavda VP, Patel AB, Vora LK, Apostolopoulos V, Uhal BD. Expert Rev Vaccines. 2022 Aug 9:1-9. doi: 10.1080/14760584.2022.2110076. Online ahead of print. PMID: 35929957

Influenza **vaccine** awareness and acceptance in kidney disease during the corononavirus disease 2019 pandemic.
Lim CC, Leeu JJ, Mok IYJ, Tan HZ, Choo JCJ. J Med Virol. 2022 Aug 2. doi: 10.1002/jmv.28039. Online ahead of print. PMID: 35916250

Double trouble: COVID-19 **vaccine** misinformation amidst conflict in Ukraine.
Zoaib Habib T, Ennab F, Matiashova L, Nawaz FA, Volkova A, Trill V, Essar MY. Ann Med Surg (Lond). 2022 Aug;80:104127. doi: 10.1016/j.amsu.2022.104127. Epub 2022 Jul 9. PMID: 35845861

Culturally relevant COVID-19 **vaccine** acceptance strategies in sub-Saharan Africa.
Ajeigbe O, Arage G, Besong M, Chacha W, Desai R, Doegah P, Hamoonga TE, Hussein H, Matchado A, Mbotwe-Sibanda S, Mukoma G, Odebode A, Olawole T, Phaswana M, Rotimi O, Silubonde TM, Thabethe N, Thiba A, Thomford NE, Wekesah F, Macnab A; Stellenbosch Institute for Advanced Study African Scholars Network. Lancet Glob Health. 2022 Aug;10(8):e1090-e1091. doi: 10.1016/S2214-109X(22)00251-0. Epub 2022 Jun 9. PMID: 35691328

Adverse events after anti-COVID-19 **vaccine** administration: a six-month experience.
Gaspari V, Viviani F, Baraldi C, Neri I, Orioni G, Pileri A. Ital J Dermatol Venerol. 2022 Aug;157(4):368-369. doi: 10.23736/S2784-8671.22.07215-2. PMID: 35916180

Persistently low readiness to vaccinate young children against COVID among **vaccine** adherent mothers in Vermont, USA.
Cioffredi LA, Kohlasch KL, Thomas E, Potter AS. Prev Med Rep. 2022 Aug;28:101841. doi: 10.1016/j.pmedr.2022.101841. Epub 2022 May 23. PMID: 35646517

Anti-PF4 testing for **vaccine**-induced immune thrombocytopenia and thrombosis (VITT): Results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide.
Reilly-Stitt C, Jennings I, Kitchen S, Makris M, Meijer P, de Maat M, Scully M, Bakchoul T, Walker ID. J Thromb Haemost. 2022 Aug;20(8):1875-1879. doi: 10.1111/jth.15766. Epub 2022 Jun 6. PMID: 35603519

Protective effects of prior third dose mRNA vaccination in rural nursing home residents during SARS-CoV-2 outbreaks.
Rhynold ES, Quan S, Orr PH, LaBine L, Singer A, St John PD. J Am Geriatr Soc. 2022 Aug 8. doi: 10.1111/jgs.17996. Online ahead of print. PMID: 35938635

Acute vulvar ulcers and the COVID-19 booster **vaccine**.
Salusti-Simpson M, Porter H, Fischer A. JAAD Case Rep. 2022 Aug;26:82-84. doi: 10.1016/j.jdcr.2022.06.019. Epub 2022 Jul 2. PMID: 35812079

Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16^{+} cancer.
Salomon N, Selmi A, Grunwitz C, Kong A, Stanganello E, Neumaier J, Petschenka J, Diken M, Kreiter S, Türeci Ö, Sahin U, Vascotto F. Cancer Immunol Immunother. 2022 Aug;71(8):1975-1988. doi: 10.1007/s00262-021-03134-9. Epub 2021 Dec 31. PMID: 34971406

Examination of phase-variable haemoglobin-haptoglobin binding proteins in non-typeable Haemophilus influenzae reveals a diverse distribution of multiple variants.
Phillips ZN, Jennison AV, Whitby PW, Stull TL, Staples M, Atack JM. FEMS Microbiol Lett. 2022 Aug 1;369(1):fnac064. doi: 10.1093/femsle/fnac064. PMID: 35867873

Multi Epitope-Based **Vaccine** Design for Protection Against *Mycobacterium tuberculosis* and SARS-CoV-2 Coinfection.
Pitaloka DAE, Izzati A, Amirah SR, Syakuran LA. Adv Appl Bioinform Chem. 2022 Aug 2;15:43-57. doi: 10.2147/AABC.S366431. eCollection 2022. PMID: 35941993

Re: Reifferscheid et al., "COVID-19 **vaccine** uptake and intention during pregnancy in Canada".
Sookaromdee P, Wiwanitkit V. Can J Public Health. 2022 Aug;113(4):559. doi: 10.17269/s41997-022-00649-1. Epub 2022 May 16. PMID: 35578017

De novo annular pustular psoriasis following mRNA COVID-19 **vaccine**.
Romagnuolo M, Pontini P, Muratori S, Marzano AV, Moltrasio C. J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e603-e605. doi: 10.1111/jdv.18114. Epub 2022 Apr 7. PMID: 35349736

Calreticulin Mutant-Induced MHC-I Skewing Supports Heteroclitic Peptide **Vaccine** Use.
[No authors listed] Cancer Discov. 2022 Aug 5;12(8):OF16. doi: 10.1158/2159-8290.CD-RW2022-115. PMID: 35748593

Safety and immunogenicity of the FINLAY-FR-1A **vaccine** in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial.
Ochoa-Azze R, Chang-Monteagudo A, Climent-Ruiz Y, Macías-Abraham C, Valenzuela-Silva C, de Los Ángeles García-García M, Jerez-Barceló Y, Triana-Marrero Y, Ruiz-Villegas L, Dairon Rodríguez-Prieto L, Guerra-Chaviano PP, Sánchez-Ramírez B, Hernández-García T, Orosa-Vázquez I, Díaz-Hernández M, Chiodo F, Calcagno A, Ghisetti V, Rodríguez-Acosta M, Noa-Romero E, Enríquez-Puertas J, Ortega-León D, Valdivia-Álvarez I, Delahanty-Fernández A, Palenzuela-Díaz A, Rodríguez-Noda L, González-Mugica R, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V. Lancet Respir Med. 2022 Aug;10(8):785-795. doi: 10.1016/S2213-2600(22)00100-X. Epub 2022 Jun 9. PMID: 35691295

Two large-scale global studies on COVID-19 **vaccine** hesitancy over time: Culture, uncertainty avoidance, and **vaccine** side-effect concerns.
Lu JG. J Pers Soc Psychol. 2022 Aug 4. doi: 10.1037/pspa0000320. Online ahead of print. PMID: 35925705

Outcomes of SARS-CoV-2 Infection in Unvaccinated Compared With Vaccinated Solid Organ Transplant Recipients: A Propensity Matched Cohort Study.
Hall VG, Al-Alahmadi G, Solera JT, Marinelli T, Cardinal H, Prasad GVR, De Serres SA, Isaac D, Mainra R, Lamarche C, Sapir-Pichhadze R, Gilmour S, Matelski J, Humar A, Kumar D. Transplantation. 2022 Aug 1;106(8):1622-1628. doi: 10.1097/TP.0000000000004178. Epub 2022 May 3. PMID: 35502801

Differences in epidemiology of enteropathogens in children pre- and post-rotavirus **vaccine** introduction in Kilifi, coastal Kenya.
Agoti CN, Curran MD, Murunga N, Ngari M, Muthumbi E, Lambisia AW, Frost SDW, Blacklaws BA, Nokes DJ, Drumright LN. Gut Pathog. 2022 Aug 1;14(1):32. doi: 10.1186/s13099-022-00506-z. PMID: 35915480

Assessing knowledge of human papillomavirus among men who have sex with men (MSM) using targeted dating applications.
Pham D, Shukla A, Welch K, Villa A. Vaccine. 2022 Aug 6:S0264-410X(22)00943-4. doi: 10.1016/j.vaccine.2022.07.048. Online ahead of print. PMID: 35945045

Safety and immunogenicity of the Rotavac and Rotasiil rotavirus vaccines administered in an interchangeable dosing schedule among healthy Indian infants: a multicentre, open-label, randomised, controlled, phase 4, non-inferiority trial.
Kanungo S, Chatterjee P, Bavdekar A, Murhekar M, Babji S, Garg R, Samanta S, Nandy RK, Kawade A, Boopathi K, Kanagasabai K, Kamal VK, Kumar VS, Gupta N, Dutta S. Lancet Infect Dis. 2022 Aug;22(8):1191-1199. doi: 10.1016/S1473-3099(22)00161-X. Epub 2022 May 16. PMID: 35588754

Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination.
Iancovici L, Khateeb D, Harel O, Peri R, Slobodin G, Hazan Y, Melamed D, Kessel A, Bar-On Y. Rheumatology (Oxford). 2022 Aug 3;61(8):3439-3447. doi: 10.1093/rheumatology/keab879. PMID: 34849628

A Multiresource Event Model Developed to Increase Access to COVID-19 Vaccines in Pima County, Arizona, Summer 2021.
Monroy A, Cullen T. Public Health Rep. 2022 Aug 2:333549221114896. doi: 10.1177/00333549221114896. Online ahead of print. PMID: 35915992

Peptide-Based Cancer **Vaccine** Delivery via the STINGΔTM-cGAMP Complex.
He Y, Hong C, Fletcher SJ, Berger AG, Sun X, Yang M, Huang S, Belcher AM, Irvine DJ, Li J, Hammond PT. Adv Healthc Mater. 2022 Aug;11(15):e2200905. doi: 10.1002/adhm.202200905. Epub 2022 Jun 19. PMID: 35670244

Adenoviral-based **vaccine** promotes neoantigen-specific CD8$^+$ T cell stemness and tumor rejection.
D'Alise AM, Brasu N, De Intinis C, Leoni G, Russo V, Langone F, Baev D, Micarelli E, Petiti L, Picelli S, Fakih M, Le DT, Overman MJ, Shields AF, Pedersen KS, Shah MA, Mukherjee S, Faivre T, Delaite P, Scarselli E, Pace L. Sci Transl Med. 2022 Aug 10;14(657):eabo7604. doi: 10.1126/scitranslmed.abo7604. Epub 2022 Aug 10. PMID: 35947675

Genetic variants of NTCP gene and hepatitis B **vaccine** failure in Taiwanese children of hepatitis B e antigen positive mothers.
Chen YH, Tsuei DJ, Lai MW, Wen WH, Chiang CL, Wu JF, Chen HL, Hsu HY, Ni YH, Chang MH. Hepatol Int. 2022 Aug;16(4):789-798. doi: 10.1007/s12072-022-10350-7. Epub 2022 May 30. PMID: 35635688

Clinical characteristics of pediatric patients with COVID-19 between Omicron era vs. pre-Omicron era.
Iijima H, Kubota M, Ogimi C. J Infect Chemother. 2022 Aug 4:S1341-321X(22)00213-6. doi: 10.1016/j.jiac.2022.07.016. Online ahead of print. PMID: 35933077

Environmental impact of COVID-19 **Vaccine** waste: A perspective on potential role of natural and biodegradable materials.

Hasija V, Patial S, Kumar A, Singh P, Ahamad T, Khan AAP, Raizada P, Hussain CM. J Environ Chem Eng. 2022 Aug;10(4):107894. doi: 10.1016/j.jece.2022.107894. Epub 2022 May 11. PMID: 35578627

COVID-19 vaccination-related small vessel vasculitis with multiorgan involvement.
Kim Y, Kang J, Lee SG, Kim GT. Z Rheumatol. 2022 Aug;81(6):509-512. doi: 10.1007/s00393-022-01159-8. Epub 2022 May 19. PMID: 35587834

Measures of tracheal lesions are more discriminatory and reproducible indications of chronic respiratory disease caused by *Mycoplasma gallisepticum* in poultry.
Kulappu Arachchige SN, Underwood GJ, Andrews DM, Abeykoon AMH, Wawegama NK, Browning GF. Avian Pathol. 2022 Aug 1:1-11. doi: 10.1080/03079457.2022.2103396. Online ahead of print. PMID: 35849061

Young African Americans' Communication with Family Members About COVID-19: Impact on Vaccination Intention and Implications for Health Communication Interventions.
Francis DB, Mason N, Occa A. J Racial Ethn Health Disparities. 2022 Aug;9(4):1550-1556. doi: 10.1007/s40615-021-01094-5. Epub 2021 Jul 16. PMID: 34272682

Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus **vaccine** against SARS-CoV-2.
Shinjo SK, de Souza FHC, Borges IBP, Dos Santos AM, Miossi R, Misse RG, Medeiros-Ribeiro AC, Saad CGS, Yuki EFN, Pasoto SG, Kupa LVK, Ceneviva C, Seraphim JC, Pedrosa TN, Vendramini MBG, Silva CA, Aikawa NE, Bonfá E. Rheumatology (Oxford). 2022 Aug 3;61(8):3351-3361. doi: 10.1093/rheumatology/keab773. PMID: 34664616

Exploring the impact of Quebec's **vaccine** lottery and **vaccine** passports on Covid-19 vaccination intention: Findings from repeated cross-sectional surveys.
Dubé È, Dionne M, Rochette L. Hum Vaccin Immunother. 2022 Aug 10:2100168. doi: 10.1080/21645515.2022.2100168. Online ahead of print. PMID: 35947802

Safety and immunogenicity of mRNA-LNP COVID-19 **vaccine** CVnCoV in Latin American adults: A phase 2 randomized study.
Sáez-Llorens X, Lanata C, Aranguren E, Celis CR, Cornejo R, DeAntonio R, Ecker L, Garrido D, Gil AI, Gonzales M, Hess-Holtz M, Leroux-Roels G, Junker H, Kays SK, Koch SD, Lazzaro S, Mann P, Quintini G, Srivastava B, Vahrenhorst D, von Eisenhart-Rothe P, Wolz OO, Oostvogels L. Vaccine X. 2022 Aug;11:100189. doi: 10.1016/j.jvacx.2022.100189. Epub 2022 Jul 1. PMID: 35791320

"Something for us": Co-development of the COVID-19 Social Site, a web app for long-term care workers.
Saunders C, Sierpe A, Stevens G, Elwyn G, Cantrell M, Engel J, Gonzalez M, Hayward M, Huebner J, Johnson L, Jimenez A, Little R, McKenna C, Onteeru M, Oo Khine M, Pogue J, Salinas Vargas JL, Schmidt P, Thomeer R, Durand MA. J Med Internet Res. 2022 Aug 3. doi: 10.2196/38359. Online ahead of print. PMID: 35926074

Superficial thrombophlebitis in ipsilateral breast after COVID-19 vaccination.
Aran S, Kayder OO, Chopra T, Abujudeh H. Radiol Case Rep. 2022 Jun 13;17(8):2883-2887. doi: 10.1016/j.radcr.2022.05.018. eCollection 2022 Aug. PMID: 35711742

Leave no one behind: inclusion of alpha-1 antitrypsin deficiency patients in COVID-19 **vaccine** trials.
Yang C, Zhao H, Tebbutt SJ. Eur J Hum Genet. 2022 Aug;30(8):872-874. doi: 10.1038/s41431-022-01047-4. Epub 2022 Jan 28. PMID: 35087186

To vaccinate or not: The relationship between conscientiousness and individual attitudes toward vaccination in real-life contexts.
Li H. Scand J Psychol. 2022 Aug;63(4):376-382. doi: 10.1111/sjop.12816. Epub 2022 Mar 24. PMID: 35325488

Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
Bárczi E, Varga V, Nagy A, Eszes N, Jáky-Kováts Z, Müller V, Bohács A. Immun Inflamm Dis. 2022 Aug;10(8):e646. doi: 10.1002/iid3.646. PMID: 35894705

Effects of an anti-gonadoliberin releasing hormone **vaccine** on testicular, epididymal and spermatogenic development in the horse.
Botha AE, Schulman ML, Birrell J, du Plessis L, Laver PN, Soley J, Colenbrander B, Bertschinger HJ. Reprod Domest Anim. 2022 Aug;57(8):919-927. doi: 10.1111/rda.14141. Epub 2022 May 12. PMID: 35500167

Efficacy of an ALDH peptide-based dendritic cell **vaccine** targeting cancer stem cells.
Liao F, Zhang J, Hu Y, Najafabadi AH, Moon JJ, Wicha MS, Kaspo B, Whitfield J, Chang AE, Li Q. Cancer Immunol Immunother. 2022 Aug;71(8):1959-1973. doi: 10.1007/s00262-021-03129-6. Epub 2022 Jan 31. PMID: 35098344

Public health and budgetary impact of 20-valent pneumococcal conjugate **vaccine** for adults in England.
Mugwagwa T, Averin A, Atwood M, Sato R, Vyse A, Campling J, Weycker D, Slack M, Ellsbury G, Mendes D. Expert Rev Vaccines. 2022 Aug 8:1-11. doi: 10.1080/14760584.2022.2104250. Online ahead of print. PMID: 35929956

Characterization of Emerging Serotype 19A Pneumococcal Strains in Invasive Disease and Carriage, Belgium.
Desmet S, Theeten H, Laenen L, Cuypers L, Maes P, Bossuyt W, Van Heirstraeten L, Peetermans WE, Lagrou K. Emerg Infect Dis. 2022 Aug;28(8):1606-1614. doi: 10.3201/eid2808.212440. PMID: 35876488

Factors associated with COVID-19 **vaccine** uptake among French population aged 65 years and older: results from a national online survey.
Jung YJ, Gagneux-Brunon A, Bonneton M, Botelho-Nevers E, Verger P, Ward JK, Launay O. BMC Geriatr. 2022 Aug 2;22(1):637. doi: 10.1186/s12877-022-03338-3. PMID: 35918635

Serological response to a third booster dose of BNT162b2 COVID-19 **vaccine** among seronegative cancer patients.
Shmueli ES, Lawrence YR, Rahav G, Itay A, Lustig Y, Halpern N, Boursi B, Margalit O. Cancer Rep (Hoboken). 2022 Aug;5(8):e1645. doi: 10.1002/cnr2.1645. Epub 2022 Jun 2. PMID: 35652556

Attitudes and behaviors of obstetricians and gynecologists toward HPV vaccination: a 7-year follow-up survey in Japan.

Oka E, Ueda Y, Nagase Y, Sawada M, Egawa-Takata T, Yagi A, Kakuda M, Nakagawa S, Hiramatsu K, Miyoshi A, Kobayashi E, Kimura T, Kimura T. Int J Clin Oncol. 2022 Aug;27(8):1356-1363. doi: 10.1007/s10147-022-02173-1. Epub 2022 May 7. PMID: 35525903

Omicron-specific mRNA **vaccine** elicits potent immune responses in mice, hamsters, and nonhuman primates.
Wu Y, Shen Y, Wu N, Zhang X, Chen S, Yang C, Zhou J, Wu Y, Chen D, Wang L, Wang C, Zhang H, Xia N, Chiu S, Wang Y. Cell Res. 2022 Aug 1:1-4. doi: 10.1038/s41422-022-00706-x. Online ahead of print. PMID: 35915244

Predictors of COVID-19 **Vaccine** Uptake in Health Care Workers: Correspondence.
Mungmunpuntipantip R, Wiwanitkit V. J Occup Environ Med. 2022 Aug 1;64(8):e522. doi: 10.1097/JOM.0000000000002582. Epub 2022 Jun 11. PMID: 35672920

A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an *in situ* **vaccine** for cisplatin-ineligible MIBC: the RAD **VACCINE** MIBC trial.
Satkunasivam R, Lim K, Teh BS, Guzman J, Zhang J, Farach A, Chen SH, Wallis CJ, Efstathiou E, Esnaola NF, Sonpavde GP. Future Oncol. 2022 Aug;18(25):2771-2781. doi: 10.2217/fon-2022-0380. Epub 2022 Jun 15. PMID: 35703113

Primary care professionals' support for Covid-19 vaccination mandates: Findings from a US national survey.
Grabert BK, Gilkey MB, Huang Q, Yi Kong W, Thompson P, Brewer NT. Prev Med Rep. 2022 Aug;28:101849. doi: 10.1016/j.pmedr.2022.101849. Epub 2022 May 31. PMID: 35662856
Post-COVID-19 **Vaccine** Small-Fiber Neuropathy and Tinnitus Treated with Plasma Exchange.
Schelke MW, Barcavage S, Lampshire E, Brannagan TH 3rd. Muscle Nerve. 2022 Aug 7. doi: 10.1002/mus.27696. Online ahead of print. PMID: 35934893

Mobile app to perform anonymized longitudinal studies in the context of COVID-19 adverse drug reaction monitoring, leveraging the citizenship engagement.
Di Filippo M, Avellone A, Belingheri M, Paladino ME, Riva MA, Zambon A, Pescini D. JMIR Hum Factors. 2022 Aug 2. doi: 10.2196/38701. Online ahead of print. PMID: 35930561

Factors Associated with Delayed or Missed Second-Dose mRNA COVID-19 Vaccination among Persons >12 Years of Age, United States.
Meng L, Murthy NC, Murthy BP, Zell E, Saelee R, Irving M, Fast HE, Roman PC, Schiller A, Shaw L, Black CL, Gibbs-Scharf L, Harris L, Chorba T. Emerg Infect Dis. 2022 Aug;28(8):1633-1641. doi: 10.3201/eid2808.220557. Epub 2022 Jul 7. PMID: 35798008

Factors Related to the Intention to Get Vaccinated Against COVID-19 in the Province of New Brunswick, Canada.
Lachance-Grzela M, Charbonneau A, Jbilou J, Dubé A, Richard J. J Community Health. 2022 Aug;47(4):674-679. doi: 10.1007/s10900-022-01093-5. Epub 2022 May 14. PMID: 35567712

Prior influenza **vaccine** is not a risk factor for bacterial coinfection in patients admitted to the ICU due to severe influenza.

Proaños NJ, Reyes LF, Bastidas A, Martín-Loeches I, Díaz E, Suberviola B, Moreno G, Bodí M, Nieto M, Estella A, Sole-Violán J, Curcio D, Papiol E, Guardiola J, Rodríguez A; on behalf GETGAG SEMICYUC Working Group. Med Intensiva (Engl Ed). 2022 Aug;46(8):436-445. doi: 10.1016/j.medine.2021.05.009. PMID: 35868720

CpG 1018® adjuvant enhances Tdap immune responses against Bordetella pertussis in mice.
DeJong MA, Wolf MA, Bitzer GJ, Hall JM, Sen-Kilic E, Blake JM, Petty JE, Wong TY, Barbier M, Campbell JD, Bevere JR, Damron FH. Vaccine. 2022 Aug 1:S0264-410X(22)00915-X. doi: 10.1016/j.vaccine.2022.07.030. Online ahead of print. PMID: 35927132

A self-adjuvanting anti-tumor nanoliposomal **vaccine** based on fluorine-substituted MUC1 glycopeptide.
Dong P, Cheng S, Wang Y, Gao H, Zhang Y, Zhu T, Yu P, Meng X. Chem Commun (Camb). 2022 Aug 2;58(62):8642-8645. doi: 10.1039/d2cc02143a. PMID: 35820186

Early experience with varicella vaccination in pediatric heart transplant recipients.
Dipchand AI, Seifert-Hansen M. J Heart Lung Transplant. 2022 Aug;41(8):1023-1026. doi: 10.1016/j.healun.2022.02.004. Epub 2022 Feb 15. PMID: 35279390

Long-term effects of Pfizer-BioNTech COVID-19 vaccinations on platelets.
Zhou Y, Nishikawa M, Kanno H, Yang R, Ibayashi Y, Xiao TH, Peterson W, Herbig M, Nitta N, Miyata S, Kanthi Y, Rohde GK, Moriya K, Yatomi Y, Goda K. Cytometry A. 2022 Aug 8. doi: 10.1002/cyto.a.24677. Online ahead of print. PMID: 35938513

The role of social media in monitoring COVID-19 **vaccine** uptake.
Garett R, Young SD. J Eval Clin Pract. 2022 Aug;28(4):650-652. doi: 10.1111/jep.13656. PMID: 35856457

Re-assessing reactions to influenza vaccination initially classified as **vaccine** allergies.
Carr BZ, Spriggs K, Ojaimi S, Leahy E, Barnes SL. Med J Aust. 2022 Aug 1;217(3):155-156. doi: 10.5694/mja2.51593. Epub 2022 Jun 3. PMID: 35656786

CMR Imaging After Myocarditis Associated with mRNA COVID-19 **Vaccine**: Correspondence.
Mungmunpuntipantip R, Wiwanitkit V. Pediatr Cardiol. 2022 Aug;43(6):1401. doi: 10.1007/s00246-022-02896-y. Epub 2022 Apr 4. PMID: 35376967

"Is Omicron mild"? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies.
Rajpal VR, Sharma S, Kumar A, Chand S, Joshi L, Chandra A, Babbar S, Goel S, Raina SN, Shiran B. J Med Virol. 2022 Aug;94(8):3521-3539. doi: 10.1002/jmv.27749. Epub 2022 Apr 27. PMID: 35355267

Intranasal administration of a virus like particles-based **vaccine** induces neutralizing antibodies against SARS-CoV-2 and variants of concern.
Rothen DA, Krenger PS, Nonic A, Balke I, Vogt AS, Chang X, Manenti A, Vedovi F, Resevica G, Walton SM, Zeltins A, Montomoli E, Vogel M, Bachmann MF, Mohsen MO. Allergy. 2022 Aug;77(8):2446-2458. doi: 10.1111/all.15311. Epub 2022 Apr 15. PMID: 35403221

Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey.

Bechman K, Cook ES, Dand N, Yiu ZZN, Tsakok T, Meynell F, Coker B, Vincent A, Bachelez H, Barbosa I, Brown MA, Capon F, Contreras CR, De La Cruz C, Meglio PD, Gisondi P, Jullien D, Kelly J, Lambert J, Lancelot C, Langan SM, Mason KJ, McAteer H, Moorhead L, Naldi L, Norton S, Puig L, Spuls PI, Torres T, Urmston D, Vesty A, Warren RB, Waweru H, Weinman J, Griffiths CEM, Barker JN, Smith CH, Galloway JB, Mahil SK; PsoProtect study group. Br J Dermatol. 2022 Aug;187(2):254-256. doi: 10.1111/bjd.21042. Epub 2022 May 3. PMID: 35104366

A multilingual dataset of COVID-19 vaccination attitudes on Twitter.
Chen N, Chen X, Pang J. Data Brief. 2022 Aug 2;44:108503. doi: 10.1016/j.dib.2022.108503. Online ahead of print. PMID: 35935093

Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
Gattinger P, Kratzer B, Tulaeva I, Niespodziana K, Ohradanova-Repic A, Gebetsberger L, Borochova K, Garner-Spitzer E, Trapin D, Hofer G, Keller W, Baumgartner I, Tancevski I, Khaitov M, Karaulov A, Stockinger H, Wiedermann U, Pickl WF, Valenta R. Allergy. 2022 Aug;77(8):2431-2445. doi: 10.1111/all.15305. Epub 2022 Apr 15. PMID: 35357709

Conjugate of structurally reassigned pneumococcal serotype 31 polysaccharide with CRM197 elicited potent immune response.
Sun T, Mai S, Mao H, Li H, Duan Y, Meng S, Bao J, Ding N, Zong C. Carbohydr Polym. 2022 Aug 1;289:119414. doi: 10.1016/j.carbpol.2022.119414. Epub 2022 Apr 2. PMID: 35483835

Effectiveness of the 10-valent pneumococcal conjugate **vaccine** on pediatric pneumonia confirmed by ultrasound: a matched case-control study.
Checkley W, Hossen S, McCollum ED, Pervaiz F, Miele CH, Chavez MA, Moulton LH, Simmons N, Roy AD, Chowdhury NH, Ahmed S, Begum N, Quaiyum A, Santosham M, Baqui AH. Respir Res. 2022 Aug 1;23(1):198. doi: 10.1186/s12931-022-02115-5. PMID: 35915495

Syringe Service Program Perspectives on Barriers, Readiness, and Programmatic Needs to Support Rollout of the COVID-19 **Vaccine**.
Corcorran MA, Austin EJ, Behrends CN, Briggs ES, Frost MC, Juarez AM, Frank ND, Healy E, Prohaska SM, LaKosky PA, Kapadia SN, Perlman DC, Schackman BR, Des Jarlais DC, Williams EC, Glick SN. J Addict Med. 2022 Aug 2. doi: 10.1097/ADM.0000000000001036. Online ahead of print. PMID: 35916422

Oral immunization of recombinant Saccharomyces cerevisiae expressing fiber-2 of fowl adenovirus serotype 4 induces protective immunity against homologous infection.
Cao H, Hua D, Zhang H, Zhang H, Liu N, Feng Z, Li H, Zhao B, Zhang L, Guo Y, Huang J, Zhang L. Vet Microbiol. 2022 Aug;271:109490. doi: 10.1016/j.vetmic.2022.109490. Epub 2022 Jun 11. PMID: 35709627

Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report.
Lasagna A, Lenti MV, Cassaniti I, Sacchi P. Immunotherapy. 2022 Aug;14(12):915-925. doi: 10.2217/imt-2021-0342. Epub 2022 Jun 13. PMID: 35694999

Development and implementation of a COVID-19 **Vaccine** and Pandemic Planning course: An interprofessional education approach.

Austin RR, Philbrick AM, Roth C, Mays KA. J Interprof Educ Pract. 2022 Dec;29:100540. doi: 10.1016/j.xjep.2022.100540. Epub 2022 Aug 1. PMID: 35935733

Vaccine provider views on the impact of COVID-19 on immunisation in general practice: a qualitative study.
Morgan T, Mahimbo A, Harris M, Heywood A. Aust J Prim Health. 2022 Aug 8. doi: 10.1071/PY22003. Online ahead of print. PMID: 35934671

Humoral and Cellular Response before and after the Fourth BNT162b2 **Vaccine** Dose in patients with solid tumors on active treatment.
Lasagna A, Bergami F, Lilleri D, Percivalle E, Quaccini M, Comolli G, Sarasini A, Sammartino JC, Ferrari A, Arena F, Cicognini D, Schiavo R, Lo Cascio G, Baldanti F, Pedrazzoli P, Cassaniti I. Ann Oncol. 2022 Aug 1:S0923-7534(22)01863-4. doi: 10.1016/j.annonc.2022.07.012. Online ahead of print. PMID: 35926815

A Clinical Case of COVID-19 **Vaccine**-Associated Guillain-Barré Syndrome.
Hilts A, Schreiber A, Singh A. Am J Case Rep. 2022 Aug 10;23:e936896. doi: 10.12659/AJCR.936896. PMID: 35945825

Re-vaccination and adverse event recurrence in patients with adverse events following immunization.
Muñoz CE, MacDonald B, Pham-Huy A, Vaudry W, Pernica JM, Boucher FD, Constantinescu C, Sadarangani M, Bettinger JA, Tapiéro B, Morris SK, McConnell A, Cowan J, Zafack J, Upton J, Abdurrahman Z, McHenry M, Hildebrand KJ, Noya F, De Serres G, Halperin SA, Top KA; Canadian Immunization Research Network Investigators. J Pediatr. 2022 Aug 7:S0022-3476(22)00668-0. doi: 10.1016/j.jpeds.2022.07.019. Online ahead of print. PMID: 35948192

Unilateral optic neuritis after vaccination against the coronavirus disease: two case reports.
Wang J, Huang S, Yu Z, Zhang S, Hou G, Xu S. Doc Ophthalmol. 2022 Aug;145(1):65-70. doi: 10.1007/s10633-022-09880-0. Epub 2022 Jun 28. PMID: 35763179

Immunogenicity of the 13-valent pneumococcal conjugate **vaccine** followed by the 23-valent pneumococcal polysaccharide **vaccine** in people living with HIV on combination antiretroviral therapy.
Garcia Garrido HM, Schnyder JL, Haydari B, Vollaard AM, Tanck MWT, de Bree GJ, Meek B, Grobusch MP, Goorhuis A. Int J Antimicrob Agents. 2022 Aug;60(2):106629. doi: 10.1016/j.ijantimicag.2022.106629. Epub 2022 Jun 24. PMID: 35760223

The humoral response of mRNA COVID-19 **vaccine** in hematological diseases: The HEMVACO study.
Gueguen M, Khatchatourian L, Lohéac C, Dorval I, Mercier M, Le Calloch R, Mahé K, Rizcallah MJ, Hutin P, Fangous MS, Saidani N, Le Clech L. Infect Dis Now. 2022 Aug;52(5):280-285. doi: 10.1016/j.idnow.2022.05.008. Epub 2022 Jun 3. PMID: 35667558

Transcriptome and proteome analysis of innate immune responses to inactivated Leptospira and bivalent Leptospira vaccines in canine 030-D cells.
Novak A, Pennings JLA, van der Maas L, Meiring HD, Ludwig I, Verkoeijen S, Rutten V, Broere F, Sloots A. Sci Rep. 2022 Aug 4;12(1):13418. doi: 10.1038/s41598-022-16457-z. PMID: 35927283

A scoping review of literature exploring factors affecting **vaccine** uptake within Roma communities across Europe.
Cronin A, Ibrahim N. Expert Rev Vaccines. 2022 Aug 1:1-14. doi: 10.1080/14760584.2022.2104715. Online ahead of print. PMID: 35877604

Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA **vaccine** against SARS-CoV-2.
Casado JL, Vizcarra P, Haemmerle J, Velasco H, Martín-Hondarza A, Rodríguez-Domínguez MJ, Velasco T, Martín S, Romero-Hernández B, Fernández-Escribano M, Vallejo A. Vaccine X. 2022 Aug;11:100165. doi: 10.1016/j.jvacx.2022.100165. Epub 2022 May 2. PMID: 35529539 F

Human papillomavirus **vaccine** communication materials for young people in English-speaking countries: A content analysis.
Fisher H, Chantler T, Mounier-Jack S, Audrey S. Health Educ J. 2022 Aug;81(5):513-528. doi: 10.1177/00178969221092135. Epub 2022 Apr 14. PMID: 35910267

Keratoplasty rejection after messenger RNA **vaccine** (BNT162b2) for COVID-19.
Eduarda Andrade E Andrade M, Rodrigues JC, Junior EF, de Lima MHC. Indian J Ophthalmol. 2022 Aug;70(8):3134-3136. doi: 10.4103/ijo.IJO_1021_22. PMID: 35918988

Surveillance on Adverse Events Following COVISHIELD (ChAdOx1 nCoV-19) vaccination in Goa, India: An observational study.
Jose D, Dhupdale N, Cacodcar JA, Kamat U. Curr Drug Saf. 2022 Aug 3. doi: 10.2174/1574886317666220803104438. Online ahead of print. PMID: 35927820

Allergic reactions to the coronavirus disease 2019 **vaccine** (ARCOV) study: The McGill University Health Centre experience.
ALMuhizi F, Fein M, Gabrielli S, Gilbert L, Tsoukas C, Ben-Shoshan M, Copaescu AM, Isabwe GAC. Ann Allergy Asthma Immunol. 2022 Aug;129(2):182-188.e1. doi: 10.1016/j.anai.2022.05.014. Epub 2022 May 21. PMID: 35609744

mRNA COVID-19 **Vaccine**-Associated Subserosal Eosinophilic Gastroenteritis: A Case Report.
Lee JY, Lee JH. J Korean Med Sci. 2022 Aug 1;37(30):e233. doi: 10.3346/jkms.2022.37.e233. PMID: 35916045

Authors' response: Re: Reifferscheid et al., "COVID-19 **vaccine** uptake and intention during pregnancy in Canada".
MacDonald SE, Reifferscheid L, Bettinger JA, Robinson J, Sadarangani M, Dubé E, MacDonald NE, Marfo E, Assi A, Gagneur A, Driedger SM. Can J Public Health. 2022 Aug;113(4):560-561. doi: 10.17269/s41997-022-00657-1. PMID: 35641850

Implications of the SARS-CoV-2 subvariants BA.4 and BA.5.
Rahimi F, Talebi Bezmin Abadi A. Int J Surg. 2022 Aug 2;104:106806. doi: 10.1016/j.ijsu.2022.106806. Online ahead of print. PMID: 35926828

Predictors of **vaccine** hesitancy during the COVID-19 pandemic in Austria : A population-based cross-sectional study.

Till B, Niederkrotenthaler T. Wien Klin Wochenschr. 2022 Aug 10. doi: 10.1007/s00508-022-02061-8. Online ahead of print. PMID: 35947223

Cost-utility analysis of the universal pneumococcal vaccination programme for older adults in Norway.
Nymark LS, Dag Berild J, Lyngstad TM, Askeland Winje B, Frimann Vestrheim D, Aaberge I, Juvet LK, Wolff E. Hum Vaccin Immunother. 2022 Aug 2:2101333. doi: 10.1080/21645515.2022.2101333. Online ahead of print. PMID: 35917277

'Get your own house in order': Qualitative dialogue groups with nonvaccinating parents on how measles outbreaks in their community should be managed.
Wiley K, Robinson P, Degeling C, Ward P, Leask J, Carter S. Health Expect. 2022 Aug;25(4):1678-1690. doi: 10.1111/hex.13511. Epub 2022 May 12. PMID: 35548872

Vaccination against COVID-19 as prevention of occupational disease in University of Defence members in the Czech Republic - motivation for vaccination and reasons for hesitancy.
Kupsova B, Pavlik V, Horacek JM, Stepanek L. Bratisl Lek Listy. 2022 Aug 1. doi: 10.4149/BLL_2022_120. Online ahead of print. PMID: 35913011

A case of transient POTS following COVID-19 **vaccine**.
Park J, Kim S, Lee J, An JY. Acta Neurol Belg. 2022 Aug;122(4):1081-1083. doi: 10.1007/s13760-022-02002-2. Epub 2022 Jun 20. PMID: 35725868

Neutralization against Omicron variant in transplant recipients after three doses of mRNA **vaccine**.
Kumar D, Hu Q, Samson R, Ferreira VH, Hall VG, Ierullo M, Majchrzak-Kita B, Hardy W, Gingras AC, Humar A. Am J Transplant. 2022 Aug;22(8):2089-2093. doi: 10.1111/ajt.17020. Epub 2022 Mar 21. PMID: 35266606

Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
Sansone G, Bonifati DM. J Neurol. 2022 Aug;269(8):3965-3981. doi: 10.1007/s00415-022-11140-9. Epub 2022 May 3. PMID: 35503373

Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: Is inactivated **vaccine** effective?
Murt A, Altiparmak MR, Yadigar S, Yalin SF, Ozbey D, Yildiz Z, Kocazeybek B, Pekpak M, Ataman MR. Ther Apher Dial. 2022 Aug;26(4):769-774. doi: 10.1111/1744-9987.13752. Epub 2021 Nov 16. PMID: 34741418

COVID-19 **vaccine**-associated ganulomatous mass mimicking a sarcoma: a case report.
Quintero D, Patel N, Harris G, Maristany A, Alani A, Rosenberg AE, Conway SA, Jose J. Radiol Case Rep. 2022 Jun 3;17(8):2775-2778. doi: 10.1016/j.radcr.2022.05.035. eCollection 2022 Aug. PMID: 35677708

SARS-CoV-2 antibody response after BNT162b2 mRNA **vaccine** in healthcare workers: Nine-month of follow-up.
Mastroianni F, Guida P, Bellanova G, Valentina De Nicolò E, Righetti G, Formoso M, Celani F. Vaccine X. 2022 Aug;11:100175. doi: 10.1016/j.jvacx.2022.100175. Epub 2022 Jun 6. PMID: 35692461

Lower **vaccine**-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third **vaccine** dose.
Renia L, Goh YS, Rouers A, Le Bert N, Chia WN, Chavatte JM, Fong SW, Chang ZW, Zhuo NZ, Tay MZ, Chan YH, Tan CW, Yeo NK, Amrun SN, Huang Y, Wong JXE, Hor PX, Loh CY, Wang B, Ngoh EZX, Salleh SNM, Carissimo G, Dowla S, Lim AJ, Zhang J, Lim JME, Wang CI, Ding Y, Pada S, Sun LJ, Somani J, Lee ES, Ong DLS; SCOPE Cohort Study Group, Leo YS, MacAry PA, Lin RTP, Wang LF, Ren EC, Lye DC, Bertoletti A, Young BE, Ng LFP. Nat Commun. 2022 Aug 8;13(1):4615. doi: 10.1038/s41467-022-32312-1. PMID: 35941158

Public attitudes about equitable COVID-19 **vaccine** allocation: a randomised experiment of race-based versus novel place-based frames.
Schmidt H, Shaikh SJ, Sadecki E, Buttenheim A, Gollust S. J Med Ethics. 2022 Aug 4:medethics-2022-108194. doi: 10.1136/jme-2022-108194. Online ahead of print. PMID: 35927020

Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 **Vaccine** MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study.
Hsieh SM, Chang SC, Cheng HY, Shih SR, Lien CE. Infect Dis Ther. 2022 Aug;11(4):1493-1504. doi: 10.1007/s40121-022-00652-6. Epub 2022 May 17. PMID: 35579840

COVID-19 cases, hospitalizations and deaths after vaccination: a cohort event monitoring study, Islamic Republic of Iran.
Hosseinzadeh A, Sahab-Negah S, Nili S, Aliyari R, Goli S, Fereidouni M, Alami A, Shati M, Ahmadnezhad E, Mehravaran S, Fateh M, Khajeha H, Emamian Z, Behmanesh E, Mahdavi S, Enayatrad M, Mangolian Shahrbabaki P, Ansari-Moghaddam A, Heidarzadeh A, Shahraki-Sanavi F, Hashemi Shahri SM, Dehghan M, Amini Moridani M, Sheibani H, Abbaszadeh M, Jafari R, Valikhani M, Binesh E, Vahedi H, Chaman R, Khodashahi R, Amini M, Jabbari Azad F, Rezaeitalab F, Amel Jamehdar S, Eshraghi A, Sharifi H, Hashemi Bajgani SM, Mahdavi A, Jafarzadeh A, Farokhnia M, Ebrahimi S, Pardakhti A, Ghaderi E, Soltani H, Jadidoleslami S, Arianejad A, Gavili H, Moradveisi B, Motamedi D, Zare H, Kazemi T, Emamian MH. Bull World Health Organ. 2022 Aug 1;100(8):474-483. doi: 10.2471/BLT.22.288073. Epub 2022 Jun 22. PMID: 35923277

Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 **vaccine** in Brazilian healthcare workers.
Lin-Wang HT, Lemes RC, da Silva Farias E, Bajgelman MC, Franchini KG, Viana R, Gun C. J Med Virol. 2022 Aug;94(8):3714-3721. doi: 10.1002/jmv.27782. Epub 2022 Apr 27. PMID: 35420709

Management of oral lesions following COVID-19 vaccination.
Joseph B, Yadalam PK, Anegundi RV. Oral Dis. 2022 Aug 7. doi: 10.1111/odi.14342. Online ahead of print. PMID: 35933735

DNA **vaccine** dual-expressing viral hemorrhagic septicemia virus glycoprotein and C-C motif chemokine ligand 19 induces the expression of immune-related genes in zebrafish (Danio rerio).
Kim JY, Kim HJ, Park JS, Kwon SR. J Microbiol. 2022 Aug 1. doi: 10.1007/s12275-022-2231-8. Online ahead of print. PMID: 35913595

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 **vaccine** in Chinese adults: a randomised, open-label, single-centre trial.
Li JX, Wu SP, Guo XL, Tang R, Huang BY, Chen XQ, Chen Y, Hou LH, Liu JX, Zhong J, Pan HX, Shi FJ, Xu XY, Li ZP, Zhang XY, Cui LB, Tan WJ, Chen W, Zhu FC; CanSino COVID-19 Study Group. Lancet Respir Med. 2022 Aug;10(8):739-748. doi: 10.1016/S2213-2600(22)00087-X. Epub 2022 May 20. PMID: 35605625

[Expert consensus on the use of combination **vaccine** and simultaneous immunization in children aged 0-12 months].
Immunization Service Guidance and Evaluation Committee, China Association for Vaccines. Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Aug 6;56(8):1035-1041. doi: 10.3760/cma.j.cn112150-20220429-00427. PMID: 35922228

Th2-Biased Transcriptional Profile Predicts HIV Envelope-Specific Polyfunctional CD4$^+$ T Cells That Correlated with Reduced Risk of Infection in RV144 Trial.
Cohen KW, Tian Y, Thayer C, Seese A, Amezquita R, McElrath MJ, De Rosa SC, Gottardo R. J Immunol. 2022 Aug 1;209(3):526-534. doi: 10.4049/jimmunol.2101211. Epub 2022 Jul 8. PMID: 35803696

Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV **vaccine**: A comparative study among healthcare professionals of Nepal.
Rayamajhi S, Rafi MA, Tripathi N, Dongol AS, Pandey M, Rayamajhi S, Bhandari S, Shrestha P, Hasan MT, Hossain MG. PLoS One. 2022 Aug 10;17(8):e0272729. doi: 10.1371/journal.pone.0272729. eCollection 2022. PMID: 35947626

COVID-19 update: FDA authorizes Novavax COVID-19 **vaccine**.
[No authors listed] Med Lett Drugs Ther. 2022 Aug 8;64(1656):121-122. PMID: 35921073

Efficacy and safety of an inactivated whole-virion **vaccine** against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up.
Khairullin B, Zakarya K, Orynbayev M, Abduraimov Y, Kassenov M, Sarsenbayeva G, Sultankulova K, Chervyakova O, Myrzakhmetova B, Nakhanov A, Nurpeisova A, Zhugunissov K, Assanzhanova N, Nurabayev S, Kerimbayev A, Yershebulov Z, Burashev Y, Kulmagambetov I, Davlyatshin T, Sergeeva M, Buzitskaya Z, Stukova M, Kutumbetov L. EClinicalMedicine. 2022 Jun 25;50:101526. doi: 10.1016/j.eclinm.2022.101526. eCollection 2022 Aug. PMID: 35770251

"I'm Off My Meds": Public Perception of Interactions Between SARS-CoV-2 Vaccines and Anti-Psoriatic Treatments Online.
Yee D, Reddy R, Khan S, Mehta M, Khan S, Maynard N, Zagona-Prizio C, Armstrong A. J Drugs Dermatol. 2022 Aug 1;21(8):901-905. doi: 10.36849/JDD.6853. PMID: 35946967

Inactivated genotype 1a, 2a and 3a HCV **vaccine** candidates induced broadly neutralising antibodies in mice.
Alzua GP, Pihl AF, Offersgaard A, Duarte Hernandez CR, Duan Z, Feng S, Fahnøe U, Sølund C, Weis N, Law M, Prentoe JC, Christensen JP, Bukh J, Gottwein JM. Gut. 2022 Aug 2:gutjnl-2021-326323. doi: 10.1136/gutjnl-2021-326323. Online ahead of print. PMID: 35918103

Assessing the influence of French **vaccine** critics during the two first years of the COVID-19 pandemic.
Faccin M, Gargiulo F, Atlani-Duault L, Ward JK. PLoS One. 2022 Aug 4;17(8):e0271157. doi: 10.1371/journal.pone.0271157. eCollection 2022. PMID: 35925962

An influenza virus vector candidate **vaccine** stably expressing SARS-CoV-2 receptor-binding domain produces high and long-lasting neutralizing antibodies in mice.
Zhao Y, Zhao L, Li Y, Liu Q, Deng L, Lu Y, Zhang X, Li S, Ge J, Bu Z, Ping J. Vet Microbiol. 2022 Aug;271:109491. doi: 10.1016/j.vetmic.2022.109491. Epub 2022 Jun 9. PMID: 35714529

Physical and mental health characteristics related to trust and intention toward COVID-19 **vaccine**: results from a community-based longitudinal study.
Jeon YJ, Lee Y, Yang JS, Park YS, Jung SJ. Epidemiol Health. 2022 Aug 3:e2022064. doi: 10.4178/epih.e2022064. Online ahead of print. PMID: 35940179

Effectiveness of the BNT162b2 mRNA COVID-19 **Vaccine** among Adolescents with Juvenile-onset Inflammatory Rheumatic Diseases.
Ziv A, Heshin-Bekenstein M, Haviv R, Kivity S, Netzer D, Yaron S, Schur Y, Egert T, Egert Y, Sela Y, Hashkes PJ, Uziel Y. Rheumatology (Oxford). 2022 Aug 3:keac408. doi: 10.1093/rheumatology/keac408. Online ahead of print. PMID: 35920789

Case report: mRNA COVID-19 **vaccine**-related acute pericarditis with evolution to myopericarditis.
Riddell C, Edwards NC, Stewart R. Eur Heart J Case Rep. 2022 Jul 25;6(8):ytac298. doi: 10.1093/ehjcr/ytac298. eCollection 2022 Aug. PMID: 35935395

Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza **vaccine** in adults aged ≥60 years.
Yin JK, Pepin S, van Aalst R, Loiacono MM, Samson SI. Hum Vaccin Immunother. 2022 Aug 1:2106749. doi: 10.1080/21645515.2022.2106749. Online ahead of print. PMID: 35914122

Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA **vaccine**-elicited antibodies.
Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D, Silacci-Fregni C, Bianchi S, Tortorici MA, Bowen J, Culap K, Jaconi S, Cameroni E, Snell G, Pizzuto MS, Pellanda AF, Garzoni C, Riva A; CITIID-NIHR BioResource COVID-19 Collaboration, Elmer A, Kingston N, Graves B, McCoy LE, Smith KGC, Bradley JR, Temperton N, Ceron-Gutierrez L, Barcenas-Morales G; COVID-19 Genomics UK (COG-UK) Consortium, Harvey W, Virgin HW, Lanzavecchia A, Piccoli L, Doffinger R, Wills M, Veesler D, Corti D, Gupta RK. Nature. 2022 Aug;608(7922):E24. doi: 10.1038/s41586-022-05103-3. PMID: 35864232

SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 **vaccine**.
Yavuz E, Günal Ö, Başbulut E, Şen A. J Med Virol. 2022 Aug;94(8):3768-3775. doi: 10.1002/jmv.27794. Epub 2022 Apr 23. PMID: 35434796

Older people's experience of COVID-19 restrictions on **vaccine** hesitancy: A longitudinal phenomenological study to support nurse-patient vaccination conversations.

Brooke J, Dunford S. J Adv Nurs. 2022 Aug 2. doi: 10.1111/jan.15398. Online ahead of print. PMID: 35919020

Immunoinformatic screening of Marburgvirus epitopes and computational investigations of epitope-allele complexes.
Baral P, Pavadai E, Zhou Z, Xu Y, Tison CK, Pokhrel R, Gerstman BS, Chapagain PP. Int Immunopharmacol. 2022 Aug 1;111:109109. doi: 10.1016/j.intimp.2022.109109. Online ahead of print. PMID: 35926269

One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell **vaccine** or Vero cell rabies **vaccine**, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety.
Quiambao BP, Lim JG, Bosch Castells V, Augard C, Petit C, Bravo C, Delore V, Houillon G. Vaccine. 2022 Aug 3:S0264-410X(22)00923-9. doi: 10.1016/j.vaccine.2022.07.037. Online ahead of print. PMID: 35933278

Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles.
Xiong X, Ke X, Wang L, Lin Y, Wang S, Yao Z, Li K, Luo Y, Liu F, Pan Y, Yeung SJ, Helfrich W, Zhang H. J Extracell Vesicles. 2022 Aug;11(8):e12243. doi: 10.1002/jev2.12243. PMID: 35927827

Acute coronary syndromes following COVID-19 **vaccine** application: Kounis syndrome or chance?
Rueda-Ibarra L, Manríque-Gualdron AM, Bayona-Gamboa AJ, Acuña-Ocampo JD, Picón-Jaimes YA, Lozada-Martinez ID, Narvaez-Rojas AR. Ann Med Surg (Lond). 2022 Jul 14;80:104188. doi: 10.1016/j.amsu.2022.104188. eCollection 2022 Aug. PMID: 35855447

New-onset psoriasis after Comirnaty (BNT162b2, BioNTech/Pfizer) **vaccine** successfully treated with ixekizumab.
Cortonesi G, Orsini C, Rubegni P, Trovato E. Dermatol Ther. 2022 Aug;35(8):e15606. doi: 10.1111/dth.15606. Epub 2022 Jun 8. PMID: 35635756

Immunological characterization of chitosan adjuvanted outer membrane proteins of Salmonella enterica serovar Typhi as multi-epitope typhoid **vaccine** candidate.
Ayub A, Usman M, Ihsan A, Ain Q, Awan AB, Wajid M, Ali A, Haque A, Iqbal M, Sarwar Y. Mol Biol Rep. 2022 Aug;49(8):7377-7387. doi: 10.1007/s11033-022-07531-w. Epub 2022 Jun 17. PMID: 35713798

Vaccines against chicken coccidiosis with particular reference to previous decade: progress, challenges, and opportunities.
Zaheer T, Abbas RZ, Imran M, Abbas A, Butt A, Aslam S, Ahmad J. Parasitol Res. 2022 Aug 4:1-15. doi: 10.1007/s00436-022-07612-6. Online ahead of print. PMID: 35925452

Haematological changes and adverse events associated with BNT162b2 mRNA COVID-19 **vaccine** in patients receiving clozapine-Findings from an audit.
Lim S, Liew E, Leo A, Ng BT, Lee J. Acta Psychiatr Scand. 2022 Aug;146(2):179-181. doi: 10.1111/acps.13443. Epub 2022 Jun 15. PMID: 35582980

Letter to the editor: Nanoparticle therapeutic **vaccine** for hepatitis B: An unfulfilled dream.
Patwa AK, Rungta S, Kumar V. Hepatology. 2022 Aug;76(2):E29. doi: 10.1002/hep.32421. Epub 2022 Mar 11. PMID: 35226773

Phase 1 success for a trivalent **vaccine** for the equine encephalitis viruses.
Suhrbier A. Lancet Infect Dis. 2022 Aug;22(8):1100-1102. doi: 10.1016/S1473-3099(22)00122-0. Epub 2022 May 11. PMID: 35568050

Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell **Vaccine** Mediated T Cell Responses in Breast Cancer Model.
Barshidi A, Karpisheh V, Noukabadi FK, Kiani FK, Mohammadi M, Afsharimanesh N, Ebrahimi F, Kiaie SH, Navashenaq JG, Hojjat-Farsangi M, Zolbanin NM, Mahmoodpoor A, Hassannia H, Nami S, Jalali P, Jafari R, Jadidi-Niaragh F. Pharm Res. 2022 Aug;39(8):1851-1866. doi: 10.1007/s11095-022-03297-9. Epub 2022 Jun 17. PMID: 35715669

Efficacy of Sinopharm **Vaccine** among Stem Cell Transplant Recipient during two peaks of Delta and Omicron variants of COVID-19.
Ghasemi A, Khodashahi R, Aliakbarian M, Khaleghi E, Razmkhah B, Vahdatinia M, Far MS, Bakhti O. Curr Drug Saf. 2022 Aug 1. doi: 10.2174/1574886317666220801122822. Online ahead of print. PMID: 35927906

Immunogenicity correlation in cynomolgus monkeys between Luminex-based total IgG immunoassay and pseudovirion-based neutralization assay for a 14-valent recombinant human papillomavirus **vaccine**.
Bei L, Zhang X, Meng D, Gao S, Jia J, Zhao D, Luo C, Li X, Qiu H, Xie L. J Med Virol. 2022 Aug;94(8):3946-3955. doi: 10.1002/jmv.27763. Epub 2022 Apr 21. PMID: 35388509

Influenza **vaccine** among patients with coronary artery disease.
Mohamed H, Karim AA, Hani J, Wissam K, Ayman E; INFCAD. Eur J Intern Med. 2022 Aug 1:S0953-6205(22)00265-5. doi: 10.1016/j.ejim.2022.07.018. Online ahead of print. PMID: 35927188

New-onset kidney biopsy-proven IgA vasculitis after receiving mRNA-1273 COVID-19 **vaccine**: case report.
Nakatani S, Mori K, Morioka F, Hirata C, Tsuda A, Uedono H, Ishimura E, Tsuruta D, Emoto M. CEN Case Rep. 2022 Aug;11(3):358-362. doi: 10.1007/s13730-021-00677-9. Epub 2022 Jan 25. PMID: 35075622

Bullous pemphigoid following COVID-19 **vaccine**: An autoimmune disorder.
Aashish, Rai A, Khatri G, Priya, Hasan MM. Ann Med Surg (Lond). 2022 Aug;80:104266. doi: 10.1016/j.amsu.2022.104266. Epub 2022 Jul 31. PMID: 35936564

Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 **vaccine** in liver transplant recipients.
Meunier L, Sanavio M, Dumortier J, Meszaros M, Faure S, Ursic Bedoya J, Echenne M, Boillot O, Debourdeau A, Pageaux GP. Liver Int. 2022 Aug;42(8):1872-1878. doi: 10.1111/liv.15258. Epub 2022 Apr 2. PMID: 35338550

Commentary on "Potential risk factors for Varicella-zoster virus reactivation after COVID-19 vaccination".
Turkmen D, Altunisik N, Altunisik Toplu S. J Cosmet Dermatol. 2022 Aug;21(8):3627-3628. doi: 10.1111/jocd.14976. Epub 2022 Apr 12. PMID: 35390221

Comparative analysis of antigenic strength and *in vivo* serum antibodies concentration of tetanus toxoid **vaccine** adsorbed in Pakistan.
Zahid AS, Farooqi HMU, Ahsan A, Farooqi MA, Kausar F, Muhammad J, Ahmad A. Saudi J Biol Sci. 2022 Aug;29(8):103337. doi: 10.1016/j.sjbs.2022.103337. Epub 2022 Jun 7. PMID: 35770270

Rare cutaneous reactions after ChAdOx1 (Oxford-AstraZeneca) **vaccine**: 12 case series from Brazil.
Seque CA, Enokihara MMSS, Nascimento MM, Porro AM, Tomimori J. J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e601-e603. doi: 10.1111/jdv.18112. Epub 2022 Apr 12. PMID: 35349766

Poor Response to Inactivated SARS-CoV-2 **Vaccine** in Patients With Chronic Liver Disease.
Cao H, Fan R. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1892-1893. doi: 10.1016/j.cgh.2022.01.029. Epub 2022 Feb 3. PMID: 35123090

Estimating COVID-19 **Vaccine** Effectiveness for Skilled Nursing Facility Healthcare Personnel, California, USA.
Magro M, Parriott A, Mitsunaga T, Epson E. Emerg Infect Dis. 2022 Aug;28(8):1734-1736. doi: 10.3201/eid2808.220650. Epub 2022 Jun 22. PMID: 35732196

Seizures following COVID-19 vaccination in Mexico: a nationwide observational study.
Núñez I, García-Grimshaw M, Castillo Valencia CY, Aguilera Callejas DE, Moya Alfaro ML, Del Mar Saniger-Alba M, Gutiérrez-Romero A, Carrillo-Mezo R, Ceballos-Liceaga SE, Baptista-Rosas RC, López-Gatell H, Reyes-Terán G, Díaz-Ortega JL, Arauz A, Valdés-Ferrer SI, Hernández-Vanegas LE. Epilepsia. 2022 Aug 9. doi: 10.1111/epi.17390. Online ahead of print. PMID: 35943891

Antibody response following a Comirnaty booster dose in CoronaVac vaccinated individuals.
Bochnia-Bueno L, Nogueira MB, Genelhoud G, Raboni SM. Diagn Microbiol Infect Dis. 2022 Aug;103(4):115730. doi: 10.1016/j.diagmicrobio.2022.115730. Epub 2022 May 26. PMID: 35716421

Response to mRNA COVID-19 vaccination in three XLA patients.
Squire JD, Joshi AY. Vaccine. 2022 Aug 3:S0264-410X(22)00941-0. doi: 10.1016/j.vaccine.2022.07.046. Online ahead of print. PMID: 35934578

Response to Third Dose of **Vaccine** Against SARS-CoV-2 in Adolescent and Young Adult Kidney Transplant Recipients.
Cirillo L, Citera F, Mazzierli T, Becherucci F, Terlizzi V, Lodi L, Buti E, Romagnani P. Transplantation. 2022 Aug 1;106(8):e386-e387. doi: 10.1097/TP.0000000000004199. Epub 2022 May 18. PMID: 35581690

Trends and prospects in oral cancer **vaccine**.
Sarode GS, Kumari N, Gophane R, Ghone U, Sharma N, Sarode SC. Oral Oncol. 2022 Aug 5;133:106051. doi: 10.1016/j.oraloncology.2022.106051. Online ahead of print. PMID: 35939917

Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral **vaccine**.

Hawman DW, Meade-White K, Clancy C, Archer J, Hinkley T, Leventhal SS, Rao D, Stamper A, Lewis M, Rosenke R, Krieger K, Randall S, Khandhar AP, Hao L, Hsiang TY, Greninger AL, Gale M Jr, Berglund P, Fuller DH, Rosenke K, Feldmann H, Erasmus JH. EBioMedicine. 2022 Aug 3;83:104196. doi: 10.1016/j.ebiom.2022.104196. Online ahead of print. PMID: 35932641

Long-Term Evaluation of Sperm Parameters Following COVID-19 mRNA Vaccination.
Diaz P, Dullea A, Patel M, Blachman-Braun R, Reddy R, Khodamoradi K, Ibrahim E, Bidhan J, Ramasamy R. F S Rep. 2022 Aug 3. doi: 10.1016/j.xfre.2022.07.007. Online ahead of print. PMID: 35936108

Lupus anticoagulant activity and thrombosis post COVID-19 vaccination.
Al-Ahmad M, Al Rasheed M, Altourah L, Rodriguez-Bouza T, Shalaby N. Blood Coagul Fibrinolysis. 2022 Aug 10. doi: 10.1097/MBC.0000000000001161. Online ahead of print. PMID: 35946452

Severe de novo liver injury after Moderna vaccination - not always autoimmune hepatitis.
Nyein CM, Liew ZHS, Leow WQ, Yeong PSJ, Ho GH. J Hepatol. 2022 Aug;77(2):556-558. doi: 10.1016/j.jhep.2022.03.041. Epub 2022 Apr 18. PMID: 35439566

The impact of temporary methotrexate discontinuation for 1 week versus 2 weeks on seasonal influenza vaccination in patients with rheumatoid arthritis.
Park JK, Lee YJ, Shin K, Kang EH, Ha YJ, Park JW, Kim MJ, Kim MH, Choi SR, Jung Y, Lee JH, In Jung J, Kim JY, Winthrop KL, Lee EB. Arthritis Rheumatol. 2022 Aug 5. doi: 10.1002/art.42318. Online ahead of print. PMID: 35930728

Kidney transplantation from deceased donors with **vaccine**-induced thrombosis and thrombocytopenia (VITT): definitely feasible and safe?
Picciotto D, Bussalino E, Paoletti E. Transpl Infect Dis. 2022 Aug 4. doi: 10.1111/tid.13921. Online ahead of print. PMID: 35924729

Increased Incidence of Invasive Pneumococcal Disease among Children after COVID-19 Pandemic, England.
Bertran M, Amin-Chowdhury Z, Sheppard CL, Eletu S, Zamarreño DV, Ramsay ME, Litt D, Fry NK, Ladhani SN. Emerg Infect Dis. 2022 Aug;28(8):1669-1672. doi: 10.3201/eid2808.220304. PMID: 35876698

[Pityriasis rubra pilaris after COVID-19 vaccination: causal relationship or coincidence?].
Bramhoff AC, Wesselmann U, Bender ST, Berghoff AV, Hofmann SC, Balakirski G. Dermatologie (Heidelb). 2022 Aug;73(8):634-637. doi: 10.1007/s00105-022-04972-z. Epub 2022 Mar 16. PMID: 35296923

Enhanced antitumor activity induced by a DNA **vaccine** encoding E7 antigen fused to an ERAD-targeting sequence.
Martínez-Puente DH, Garza-Morales R, Pérez-Trujillo JJ, Bernabé-Acosta F, Villanueva-Olivo A, García-García A, Zavala-Flores LM, Rodríguez-Rocha H, Valdés J, Saucedo-Cárdenas O, Montes de Oca-Luna R, Loera-Arias MJ. J Drug Target. 2022 Aug 8:1-9. doi: 10.1080/1061186X.2022.2107651. Online ahead of print. PMID: 35896308

Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA **vaccine** in Chinese adults.

Liu X, Li Y, Wang Z, Cao S, Huang W, Yuan L, Huang YJ, Zheng Y, Chen J, Ying B, Xiang Z, Shi J, Zhao J, Huang Z, Qin CF. Cell Res. 2022 Aug;32(8):777-780. doi: 10.1038/s41422-022-00681-3. Epub 2022 Jun 14. PMID: 35701541

Subacute thyroiditis after the third dose of the COVID-19 mRNA **vaccine**. Case report.
Frangos S, Haralambous H, Michael K, Economides PA. Hell J Nucl Med. 2022 Aug 3:s002449912481. doi: 10.1967/s002449912481. Online ahead of print. PMID: 35913868

Perceived barriers to Palestinian pregnant women's acceptance of COVID-19 vaccination using the Health Believe Model: a cross-sectional study.
Qasrawi H, Abdullah I, Masri H, Maraqa B, Mohammad A, Qub L, Alkarajeh M, Dweik M, Atabeh S, Jalamneh T, Alajrami Y, Nazzal Z. Women Health. 2022 Aug 3:1-10. doi: 10.1080/03630242.2022.2108194. Online ahead of print. PMID: 35922887

The identification of polyvalent protective immunogens and immune abilities from the outer membrane proteins of Aeromonas hydrophila in fish.
Liu X, Rong N, Sun W, Jian S, Chao J, Chen C, Chen R, Ding R, Chen C, Liu Y, Zhang X. Fish Shellfish Immunol. 2022 Aug 1;128:101-112. doi: 10.1016/j.fsi.2022.07.057. Online ahead of print. PMID: 35926820

Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 **vaccine** in non-dialysis kidney disease patients.
Zhang YM, Liu XZ, Lin MM, Zan JC, Hu YT, Wang XQ, Wu WQ, Zhou TC, Lv JC, Zhang H, Yang L, Zhang ZJ. J Infect. 2022 Aug;85(2):174-211. doi: 10.1016/j.jinf.2022.05.003. Epub 2022 May 9. PMID: 35550381

Who's vaccinated? A closer look at healthcare workers' coronavirus disease 2019 (COVID-19) COVID-19 **vaccine** hesitancy and demographics.
Fossen MC, Bethany MD, Modak SR, Parris SM, Modak RM. Infect Control Hosp Epidemiol. 2022 Aug;43(8):1093-1094. doi: 10.1017/ice.2021.192. Epub 2021 May 3. PMID: 33934737

Catholic Medical Association Opposes **Vaccine** Mandates without Conscience and Religious Exemptions.
[No authors listed] Linacre Q. 2022 Aug;89(3):343-344. doi: 10.1177/00243639211042801. Epub 2021 Sep 7. PMID: 35875382

An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 **vaccine**.
Okada M, Kikuchi E, Nagasawa M, Oshiba A, Shimoda M. CEN Case Rep. 2022 Aug;11(3):376-379. doi: 10.1007/s13730-021-00679-7. Epub 2022 Feb 3. PMID: 35118635

A potential immunological silver bullet for COVID-19: The trivalent chimpanzee adenoviral serotype-68 vector (Tri:ChAd).
Ardicli O, Azkur AK, Azkur D. Allergy. 2022 Aug;77(8):2565-2567. doi: 10.1111/all.15333. Epub 2022 May 17. PMID: 35491434

A recombinant protein **vaccine** encoding Toxoplasma gondii Cyst wall 2 (dense granule protein 47) provides partial protection against acute and chronic T. gondii infection in BALB/c mice.
Tian X, Wang M, Xie T, Wan G, Sun H, Mei X, Zhang Z, Li X, Wang S. Acta Trop. 2022 Aug;232:106514. doi: 10.1016/j.actatropica.2022.106514. Epub 2022 May 14. PMID: 35580637

Effectiveness of mRNA booster **vaccine** among health Care workers in New York City during the omicron surge, December 2021- January 2022.
Robilotti EV, Whiting K, Lucca A, Poon C, Jani K, McMillen T, Freeswick S, Korenstein D, Babady NE, Seshan VE, Kamboj M. Clin Microbiol Infect. 2022 Aug 2:S1198-743X(22)00385-8. doi: 10.1016/j.cmi.2022.07.017. Online ahead of print. PMID: 35931373

Deciding about maternal pertussis vaccination: associations between intention, and needs and values in a **vaccine**-hesitant religious group.
de Munter AC, Hautvast JLA, Ruijs WLM, Henri Spaan D, Hulscher MEJL, Ruiter RAC. Vaccine. 2022 Aug 1:S0264-410X(22)00924-0. doi: 10.1016/j.vaccine.2022.07.036. Online ahead of print. PMID: 35927135

Predictors of COVID-19 **Vaccine** Uptake in Health Care Workers: A Cross-Sectional Study in Greece.
Galanis P, Moisoglou I, Vraka I, Siskou O, Konstantakopoulou O, Katsiroumpa A, Kaitelidou D. J Occup Environ Med. 2022 Aug 1;64(8):e523. doi: 10.1097/JOM.0000000000002581. Epub 2022 Jun 11. PMID: 35672912

Immunogenic Evaluation of MPEG-PCL & PLGA Nanoparticles Containing Klebsiella pneumoniae K2O1 Capsular Antigen in Pulmonary Infection Model of Mice.
Ghaderinia P, Shapouri R, Rostamizadeh K, Khodavandi A, Mahdavi M. IEEE Trans Nanobioscience. 2022 Aug 1;PP. doi: 10.1109/TNB.2022.3195483. Online ahead of print. PMID: 35914048

Stopping Oral Polio **Vaccine** (OPV) After Defeating Poliomyelitis in Low- and Middle-Income Countries: Harmful Unintended Consequences? Review of the Nonspecific Effects of OPV.
Aaby P, Nielsen S, Fisker AB, Pedersen LM, Welaga P, Hanifi SMA, Martins CL, Rodrigues A, Chumakov K, Benn CS. Open Forum Infect Dis. 2022 Jul 27;9(8):ofac340. doi: 10.1093/ofid/ofac340. eCollection 2022 Aug. PMID: 35937644

Analysis of older adults visiting the emergency department with fever as a suspected Covid-19 **vaccine**-related adverse reaction: A retrospective multicenter study.
Jeong S, Hong S, Oh T, Woo SH, Lee WJ, Kim D, Jeong WJ. J Infect Chemother. 2022 Aug;28(8):1159-1164. doi: 10.1016/j.jiac.2022.04.022. Epub 2022 May 2. PMID: 35513970

Risk of myopericarditis following COVID-19 mRNA vaccination in a large integrated health system: A comparison of completeness and timeliness of two methods.
Sharff KA, Dancoes DM, Longueil JL, Johnson ES, Lewis PF. Pharmacoepidemiol Drug Saf. 2022 Aug;31(8):921-925. doi: 10.1002/pds.5439. Epub 2022 Apr 16. PMID: 35404496

Autopsy Histopathologic Cardiac Findings in 2 Adolescents Following the Second COVID-19 **Vaccine** Dose.
Paddock CD, Reagan-Steiner S, Su JR, Oster ME, Martines RB, Bhatnagar J, Shimabukuro TT. Arch Pathol Lab Med. 2022 Aug 1;146(8):921-923. doi: 10.5858/arpa.2022-0084-LE. PMID: 35395076

Disseminated herpes zoster in an immune-competent patient after SARS-CoV-2 **vaccine** (BNT162b2 Comirnaty, Pfizer).
Zengarini C, Misciali C, Ferrari T, Dika E, La Placa M, Piraccini BM, Baraldi C. J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e622-e623. doi: 10.1111/jdv.18154. Epub 2022 Apr 26. PMID: 35429051

Refractory hypereosinophilia associated with newly diagnosed rheumatoid arthritis following inactivated BBV152 COVID-19 **vaccine**.
Singh R, Kaur U, Singh A, Chakrabarti SS. J Med Virol. 2022 Aug;94(8):3482-3487. doi: 10.1002/jmv.27742. Epub 2022 Apr 9. PMID: 35352366

Complete Genome Sequences of Three Mycoplasma gallisepticum 6/85-like Isolates.
Leigh SA, Evans JD. Microbiol Resour Announc. 2022 Aug 2:e0024422. doi: 10.1128/mra.00244-22. Online ahead of print. PMID: 35916508

A fourth dose of Omicron RBD **vaccine** enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
Zhou B, Song S, Guo H, Zhou X, Fan Q, Liu W, Cheng L, Ge X, Ju B, Zhang Z. J Med Virol. 2022 Aug;94(8):3992-3997. doi: 10.1002/jmv.27811. Epub 2022 May 6. PMID: 35474319

Efficacy of passive immunization in broiler chicks via an inactivated *Escherichia coli* autogenous **vaccine** administered to broiler breeder hens.
Keita A, Le Devendec L, Amelot M, Puterflam J, Lucas C, Bougeard S, Delannoy S, Schouler C, Fach P, Lucas P, Souillard R, Kempf I. Avian Pathol. 2022 Aug 5:1-12. doi: 10.1080/03079457.2022.2084362. Online ahead of print. PMID: 35634647

COVID-19 transmission among vaccinated laboratory workers during the second wave in eastern Uttar Pradesh, India.
Kumar N, Misra BR, Reddy MM, Deval H, Zaman K, Kant R. J Med Virol. 2022 Aug;94(8):3512-3514. doi: 10.1002/jmv.27788. Epub 2022 Apr 23. PMID: 35434827

Serosurvey in SARS-CoV-2 inactivated **vaccine**-elicited neutralizing antibodies against authentic SARS-CoV-2 and its viral variants.
Zou L, Zhang H, Zheng Z, Jiang Y, Huang Y, Lin S, Yu J, Deng X, He J, Shen C, Li B. J Med Virol. 2022 Aug 5. doi: 10.1002/jmv.28049. Online ahead of print. PMID: 35931461

A third high dose of inactivated COVID-19 **vaccine** induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial.
Cao Y, Wang X, Li S, Dong Y, Liu Y, Li J, Zhao Y, Feng Y. Sci China Life Sci. 2022 Aug;65(8):1677-1679. doi: 10.1007/s11427-022-2110-1. Epub 2022 Apr 15. PMID: 35441932

Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 **Vaccine** AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data.
Lane S, Shakir S. Drug Saf. 2022 Aug 4:1-6. doi: 10.1007/s40264-022-01217-9. Online ahead of print. PMID: 35927605

Eosinophil-rich linear IgA bullous dermatosis induced by mRNA COVID-19 booster **vaccine**.
Nahm WJ, Juarez M, Wu J, Kim RH. J Cutan Pathol. 2022 Aug 3. doi: 10.1111/cup.14305. Online ahead of print. PMID: 35922892

Safety of Booster Doses of Coronavirus Disease 2019 (COVID-19) **Vaccine** in Pregnancy in the **Vaccine** Adverse Event Reporting System.

Moro PL, Olson CK, Zhang B, Marquez P, Strid P. Obstet Gynecol. 2022 Aug 3. doi: 10.1097/AOG.0000000000004889. Online ahead of print. PMID: 35926203

Commentary on 'Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA **vaccine**'.
Turkmen D, Altunisik N. J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e606. doi: 10.1111/jdv.18117. Epub 2022 Apr 22. PMID: 35352400

No evidence of short-term impact of repeated BNT162b2 vaccination on rheumatoid arthritis homeostasis in drug-free remission.
Bozzalla Cassione E, Mansoubi M, Mazzucchelli I, Luvaro T, De Stefano L, Xoxi B, Grignaschi S, Bugatti S, Montecucco C, Manzo A. Clin Rheumatol. 2022 Aug;41(8):2605-2607. doi: 10.1007/s10067-022-06250-8. Epub 2022 Jun 22. PMID: 35729370

Severe Acute Respiratory Syndrome Coronavirus 2 **Vaccine** Boosters: An Influenza **Vaccine** Perspective.
Sayers DR. Mil Med. 2022 Aug 9:usac243. doi: 10.1093/milmed/usac243. Online ahead of print. PMID: 35943170

CD8 T Cells Contribute to **Vaccine** Protection Against SARS-CoV-2 in Macaques.
Liu J, Yu J, McMahan K, Jacob-Dolan C, He X, Giffin V, Wu C, Sciacca M, Powers O, Nampanya F, Miller J, Lifton M, Hope D, Hall K, Hachmann NP, Chung B, Anioke T, Li W, Muench J, Gamblin A, Boursiquot M, Cook A, Lewis MG, Andersen H, Barouch DH. Sci Immunol. 2022 Aug 9:eabq7647. doi: 10.1126/sciimmunol.abq7647. Online ahead of print. PMID: 35943359

Immunopotential of Pasteurella multocida bivalent outer membrane protein-based **vaccine** entrapped in aluminum hydroxide nanoparticles.
Pegu H, Tamuly S, Sharma RK, Borah P, Nath R. Braz J Microbiol. 2022 Aug 3. doi: 10.1007/s42770-022-00795-1. Online ahead of print. PMID: 35922692

Humoral Response to Heterologous SARS-CoV-2 Vaccination in Kidney Transplant Patients Is Heterogeneous and Dose Dependent.
Seija M, Rammauro F, Noboa J, Santiago J, Orihuela N, Zulberti C, Machado D, Recalde C, Astesiano R, Yandián F, Frantchez V, Guerisoli A, Morra Á, Cassinelli D, Coelho C, de Aramburu B, González-Severgnini P, Moreno R, Pippolo A, López G, Lemos M, Somariva L, López E, Fumero S, Orihuela C, Suárez AL, Rodríguez R, Acuña G, Rabaza V, Perg N, Cordero R, Reisfeld C, Olivera P, Montero P, Nogueira C, Nalerio C, Orihuela S, Curi L, Bugstaller E, Pritsch O, Nin M, Noboa O, Bianchi S. Kidney Int Rep. 2022 Aug;7(8):1887-1892. doi: 10.1016/j.ekir.2022.05.005. Epub 2022 May 13. PMID: 35582205

Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 **Vaccine** in Persons Aged ≥18 years - United States, July 2022.
Twentyman E, Wallace M, Roper LE, Anderson TC, Rubis AB, Fleming-Dutra KE, Hall E, Hsu J, Rosenblum HG, Godfrey M, Archer WR, Moulia DL, Daniel L, Brooks O, Talbot HK, Lee GM, Bell BP, Daley M, Meyer S, Oliver SE. MMWR Morb Mortal Wkly Rep. 2022 Aug 5;71(31):988-992. doi: 10.15585/mmwr.mm7131a2. PMID: 35925807

Comparative efficacy of intralesional Candida antigen, intralesional bivalent human papilloma virus **vaccine**, and cryotherapy in the treatment of common warts.

Nassar A, Alakad R, Essam R, Bakr NM, Nofal A. J Am Acad Dermatol. 2022 Aug;87(2):419-421. doi: 10.1016/j.jaad.2021.08.040. Epub 2021 Aug 28. PMID: 34464624

Nudging COVID-19 **Vaccine** Uptake by Changing the Default: A Randomized Controlled Trial.
Tentori K, Pighin S, Giovanazzi G, Grignolio A, Timberlake B, Ferro A. Med Decis Making. 2022 Aug;42(6):837-841. doi: 10.1177/0272989X221101536. Epub 2022 Jun 6. PMID: 35658775

Midwives' attitudes toward participation of pregnant individuals in a preventive **vaccine** hypothetical clinical trial.
Gagneux-Brunon A, Guyot E, Detoc M, Botelho-Nevers E, Raia-Barjat T. Vaccine. 2022 Aug 5:S0264-410X(22)00945-8. doi: 10.1016/j.vaccine.2022.07.049. Online ahead of print. PMID: 35941034

Oral administration of a whole glucan particle (WGP)-based therapeutic cancer **vaccine** targeting macrophages inhibits tumor growth.
He L, Bai Y, Xia L, Pan J, Sun X, Zhu Z, Ding J, Qi C, Tang C. Cancer Immunol Immunother. 2022 Aug;71(8):2007-2028. doi: 10.1007/s00262-021-03136-7. Epub 2022 Jan 4. PMID: 34982184

Multimodal imaging findings including high-resolution 3D T2-weighted imaging for COVID-19 **vaccine**-associated axillary lymphadenopathy in a patient with breast cancer.
Shimizu H, Mori N, Ren H, Miyashita M, Sato S, Mugikura S, Takase K. Radiol Case Rep. 2022 Jun 10;17(8):2831-2836. doi: 10.1016/j.radcr.2022.04.044. eCollection 2022 Aug. PMID: 35702667

Monkeypox: Concerns mount over **vaccine** inequity.
Taylor L. BMJ. 2022 Aug 8;378:o1971. doi: 10.1136/bmj.o1971. PMID: 35940615

Stevens-Johnson syndrome precipitated by Moderna Inc. COVID-19 **vaccine**: a case-based review of literature comparing **vaccine** and drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
Padniewski JJ, Jacobson-Dunlop E, Albadri S, Hylwa S. Int J Dermatol. 2022 Aug;61(8):923-929. doi: 10.1111/ijd.16222. Epub 2022 Apr 10. PMID: 35398905

Inactivated vaccines prevent severe COVID-19 in patients infected with the Delta variant: A comparative study of the Delta and Alpha variants from China.
Ye C, Lv Y, Kuang W, Yang L, Lu Y, Gu J, Ding F, Shen H, Yang Y. J Med Virol. 2022 Aug;94(8):3613-3624. doi: 10.1002/jmv.27759. Epub 2022 Apr 19. PMID: 35365888

Immune responses to COVID-19 **vaccine** BNT162b2 in workers at a research institute in Japan: 6-month follow-up survey.
Nishikimi A, Watanabe K, Watanabe A, Yasuoka M, Watanabe R, Fujiwara M, Oshima H, Nakagawa T, Kitagawa Y, Tokuda H, Washimi Y, Niida S, Kojima M. J Infect. 2022 Aug;85(2):174-211. doi: 10.1016/j.jinf.2022.05.016. Epub 2022 May 20. PMID: 35605803

A Variant Allele in Varicella-Zoster Virus Glycoprotein B Selected during Production of the Varicella **Vaccine** Contributes to Its Attenuation.
Sadaoka T, Depledge DP, Rajbhandari L, Breuer J, Venkatesan A, Cohen JI. mBio. 2022 Aug 2:e0186422. doi: 10.1128/mbio.01864-22. Online ahead of print. PMID: 35916400

Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273.
Pascuale CA, Varese A, Ojeda DS, Pasinovich ME, Lopez L, Rossi AH, Rodriguez PE, Miglietta EA; Laboratorio SeVa Group, Mazzitelli I, Di Diego Garcia F, Sanchez L, Rouco SO, Gonzalez Lopez Ledesma MM, Zurano JP, Mazzitelli B, Scruzzi G, Barbero P, Cardozo D, Gallego S, Borda M, Diaz M; Ministerio de Salud de la Provincia de Córdoba Group; UNC-Fac. Cs. Médicas-InViV Group, Ridao F, Rosales AB; Ministerio de Salud de la Provincia de La Rioja Group, Bhon J, Talia JM, Diangelo ME, Lacaze MA; Ministerio de Salud de la Provincia de San Luis Group, Aime B, Gutierrez SI, Ercole R, Toro R, Tau L, Delaplace L, Compagnucci MF; Universidad Nacional de La Plata Group, Sartori C, Desimone I, Echegoyen C, Velazquez P, Testa C; Ministerio de Salud de la Provincia de Buenos Aires Group, Hozbor D, Docena G, Laino CH, Kreplak N, Pifano M, Barbas G, Rearte A, Vizzotti C, Castelli JM, Geffner J, Gamarnik AV. Cell Rep Med. 2022 Aug 3:100706. doi: 10.1016/j.xcrm.2022.100706. Online ahead of print. PMID: 35926505

We Should Not Forget About Patients With Inflammatory Bowel Disease Who Received a COVID-19 Viral Vector **Vaccine**.
Lutz M, Hayney MS, Caldera F. Am J Gastroenterol. 2022 Aug 1;117(8):1329. doi: 10.14309/ajg.0000000000001791. PMID: 35435853

Covid-19 and Covid-19 **vaccine** can slide along sides: a report of two cases of unilateral periflexural exanthema.
Sechi A, Bassi A, Mazzatenta C, Cutrone M, Naldi L, Argenziano G, Piccolo V. J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e595-e596. doi: 10.1111/jdv.18093. Epub 2022 Mar 28. PMID: 35305031

Ulcerative injection site reaction after third COVID-19 **vaccine** dose with mRNA-1273.
Barei F, Marletta DA, Marti-Marti I, Maronese CA, Genovese G, Marzano AV. Dermatol Ther. 2022 Aug;35(8):e15631. doi: 10.1111/dth.15631. Epub 2022 Jun 21. PMID: 35678474

The IgM response to pneumococcal polysaccharide **vaccine** is sufficient for conferring immunity.
Cravens M, Alugupalli AS, Sandilya VK, McGeady SJ, Alugupalli KR. J Infect Dis. 2022 Aug 6:jiac339. doi: 10.1093/infdis/jiac339. Online ahead of print. PMID: 35932228

Carotid free-floating thrombus during COVID-19 **vaccine** era: causality or not?
Ferraù L, Cotroneo M, Dell'Aera C, Giammello F, Grillo F, Brizzi T, Pitrone A, Vinci SL, Musolino RF, La Spina P. Neurol Sci. 2022 Aug 3:1-5. doi: 10.1007/s10072-022-06307-1. Online ahead of print. PMID: 35921016

Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 **vaccine** in adults aged 60 years and older: a prospective cohort study.
Eliakim-Raz N, Stemmer A, Leibovici-Weisman Y, Ness A, Awwad M, Ghantous N, Erez N, Bareket-Samish A, Levy-Barda A, Ben-Zvi H, Moskovits N, Bar-Haim E, Stemmer SM. BMJ Open. 2022 Aug 2;12(8):e061584. doi: 10.1136/bmjopen-2022-061584. PMID: 35918111

Field evaluation of typhoid conjugate **vaccine** in a catch-up campaign among children aged 9 months to 15 years in Sindh, Pakistan.

Thobani RS, Yousafzai MT, Sultana S, Kazi AM, Jan M, Rafey A, Khan A, Irfan S, Ujjan IU, Brown N, Mårtensson A, Qamar FN. Vaccine. 2022 Aug 6:S0264-410X(22)00840-4. doi: 10.1016/j.vaccine.2022.06.072. Online ahead of print. PMID: 35945044

Measuring psychosocial determinants of vaccination behavior in healthcare professionals: validation of the Pro-VC-Be short-form questionnaire.
Garrison A, Fressard L, Karlsson L, Soveri A, Fasce A, Lewandowsky S, Schmid P, Gagneur A, Dubé E, Verger P. Expert Rev Vaccines. 2022 Aug 8:1-10. doi: 10.1080/14760584.2022.2108800. Online ahead of print. PMID: 35938710

Extensive cutaneous leukocytoclastic vasculitis after Sinopharm **vaccine**: Case report and review of the literature.
Azzazi Y, Abdelkader HA, Khedr H, El-Komy MHM. J Cutan Pathol. 2022 Aug;49(8):736-742. doi: 10.1111/cup.14235. Epub 2022 Apr 27. PMID: 35355299

Vaccine effectiveness of ChAdOx1 nCoV-19 against COVID-19 in a socially vulnerable community in Rio de Janeiro, Brazil: author's response.
Ranzani OT, Bozza FA. Clin Microbiol Infect. 2022 Aug;28(8):1166-1167. doi: 10.1016/j.cmi.2022.03.037. Epub 2022 Apr 6. PMID: 35398310

A nationwide survey of Italian pediatric diabetologists about COVID-19 vaccination in children and adolescents with type 1 diabetes.
Scaramuzza AE, Cherubini V, Schiaffini R, Rabbone I; Diabetes Study Group of the Italian Society for Pediatric Endocrinology and Diabetes. Acta Diabetol. 2022 Aug;59(8):1109-1111. doi: 10.1007/s00592-022-01885-0. Epub 2022 Apr 21. PMID: 35449238

COVID-19 mRNA booster **vaccine** induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation.
Reinscheid M, Luxenburger H, Karl V, Graeser A, Giese S, Ciminski K, Reeg DB, Oberhardt V, Roehlen N, Lang-Meli J, Heim K, Gross N, Baum C, Rieg S, Speer C, Emmerich F, Breisinger S, Steinmann D, Bengsch B, Boettler T, Kochs G, Schwemmle M, Thimme R, Neumann-Haefelin C, Hofmann M. Nat Commun. 2022 Aug 8;13(1):4631. doi: 10.1038/s41467-022-32324-x. PMID: 35941157

Shorter duration of protection and lower geometric mean titers against A/H3N2 antigen of the quadrivalent influenza **vaccine** in children post-allogeneic hematopoietic stem cell transplantation.
Kang KR, Kim YJ, Ahn MB, Kang HM, Kim SK, Lee JW, Chung NG, Cho B, Jeong DC, Kang JH. Bone Marrow Transplant. 2022 Aug 1:1-3. doi: 10.1038/s41409-022-01768-6. Online ahead of print. PMID: 35915154

Comment on "Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 **Vaccine** Brands".
Mungmunpuntipantip R, Wiwanitkit V. Drug Saf. 2022 Aug;45(8):923. doi: 10.1007/s40264-022-01205-z. Epub 2022 Jul 15. PMID: 35838876

Influenza vaccination coverage among health-care workers during the COVID-19 epidemic in 2020/2021 influenza season: Evidence from a web-based survey in northwestern China.

Shi X, Zhang Y, Zhou L, Zhou L, Qiao H. Hum Vaccin Immunother. 2022 Aug 3:2102354. doi: 10.1080/21645515.2022.2102354. Online ahead of print. PMID: 35920744

A spatial vaccination strategy to reduce the risk of **vaccine**-resistant variants.
Zhang X, Lobinska G, Feldman M, Dekel E, Nowak MA, Pilpel Y, Pauzner Y, Barzel B, Pauzner A. PLoS Comput Biol. 2022 Aug 10;18(8):e1010391. doi: 10.1371/journal.pcbi.1010391. Online ahead of print. PMID: 35947602

Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza **vaccine** in Finland during the influenza season 2020/21.
Syrkina O, Inamdar A, Wague S, Monfredo C, Nissilä M, Chabanon AL, Serradell L. BMC Public Health. 2022 Aug 8;22(1):1506. doi: 10.1186/s12889-022-13898-z. PMID: 35941631

Immunomodulatory activity of trifluoromethyl arylamides derived from the SRPK inhibitor SRPIN340 and their potential use as **vaccine** adjuvant.
Mendes FC, de Paiva JC, da Silva EQG, Santos MR, de Almeida Lima GD, Moreira GA, Silva LVG, de Melo Agripino J, de Souza APM, de Oliveira Mendes TA, Machado-Neves M, Teixeira RR, Silva-Júnior A, Fietto JLR, de Oliveira LL, Bressan GC. Life Sci. 2022 Aug 1:120849. doi: 10.1016/j.lfs.2022.120849. Online ahead of print. PMID: 35926588

Anti-tumor activity of a T-helper 1 multiantigen **vaccine** in a murine model of prostate cancer.
Cecil DL, Curtis B, Gad E, Gormley M, Timms AE, Corulli L, Bos R, Damle RN, Sepulveda MA, Disis ML. Sci Rep. 2022 Aug 10;12(1):13618. doi: 10.1038/s41598-022-17950-1. PMID: 35948756

Pathogenicity of a novel classical swine fever LOM **vaccine**-derived virus isolated on Jeju Island, South Korea.
Jang G, Kim JA, Park C, Song K, Kang WM, Yang K, Lee C. Vet Med Sci. 2022 Aug 9. doi: 10.1002/vms3.903. Online ahead of print. PMID: 35944180

Severely impaired humoral response against SARS-CoV-2 variants of concern following two doses of BNT162b2 **vaccine** in patients with systemic lupus erythematosus (SLE).
Mageau A, Ferré VM, Goulenok T, Charpentier C, Delory N, Francois C, Houhou-Fidouh N, Papo T, Descamps D, Sacre K. Ann Rheum Dis. 2022 Aug;81(8):1194-1196. doi: 10.1136/annrheumdis-2022-222498. Epub 2022 Apr 8. PMID: 35396228

Is the phase of the menstrual cycle relevant when getting the covid-19 **vaccine**?
Velasco-Regulez B, Fernandez-Marquez JL, Luqui N, Cerquides J, Fukelman A, Perelló J. Am J Obstet Gynecol. 2022 Aug 2:S0002-9378(22)00624-X. doi: 10.1016/j.ajog.2022.07.052. Online ahead of print. PMID: 35931128

Acute Rejection Following COVID-19 Vaccination in Penetrating Keratoplasty in a Young Male - A Case Report and Review of Literature.
Marziali E, Pasqualetti R, Bacci G, de Libero C, Caputo R. Ocul Immunol Inflamm. 2022 Aug 1:1-4. doi: 10.1080/09273948.2022.2106248. Online ahead of print. PMID: 35914312

Re: **Vaccine** effectiveness of ChAdOx1 nCoV-19 against COVID-19 in a socially vulnerable community in Rio de Janeiro, Brazil by Ranzani et al.

Zeng G. Clin Microbiol Infect. 2022 Aug;28(8):1165. doi: 10.1016/j.cmi.2022.03.008. Epub 2022 Mar 16. PMID: 35304281

HPV Vaccination Rates of 7th Grade Students After a Strong Recommending Statement from the School Nurse.
White LS, Maulucci E, Kornides M, Aryal S, Alix C, Sneider D, Gagnon J, Winfield EC, Fontenot HB. J Sch Nurs. 2022 Aug 9:10598405221118824. doi: 10.1177/10598405221118824. Online ahead of print. PMID: 35942704

The mediating role of product judgment and country of origin effect on health literacy and behavioral intention: A study on COVID-19 vaccines perception of Turkish consumers.
Bayır T, Kılıç B, Durmaz Y. Hum Vaccin Immunother. 2022 Aug 5:2107838. doi: 10.1080/21645515.2022.2107838. Online ahead of print. PMID: 35930732

Autopsy Histopathologic Cardiac Findings in 2 Adolescents Following the Second COVID-19 **Vaccine** Dose: Cytokine Storm, Hypersensitivity, or Something Else.
Kounis NG, Mplani V, Koniari I. Arch Pathol Lab Med. 2022 Aug 1;146(8):924. doi: 10.5858/arpa.2022-0102-LE. PMID: 35395083

Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate **Vaccine** (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".
Gomez JA, Guevara JN, Carlos JC, de Castro JA, Josue DR, Rodriguez E. Infect Dis Ther. 2022 Aug;11(4):1757-1761. doi: 10.1007/s40121-022-00640-w. Epub 2022 May 16. PMID: 35575972

The recombinant subunit **vaccine** encapsulated by alginate-chitosan microsphere enhances the immune effect against Micropterus salmoides rhabdovirus.
Xu FF, Jiang FY, Zhou GQ, Xia JY, Yang F, Zhu B. J Fish Dis. 2022 Aug 9. doi: 10.1111/jfd.13697. Online ahead of print. PMID: 35944110

A case of multisystem inflammatory syndrome (MIS-A) in an adult woman 18 days after COVID-19 vaccination.
Stappers S, Ceuleers B, Van Brusselen D, Willems P, de Tavernier B, Verlinden A. Acta Clin Belg. 2022 Aug;77(4):772-777. doi: 10.1080/17843286.2021.1977899. Epub 2021 Sep 12. PMID: 34511054

Protection against MIS-C outweighs the risk of myocarditis after Covid-19 vaccination in children.
Mariani M, Caorsi R, Consolaro A, Brisca G, Sticchi C, Gattorno M, Castagnola E, Ravelli A. Ital J Pediatr. 2022 Aug 4;48(1):142. doi: 10.1186/s13052-022-01335-1. PMID: 35927681

The impact of Loa loa microfilaraemia on research subject retention during a whole sporozoite malaria **vaccine** trial in Equatorial Guinea.
Manock SR, Nsue VU, Olotu A, Mpina M, Nyakarungu E, Raso J, Mtoro A, Ondo Mangue ME, Ntutumu Pasialo BE, Nguema R, Riyahi P, Schindler T, Daubenberger C, Church LWP, Billingsley PF, Richie TL, Abdulla S, Hoffman SL. Trans R Soc Trop Med Hyg. 2022 Aug 5;116(8):745-749. doi: 10.1093/trstmh/trac019. PMID: 35394038

Improved humoral immunogenicity with mRNA-1273 versus BNT162b2 as third **vaccine** dose among solid organ transplant recipients seronegative after two BNT162b2 doses.

Chang A, Chiang TP, Kim JD, Mitchell J, Alejo JL, Jefferis AA, Avery RK, Tobian AAR, Levan ML, Warren DS, Garonzik-Wang JM, Massie AB, Segev DL, Werbel WA. Clin Transplant. 2022 Aug;36(8):e14738. doi: 10.1111/ctr.14738. Epub 2022 Jun 14. PMID: 35670813

Mammographic findings of diffuse axillary tail trabecular thickening following immunization with mRNA COVID-19 vaccines: Case series study.
Adam R, Duong T, Hodges L, Staeger-Hirsch C, Maldjian T. Radiol Case Rep. 2022 Jun 10;17(8):2841-2849. doi: 10.1016/j.radcr.2022.04.028. eCollection 2022 Aug. PMID: 35702669

NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses.
Rydyznski Moderbacher C, Kim CJ, Mateus J, Plested JS, Zhu M, Cloney-Clark S, Weiskopf D, Sette A, Fries L, Glenn G, Crotty S. J Clin Invest. 2022 Aug 9:e160898. doi: 10.1172/JCI160898. Online ahead of print. PMID: 35943810

Response to Gomez et al.'s Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate **Vaccine** (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".
Perdrizet J, Horn E, Nua W, Perez-Peralta J, Nailes J, Santos J, Ong-Lim A. Infect Dis Ther. 2022 Aug;11(4):1763-1765. doi: 10.1007/s40121-022-00641-9. Epub 2022 May 16. PMID: 35575973

Authors' Reply to Mungmunpuntipantip et al.'s Comment on "Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 **Vaccine** Brands".
Kant A, van Hunsel F. Drug Saf. 2022 Aug;45(8):925-926. doi: 10.1007/s40264-022-01207-x. Epub 2022 Jul 15. PMID: 35838877

A case of cutaneous arteritis after administration of mRNA coronavirus disease 2019 **vaccine**.
Iwata JI, Kanetsuna Y, Takano A, Horiuchi Y. Dermatol Ther. 2022 Aug;35(8):e15618. doi: 10.1111/dth.15618. Epub 2022 Jun 15. PMID: 35661518

Effectiveness of third **vaccine** dose for coronavirus disease 2019 during the Omicron variant pandemic: a prospective observational study in Japan.
Akaishi T, Kushimoto S, Katori Y, Sugawara N, Egusa H, Igarashi K, Fujita M, Kure S, Takayama S, Abe M, Kikuchi A, Ohsawa M, Ishizawa K, Abe Y, Imai H, Inaba Y, Iwamatsu-Kobayashi Y, Nishioka T, Onodera K, Ishii T. Sci Rep. 2022 Aug 10;12(1):13589. doi: 10.1038/s41598-022-17990-7. PMID: 35948626

Computer-Aided Tools and Resources for Fungal Pathogens: An Application of Reverse Vaccinology for Mucormycosis.
Bhargav A, Fatima F, Chaurasia P, Seth S, Ramachandran S. Monoclon Antib Immunodiagn Immunother. 2022 Aug 8. doi: 10.1089/mab.2021.0039. Online ahead of print. PMID: 35939284

Application of reverse vaccinology to design a multi-epitope subunit **vaccine** against a new strain of Aeromonas veronii.
Islam SI, Mou MJ, Sanjida S. J Genet Eng Biotechnol. 2022 Aug 8;20(1):118. doi: 10.1186/s43141-022-00391-8. PMID: 35939149

Estimating **Vaccine** Effectiveness from Linking Population-Based Health Registries: Some Sources of Bias.

Brookmeyer R, Morrison D. Am J Epidemiol. 2022 Aug 8:kwac145. doi: 10.1093/aje/kwac145. Online ahead of print. PMID: 35938874

Immune response to SARS-CoV-2 mRNA **vaccine** in psoriasis patients treated with biologics.
Marovt M, Deželak P, Ekart R, Marko PB. Clin Exp Dermatol. 2022 Aug 8. doi: 10.1111/ced.15347. Online ahead of print. PMID: 35938595

Hypersensitivity Lymphohistiocytic Myocarditis After Moderna mRNA-1273 **Vaccine**.
Kounis NG, Mplani V, Kouni S, Plotas P, Koniari I. Am J Clin Pathol. 2022 Aug 8:aqac090. doi: 10.1093/ajcp/aqac090. Online ahead of print. PMID: 35938624

Understanding Covid **Vaccine** Efficacy over Time - Bridging a Gap Between Public Health and Health Care.
Kohane I, Omenn GS. N Engl J Med. 2022 Aug 11;387(6):483-485. doi: 10.1056/NEJMp2201084. Epub 2022 Aug 6. PMID: 35929811

Local myofascitis of the deltoid muscle after administration of the AstraZeneca (AZD1222) COVID-19 **vaccine**: two cases, infectious and inflammatory.
Yoon JP, Jung YS, Kim DH. JSES Rev Rep Tech. 2022 Aug;2(3):376-379. doi: 10.1016/j.xrrt.2022.04.005. Epub 2022 May 10. PMID: 35571584

Pfizer COVID **vaccine** efficacy in children aged 5-11 years.
[No authors listed] J Paediatr Child Health. 2022 Aug 8. doi: 10.1111/jpc.16148. Online ahead of print. PMID: 35938773

COVID **vaccine**-associated myocarditis in an 8-year-old patient - ERRATUM.
Mehta K, Cohen R, Kelly B, Grosse-Wortmann L. Cardiol Young. 2022 Aug 9:1. doi: 10.1017/S1047951122002657. Online ahead of print. PMID: 35942708

Increased induction of *de novo* serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2.
Irure-Ventura J, Lara Belmar-Vega, Gema Fernández-Fresnedo, González-López E, Castro-Hernández C, Rodrigo-Calabia E, Heras-Vicario M, Ruiz San Millán JC, López-Hoyos M. iScience. 2022 Aug 2;25(8):104847. doi: 10.1016/j.isci.2022.104847. Online ahead of print. PMID: 35937087

Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA **vaccine** response in elderly people.
Vitallé J, Pérez-Gómez A, Ostos FJ, Gasca-Capote C, Jiménez-Leon MR, Bachiller S, Rivas-Jeremías I, Silva-Sánchez MDM, Ruiz-Mateos AM, Martín-Sánchez MÁ, López-Cortes LF, Rafii El Idrissi Benhnia M, Ruiz-Mateos E. JCI Insight. 2022 Aug 9:e161045. doi: 10.1172/jci.insight.161045. Online ahead of print. PMID: 35943812

A case of coronavirus disease 2019 messenger RNA **vaccine** tolerance and immune response despite presence of anti-polyethylene glycol antibodies.
Corey KB, Koo G, Stone CA Jr, Kroop SF, Fissell WH, Kozlowski S, Zhou ZH, Phillips EJ. Ann Allergy Asthma Immunol. 2022 Aug;129(2):246-248. doi: 10.1016/j.anai.2022.05.013. Epub 2022 May 20. PMID: 35605816

New-onset myasthenia gravis confirmed by electrodiagnostic studies after a third dose of SARS-CoV-2 mRNA-1273 **vaccine**: a case report.
Slavin E, Fitzig J, Neubert C, Garcia-Lopez F, Cuevas-Trisan R. Am J Phys Med Rehabil. 2022 Aug 2. doi: 10.1097/PHM.0000000000002076. Online ahead of print. PMID: 35930797

Variability in COVID-19 vaccination rates in pregnant women: **Vaccine** hesitancy or supply limitations?
Goldenberg RL, Naqvi S, Saleem S, McClure E. BJOG. 2022 Aug 3. doi: 10.1111/1471-0528.17257. Online ahead of print. PMID: 35920174

Development of a pentavalent broadly protective nucleoside-modified mRNA **vaccine** against influenza B viruses.
Pardi N, Carreño JM, O'Dell G, Tan J, Bajusz C, Muramatsu H, Rijnink W, Strohmeier S, Loganathan M, Bielak D, Sung MMH, Tam YK, Krammer F, McMahon M. Nat Commun. 2022 Aug 9;13(1):4677. doi: 10.1038/s41467-022-32149-8. PMID: 35945226

A Pilot Test of a Workshop for Pediatric Clinicians About Communicating with Parents About the HPV **Vaccine** Using the C-LEAR Approach.
Bylund CL, Thompson LA, Hansen M, Staras SAS. J Cancer Educ. 2022 Aug 9:1-7. doi: 10.1007/s13187-022-02188-2. Online ahead of print. PMID: 35941410

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate **vaccine** recently licensed in the United States for individuals ≥2 years of age.
Marshall GS, Pelton SI, Robertson CA, Oster P. Hum Vaccin Immunother. 2022 Aug 10:2099142. doi: 10.1080/21645515.2022.2099142. Online ahead of print. PMID: 35947774

Immunogenicity After a Heterologous BNT262b2 Versus Homologous Booster in Kidney Transplant Recipients Receiving 2 Doses of CoronaVac **Vaccine**: A Prospective Cohort Study.
Medina-Pestana J, Almeida Viana L, Nakamura MR, Lucena EF, Granato CFH, Dreige YC, Amorim LVP, Chow CYZ, Demarchi Foresto R, Roberto Requião-Moura L, Tedesco-Silva H, Cristelli MP. Transplantation. 2022 Aug 5. doi: 10.1097/TP.0000000000004260. Online ahead of print. PMID: 35939382

New "Universal" Flu **Vaccine** Candidate Enters Clinical Trial.
Larkin HD. JAMA. 2022 Aug 9;328(6):518. doi: 10.1001/jama.2022.13252. PMID: 35943485

Tracheal cellular immune response in chickens inoculated with Mycoplasma synoviae **vaccine**, MS-H or its parent strain 86079/7NS.
Omotainse OS, Wawegama NK, Kulappu Arachchige SN, C Coppo MJ, Vaz PK, Woodward AP, Kordafshari S, Bogeski M, Stevenson M, Noormohammadi AH, Stent AW. Vet Immunol Immunopathol. 2022 Aug 4;251:110472. doi: 10.1016/j.vetimm.2022.110472. Online ahead of print. PMID: 35940079

Author Correction: Antibody responses to the RTS,S/AS01$_E$ **vaccine** and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique.
Sánchez L, Vidal M, Jairoce C, Aguilar R, Ubillos I, Cuamba I, Nhabomba AJ, Williams NA, Díez-Padrisa N, Cavanagh D, Angov E, Coppel RL, Gaur D, Beeson JG, Dutta S, Aide P, Campo JJ, Moncunill G, Dobaño C. NPJ Vaccines. 2022 Aug 8;7(1):91. doi: 10.1038/s41541-022-00515-8. PMID: 35941348

Vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous sinus thrombosis (CVST): a case report from Malaysia.
Liam CCK, Tee YJ, Boo YL, Lim YS, Shamsuddin AR, Lim SM. Blood Res. 2022 Aug 3. doi: 10.5045/br.2022.2022128. Online ahead of print. PMID: 35920095

T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated **vaccine**.
Li Y, Wang X, Jin J, Ma Z, Liu Y, Zhang X, Su B. J Med Virol. 2022 Aug;94(8):3998-4004. doi: 10.1002/jmv.27814. Epub 2022 May 6. PMID: 35474581

Factors associated with severe or fatal clinical manifestations of SARS-CoV-2 infection after receiving the third dose of **vaccine**.
Corrao G, Franchi M, Cereda D, Bortolan F, Leoni O, Jara J, Valenti G, Pavesi G. J Intern Med. 2022 Aug 9. doi: 10.1111/joim.13551. Online ahead of print. PMID: 35943414

Impact of vaccination on SARS-CoV-2 seroprevalence rate in French blood donors: an assessment as of july 2021.
Gallian P, Slimani A, Malard L, Morel P, de Lamballerie X. Transfus Clin Biol. 2022 Aug 4:S1246-7820(22)00092-1. doi: 10.1016/j.tracli.2022.08.002. Online ahead of print. PMID: 35934226

[A Patient Developing Guillain-Barré Syndrome After Receiving the BNT162b2 COVID-19 mRNA **Vaccine**].
Oshibe N, Honda M, Koga M, Sato R, Oishi M, Kanda T. Brain Nerve. 2022 Aug;74(8):1025-1030. doi: 10.11477/mf.1416202173. PMID: 35941801

A Clinical Educational Intervention to Increase HPV Vaccination Rates Among Pediatric Patients Through Enhanced Recommendations.
Davis KR, Norman SL, Olson BG, Demirel S, Taha AA. J Pediatr Health Care. 2022 Aug 3:S0891-5245(22)00177-8. doi: 10.1016/j.pedhc.2022.07.003. Online ahead of print. PMID: 35933285

Is tailored messaging more effective? An analysis of a digital health intervention to promote HPV vaccination intent among Latinx.
Reno JE, Sevick C, Maertens J, Dempsey AF. J Behav Med. 2022 Aug 4. doi: 10.1007/s10865-022-00340-3. Online ahead of print. PMID: 35927547

Safety of COVID-19 **vaccine** challenge in patients with immediate adverse reactions to prior doses: A multi-centre cohort study.
De Luca JF, Awad A, Vogrin S, Douglas AP, Lutjen A, Gordon SF, Crawford NW, Barnes S, Trubiano JA. Allergy. 2022 Aug 4. doi: 10.1111/all.15467. Online ahead of print. PMID: 35924675

COVID-19 **vaccine** effectiveness against SARS-CoV-2 infection in the United States prior to the Delta and Omicron-associated surges: a retrospective cohort study of repeat blood donors.
Grebe E, Yu EA, Bravo MD, Welte A, Bruhn RL, Stone M, Green V, Williamson PC, Feldstein LR, Jones JM, Busch MP, Custer B. J Infect Dis. 2022 Aug 3:jiac318. doi: 10.1093/infdis/jiac318. Online ahead of print. PMID: 35921537

A Novel Development of Sarcoidosis following COVID-19 Vaccination and a Literature Review.
Numakura T, Murakami K, Tamada T, Yamaguchi C, Inoue C, Ohkouchi S, Tode N, Sano H, Aizawa H, Sato K, Mitsune A, Kurosawa H, Nakazawa T, Sugiura H. Intern Med. 2022 Aug 10. doi: 10.2169/internalmedicine.0104-22. Online ahead of print. PMID: 35945009

Immunogenicity of the BNT162b2 COVID-19 **vaccine** as a third dose (booster) following two doses of different primary series regimens in Thailand.
Wanlapakorn N, Suntronwong N, Kanokudom S, Assawakosri S, Nilyanimit P, Yorsaeng R, Chansaenroj J, Poovorawan Y. Pathog Glob Health. 2022 Aug 3:1-3. doi: 10.1080/20477724.2022.2108646. Online ahead of print. PMID: 35920191

Unlikely influence of ABO blood group polymorphism on antibody response to COVID-19 mRNA **vaccine** against SARS-CoV-2 spike protein.
Yamamoto F, Cid E, Yamamoto M, Muñiz-Diaz E. Vox Sang. 2022 Aug 2. doi: 10.1111/vox.13341. Online ahead of print. PMID: 35919938

Response to 'Unlikely influence of ABO blood group polymorphism on antibody response to COVID-19 mRNA **vaccine** against SARS-CoV-2 spike protein'.
Bordino V, Vicentini C, Zotti CM. Vox Sang. 2022 Aug 2. doi: 10.1111/vox.13340. Online ahead of print. PMID: 35919936

Addressing the social issues around vaccination could be the pivotal strategy to achieve the 2022 COVID-19 vaccination coverage target.
Ayeni GO, Idris IO, Adebisi YA. Ann Med Surg (Lond). 2022 Aug;80:104299. doi: 10.1016/j.amsu.2022.104299. Epub 2022 Jul 31. PMID: 35936562

A circular mRNA **vaccine** prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.
Seephetdee C, Bhukhai K, Buasri N, Leelukkanaveera P, Lerdwattanasombat P, Manopwisedjaroen S, Phueakphud N, Kuhaudomlarp S, Olmedillas E, Saphire EO, Thitithanyanont A, Hongeng S, Wongtrakoongate P. Antiviral Res. 2022 Aug;204:105370. doi: 10.1016/j.antiviral.2022.105370. Epub 2022 Jun 27. PMID: 35772601

Incidence of influenza and other respiratory viruses among pregnant women: A multi-country, multiyear cohort.
Azziz-Baumgartner E, Veguilla V, Calvo A, Franco D, Dominguez R, Rauda R, Armero J, Hall AJ, Pascale JM, González R. Int J Gynaecol Obstet. 2022 Aug;158(2):359-367. doi: 10.1002/ijgo.14018. Epub 2021 Dec 11. PMID: 34767628

A single immunization with cellular **vaccine** confers dual protection against SARS-CoV-2 and cancer.
Shimizu K, Ueda S, Kawamura M, Satoh M, Fujii SI. Cancer Sci. 2022 Aug;113(8):2536-2547. doi: 10.1111/cas.15434. Epub 2022 Jun 7. PMID: 35598170

Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects.
Edwards DK, Carfi A. Curr Opin Immunol. 2022 Aug;77:102214. doi: 10.1016/j.coi.2022.102214. Epub 2022 Jun 4. PMID: 35671599

African Swine Fever Control and Prevention: An Update on **Vaccine** Development.
Urbano AC, Ferreira F. Emerg Microbes Infect. 2022 Aug 1:1-37. doi: 10.1080/22221751.2022.2108342. Online ahead of print. PMID: 35912875

Polysaccharide and conjugate vaccines to *Streptococcus pneumoniae* generate distinct humoral responses.
Davies LRL, Cizmeci D, Guo W, Luedemann C, Alexander-Parrish R, Grant L, Isturiz R, Theilacker C, Jodar L, Gessner BD, Alter G. Sci Transl Med. 2022 Aug 3;14(656):eabm4065. doi: 10.1126/scitranslmed.abm4065. Epub 2022 Aug 3. PMID: 35921476

The ring vaccination trial design for the estimation of **vaccine** efficacy and effectiveness during infectious disease outbreaks.
Dean NE, Longini IM. Clin Trials. 2022 Aug;19(4):402-406. doi: 10.1177/17407745211073594. Epub 2022 Jan 21. PMID: 35057647

Comparative proteomic analysis of PK15 swine kidney cells infected with a pseudorabies pathogenic variant and the Bartha-K/61 **vaccine** strain.
Zhang H, Zhang R, Wang F, Li G, Wen Y, Shan H. Microb Pathog. 2022 Aug 4:105698. doi: 10.1016/j.micpath.2022.105698. Online ahead of print. PMID: 35934202

Protective immunity by DNA **vaccine** against Micropterus salmoides rhabdovirus.
Yang B, Guo ZR, Zhao Z, Wang T, Yang F, Ling F, Zhu B, Wang GX. J Fish Dis. 2022 Aug 5. doi: 10.1111/jfd.13672. Online ahead of print. PMID: 35930453

An integrated and continuous downstream process for microbial virus-like particle **vaccine** biomanufacture.
Gerstweiler L, Billakanti J, Bi J, Middelberg APJ. Biotechnol Bioeng. 2022 Aug;119(8):2122-2133. doi: 10.1002/bit.28118. Epub 2022 May 10. PMID: 35478403

Abrupt worsening of occult IgA nephropathy after the first dose of SARS-CoV-2 vaccination.
Fujita Y, Yoshida K, Ichikawa D, Shibagaki Y, Yazawa M. CEN Case Rep. 2022 Aug;11(3):302-308. doi: 10.1007/s13730-021-00670-2. Epub 2022 Jan 6. PMID: 34988883

Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden.
Femel J, van Hooren L, Herre M, Cedervall J, Saupe F, Huijbers EJM, Verboogen DRJ, Reichel M, Thijssen VL, Griffioen AW, Hellman L, Dimberg A, Olsson AK. Cancer Immunol Immunother. 2022 Aug;71(8):2029-2040. doi: 10.1007/s00262-021-03139-4. Epub 2022 Jan 11. PMID: 35018481

Impact of SARS-CoV-2 Mu variant on **vaccine** effectiveness: A comparative genomics study at the peak of the third wave in Bogota, Colombia.
Ramirez AL, Luna N, Patiño LH, Castañeda S, Muñoz M, Ballesteros N, Perez J, Correa-Cárdenas CA, Duque MC, Mendez C, Oliveros C, Paniz-Mondolfi AE, Ramírez JD. J Med Virol. 2022 Aug;94(8):3988-3991. doi: 10.1002/jmv.27808. Epub 2022 May 3. PMID: 35474317

Increasing seroprevalence but waning herd immunity against measles after elimination: Longitudinal seroepidemiology of measles in Osaka Prefecture, Japan, 2003-2020.

Kurata T, Miyama T, Kanbayashi D, Kaida Y, Aoyama I, Ikemori R, Banno F, Kawahata T, Mori H, Motomura K. Vaccine. 2022 Aug 1:S0264-410X(22)00909-4. doi: 10.1016/j.vaccine.2022.07.025. Online ahead of print. PMID: 35927136

Use of heated tobacco products, moderate alcohol drinking, and anti-SARS-CoV-2 IgG antibody titers after BNT162b2 vaccination among Japanese healthcare workers.
Yamamoto S, Tanaka A, Ohmagari N, Yamaguchi K, Ishitsuka K, Morisaki N, Kojima M, Nishikimi A, Tokuda H, Inoue M, Tanaka S, Umezawa J, Okubo R, Nishimura K, Konishi M, Miyo K, Mizoue T. Prev Med. 2022 Aug;161:107123. doi: 10.1016/j.ypmed.2022.107123. Epub 2022 Jul 1. PMID: 35787841

Development and Validation of a Sensitive and Robust Multiplex Antigen Capture Assay to Quantify Streptococcus pneumoniae Serotype-Specific Capsular Polysaccharides in Urine.
Rajam G, Zhang Y, Antonello JM, Grant-Klein RJ, Cook L, Panemangalore R, Pham H, Cooper S, Steinmetz TD, Nguyen J, Pletz MW, Barten-Neiner G, Murphy RD, Rubinstein LJ, Nolan KM. mSphere. 2022 Aug 1:e0011422. doi: 10.1128/msphere.00114-22. Online ahead of print. PMID: 35913133

Targeting T_{FH} cells in human diseases and vaccination: rationale and practice.
Yu D, Walker LSK, Liu Z, Linterman MA, Li Z. Nat Immunol. 2022 Aug;23(8):1157-1168. doi: 10.1038/s41590-022-01253-8. Epub 2022 Jul 11. PMID: 35817844

Anti-spike protein antibody responses to BNT162b2 mRNA **vaccine**: A single-center survey in a COVID-19 non-epidemic area in Japan.
Mokuda S, Kawanishi N, Kuroshima S, Kono J, Nakayama H, Mieno H, Kawamoto M. Vaccine X. 2022 Aug;11:100173. doi: 10.1016/j.jvacx.2022.100173. Epub 2022 Jun 7. PMID: 35692460

Salmonellacidal antibody response to Salmonella enterica serovar Typhi in enteric fever and after vaccination with Vi capsular polysaccharide.
Barai L, Hasan MR, Haq JA, Ahsan CR. Int J Infect Dis. 2022 Aug;121:120-125. doi: 10.1016/j.ijid.2022.05.022. Epub 2022 May 11. PMID: 35568365

Cell-penetrating peptides enhance peptide **vaccine** accumulation and persistence in lymph nodes to drive immunogenicity.
Backlund CM, Holden RL, Moynihan KD, Garafola D, Farquhar C, Mehta NK, Maiorino L, Pham S, Iorgulescu JB, Reardon DA, Wu CJ, Pentelute BL, Irvine DJ. Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2204078119. doi: 10.1073/pnas.2204078119. Epub 2022 Aug 1. PMID: 35914154

COVID-19 **vaccine**-related frequently asked questions (FAQs) by people with epilepsy and carers in Iran; educational video is included.
Asadi-Pooya AA, Karimi A, Razavizadegan SMA, Ashjazadeh N, Nemati H. Epilepsy Behav. 2022 Aug;133:108763. doi: 10.1016/j.yebeh.2022.108763. Epub 2022 May 19. PMID: 35696935

Conjugation with 8-arm PEG and CRM_{197} enhances the immunogenicity of SARS-CoV-2 ORF8 protein.
Tang X, Yu W, Shen L, Qi J, Hu T. Int Immunopharmacol. 2022 Aug;109:108922. doi: 10.1016/j.intimp.2022.108922. Epub 2022 Jun 6. PMID: 35687905

Effectiveness of Bacillus Calmette-Guérin vaccination against severe childhood tuberculosis in China: a case-based, multicenter retrospective study.

Liao Q, Zheng Y, Wang Y, Ye L, Liu X, Jiao W, Liu Y, Zhu Y, Jia J, Sun L, Shen A, Wan C. Int J Infect Dis. 2022 Aug;121:113-119. doi: 10.1016/j.ijid.2022.04.023. Epub 2022 Apr 14. PMID: 35429637

Misinformation About COVID-19 Vaccines on Social Media: Rapid Review.
Skafle I, Nordahl-Hansen A, Quintana DS, Wynn R, Gabarron E. J Med Internet Res. 2022 Aug 4;24(8):e37367. doi: 10.2196/37367. PMID: 35816685

Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort study.
Jia M, Wang X, Gong W, Zhong J, Leng Z, Ren L, Feng L, Guo L, Gao L, Liang X, Chen E, Tang W, Huang Q, Zhang Q, Jiang G, Zhao S, Liu Z, Feng Y, Qi L, Ma L, Huang T, Yue Y, Wang J, Jiang B, Xu L, Wang J, Yang W, Wang C. J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28055. Online ahead of print. PMID: 35941840

Clostridium haemolyticum, a review of beta toxin and insights into the antigen design for **vaccine** development.
Alves MLF, Ferreira MRA, Rodrigues RR, Conceição FR. Mol Immunol. 2022 Aug;148:45-53. doi: 10.1016/j.molimm.2022.05.007. Epub 2022 Jun 2. PMID: 35665660

Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency.
Frumento N, Figueroa A, Wang T, Zahid MN, Wang S, Massaccesi G, Stavrakis G, Crowe JE Jr, Flyak AI, Ji H, Ray SC, Shaw GM, Cox AL, Bailey JR. J Clin Invest. 2022 Aug 1;132(15):e160058. doi: 10.1172/JCI160058. PMID: 35588376

Treatment of Multiple Sclerosis.
Cross A, Riley C. Continuum (Minneap Minn). 2022 Aug 1;28(4):1025-1051. doi: 10.1212/CON.0000000000001170. PMID: 35938656

Nanobionics: From plant empowering to the infectious disease treatment.
Hassanzadeh P, Atyabi F, Dinarvand R. J Control Release. 2022 Aug 5;349:890-901. doi: 10.1016/j.jconrel.2022.07.028. Online ahead of print. PMID: 35901860

Constrictive pericarditis following mRNA COVID-19 vaccination in a patient with systemic sclerosis.
Misumi I, Ogata A, Fukuda K, Sato K, Nagano M, Usuku H, Tsujita K. J Cardiol Cases. 2022 Aug;26(2):97-100. doi: 10.1016/j.jccase.2022.03.014. Epub 2022 Apr 4. PMID: 35401886

Autopsy Histopathologic Cardiac Findings in 2 Adolescents Following the Second COVID-19 **Vaccine** Dose.
Gill JR, Tashjian R, Duncanson E. Arch Pathol Lab Med. 2022 Aug 1;146(8):925-929. doi: 10.5858/arpa.2021-0435-SA. PMID: 35157759

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant.
Nanishi E, McGrath ME, O'Meara TR, Barman S, Yu J, Wan H, Dillen CA, Menon M, Seo HS, Song K, Xu AZ, Sebastian L, Brook B, Bosco AN, Borriello F, Ernst RK, Barouch DH, Dhe-Paganon S, Levy O, Frieman MB, Dowling DJ. Commun Biol. 2022 Aug 6;5(1):790. doi: 10.1038/s42003-022-03765-3. PMID: 35933439

Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections.
Zou J, Xie X, Liu M, Shi PY, Ren P. mBio. 2022 Aug 4:e0199622. doi: 10.1128/mbio.01996-22. Online ahead of print. PMID: 35924850

Coaching and Communication Training for HPV Vaccination: A Cluster Randomized Trial.
Gilkey MB, Grabert BK, Heisler-MacKinnon J, Bjork A, Boynton MH, Kim K, Alton Dailey S, Liu A, Todd KG, Schauer SL, Sill D, Coley S, Brewer NT. Pediatrics. 2022 Aug 1;150(2):e2021052351. doi: 10.1542/peds.2021-052351. PMID: 35818840

Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination.
Lu J, He Y, Terkeltaub R, Sun M, Ran Z, Xu X, Wang C, Li X, Hu S, Xue X, Yan F, Zhang H, Yin H, Shi Y, Dalbeth N, Li C. Ann Rheum Dis. 2022 Aug;81(8):1189-1193. doi: 10.1136/annrheumdis-2022-222199. Epub 2022 Mar 11. PMID: 35277390

Prevaccine Human Papillomavirus Status in Invasive and Intraepithelial Lesions of the Vulva in New Zealand Women.
Bigby SM, Eva LJ, Tous S, de Sanjosé S, Bosch X, Alemany L, Chang KCT, Jones RW. J Low Genit Tract Dis. 2022 Aug 4. doi: 10.1097/LGT.0000000000000687. Online ahead of print. PMID: 35930419

Spatial-temporal-demographic and virological changes of hand, foot and mouth disease incidence after vaccination in a vulnerable region of China.
Huang L, Wang T, Liu X, Fu Y, Zhang S, Chu Q, Nie T, Tu H, Chen J, Fan Y. BMC Public Health. 2022 Aug 1;22(1):1468. doi: 10.1186/s12889-022-13860-z. PMID: 35915424

Lower frequency of T stem cell memory (TSCM) cells in hepatitis B **vaccine** nonresponders.
Vakili ME, Faghih Z, Sarvari J, Doroudchi M, Hosseini SN, Kabelitz D, Kalantar K. Immunol Res. 2022 Aug;70(4):469-480. doi: 10.1007/s12026-022-09278-9. Epub 2022 Apr 20. PMID: 35445310

Association of hepatitis B **vaccine** response to vitamin D supplementation and ultraviolet B (UVB) exposure during different time intervals in experimental animals.
Youssry S, Shalaby T, Maher AS, Ghoneim H. Immunol Res. 2022 Aug;70(4):537-545. doi: 10.1007/s12026-022-09287-8. Epub 2022 May 19. PMID: 35585421

Assessing an O-antigen deficient, live attenuated Salmonella Gallinarium strain that is DIVA compatible, environmentally safe, and protects chickens against fowl typhoid.
Senevirathne A, Hewawaduge C, Lee JH. Dev Comp Immunol. 2022 Aug;133:104433. doi: 10.1016/j.dci.2022.104433. Epub 2022 May 11. PMID: 35568244

Interventions delivered in secondary or tertiary medical care settings to improve routine vaccination uptake in children and young people: a scoping review.
Blagden S, Newell K, Ghazarians N, Sulaiman S, Tunn L, Odumala M, Isba R, Edge R. BMJ Open. 2022 Aug 2;12(8):e061749. doi: 10.1136/bmjopen-2022-061749. PMID: 35918116

Identifying a Single Optimal Integrated Cervical Cancer Prevention Policy in Norway: A Cost-Effectiveness Analysis.
Portnoy A, Pedersen K, Nygård M, Trogstad L, Kim JJ, Burger EA. Med Decis Making. 2022 Aug;42(6):795-807. doi: 10.1177/0272989X221082683. Epub 2022 Mar 8. PMID: 35255741

Chilblains After SARS-CoV-2 Vaccination: Coincidence or Real Association?
Karamanakos A, Evangelatos G, Pappa M, Fragiadaki K, Fanouriakis A, Fragoulis GE. J Rheumatol. 2022 Aug 1:jrheum.220487. doi: 10.3899/jrheum.220487. Online ahead of print. PMID: 35914789

BNT162b2 mRNA Vaccination Against COVID-19 is Associated with Decreased Likelihood of Multisystem Inflammatory Syndrome in U.S. Children Ages 5-18 Years.
Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Orzel AO, Young CC, Boom JA, Sahni LC, Maddux AB, Bline KE, Kamidani S, Tarquinio KM, Chiotos K, Schuster JE, Cullimore ML, Heidemann SM, Hobbs CV, Nofziger RA, Pannaraj PS, Cameron MA, Walker TC, Schwartz SP, Michelson KN, Coates BM, Flori HR, Mack EH, Smallcomb L, Gertz SJ, Bhumbra SS, Bradford TT, Levy ER, Kong M, Irby K, Cvijanovich NZ, Zinter MS, Bowens C, Crandall H, Hume JR, Patel MM, Campbell AP, Randolph AG; Overcoming COVID-19 Investigators. Clin Infect Dis. 2022 Aug 4:ciac637. doi: 10.1093/cid/ciac637. Online ahead of print. PMID: 35924406

Risk factors influencing seroconversion after inactive SARS-CoV-2 vaccination in people living with obesity.
Kara Z, Akçin R, Demir AN, Dinc HO, Kocazeybek B, Yumuk VD. Obes Facts. 2022 Aug 3. doi: 10.1159/000525555. Online ahead of print. PMID: 35921804

Major considerations in vaccinating children in Africa against COVID-19.
Osakuade OW, Anyam NV. Vaccine X. 2022 Dec;12:100199. doi: 10.1016/j.jvacx.2022.100199. Epub 2022 Aug 5. PMID: 35945971

Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer **vaccine** and TCR-engineered T cell therapy.
Mallet M, Boulos RE, Alcazer V, Bonaventura P, Estornes Y, Chuvin N, Depil S. Eur J Cancer. 2022 Aug;171:96-105. doi: 10.1016/j.ejca.2022.05.008. Epub 2022 Jun 14. PMID: 35714452

Operational lessons learned in conducting an international study on pharmacovigilance in pregnancy in resource-constrained settings: The WHO Global **Vaccine** safety Multi-Country collaboration project.
Sharan A, Jahagirdar S, Stuurman AL, Elango V, Riera-Montes M, Kumar Kashyap N, Kumar Arora N, Mathai M, Mangtani P, Devlieger H, Anderson S, Whitaker B, Wong HL, Cutland CL, Guillard Maure C; WHO Global Vaccine Safety Multi-Country Collaboration Sites. Vaccine X. 2022 Aug;11:100160. doi: 10.1016/j.jvacx.2022.100160. Epub 2022 Apr 9. PMID: 35434599

Direct T-cell Presentation by cDC1: The Key Feature for Cancer **Vaccine** Success?
Hubert M, Caux C, Valladeau-Guilemond J. Cancer Immunol Res. 2022 Aug 3;10(8):918. doi: 10.1158/2326-6066.CIR-22-0473. PMID: 35802596

Factors affecting poor measles vaccination coverage in sub-Saharan Africa with a special focus on Nigeria: a narrative review.
Majekodunmi OB, Oladele EA, Greenwood B. Trans R Soc Trop Med Hyg. 2022 Aug 5;116(8):686-693. doi: 10.1093/trstmh/trac013. PMID: 35294971

Vaccine hesitancy and cognitive biases: Evidence for tailored communication with parents.
Casigliani V, Menicagli D, Fornili M, Lippi V, Chinelli A, Stacchini L, Arzilli G, Scardina G, Baglietto L, Lopalco P, Tavoschi L. Vaccine X. 2022 Jul 2;11:100191. doi: 10.1016/j.jvacx.2022.100191. eCollection 2022 Aug. PMID: 35859887

New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort.
Gasparotto M, Bindoli S, Padoan R, Cozzi G, Depascale R, Zanatta E, Giollo A, Gatto M, Zen M, Schiavon F, Ramonda R, Sfriso P, Doria A, Iaccarino L. Clin Exp Rheumatol. 2022 Aug 5. doi: 10.55563/clinexprheumatol/vx44zn. Online ahead of print. PMID: 35930472

Global epidemiology of **vaccine**-derived poliovirus 2016-2021: A descriptive analysis and retrospective case-control study.
Lai YA, Chen X, Kunasekaran M, Rahman B, MacIntyre CR. EClinicalMedicine. 2022 Jun 25;50:101508. doi: 10.1016/j.eclinm.2022.101508. eCollection 2022 Aug. PMID: 35784443

Investigation and long-term monitoring of the presence of neutralizing antibody in patients with COVID-19 disease of different clinical severity.
Kaygusuz S, Korukluoğlu G, Coşgun Y, Şahin Ö, Arslan F. J Med Virol. 2022 Aug;94(8):3596-3604. doi: 10.1002/jmv.27751. Epub 2022 Apr 11. PMID: 35365870

Natural History of Myocardial Injury Following COVID-19 **Vaccine** Associated Myocarditis.
Alhussein MM, Rabbani M, Sarak B, Dykstra S, Labib D, Flewitt J, Lydell CP, Howarth AG, Filipchuck N, Kealey A, Colbert J, Guron N, Kolman L, Merchant N, Bandali M, Bristow M, White JA. Can J Cardiol. 2022 Aug 6:S0828-282X(22)00500-1. doi: 10.1016/j.cjca.2022.07.017. Online ahead of print. PMID: 35944800

Public attitudes on social media toward vaccination before and during the COVID-19 pandemic.
Shah U, Biswas MR, Ali R, Ali H, Shah Z. Hum Vaccin Immunother. 2022 Aug 3:2101835. doi: 10.1080/21645515.2022.2101835. Online ahead of print. PMID: 35920771

Spatial delivery of immune cues to lymph nodes to define therapeutic outcomes in cancer vaccination.
Andorko JI, Tsai SJ, Gammon JM, Carey ST, Zeng X, Gosselin EA, Edwards C, Shah SA, Hess KL, Jewell CM. Biomater Sci. 2022 Aug 9;10(16):4612-4626. doi: 10.1039/d2bm00403h. PMID: 35796247

Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.
Monteil V, Eaton B, Postnikova E, Murphy M, Braunsfeld B, Crozier I, Kricek F, Niederhöfer J, Schwarzböck A, Breid H, Devignot S, Klingström J, Thålin C, Kellner MJ, Christ W, Havervall S, Mereiter S, Knapp S, Sanchez Jimenez A, Bugajska-Schretter A, Dohnal A, Ruf C, Gugenberger R, Hagelkruys A, Montserrat N, Kozieradzki I, Hasan Ali O, Stadlmann J, Holbrook MR, Schmaljohn C, Oostenbrink C, Shoemaker RH, Mirazimi A, Wirnsberger G, Penninger JM. EMBO Mol Med. 2022 Aug 8;14(8):e15230. doi: 10.15252/emmm.202115230. Epub 2022 Jul 4. PMID: 35781796

COVID-19 **Vaccine** Uptake and Its Impacts in a Cohort of Gay and Bisexual Men in Australia.
Prestage G, Storer D, Jin F, Haire B, Maher L, Philpot S, Bavinton B, Saxton P, Murphy D, Holt M, Bourne A, Hammoud MA. AIDS Behav. 2022 Aug;26(8):2692-2702. doi: 10.1007/s10461-022-03611-x. Epub 2022 Feb 8. PMID: 35132480

Miller Fisher syndrome following COVID-19 vaccines: A scoping review.
Kim JE, Yoon BA, Kim YH, Kim JK, Bae JS. Acta Neurol Scand. 2022 Aug 8. doi: 10.1111/ane.13687. Online ahead of print. PMID: 35938305

Immunomodulatory effect of mycobacterial outer membrane vesicles coated nanoparticles.
George E, Goswami A, Lodhiya T, Padwal P, Iyer S, Gauttam I, Sethi L, Jeyasankar S, Sharma PR, Dravid AA, Mukherjee R, Agarwal R. Biomater Adv. 2022 Aug;139:213003. doi: 10.1016/j.bioadv.2022.213003. Epub 2022 Jun 27. PMID: 35882150

Subacute Thyroiditis Following SARS-CoV-2 Vaccines: Six Cases Report and Review of the Literature.
Kurtulmus N, Kayikci K. Horm Metab Res. 2022 Aug;54(8):556-561. doi: 10.1055/a-1804-9561. Epub 2022 Mar 22. PMID: 35318621

World Dengue Day: A call for action.
Srisawat N, Thisyakorn U, Ismail Z, Rafiq K, Gubler DJ; ADVA-ISNTD World Dengue Day Committee. PLoS Negl Trop Dis. 2022 Aug 4;16(8):e0010586. doi: 10.1371/journal.pntd.0010586. eCollection 2022 Aug. PMID: 35925876

Dataset to explore factors affecting COVID-19 vaccination intention. Evidence from Morocco.
Abdessadek M, Ben-Saghroune H, Boubker O, Iken I, Abid H, Amraoui BE, Khabbal Y. Data Brief. 2022 Aug;43:108365. doi: 10.1016/j.dib.2022.108365. Epub 2022 Jun 9. PMID: 35702364

Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures.
Li L, Zhou J, Dong X, Liao Q, Zhou D, Zhou Y. Int Immunopharmacol. 2022 Aug;109:108929. doi: 10.1016/j.intimp.2022.108929. Epub 2022 Jun 11. PMID: 35700581

Humoral response to BNT162b2 mRNA COVID-19 **vaccine** in peritoneal and hemodialysis patients: A comparative study.
Duarte R, Roldão M, Figueiredo C, Luz I, Ferrer F, Gonçalves H, Sofia F, Lopes K. Ther Apher Dial. 2022 Aug;26(4):790-796. doi: 10.1111/1744-9987.13766. Epub 2021 Dec 14. PMID: 34837463

Refolding and characterization of a diabody against Pfs25, a **vaccine** candidate of Plasmodiumfalciparum.
Jagannath DK, Valiyaparambil A, Viswanath VK, Hurakadli MA, Kamariah N, Jafer AC, Patole C, Pradhan S, Kumar N, Lakshminarasimhan A. Anal Biochem. 2022 Aug 6:114830. doi: 10.1016/j.ab.2022.114830. Online ahead of print. PMID: 35944694

Evaluation of a bivalent recombinant **vaccine** candidate targeting norovirus and rotavirus: Antibodies to rotavirus NSP4 exert antidiarrheal effects without virus neutralization.
Cao H, Wu J, Luan N, Wang Y, Lin K, Liu C. J Med Virol. 2022 Aug;94(8):3847-3856. doi: 10.1002/jmv.27809. Epub 2022 May 6. PMID: 35474320

Effect of pneumococcal conjugate **vaccine** on prevalence of otitis media with effusion among children in Vietnam.
Toizumi M, Satoh C, Quilty BJ, Nguyen HAT, Madaniyazi L, Le LT, Ng CFS, Hara M, Iwasaki C, Takegata M, Kitamura N, Nation ML, Satzke C, Kumai Y, Do HT, Bui MX, Mulholland K, Flasche S, Dang DA,

Kaneko K, Yoshida LM. Vaccine. 2022 Aug 4:S0264-410X(22)00944-6. doi: 10.1016/j.vaccine.2022.07.047. Online ahead of print. PMID: 35934579

Absolute Lymphocyte Count After COVID-19 Vaccination Is Associated with **Vaccine**-Induced Hypermetabolic Lymph Nodes on ^{18}F-FDG PET/CT: A Focus in Breast Cancer Care.
Seban RD, Richard C, Nascimento-Leite C, Ghidaglia J, Provost C, Gonin J, Tourneau CL, Romano E, Deleval N, Champion L. J Nucl Med. 2022 Aug;63(8):1231-1238. doi: 10.2967/jnumed.121.263082. Epub 2021 Dec 2. PMID: 34857663

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
Schultz BM, Melo-González F, Duarte LF, Gálvez NMS, Pacheco GA, Soto JA, Berríos-Rojas RV, González LA, Moreno-Tapia D, Rivera-Pérez D, Ríos M, Vázquez Y, Hoppe-Elsholz G, Andrade-Parra CA, Vallejos OP, Piña-Iturbe A, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W; CoronaVac03CL Study Group, González-Aramundiz JV, González PA, Abarca K, Kalergis AM, Bueno SM. mBio. 2022 Aug 10:e0142322. doi: 10.1128/mbio.01423-22. Online ahead of print. PMID: 35946814

Rotavirus VP4 Epitope of a Broadly Neutralizing Human Antibody Defined by Its Structure Bound with an Attenuated-Strain Virion.
Jenni S, Li Z, Wang Y, Bessey T, Salgado EN, Schmidt AG, Greenberg HB, Jiang B, Harrison SC. J Virol. 2022 Aug 4:e0062722. doi: 10.1128/jvi.00627-22. Online ahead of print. PMID: 35924923

Incidence and severity of COVID-19 infection post-vaccination: a survey among Indian doctors.
Parameswaran A, Apsingi S, Eachempati KK, Dannana CS, Jagathkar G, Iyer M, Aribandi H. Infection. 2022 Aug;50(4):889-895. doi: 10.1007/s15010-022-01758-2. Epub 2022 Feb 7. PMID: 35129788

Pandemic 1918 Influenza Virus Does Not Cause Lethal Infection in Rhesus or Cynomolgus Macaques.
Chan M, Tiwary M, Wu HL, Tailor N, Vendramelli R, Audet J, Warner BM, Tierney K, Albietz A, Truong T, Doan K, Bello A, Willman M, Griffin BD, Hanley PW, Lovaglio J, Safronetz D, Strong J, Sacha JB, Kobasa D. J Virol. 2022 Aug 4:e0072822. doi: 10.1128/jvi.00728-22. Online ahead of print. PMID: 35924920

Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases.
Shakoei S, Kalantari Y, Nasimi M, Tootoonchi N, Ansari MS, Razavi Z, Etesami I. Dermatol Ther. 2022 Aug;35(8):e15651. doi: 10.1111/dth.15651. Epub 2022 Jul 4. PMID: 35716105
Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants.
Amano M, Otsu S, Maeda K, Uemura Y, Shimizu Y, Omata K, Matsuoka M, Shimada S, Mitsuya H. Sci Rep. 2022 Aug 8;12(1):13524. doi: 10.1038/s41598-022-17071-9. PMID: 35941265

Blockade of the Adenylate Cyclase Toxin Synergizes with Opsonizing Antibodies to Protect Mice against Bordetella pertussis.
DiVenere AM, Amengor D, Silva RP, Goldsmith JA, McLellan JS, Maynard JA. mBio. 2022 Aug 3:e0152722. doi: 10.1128/mbio.01527-22. Online ahead of print. PMID: 35920558

Yellow fever **vaccine** safety in immunocompromised individuals: a systematic review and meta-analysis.
Araújo Lagos LW, Jesus Lopes de Abreu A, Caetano R, Braga JU. J Travel Med. 2022 Aug 10:taac095. doi: 10.1093/jtm/taac095. Online ahead of print. PMID: 35947986

COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis.
Deodhar A, Bhana S, Winthrop K, Gensler LS. Rheumatol Ther. 2022 Aug;9(4):993-1016. doi: 10.1007/s40744-022-00462-9. Epub 2022 May 22. PMID: 35598255

Immunogenicity and safety of SARS-CoV-2 mRNA **vaccine** in patients with nephrotic syndrome receiving immunosuppressive agents.
Kamei K, Ogura M, Sato M, Nishi K, Shoji K, Funaki T, Ogimi C, Ito S. Pediatr Nephrol. 2022 Aug 1:1-8. doi: 10.1007/s00467-022-05633-y. Online ahead of print. PMID: 35913562

Racial And Ethnic Disparities In COVID-19 Booster Uptake.
Baker L, Phillips B, Faherty LJ, Ringel JS, Kranz AM. Health Aff (Millwood). 2022 Aug;41(8):1202-1207. doi: 10.1377/hlthaff.2022.00287. PMID: 35914210

Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis.
Staadegaard L, Rönn MM, Soni N, Bellerose ME, Bloem P, Brisson M, Maheu-Giroux M, Barnabas RV, Drolet M, Mayaud P, Dalal S, Boily MC. EClinicalMedicine. 2022 Aug 3;52:101585. doi: 10.1016/j.eclinm.2022.101585. eCollection 2022 Oct. PMID: 35936024

An autopsy case of COVID-19-like acute respiratory distress syndrome after mRNA-1273 SARS-CoV-2 vaccination.
Yoshimura Y, Sasaki H, Miyata N, Miyazaki K, Okudela K, Tateishi Y, Hayashi H, Kawana-Tachikawa A, Iwashita H, Maeda K, Ihama Y, Hatayama Y, Ryo A, Tachikawa N. Int J Infect Dis. 2022 Aug;121:98-101. doi: 10.1016/j.ijid.2022.04.057. Epub 2022 Apr 30. PMID: 35500794

Covid-19 vaccination in pregnancy.
Badell ML, Dude CM, Rasmussen SA, Jamieson DJ. BMJ. 2022 Aug 10;378:e069741. doi: 10.1136/bmj-2021-069741. PMID: 35948352

Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques.
He WT, Yuan M, Callaghan S, Musharrafieh R, Song G, Silva M, Beutler N, Lee WH, Yong P, Torres JL, Melo M, Zhou P, Zhao F, Zhu X, Peng L, Huang D, Anzanello F, Ricketts J, Parren M, Garcia E, Ferguson M, Rinaldi W, Rawlings SA, Nemazee D, Smith DM, Briney B, Safonova Y, Rogers TF, Dan JM, Zhang Z, Weiskopf D, Sette A, Crotty S, Irvine DJ, Ward AB, Wilson IA, Burton DR, Andrabi R. Sci Transl Med. 2022 Aug 10;14(657):eabl9605. doi: 10.1126/scitranslmed.abl9605. Epub 2022 Aug 10. PMID: 35947674

PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza **vaccine**.
Herati RS, Knorr DA, Vella LA, Silva LV, Chilukuri L, Apostolidis SA, Huang AC, Muselman A, Manne S, Kuthuru O, Staupe RP, Adamski SA, Kannan S, Kurupati RK, Ertl HCJ, Wong JL, Bournazos S, McGettigan S, Schuchter LM, Kotecha RR, Funt SA, Voss MH, Motzer RJ, Lee CH, Bajorin DF, Mitchell TC, Ravetch JV, Wherry EJ. Nat Immunol. 2022 Aug;23(8):1183-1192. doi: 10.1038/s41590-022-01274-3. Epub 2022 Jul 28. PMID: 35902637

[LRG47/EBP50 recombinant lentivirus-targeted vector **vaccine** enhances anti-tuberculosis immunity of RAW264.7 macrophages and its mechanism].
Guo Y, Zhou J, Le F, Wang Y, Fu P, Su R, Huang Z, Luo Q, Li J. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2022 Aug;38(8):679-684. PMID: 35851080

A SARS-CoV-2 Outbreak Among Nursing Home Residents Vaccinated with a Booster Dose of mRNA COVID-19 **Vaccine**.
Ripabelli G, Sammarco ML, Rezza G, D'Amico A, De Dona R, Iafigliola M, Parente A, Samprati N, Santagata A, Adesso C, Natale A, Di Palma MA, Cannizzaro F, Dentizzi C, Stefanelli P, Tamburro M. J Community Health. 2022 Aug;47(4):598-603. doi: 10.1007/s10900-022-01082-8. Epub 2022 Mar 25. PMID: 35334031

Navigating the unknown: the coronavirus disease 2019 pandemic and solid organ transplantation.
Safa K, Kotton CN. Curr Opin Infect Dis. 2022 Aug 1;35(4):288-294. doi: 10.1097/QCO.0000000000000852. Epub 2022 Jul 5. PMID: 35849518

Highly efficient protein expression of Plasmodium vivax surface antigen, Pvs25, by silkworm and its biochemical analysis.
Miyata T, Minamihata K, Kurihara K, Kamizuru Y, Gotanda M, Obayashi M, Kitagawa T, Sato K, Kimura M, Oyama K, Ikeda Y, Tamaki Y, Lee JM, Sakao K, Hamanaka D, Kusakabe T, Tachibana M, Ibrahim HR. Protein Expr Purif. 2022 Aug;195-196:106096. doi: 10.1016/j.pep.2022.106096. Epub 2022 Apr 21. PMID: 35460871

Designing and development of epitope-based vaccines against *Helicobacter pylori*.
Mohammadzadeh R, Soleimanpour S, Pishdadian A, Farsiani H. Crit Rev Microbiol. 2022 Aug;48(4):489-512. doi: 10.1080/1040841X.2021.1979934. Epub 2021 Sep 24. PMID: 34559599

Acute Bulbar Palsy-Plus Variant of Guillain-Barré Syndrome in a 3-Year-Old Girl.
Dukkipati SS, Zhou DJ, Powers AM, Piccione EA, Koh S. Child Neurol Open. 2022 Aug 1;9:2329048X221115476. doi: 10.1177/2329048X221115476. eCollection 2022 Jan-Dec. PMID: 35936111

COVID-19 mRNA **vaccine** effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study.
Tang F, Hammel IS, Andrew MK, Ruiz JG. Lancet Healthy Longev. 2022 Aug 1. doi: 10.1016/S2666-7568(22)00166-0. Online ahead of print. PMID: 35935474

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants.
van Doremalen N, Schulz JE, Adney DR, Saturday TA, Fischer RJ, Yinda CK, Thakur N, Newman J, Ulaszewska M, Belij-Rammerstorfer S, Saturday G, Spencer AJ, Bailey D, Russell CA, Gilbert SC, Lambe T, Munster VJ. Nat Commun. 2022 Aug 8;13(1):4610. doi: 10.1038/s41467-022-32248-6. PMID: 35941149

Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G Levels After the Pfizer-BioNTech Booster Dose for Coronavirus Disease 2019 (COVID-19) Vaccination During the Second Trimester of Pregnancy.

Kugelman N, Nahshon C, Shaked-Mishan P, Kleifeld S, Cohen N, Sher ML, Zahran H, Barsha H, Assaf W, Shalabna E, Stein N, Lavie O, Kedar R, Riskin-Mashiah S. Obstet Gynecol. 2022 Aug 1;140(2):187-193. doi: 10.1097/AOG.0000000000004867. Epub 2022 May 27. PMID: 35852268

COVID-19 Vaccination Intentions, Concerns, and Facilitators Among US Parents of Children Ages 6 Months Through 4 Years.
Scherer AM, Gidengil CA, Gedlinske AM, Parker AM, Askelson NM, Woodworth KR, Petersen CA, Lindley MC. JAMA Netw Open. 2022 Aug 1;5(8):e2227437. doi: 10.1001/jamanetworkopen.2022.27437. PMID: 35921107

Post-vaccination infection rates and modification of COVID-19 symptoms in vaccinated UK school-aged children and adolescents: A prospective longitudinal cohort study.
Molteni E, Canas LS, Kläser K, Deng J, Bhopal SS, Hughes RC, Chen L, Murray B, Kerfoot E, Antonelli M, Sudre CH, Pujol JC, Polidori L, May A, Hammers PA, Wolf J, Spector PTD, Steves CJ, Ourselin PS, Absoud M, Modat M, Duncan PEL. Lancet Reg Health Eur. 2022 Aug;19:100429. doi: 10.1016/j.lanepe.2022.100429. Epub 2022 Jul 8. PMID: 35821715

Impact of COVID-19 **vaccine** on clinical characteristics and outcome of hospitalized COVID-19 patients during the fourth wave of the pandemic in Tuzla Canton, Bosnia and Herzegovina.
Porobić-Jahić H, Piljić D, Jahić R, Mujić M, Trnačević A, Petrović J, Mustafić S, Jahić N, Tihić N. Med Glas (Zenica). 2022 Aug 1;19(2). doi: 10.17392/1500-22. Online ahead of print. PMID: 35924805

Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study.
Terada M, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, Hisada T, Uemoto Y, Akiko Kato, Yamanaka N, Sugiura H, Mita K, Wada A, Takahashi E, Saito K, Yoshioka R, Toyama T. Breast Cancer Res Treat. 2022 Aug 8:1-13. doi: 10.1007/s10549-022-06693-2. Online ahead of print. PMID: 35941421

[Le cancer du col de l'utérus au Maroc : une revue systématique].
Arechkik A, Lahlou L, Obtel M, Kharbach A, Razine R. Rev Epidemiol Sante Publique. 2022 Aug 1:S0398-7620(22)00708-8. doi: 10.1016/j.respe.2022.05.008. Online ahead of print. PMID: 35927117

SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines.
Di Giacomo AM, Giacobini G, Anichini G, Gandolfo C, D'alonzo V, Calabrò L, Lofiego MF, Cusi MG, Maio M. Eur J Cancer. 2022 Aug;171:143-149. doi: 10.1016/j.ejca.2022.05.018. Epub 2022 May 25. PMID: 35717822

SARS-CoV-2 **vaccine** humoral response in adults with Down syndrome.
Sali M, Carfì A, Di Paola A, Pereyra Boza M, Zampino G, Sanguinetti M, Landi F, Onder G. Clin Microbiol Infect. 2022 Aug;28(8):1155.e1-1155.e4. doi: 10.1016/j.cmi.2022.04.008. Epub 2022 Apr 21. PMID: 35461998

Acquired aplastic anemia following SARS-CoV-2 vaccination.
Röth A, Bertram S, Schroeder T, Haverkamp T, Voigt S, Holtkamp C, Klump H, Wörmann B, Reinhardt HC, Alashkar F. Eur J Haematol. 2022 Aug;109(2):186-194. doi: 10.1111/ejh.13788. Epub 2022 Jun 1. PMID: 35592930

IgA vasculitis with transient glomerular hematuria, diarrhea, and pericarditis following COVID-19 mRNA vaccination in a young patient with possible pre-existing ulcerative colitis.
Ito C, Odajima K, Niimura Y, Fujii M, Sone M, Asakawa S, Arai S, Yamazaki O, Tamura Y, Saito K, Tada Y, Yamamoto T, Kozuma K, Shibata S, Fujigaki Y. CEN Case Rep. 2022 Aug 4:1-7. doi: 10.1007/s13730-022-00727-w. Online ahead of print. PMID: 35927545

Factors influencing refugees' willingness to accept COVID-19 vaccines in Greater Sydney: a qualitative study.
Mahimbo A, Kang M, Sestakova L, Smith M, Dawson A. Aust N Z J Public Health. 2022 Aug;46(4):502-510. doi: 10.1111/1753-6405.13252. Epub 2022 May 12. PMID: 35555951

Pulmonary embolism with junctional tachycardia: A serious complication after COVID-19 vaccination.
Miri C, Bouchlarhem A, Boulouiz S, El Ouafi N, Bazid Z. Ann Med Surg (Lond). 2022 Aug;80:103983. doi: 10.1016/j.amsu.2022.103983. Epub 2022 Jun 28. PMID: 35784614

Platform for Active **Vaccine** Formulation Using a Two-Mode Enhancement Mechanism of Epitope Presentation by Pickering Emulsion.
Mechrez G, Mani KA, Saha A, Lachman O, Luria N, Molad O, Kotliarevski L, Zelinger E, Smith E, Yaakov N, Stone DS, Reches M, Dombrovsky A. ACS Appl Bio Mater. 2022 Aug 1. doi: 10.1021/acsabm.2c00410. Online ahead of print. PMID: 35913405

How COVID-19 has impacted immunisation service delivery in Australia: a national study.
Giles ML, O'Bryan J, Angliss M, Lee S, Krishnaswamy S. Aust N Z J Public Health. 2022 Aug;46(4):495-501. doi: 10.1111/1753-6405.13260. Epub 2022 May 26. PMID: 35616400

Pituitary apoplexy after COVID-19 vaccination: A case report.
Zainordin NA, Hatta SFWM, Ab Mumin N, Shah FZM, Ghani RA. J Clin Transl Endocrinol Case Rep. 2022 Aug 4:100123. doi: 10.1016/j.jecr.2022.100123. Online ahead of print. PMID: 35942396

COVID-19 **Vaccine** Compliance in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Shkalim Zemer V, Hoshen M, Gerstein M, Richenberg Y, Jacobson E, Grossu R, Cohen M, Cohen HA. Int J Psychiatry Med. 2022 Aug 8:912174221116734. doi: 10.1177/00912174221116734. Online ahead of print. PMID: 35940286

Systematic lupus erythematous patients following COVID-19 vaccination: Its flares up and precautions.
Khatri G, Priya, Shaikh S, Aashish, Rai A, Cheema HA, Essar MY. Ann Med Surg (Lond). 2022 Aug;80:104282. doi: 10.1016/j.amsu.2022.104282. Epub 2022 Jul 31. PMID: 35936557

From Human Papillomavirus to COVID-19: Adolescent Autonomy and Minor Consent for Vaccines.
Mihaly LK, Schapiro NA, English A. J Pediatr Health Care. 2022 Aug 5:S0891-5245(22)00175-4. doi: 10.1016/j.pedhc.2022.06.007. Online ahead of print. PMID: 35941049

Quantitative Analysis of Vertical Transmission of Maternal SARS-CoV-2 Antibodies to Neonates and Young Infants Following Immunization During Pregnancy.
Golan N, Ashkenazi S, Davidovich R, Levinsky A, Bar Chaim A, Abu Hamad R, Raveh O, Yitzhaki S, Livni G. J Pediatric Infect Dis Soc. 2022 Aug 5:piac065. doi: 10.1093/jpids/piac065. Online ahead of print. PMID: 35929547

Strong Response to SARS-CoV-2 **Vaccine** Additional Doses Among Patients With Inflammatory Bowel Diseases.
Long MD, Weaver KN, Zhang X, Chun K, Kappelman MD; PREVENT-COVID Study Group. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1881-1883.e1. doi: 10.1016/j.cgh.2022.01.056. Epub 2022 Feb 9. PMID: 35150924

COVID-19 and Inborn Errors of Immunity.
Delmonte OM, Castagnoli R, Notarangelo LD. Physiology (Bethesda). 2022 Aug 9. doi: 10.1152/physiol.00016.2022. Online ahead of print. PMID: 35944006

Evaluating the psychometric properties of the Chinese version of the modified Carolina Human Papillomavirus immunisation attitudes and beliefs scale among Chinese adolescent girls.
Pak Chun Chau J, Hoi Shan Lo S, Butt L, Chow Choi K. Prev Med Rep. 2022 Jul 9;28:101902. doi: 10.1016/j.pmedr.2022.101902. eCollection 2022 Aug. PMID: 35845821

Intra-genomic heterogeneity in CpG dinucleotide composition in dengue virus.
Jaglan A, Satija S, Singh D, Phartyal R, Verma M. Acta Trop. 2022 Aug;232:106501. doi: 10.1016/j.actatropica.2022.106501. Epub 2022 May 2. PMID: 35513073

An alphavirus-derived self-amplifying mRNA encoding PpSP15-LmSTI1 fusion protein for the design of a **vaccine** against leishmaniasis.
Savar NS, Shengjuler D, Doroudian F, Vallet T, Mac Kain A, Arashkia A, Khamesipour A, Lundstrom K, Vignuzzi M, Niknam HM. Parasitol Int. 2022 Aug;89:102577. doi: 10.1016/j.parint.2022.102577. Epub 2022 Mar 14. PMID: 35301120

Oil-in-ionic liquid nanoemulsion-based adjuvant simultaneously enhances the stability and immune responses of inactivated foot-and-mouth disease virus.
Lin X, Yang Y, Li S, Li Z, Sheng Y, Su Z, Zhang S. Int J Pharm. 2022 Aug 5;625:122083. doi: 10.1016/j.ijpharm.2022.122083. Online ahead of print. PMID: 35934167

cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1.
Ferris ST, Ohara RA, Ou F, Wu R, Huang X, Kim S, Chen J, Liu TT, Schreiber RD, Murphy TL, Murphy KM. Cancer Immunol Res. 2022 Aug 3;10(8):920-931. doi: 10.1158/2326-6066.CIR-21-0865. PMID: 35648641

New-Onset IgA nephropathy Following COVID-19 Vaccination.
Ma Y, Xu G. QJM. 2022 Aug 3:hcac185. doi: 10.1093/qjmed/hcac185. Online ahead of print. PMID: 35920797

COVID-19 pandemic vaccination strategies of early 2021 based on behavioral differences between residents of Tokyo and Osaka, Japan.
Yasuda H, Ito F, Hanaki KI, Suzuki K. Arch Public Health. 2022 Aug 4;80(1):180. doi: 10.1186/s13690-022-00933-z. PMID: 35927683

Longitudinal change in depressive symptoms among healthcare professionals with and without COVID-19 **vaccine** hesitancy from October 2020 to June 2021 in Japan.

Asaoka H, Koido Y, Kawashima Y, Ikeda M, Miyamoto Y, Nishi D. Ind Health. 2022 Aug 1;60(4):387-394. doi: 10.2486/indhealth.2021-0164. Epub 2021 Oct 29. PMID: 34719601 F

Intravenous BCG driven antigen recognition in a murine tuberculosis model.
Singh S, Bolz M, Cornelius A, Desvignes L. Comp Immunol Microbiol Infect Dis. 2022 Aug;87:101838. doi: 10.1016/j.cimid.2022.101838. Epub 2022 Jun 7. PMID: 35700556

Long-term antibody response following SPUTNIK V primary vaccination in healthcare workers with and without history of SARS-CoV-2 infection: Prospective cohort study from a hospital in Argentina.
Gentile A, Castellano VE, Pacchiotti A, Weinberger N, Diana Menéndez S, Del Pino M, Carciofi G, Lamy P, Mistchenko AS. Vaccine X. 2022 Aug;11:100187. doi: 10.1016/j.jvacx.2022.100187. Epub 2022 Jun 18. PMID: 35755140

COVID-19 **vaccine** effectiveness against symptomatic SARS-CoV-2 infection during Delta-dominant and Omicron-dominant periods in Japan: a multi-center prospective case-control study (FASCINATE study).
Arashiro T, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, Arioka H, Yanai H, Kuramochi J, Ihara G, Chubachi K, Yanagisawa N, Nagura Y, Kato Y, Ueda A, Numata A, Kato H, Ishii K, Ooki T, Oka H, Nishida Y, Stucky A, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Clin Infect Dis. 2022 Aug 3:ciac635. doi: 10.1093/cid/ciac635. Online ahead of print. PMID: 35918782

Incidence of Acute Chest Syndrome in Children With Sickle Cell Disease Following Implementation of the 13-Valent Pneumococcal Conjugate **Vaccine** in France.
Assad Z, Michel M, Valtuille Z, Lazzati A, Boizeau P, Madhi F, Gaschignard J, Pham LL, Caseris M, Cohen R, Kaguelidou F, Varon E, Alberti C, Faye A, Angoulvant F, Koehl B, Ouldali N. JAMA Netw Open. 2022 Aug 1;5(8):e2225141. doi: 10.1001/jamanetworkopen.2022.25141. PMID: 35917121

Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study.
Paternina-Caicedo A, Jit M, Alvis-Guzmán N, Fernández JC, Hernández J, Paz-Wilches JJ, Rojas-Suarez J, Dueñas-Castell C, Alvis-Zakzuk NJ, Smith AD, Hoz-Restrepo F. Lancet Reg Health Am. 2022 Aug;12:100296. doi: 10.1016/j.lana.2022.100296. Epub 2022 Jul 1. PMID: 35791428

Determinants of COVID-19 Breakthrough Infections and Severity in ChAdOx1 nCoV-19-Vaccinated Priority Groups.
Kaur U, Bala S, Ojha B, Pathak BK, Joshi A, Yadav AK, Singh A, Kansal S, Chakrabarti SS. Am J Trop Med Hyg. 2022 Aug 8:tpmd220172. doi: 10.4269/ajtmh.22-0172. Online ahead of print. PMID: 35940202

Increase in Haemophilus influenzae Detection in 13-Valent Pneumococcal Conjugate **Vaccine** Immunized Children With Acute Otitis Media.
Klein A, Tamir SO, Sorek N, Hanun G, Yeshayahu Y, Marom T. Pediatr Infect Dis J. 2022 Aug 1;41(8):678-680. doi: 10.1097/INF.0000000000003561. Epub 2022 Jul 13. PMID: 35436266

Sensitivity of the Elecsys Nucleocapsid Assay for the Detection of Preceding SARS-CoV-2 Infections.
Grunau B, Tom J, Asamoah-Boaheng M, O'Brien SF, Drews SJ, Sediqi S, Lavoie PM, Barakauskas V, Goldfarb DM. Open Forum Infect Dis. 2022 Jul 26;9(8):ofac349. doi: 10.1093/ofid/ofac349. eCollection 2022 Aug. PMID: 35937649

The pathogenesis of Nipah virus: A review.
Devnath P, Wajed S, Chandra Das R, Kar S, Islam I, Masud HMAA. Microb Pathog. 2022 Aug 5:105693. doi: 10.1016/j.micpath.2022.105693. Online ahead of print. PMID: 35940443

Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV.
Chammartin F, Kusejko K, Pasin C, Trkola A, Briel M, Amico P, Stoekle MP, Eichenberger AL, Hasse B, Braun DL, Schuurmans MM, Müller TF, Tamm M, Mueller NJ, Rauch A, Koller MT, Günthard HF, Bucher HC, Speich B, Abela IA; and the Swiss HIV Cohort Study. AIDS. 2022 Aug 1;36(10):1465-1468. doi: 10.1097/QAD.0000000000003246. Epub 2022 Jul 9. PMID: 35876706

Household Secondary Attack Rates of SARS-CoV-2 Omicron Variant, South Korea, February 2022.
Lim DS, Choe YJ, Man Kim Y, Lee SE, Jang EJ, Kim J, Park YJ. Emerg Infect Dis. 2022 Aug;28(8):1731-1734. doi: 10.3201/eid2808.220384. Epub 2022 Jul 7. PMID: 35798007

Serial Intervals for SARS-CoV-2 Omicron and Delta Variants, Belgium, November 19-December 31, 2021.
Kremer C, Braeye T, Proesmans K, André E, Torneri A, Hens N. Emerg Infect Dis. 2022 Aug;28(8):1699-1702. doi: 10.3201/eid2808.220220. Epub 2022 Jun 22. PMID: 35732195

Invariant in variants.
Liu C, Wu CW. Ultrasonics. 2022 Aug;124:106749. doi: 10.1016/j.ultras.2022.106749. Epub 2022 Apr 8. PMID: 35405598

Exploring the ethics of genetic prioritisation for COVID-19 vaccines.
Bruce J, Johnson SB. Eur J Hum Genet. 2022 Aug;30(8):875-879. doi: 10.1038/s41431-022-01058-1. Epub 2022 Mar 7. PMID: 35250030

Hepatitis B and C in Children.
Sperry AB, Bennett A, Wen J. Clin Liver Dis. 2022 Aug;26(3):403-420. doi: 10.1016/j.cld.2022.03.005. Epub 2022 Jun 25. PMID: 35868682

Immunodeficiency Hiding in Plain Sight.
Argyle TC, Singh A, Abdullah F. Cureus. 2022 Aug 1;14(8):e27571. doi: 10.7759/cureus.27571. eCollection 2022 Aug. PMID: 35928175

Unusual global outbreak of monkeypox: what should we do?
Zhu M, Ji J, Shi D, Lu X, Wang B, Wu N, Wu J, Yao H, Li L. Front Med. 2022 Aug 9:1-11. doi: 10.1007/s11684-022-0952-z. Online ahead of print. PMID: 35943705

Controlled temperature chain for vaccination in low- and middle-income countries: a realist evidence synthesis.
Seaman CP, Kahn AL, Kristensen D, Steinglass R, Spasenoska D, Scott N, Morgan C. Bull World Health Organ. 2022 Aug 1;100(8):491-502. doi: 10.2471/BLT.21.287696. Epub 2022 Jun 22. PMID: 35923285

Multisystem Inflammatory Syndrome Following SARS-CoV-2 Vaccination in Two Children.
Karatzios C, Scuccimarri R, Chédeville G, Basfar W, Bullard J, Stein DR. Pediatrics. 2022 Aug 1;150(2):e2021055956. doi: 10.1542/peds.2021-055956. PMID: 35614536

Pregnant and breastfeeding women's attitudes and fears regarding the COVID-19 vaccination.
Schaal NK, Zöllkau J, Hepp P, Fehm T, Hagenbeck C. Arch Gynecol Obstet. 2022 Aug;306(2):365-372. doi: 10.1007/s00404-021-06297-z. Epub 2021 Oct 27. PMID: 34705115

Opt-out policy and its improvements promote COVID-19 vaccinations.
Liu X, Zhao N, Li S, Zheng R. Soc Sci Med. 2022 Aug;307:115120. doi: 10.1016/j.socscimed.2022.115120. Epub 2022 Jun 22. PMID: 35792410

Lymphohistiocytic Myocarditis Possibly Due to Moderna mRNA-1273 **Vaccine**.
Chow BT, Lai CK. Am J Clin Pathol. 2022 Aug 4;158(2):167-172. doi: 10.1093/ajcp/aqac029. PMID: 35285858

Immune responses and protective immunity in Pangasius pangasius (Hamilton, 1822) as induced by outer membrane proteins of Edwardsiella tarda and aluminium hydroxide adjuvant complex.
Adikesavalu H, Abraham TJ, Joardar SN. Vet Res Commun. 2022 Aug 5. doi: 10.1007/s11259-022-09978-5. Online ahead of print. PMID: 35927371

Adverse events after BNT162b2 mRNA COVID-19 vaccination in health care workers and medical students in Japan.
Namiki T, Komine-Aizawa S, Takada K, Takano C, Trinh QD, Hayakawa S. J Infect Chemother. 2022 Aug;28(8):1220-1224. doi: 10.1016/j.jiac.2022.05.002. Epub 2022 May 11. PMID: 35577684

A 17-year-old male with acute myocarditis following mRNA-1273 vaccination in Japan.
Iwamuro A, Sasa T, Kawai T, Taguchi M, Izuhara M, Uegaito T, Shioji K. J Cardiol Cases. 2022 Aug;26(2):108-110. doi: 10.1016/j.jccase.2022.03.012. Epub 2022 Apr 26. PMID: 35495897

Comparative analysis of the biological characteristics of three CV-A10 clones adaptively cultured on Vero cells.
Zhao H, Yang T, Yue L, Li H, Xie T, Xiang H, Wang J, Wei X, Zhang Y, Xie Z. J Med Virol. 2022 Aug;94(8):3820-3828. doi: 10.1002/jmv.27796. Epub 2022 May 9. PMID: 35437759

Taiwan's Response to Influenza: A Seroepidemiological Evaluation of Policies and Implications for Pandemic Preparedness.
Ho PI, Liu W, Li TZ, Chan TC, Ku CC, Lien YH, Shen YD, Chen JR, Yen MY, Tu YK, Lin WY, Compans R, Lee PI, King CC. Int J Infect Dis. 2022 Aug;121:226-237. doi: 10.1016/j.ijid.2022.02.038. Epub 2022 Feb 27. PMID: 35235824

Health-care utilization for sinusitis after pneumococcal vaccination in patients with low antibody titers.
Bareiss AK, Kattar N, Tivis R, Unis G, Do T, Montelibano L, Price-Haywood EG, McCoul E. Int Forum Allergy Rhinol. 2022 Aug;12(8):1018-1024. doi: 10.1002/alr.22954. Epub 2022 Jan 10. PMID: 34962358

Downward Trend in Resident Myringotomy and Tympanostomy Tube Experience.
Dermody SM, Johng SY, Watkins MO, Malekzadeh S, Ahn J, Harley EH Jr. Ann Otol Rhinol Laryngol. 2022 Aug;131(8):874-879. doi: 10.1177/00034894211047478. Epub 2021 Sep 23. PMID: 34553634

A Review On Edible Vaccines And Biopharmaceutical Products From Plants.
Paradia PK, Bhavale R, Agnihotri T, Jain A. Curr Pharm Biotechnol. 2022 Aug 3. doi: 10.2174/1389201023666220803151039. Online ahead of print. PMID: 35927823

Evaluation of Effectiveness of Global COVID-19 Vaccination Campaign.
He D, Ali ST, Fan G, Gao D, Song H, Lou Y, Zhao S, Cowling BJ, Stone L. Emerg Infect Dis. 2022 Aug 1;28(9). doi: 10.3201/eid2809.212226. Online ahead of print. PMID: 35914516

Trained immunity: implications for vaccination.
Geckin B, Konstantin Föhse F, Domínguez-Andrés J, Netea MG. Curr Opin Immunol. 2022 Aug;77:102190. doi: 10.1016/j.coi.2022.102190. Epub 2022 May 18. PMID: 35597182

Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis.
Mehrabi Nejad MM, Shobeiri P, Dehghanbanadaki H, Tabary M, Aryannejad A, Haji Ghadery A, Shabani M, Moosaie F, SeyedAlinaghi S, Rezaei N. Virol J. 2022 Aug 8;19(1):132. doi: 10.1186/s12985-022-01858-3. PMID: 35941646

Humoral and cellular response of COVID-19 **vaccine** among solid organ transplant recipients: A systematic review and meta-analysis.
Meshram HS, Kute V, Rane H, Dave R, Banerjee S, Mishra V, Chauhan S. Transpl Infect Dis. 2022 Aug 4. doi: 10.1111/tid.13926. Online ahead of print. PMID: 35924679

Effectiveness Associated With BNT162b2 **Vaccine** Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years.
Tartof SY, Frankland TB, Slezak JM, Puzniak L, Hong V, Xie F, Ackerson BK, Valluri SR, Jodar L, McLaughlin JM. JAMA Netw Open. 2022 Aug 1;5(8):e2225162. doi: 10.1001/jamanetworkopen.2022.25162. PMID: 35921109

Real-world effectiveness of BNT162b2 **vaccine** against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia.
Husin M, Tok PSK, Suah JL, Thevananthan T, Tng BH, Peariasamy KM, Sivasampu S. Int J Infect Dis. 2022 Aug;121:55-57. doi: 10.1016/j.ijid.2022.04.053. Epub 2022 Apr 30. PMID: 35500793

COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper.
Rakusa M, Öztürk S, Moro E, Helbok R, Bassetti CL, Beghi E, Bereczki D, Bodini B, Di Liberto G, Jenkins TM, Macerollo A, Maia LF, Martinelli-Boneschi F, Pisani A, Priori A, Sauerbier A, Soffietti R, Taba P, von Oertzen TJ, Zedde M, Crean M, Burlica A, Cavallieri F, Sellner J; European Academy of Neurology NeuroCOVID-19 Task Force. Eur J Neurol. 2022 Aug;29(8):2163-2172. doi: 10.1111/ene.15368. Epub 2022 May 10. PMID: 35460319

Leishmania LiHyC protein is immunogenic and induces protection against visceral leishmaniasis.
Machado AS, Lage DP, Vale DL, Freitas CS, Linhares FP, Cardoso JMO, Oliveira-da-Silva JA, Pereira IAG, Ramos FF, Tavares GSV, Ludolf F, Bandeira RS, Maia LGN, Menezes-Souza D, Duarte MC, Chávez-Fumagalli MA, Roatt BM, Christodoulides M, Martins VT, Coelho EAF. Parasite Immunol. 2022 Aug;44(8):e12921. doi: 10.1111/pim.12921. Epub 2022 Apr 27. PMID: 35437797

Guardians of the oral and nasopharyngeal galaxy: IgA and protection against SARS-CoV-2 infection.
Sheikh-Mohamed S, Sanders EC, Gommerman JL, Tal MC. Immunol Rev. 2022 Aug;309(1):75-85. doi: 10.1111/imr.13118. Epub 2022 Jul 11. PMID: 35815463

On the size-regulation of RNA-loaded lipid nanoparticles synthesized by microfluidic device.
Okuda K, Sato Y, Iwakawa K, Sasaki K, Okabe N, Maeki M, Tokeshi M, Harashima H. J Control Release. 2022 Aug;348:648-659. doi: 10.1016/j.jconrel.2022.06.017. Epub 2022 Jun 18. PMID: 35716883

Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond.
Oberemok VV, Andreeva OA, Laikova KV, Novikov IA, Kubyshkin AV. Inflamm Res. 2022 Aug;71(7-8):729-739. doi: 10.1007/s00011-022-01582-2. Epub 2022 May 6. PMID: 35523969

Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
Suntronwong N, Kanokudom S, Auphimai C, Assawakosri S, Thongmee T, Vichaiwattana P, Duangchinda T, Chantima W, Pakchotanon P, Chansaenroj J, Puenpa J, Nilyanimit P, Srimuan D, Thatsanatorn T, Sudhinaraset N, Wanlapakorn N, Mongkolsapaya J, Poovorawan Y. J Med Virol. 2022 Aug 4. doi: 10.1002/jmv.28044. Online ahead of print. PMID: 35924475

Inflammatory immune-mediated adverse reactions induced by COVID-19 vaccines in previously injected patients with soft tissue fillers: A case series of 20 patients.
Alijotas-Reig J, García-GImenez V, Velthuis PJ, Niessen FB, Decates TS. J Cosmet Dermatol. 2022 Aug;21(8):3181-3187. doi: 10.1111/jocd.15117. Epub 2022 Jun 10. PMID: 35621234

Isolation and identification of sporozoite membrane protein of Cryptosporidium parvum and evaluation of calmodulin-like protein immune protection.
Huang Y, Chen Y, Liu Y, Mi R, Han X, Gong H, Cheng L, Chen Z. Parasite Immunol. 2022 Aug;44(8):e12937. doi: 10.1111/pim.12937. Epub 2022 Jun 29. PMID: 35652261

The Monkeypox Outbreak and Implications for Dental Practice.
Samaranayake L, Anil S. Int Dent J. 2022 Aug 4:S0020-6539(22)00179-4. doi: 10.1016/j.identj.2022.07.006. Online ahead of print. PMID: 35934521

Infection with SARS-CoV-2 Omicron Variant 24 Days after Non-Omicron Infection, Pennsylvania, USA.
Seid AG, Yirko T, Sayeed S, Plipat N. Emerg Infect Dis. 2022 Aug 1;28(9). doi: 10.3201/eid2809.220539. Online ahead of print. PMID: 35914519

Using infographics to reduce the negative effects of jargon on intentions to vaccinate against COVID-19.
Riggs EE, Shulman HC, Lopez R. Public Underst Sci. 2022 Aug;31(6):751-765. doi: 10.1177/09636625221077385. Epub 2022 Mar 10. PMID: 35266427

Vulvar Aphthous Ulcers in an Adolescent After Coronavirus Disease 2019 (COVID-19) Vaccination.
Scott SM, Alaniz V, Appiah L, Buyers E, Holton C, Huguelet P. Obstet Gynecol. 2022 Aug 3. doi: 10.1097/AOG.0000000000004885. Online ahead of print. PMID: 35930388

Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January-March 2022.
Mefsin YM, Chen D, Bond HS, Lin Y, Cheung JK, Wong JY, Ali ST, Lau EHY, Wu P, Leung GM, Cowling BJ. Emerg Infect Dis. 2022 Aug 1;28(9). doi: 10.3201/eid2809.220613. Online ahead of print. PMID: 35914518

Bilateral Avid Axillary Nodes on FDG PET/CT Due to Concurrent Booster COVID-19 Immunization and Seasonal Influenza Vaccination.
Nawwar AA, Searle J, Lyburn ID. Clin Nucl Med. 2022 Aug 1;47(8):712-713. doi: 10.1097/RLU.0000000000004169. Epub 2022 Apr 5. PMID: 35384871

Leishmaniasis control in the light of the COVID-19 pandemic in Africa.
Uwishema O, Sapkota S, Wellington J, Onyeaka CVP, Onyeaka H. Ann Med Surg (Lond). 2022 Aug;80:104263. doi: 10.1016/j.amsu.2022.104263. Epub 2022 Jul 31. PMID: 35936565

Proportionality, wrongs and equipoise for natural immunity exemptions: response to commentators.
Pugh J, Savulescu J, Brown RC, Wilkinson D. J Med Ethics. 2022 Aug 4:medethics-2022-108450. doi: 10.1136/jme-2022-108450. Online ahead of print. PMID: 35927021

SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at midterm after Comirnaty® COVID-19 vaccination.
Torres I, Bellido-Blasco JB, Gimeno C, Burgos JS, Albert E, Moya-Malo R, Gascó-Laborda JC, Tornero A, Soriano J, Meseguer-Ferrer N, Martínez-Serrano M, Ortíz-Rambla J, Buj H, Hernández N, Peiró S, Salas D, Limón R, Vanaclocha H, Sánchez-Payá J, Díez-Domingo J, Comas I, González-Candelas F, Navarro D; Valencian vaccine research program (ProVaVac) study group. J Med Virol. 2022 Aug;94(8):3776-3782. doi: 10.1002/jmv.27799. Epub 2022 Apr 27. PMID: 35445415

COVID-19 and vaccination during pregnancy: a systematic analysis using Korea National Health Insurance claims data.
Ahn KH, Kim HI, Lee KS, Heo JS, Kim HY, Cho GJ, Hong SC, Oh MJ, Kim HJ. Obstet Gynecol Sci. 2022 Aug 2. doi: 10.5468/ogs.22060. Online ahead of print. PMID: 35916014

COVID-19 **vaccine** humoral response in frequent platelet donors with plateletpheresis-associated lymphopenia.
Laumaea AE, Lewin A, Chatterjee D, Marchitto L, Ding S, Gendron-Lepage G, Goyette G, Allard MÈ, Simard C, Tremblay T, Perreault J, Duerr R, Finzi A, Bazin R. Transfusion. 2022 Aug 2. doi: 10.1111/trf.17037. Online ahead of print. PMID: 35919021

Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches.
Davodabadi F, Sarhadi M, Arabpour J, Sargazi S, Rahdar A, Díez-Pascual AM. J Control Release. 2022 Aug 3;349:844-875. doi: 10.1016/j.jconrel.2022.07.036. Online ahead of print. PMID: 35908621

Vaccination barriers and opportunities at syringe services programs in the United States, June-August 2021-A cross-sectional survey.
Montgomery MP, Zhong Y, Roberts E, Asher A, Bixler D, Doshani M, Christensen A, Eckert M, Weng MK, Carry M, Samuel CR, Teshale EH. Drug Alcohol Depend. 2022 Aug 1;237:109540. doi: 10.1016/j.drugalcdep.2022.109540. Epub 2022 Jun 16. PMID: 35753280

A comprehensive analysis of avian lymphoid leukosis-like lymphoma transcriptomes including identification of LncRNAs and the expression profiles.
Dong K, Heidari M, Mays J, Chang S, Xie Q, Zhang L, Ai Y, Zhang H. PLoS One. 2022 Aug 8;17(8):e0272557. doi: 10.1371/journal.pone.0272557. eCollection 2022. PMID: 35939448

An insight into differential protein abundance throughout Leishmania donovani promastigote growth and differentiation.
Alcolea PJ, Alonso A, García-Tabares F, Larraga J, Martins LTC, Loayza FJ, Ruiz-García S, Larraga V. Int Microbiol. 2022 Aug 5:1-18. doi: 10.1007/s10123-022-00259-4. Online ahead of print. PMID: 35930160

Self-reported mask use among persons with or without SARS CoV-2 vaccination -United States, December 2020-August 2021.
Calamari LE, Tjaden AH, Edelstein SL, Weintraub WS, Santos R, Gibbs M, Ward J, Santacatterina M, Bertoni AG, Ward LM, Saydah S, Plumb ID, Runyon MS; COVID-19 Community Research Partnership Study Group. Prev Med Rep. 2022 Aug;28:101857. doi: 10.1016/j.pmedr.2022.101857. Epub 2022 Jun 9. PMID: 35706687

Clozapine and COVID-19 Vaccination: Effects on blood levels and leukocytes. An observational cohort study.
Veerman SRT, Moscou T, Bogers JPAM, Cohen D, Schulte PFJ. Acta Psychiatr Scand. 2022 Aug;146(2):168-178. doi: 10.1111/acps.13428. Epub 2022 Apr 1. PMID: 35322409
regCOVID: Tracking publications of registered COVID-19 studies.
Mayer CS, Huser V. BMC Med Res Methodol. 2022 Aug 10;22(1):221. doi: 10.1186/s12874-022-01703-9. PMID: 35948881

Taking cues from convalescence to improve vaccines against hepatitis C virus.
Sreekumar BK, Taha TY, Ott M. J Clin Invest. 2022 Aug 1;132(15):e161819. doi: 10.1172/JCI161819. PMID: 35912856

Dengue Shock Syndrome: Its Similarity with Anaphylaxis and with the Homeopathic Medicine Apis mellifica (European Honeybee).
Richardson-Boedler C. Homeopathy. 2022 Aug;111(3):226-231. doi: 10.1055/s-0041-1734027. Epub 2021 Nov 8. PMID: 34749419

An introduction to spillover effects in cluster randomized trials with noncompliance.
Keele L, Kang H. Clin Trials. 2022 Aug;19(4):375-379. doi: 10.1177/17407745221093580. Epub 2022 May 5. PMID: 35510562

Immunotherapy in Ovarian Cancer.
Siminiak N, Czepczyński R, Zaborowski MP, Iżycki D. Arch Immunol Ther Exp (Warsz). 2022 Aug 9;70(1):19. doi: 10.1007/s00005-022-00655-8. PMID: 35941287

Fulminant Myocarditis 24 Days after Coronavirus Disease Messenger Ribonucleic Acid Vaccination.
Kawano H, Motokawa T, Kurohama H, Okano S, Akashi R, Yonekura T, Ikeda S, Izumikawa K, Maemura K. Intern Med. 2022 Aug 1;61(15):2319-2325. doi: 10.2169/internalmedicine.9800-22. Epub 2022 May 31. PMID: 35650138

COVID-19 **Vaccine**-related Information Seeking and Scanning: A Test of Mediators between Information Acquisition and Vaccination Intention among Unvaccinated Black Americans.
Zhuang J, Cobb C. J Health Commun. 2022 Aug 10:1-9. doi: 10.1080/10810730.2022.2107739. Online ahead of print. PMID: 35946508

Crowdfunding narratives and the valuation of vaccines for COVID-19.
Snyder J, Goldenberg M, Crooks VA, Katz R. Vaccine. 2022 Aug 3:S0264-410X(22)00946-X. doi: 10.1016/j.vaccine.2022.07.050. Online ahead of print. PMID: 35933276

Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.
Strobel SB, Machiraju D, Kälber KA, Hassel JC. Cancer Immunol Immunother. 2022 Aug;71(8):2051-2056. doi: 10.1007/s00262-021-03133-w. Epub 2021 Dec 23. PMID: 34940894

Vaccination coverage at seven months of age in Limpopo Province, South Africa: A cross-sectional survey.
Killion JP, Silverman DT, Evans D, Coetzee L, Tarullo AR, Hamer DH, Rockers PC. Glob Health Promot. 2022 Aug 4:17579759221107037. doi: 10.1177/17579759221107037. Online ahead of print. PMID: 35927890

The use of the Dark Web as a COVID-19 information source: A three-country study.
Sirola A, Nuckols J, Nyrhinen J, Wilska TA. Technol Soc. 2022 Aug;70:102012. doi: 10.1016/j.techsoc.2022.102012. Epub 2022 Jun 10. PMID: 35702316

Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis.
Benucci M, Damiani A, Gobbi FL, Lari B, Grossi V, Infantino M, Manfredi M. Immunol Res. 2022 Aug;70(4):493-500. doi: 10.1007/s12026-022-09283-y. Epub 2022 May 11. PMID: 35543863

COVID-19 mRNA **Vaccine** in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis.
Ito Y, Honda A, Kurokawa M. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e691-e707. doi: 10.1016/j.clml.2022.03.012. Epub 2022 Mar 28. PMID: 35459624

Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004-20: a national surveillance study.
Sempere J, Llamosí M, López Ruiz B, Del Río I, Pérez-García C, Lago D, Gimeno M, Coronel P, González-Camacho F, Domenech M, Yuste J. Lancet Microbe. 2022 Aug 3:S2666-5247(22)00127-6. doi: 10.1016/S2666-5247(22)00127-6. Online ahead of print. PMID: 35932764

Comparative effectiveness of individual pneumococcal vaccines with dual pneumococcal vaccination in older United States Veterans.
Narsingam S, Munson J, Drescher F. Vaccine. 2022 Aug 1:S0264-410X(22)00922-7. doi: 10.1016/j.vaccine.2022.07.035. Online ahead of print. PMID: 35927134

Notifiable Infectious Diseases Among Organ Transplant Recipients: A Data-Linked Cohort Study, 2000-2015.

Waller KMJ, De La Mata NL, Wyburn KR, Hedley JA, Rosales BM, Kelly PJ, Ramachandran V, Shah KK, Morton RL, Rawlinson WD, Webster AC. Open Forum Infect Dis. 2022 Aug 3;9(8):ofac337. doi: 10.1093/ofid/ofac337. eCollection 2022 Aug. PMID: 35937651

Adherence to Covid-19 mitigation measures and its associated factors among health care workers at referral hospitals in Amhara regional state of Ethiopia.
Aemro A, Fentie B, Wassie M. PLoS One. 2022 Aug 5;17(8):e0272570. doi: 10.1371/journal.pone.0272570. eCollection 2022. PMID: 35930572

COVID-19 Outcomes and Risk Factors Among People Living with HIV.
Spinelli MA, Jones BLH, Gandhi M. Curr HIV/AIDS Rep. 2022 Aug 5:1-8. doi: 10.1007/s11904-022-00618-w. Online ahead of print. PMID: 35930187

Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans.
Young-Xu Y, Zwain GM, Izurieta HS, Korves C, Powell EI, Smith J, Balajee A, Holodniy M, Beenhouwer DO, Rodriguez-Barradas MC, Brown ST, Marconi VC. BMJ Open. 2022 Aug 3;12(8):e063935. doi: 10.1136/bmjopen-2022-063935. PMID: 35922100

Impact of the COVID-19 pandemic on people with epilepsy: findings from the US arm of the COV-E study.
Dugan P, Carroll E, Thorpe J, Jette N, Agarwal P, Ashby S, Hanna J, French J, Devinsky O, Sen A; COVID-19 Epilepsy COV-E Study Group. Epilepsia Open. 2022 Aug 5. doi: 10.1002/epi4.12637. Online ahead of print. PMID: 35929180

Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 - 21 years old: A Systematic Review and Meta-analysis.
Sadeghi S, Kalantari Y, Shokri S, Fallahpour M, Nafissi N, Goodarzi A, Valizadeh R. J Clin Virol. 2022 Aug;153:105196. doi: 10.1016/j.jcv.2022.105196. Epub 2022 Jun 3. PMID: 35716417

Improving adjuvanticity of crude polysaccharides from cultivated Artemisia rupestris L. for influenza **vaccine** by promoting long-term immunity and T_H1/T_H2 response with dose-sparing effect.
Li Q, Weng X, Xiao P, Yang Y, Zhang A. J Ethnopharmacol. 2022 Aug 10;294:115350. doi: 10.1016/j.jep.2022.115350. Epub 2022 May 6. PMID: 35533909

COVID-19 **vaccine** hesitancy in Sweden and Italy: The role of trust in authorities.
Raffetti E, Mondino E, Di Baldassarre G. Scand J Public Health. 2022 Aug;50(6):803-809. doi: 10.1177/14034948221099410. Epub 2022 Jun 2. PMID: 35656576

Current efforts and challenges facing responses to Monkeypox in United Kingdom.
Idris I, Adesola RO. Biomed J. 2022 Aug 5:S2319-4170(22)00118-4. doi: 10.1016/j.bj.2022.07.007. Online ahead of print. PMID: 35940428

Federation of Clinical Immunology Societies Goes South 2021: advanced course on molecular and cellular translational immunology.

Diethelm-Varela B, Reyes A, Rosenstein Y, Kalil J, Hill M, Docena G, Anegon I, González PA, Kalergis AM. Immunotherapy. 2022 Aug;14(11):839-842. doi: 10.2217/imt-2022-0075. Epub 2022 Jun 27. PMID: 35757836

Information disclosure of COVID-19 specific medicine and stock price crash risk in China.
Duan J, Lin J. Financ Res Lett. 2022 Aug;48:102890. doi: 10.1016/j.frl.2022.102890. Epub 2022 Apr 18. PMID: 35463295

[Advances in clinical research of virus vector-based COVID-19 vaccines].
Li ZP, Zhu FC, Li J. Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Aug 6;56(8):1127-1135. doi: 10.3760/cma.j.cn112150-20211101-01008. PMID: 35922243

Monkeypox - A danger approaching Asia.
Liu X, Zhu Z, Miao Q, Lim JW, Lu H. Biosci Trends. 2022 Aug 2. doi: 10.5582/bst.2022.01343. Online ahead of print. PMID: 35922921

Factors Associated With COVID-19 Breakthrough Infections in Large Midwestern Healthcare System: Implications for Vulnerable Healthcare Personnel.
Rivelli A, Fitzpatrick V, Copeland K, Richards J. J Occup Environ Med. 2022 Aug 1;64(8):635-641. doi: 10.1097/JOM.0000000000002576. Epub 2022 Jun 9. PMID: 35673248

Developmental Origins of Health and Disease, resilience and social justice in the COVID era.
Penkler M, Jacob CM, Müller R, Kenney M, Norris SA, da Costa CP, Richardson SS, Roseboom TJ, Hanson M. J Dev Orig Health Dis. 2022 Aug;13(4):413-416. doi: 10.1017/S204017442100060X. Epub 2021 Oct 28. PMID: 34709151

Whole-genome sequencing of live attenuated bovine adenovirus type 7 **vaccine** strain TS-GT suggests biomarkers for virulence attenuation.
Kumagai A, Kajikawa S, Miyazaki A, Hatama S. J Vet Med Sci. 2022 Aug 1;84(8):1118-1120. doi: 10.1292/jvms.22-0198. Epub 2022 Jun 28. PMID: 35768217

Real-world evidence from over one million COVID-19 vaccinations is consistent with reactivation of the varicella-zoster virus.
Hertel M, Heiland M, Nahles S, von Laffert M, Mura C, Bourne PE, Preissner R, Preissner S. J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1342-1348. doi: 10.1111/jdv.18184. Epub 2022 May 13. PMID: 35470920

Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience.
Farina A, Falso S, Cornacchini S, Spagni G, Monte G, Mariottini A, Massacesi L, Barilaro A, Evoli A, Damato V. Eur J Neurol. 2022 Aug;29(8):2505-2510. doi: 10.1111/ene.15348. Epub 2022 Apr 17. PMID: 35390184

Effectiveness of mRNA COVID-19 Vaccines in Adolescents Over 6 Months.
Amodio E, Genovese D, Mazzeo L, Martino L, Restivo V, Vella G, Calamusa G, Vitale F. Pediatrics. 2022 Aug 10. doi: 10.1542/peds.2022-057394. Online ahead of print. PMID: 35945678

Uncovering SARS-COV-2 **vaccine** uptake and COVID-19 impacts among First Nations, Inuit and Métis Peoples living in Toronto and London, Ontario.
Smylie J, McConkey S, Rachlis B, Avery L, Mecredy G, Brar R, Bourgeois C, Dokis B, Vandevenne S, Rotondi MA. CMAJ. 2022 Aug 2;194(29):E1018-E1026. doi: 10.1503/cmaj.212147. PMID: 35918087

Attitude and Acceptance of COVID-19 **Vaccine** in Parents and Adolescents: A Nationwide Survey.
Lee H, Choe YJ, Kim S, Cho HK, Choi EH, Lee J, Bae H, Choi SR, You M. J Adolesc Health. 2022 Aug;71(2):164-171. doi: 10.1016/j.jadohealth.2022.05.018. Epub 2022 Jun 16. PMID: 35718652

Analysis of immune response in BALB/c mice immunized with recombinant plasmids pMZ-X3-Ts14-3-3.3 and pMZ-X3-sp-Ts14-3-3.3 of Taenia solium.
Zhang Y, Luo B, Liu MC, OuYang RH, Fan XM, Jiang N, Yang FJ, Wang LJ, Zhou BY. Acta Trop. 2022 Aug;232:106517. doi: 10.1016/j.actatropica.2022.106517. Epub 2022 May 17. PMID: 35595093

At what frequency of vaccination do the vaccinated potentially pose an equal risk to the unvaccinated for transmission of SARS-CoV-2 inside restaurants in New York City?
Wormser GP, Visintainer P. Wien Klin Wochenschr. 2022 Aug 10. doi: 10.1007/s00508-022-02067-2. Online ahead of print. PMID: 35947224

Comprehensive approaches for the detection of Burkholderia pseudomallei and diagnosis of melioidosis in human and environmental samples.
Oslan SNH, Yusoff AH, Mazlan M, Lim SJ, Khoo JJ, Oslan SN, Ismail A. Microb Pathog. 2022 Aug;169:105637. doi: 10.1016/j.micpath.2022.105637. Epub 2022 Jun 13. PMID: 35710088

COVID-19 Vaccination and The Eye.
Wang MTM, Niederer RL, McGhee CNJ, Danesh-Meyer HV. Am J Ophthalmol. 2022 Aug;240:79-98. doi: 10.1016/j.ajo.2022.02.011. Epub 2022 Feb 25. PMID: 35227700

The impact of COVID-19 on public health systems in the Pacific Island Countries and Territories.
Bell L, van Gemert C, Merilles OE Jr, Cash HL, Stoové M, Hellard M. Lancet Reg Health West Pac. 2022 Jun 24;25:100498. doi: 10.1016/j.lanwpc.2022.100498. eCollection 2022 Aug. PMID: 35785109

Global respiratory virus surveillance: strengths, gaps, and way forward.
Gupta S, Gupta T, Gupta N. Int J Infect Dis. 2022 Aug;121:184-189. doi: 10.1016/j.ijid.2022.05.032. Epub 2022 May 15. PMID: 35584744

Neonatal BCG vaccination is associated with a long-term DNA methylation signature in circulating monocytes.
Bannister S, Kim B, Domínguez-Andrés J, Kilic G, Ansell BRE, Neeland MR, Moorlag SJCFM, Matzaraki V, Vlahos A, Shepherd R, Germano S, Bahlo M, Messina NL, Saffery R, Netea MG, Curtis N, Novakovic B. Sci Adv. 2022 Aug 5;8(31):eabn4002. doi: 10.1126/sciadv.abn4002. Epub 2022 Aug 5. PMID: 35930640

Improved efficiency for cross-arm comparisons via platform designs.
Huang TJ, Luedtke A; AMP INVESTIGATOR GROUP. Biostatistics. 2022 Aug 8:kxac030. doi: 10.1093/biostatistics/kxac030. Online ahead of print. PMID: 35939566

Systemic sclerosis in the time of COVID-19.
Hoffmann-Vold AM, Distler O, Bruni C, Denton CP, de Vries-Bouwstra J, Matucci Cerinic M, Vonk MC, Gabrielli A. Lancet Rheumatol. 2022 Aug;4(8):e566-e575. doi: 10.1016/S2665-9913(22)00130-8. Epub 2022 Jul 21. PMID: 35891634

Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines.
Liu X, Zhang Y, Zhou S, Dain L, Mei L, Zhu G. J Control Release. 2022 Aug;348:84-94. doi: 10.1016/j.jconrel.2022.05.043. Epub 2022 Jun 2. PMID: 35649485

Prioritization of COVID-19 vaccination. The added value of the "VALIDATE" approach.
Refolo P, Bloemen B, Corsano B, Grin J, Gutierrez-Ibarluzea I, Hofmann B, Oortwijn W, Sampietro-Colom L, Sandman L, van der Wilt GJ, Sacchini D. Health Policy. 2022 Aug;126(8):770-776. doi: 10.1016/j.healthpol.2022.05.005. Epub 2022 May 20. PMID: 35623910

DRPADC: A novel drug repositioning algorithm predicting adaptive drugs for COVID-19.
Xie G, Xu H, Li J, Gu G, Sun Y, Lin Z, Zhu Y, Wang W, Wang Y, Shao J. Comput Chem Eng. 2022 Aug 4:107947. doi: 10.1016/j.compchemeng.2022.107947. Online ahead of print. PMID: 35942213

A 54-Year-Old Man With Migratory Pulmonary Consolidation and Progressive Dyspnea.
Ma JY, Chuang CH. Chest. 2022 Aug;162(2):e85-e88. doi: 10.1016/j.chest.2022.03.004. PMID: 35940668

Never Thought I was Going to be Placed in a Situation Like This: In the Shoes of the Doctor Responsible for Municipal Health, Back in My Country, Perú.
Morante-Osores R, Runzer-Colmenares FM, Parodi JF. J Popul Ageing. 2022 Aug 1:1-8. doi: 10.1007/s12062-022-09381-7. Online ahead of print. PMID: 35937280

Strengthening vaccines and medicines manufacturing capabilities in Africa: challenges and perspectives.
Saied AA, Metwally AA, Dhawan M, Choudhary OP, Aiash H. EMBO Mol Med. 2022 Aug 8;14(8):e16287. doi: 10.15252/emmm.202216287. Epub 2022 Jun 27. PMID: 35758210

Comparative efficacy of postbiotic, probiotic, and antibiotic against necrotic enteritis in broiler chickens.
Abd El-Ghany WA, Abdel-Latif MA, Hosny F, Alatfeehy NM, Noreldin AE, Quesnell RR, Chapman R, Sakai L, Elbestawy AR. Poult Sci. 2022 Aug;101(8):101988. doi: 10.1016/j.psj.2022.101988. Epub 2022 Jun 4. PMID: 35809347

Haemaphysalis longicornis calreticulin is not an effective molecular tool for tick bite diagnosis and disruption of tick infestations.
Zheng W, Hu H, Jiang J, Sun X, Fu R, Tao H, Liu Y, Chen H, Ma H, Chen S. Vet Parasitol. 2022 Aug 4;309:109775. doi: 10.1016/j.vetpar.2022.109775. Online ahead of print. PMID: 35939902

The origins, isolation, and biological characterization of rodent malaria parasites.
Pattaradilokrat S, Wu J, Xu F, Su XZ. Parasitol Int. 2022 Aug 1;91:102636. doi: 10.1016/j.parint.2022.102636. Online ahead of print. PMID: 35926694

Routine SARS-CoV-2 vaccination for all children.
De Paris K, Permar SR. Immunol Rev. 2022 Aug;309(1):90-96. doi: 10.1111/imr.13108. Epub 2022 Jul 7. PMID: 35799475

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.
Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, Cantoni D, Scott S, Logan N, Ashraf S, Manali M, Szemiel A, Cowton V, Vink E, Harvey WT, Davis C, Asamaphan P, Smollett K, Tong L, Orton R, Hughes J, Holland P, Silva V, Pascall DJ, Puxty K, da Silva Filipe A, Yebra G, Shaaban S, Holden MTG, Pinto RM, Gunson R, Templeton K, Murcia PR, Patel AH, Klenerman P, Dunachie S; PITCH Consortium; COVID-19 Genomics UK (COG-UK) Consortium, Haughney J, Robertson DL, Palmarini M, Ray S, Thomson EC. Nat Microbiol. 2022 Aug;7(8):1161-1179. doi: 10.1038/s41564-022-01143-7. Epub 2022 Jul 7. PMID: 35798890

SARS-CoV-2 variants and pregnant Women: A cause for Concern?
Onyinyechi Chionuma J, Onyeaka H, Ekwebelem OC, Darlington Nnaji N. Vaccine X. 2022 Jun 18;11:100185. doi: 10.1016/j.jvacx.2022.100185. eCollection 2022 Aug. PMID: 35747762

Potential linear B-cells epitope change to a helix structure in the spike of Omicron 21L or BA.2 predicts increased SARS-CoV-2 antibodies evasion.
Al-Zyoud W, Haddad H. Virology. 2022 Aug;573:84-95. doi: 10.1016/j.virol.2022.06.010. Epub 2022 Jun 16. PMID: 35732100

A comparative analysis of COVID-19 vaccination certificates in 12 countries/regions around the world: Rationalising health policies for international travel and domestic social activities during the pandemic.
Wang B, Ping Y. Health Policy. 2022 Aug;126(8):755-762. doi: 10.1016/j.healthpol.2022.05.016. Epub 2022 May 29. PMID: 35680529

Intervention strategies with 2D cellular automata for testing SARS-CoV-2 and reopening the economy.
Lugo I, Alatriste-Contreras MG. Sci Rep. 2022 Aug 5;12(1):13481. doi: 10.1038/s41598-022-17665-3. PMID: 35931726

Camptothesome elicits immunogenic cell death to boost colorectal cancer immune checkpoint blockade.
Wang Z, Li W, Park J, Gonzalez KM, Scott AJ, Lu J. J Control Release. 2022 Aug 1:S0168-3659(22)00478-3. doi: 10.1016/j.jconrel.2022.07.042. Online ahead of print. PMID: 35926754

Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein.
van Schooten J, Farokhi E, Schorcht A, van den Kerkhof TLGM, Gao H, van der Woude P, Burger JA, Meesters TGR, Bijl T, Ghalaiyini R, Turner HL, Dorning J, van Schaik BDC, van Kampen AHC, Labranche CC, Stanfield RL, Sok D, Montefiori DC, Burton DR, Seaman MS, Ozorowski G, Wilson IA, Sanders RW, Ward AB, van Gils MJ. Nat Commun. 2022 Aug 3;13(1):4515. doi: 10.1038/s41467-022-32208-0. PMID: 35922441

SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity.
Manali M, Bissett LA, Amat JAR, Logan N, Scott S, Hughes EC, Harvey WT, Orton R, Thomson EC, Gunson RN, Viana M, Willett B, Murcia PR. J Infect Dis. 2022 Aug 3:jiac332. doi: 10.1093/infdis/jiac332. Online ahead of print. PMID: 35920058

Orbital Inflammatory Pseudotumor following mRNA COVID-19 Vaccination.
Yucel Gencoglu A, Mangan MS. Ocul Immunol Inflamm. 2022 Aug 1:1-4. doi: 10.1080/09273948.2022.2093757. Online ahead of print. PMID: 35914301

LNIT-Local nasal immunotherapy in allergic rhinitis: revisited evidence and perspectives.
Kanjanawasee D, Tantilipikorn P. Curr Opin Allergy Clin Immunol. 2022 Aug 1;22(4):259-267. doi: 10.1097/ACI.0000000000000830. Epub 2022 Jul 2. PMID: 35779069

qPCR screening for Yersinia ruckeri clonal complex 1 against a background of putatively avirulent strains in Norwegian aquaculture.
Riborg A, Gulla S, Strand D, Wiik-Nielsen J, Rønneseth A, Welch TJ, Spilsberg B, Colquhoun DJ. J Fish Dis. 2022 Aug;45(8):1211-1224. doi: 10.1111/jfd.13656. Epub 2022 Jun 1. PMID: 35648597

Crosstalk between R848 and abortive HIV-1 RNA-induced signaling enhances antiviral immunity.
Stunnenberg M, van Hamme JL, Zijlstra-Willems EM, Gringhuis SI, Geijtenbeek TBH. J Leukoc Biol. 2022 Aug;112(2):289-298. doi: 10.1002/JLB.4A0721-365R. Epub 2022 Jan 4. PMID: 34982481

An immunoprophylactic evaluation of *Ld*-ODC derived HLA-A0201 restricted peptides against visceral leishmaniasis.
Pandey RK, Dikhit MR, Lokhande KB, Pandey K, Das P, Bimal S. J Biomol Struct Dyn. 2022 Aug;40(13):6086-6096. doi: 10.1080/07391102.2021.1876773. Epub 2021 Feb 19. PMID: 33602055

Autolysosomal acidification failure as a primary driver of Alzheimer disease pathogenesis.
Lee JH, Nixon RA. Autophagy. 2022 Aug 10. doi: 10.1080/15548627.2022.2110729. Online ahead of print. PMID: 35947489

Fasciola hepatica Cathepsin L Zymogens: Immuno-Proteomic Evidence for Highly Immunogenic Zymogen-Specific Conformational Epitopes to Support Diagnostics Development.
Collett CF, Phillips HC, Fisher M, Smith S, Fenn C, Goodwin P, Morphew RM, Brophy PM. J Proteome Res. 2022 Aug 5;21(8):1997-2010. doi: 10.1021/acs.jproteome.2c00299. Epub 2022 Jul 18. PMID: 35849550

Diabetes and COVID-19: Short- and Long-Term Consequences.
Steenblock C, Hassanein M, Khan EG, Yaman M, Kamel M, Barbir M, Lorke DE, Rock JA, Everett D, Bejtullah S, Heimerer A, Tahirukaj E, Beqiri P, Bornstein SR. Horm Metab Res. 2022 Aug;54(8):503-509. doi: 10.1055/a-1878-9566. Epub 2022 Jun 20. PMID: 35724689

Case Report: Pharyngeal Diphtheria in a Pregnant Woman from South India.
Pattar SS, Deepashree R, Sumana MN, Sujatha SR, Tejashree A, Rao R, Murthy N. Am J Trop Med Hyg. 2022 Aug 1:tpmd210746. doi: 10.4269/ajtmh.21-0746. Online ahead of print. PMID: 35914688

Main changes in the "COVID-19 in paediatrics" clinical practice guideline.
González de Dios J, Martínez Rubio V, Giménez Díaz de Atauri Á, Ochoa Sangrador C, Rodríguez-Salinas Pérez E, Flores Villar S, Cuervo Valdés JJ; en representación del Grupo de Trabajo de Pediatría Basada en la Evidencia de la AEP y AEPap. An Pediatr (Engl Ed). 2022 Aug;97(2):129.e1-129.e8. doi: 10.1016/j.anpede.2022.06.006. Epub 2022 Jul 7. PMID: 35871151

Spinosad topical suspension (0.9%): a new topical treatment for scabies.
Fernando DD, Fischer K. Expert Rev Anti Infect Ther. 2022 Aug 9:1-6. doi: 10.1080/14787210.2022.2099376. Online ahead of print. PMID: 35799317

Phylogenetic analysis of lumpy skin disease virus isolates in Russia in 2019-2021.
Krotova A, Mazloum A, Byadovskaya O, Sprygin A. Arch Virol. 2022 Aug;167(8):1693-1699. doi: 10.1007/s00705-022-05487-7. Epub 2022 Jun 6. PMID: 35666394

Synthesis of 10,10'-bis(trifluoromethyl) marinopyrrole A derivatives and evaluation of their antiviral activities in vitro.
Xiao Y, Yang J, Zou L, Wu P, Li W, Yan Y, Li Y, Li S, Song H, Zhong W, Qin Y. Eur J Med Chem. 2022 Aug 5;238:114436. doi: 10.1016/j.ejmech.2022.114436. Epub 2022 May 6. PMID: 35598412

Rabies healthcare-seeking behaviors of urban and peri-urban residents: Results from a rabies knowledge, attitudes, and practices survey, Bangladesh, 2018.
Ross YB, Hoque M, Blanton JD, Kennedy ED, Rana MS, Tahmina S, Bonaparte S, Head JR, Wallace RM. PLoS Negl Trop Dis. 2022 Aug 9;16(8):e0010634. doi: 10.1371/journal.pntd.0010634. Online ahead of print. PMID: 35944018

Uncovering cryptic pockets in the SARS-CoV-2 spike glycoprotein.
Zuzic L, Samsudin F, Shivgan AT, Raghuvamsi PV, Marzinek JK, Boags A, Pedebos C, Tulsian NK, Warwicker J, MacAry P, Crispin M, Khalid S, Anand GS, Bond PJ. Structure. 2022 Aug 4;30(8):1062-1074.e4. doi: 10.1016/j.str.2022.05.006. Epub 2022 Jun 3. PMID: 35660160

Presence at a distance: Video chat supports intergenerational sensitivity and positive infant affect during COVID-19.
Roche E, Rocha-Hidalgo J, Piper D, Strouse GA, Neely LI, Ryu J, Myers LJ, McClure E, Troseth GL, Zosh JM, Barr R. Infancy. 2022 Aug 6. doi: 10.1111/infa.12491. Online ahead of print. PMID: 35932232

Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections.
Stærke NB, Reekie J, Nielsen H, Benfield T, Wiese L, Knudsen LS, Iversen MB, Iversen K, Fogh K, Bodilsen J, Juhl MR, Lindvig SO, Øvrehus A, Madsen LW, Klastrup V, Andersen SD, Juhl AK, Andreasen SR, Ostrowski SR, Erikstrup C, Fischer TK, Tolstrup M, Østergaard L, Johansen IS, Lundgren J, Søgaard OS. Nat Commun. 2022 Aug 1;13(1):4466. doi: 10.1038/s41467-022-32254-8. PMID: 35915081

Herpetic Eye Disease Following the SARS-CoV-2 Vaccinations.
Cohen S, Olshaker H, Fischer N, Vishnevskia-Dai V, Hagin D, Rosenblatt A, Zur D, Habot-Wilner Z. Ocul Immunol Inflamm. 2022 Aug 1:1-12. doi: 10.1080/09273948.2022.2103831. Online ahead of print. PMID: 35914308

Bilateral Acute Macular Neuroretinopathy after COVID-19 Vaccination and Infection.
Bellur S, Zeleny A, Patronas M, Jiramongkolchai K, Kodati S. Ocul Immunol Inflamm. 2022 Aug 1:1-4. doi: 10.1080/09273948.2022.2093753. Online ahead of print. PMID: 35914286

[Main changes in the «COVID-19 in paediatrics» clinical practice guideline].
González de Dios J, Martínez Rubio V, Giménez Díaz de Atauri Á, Ochoa Sangrador C, Rodríguez-Salinas Pérez E, Flores Villar S, Cuervo Valdés JJ; en representación del Grupo de Trabajo de Pediatría Basada en la Evidencia de la AEP y AEPap. An Pediatr (Barc). 2022 Aug;97(2):129.e1-129.e8. doi: 10.1016/j.anpedi.2022.06.015. Epub 2022 Jun 28. PMID: 35782910

Expanding japanese encephalitis vaccination to selected endemic indonesia provinces: A cost-effectiveness analysis.
Kosen S, Khoe LC, Indriasih E, Tarigan I, Iriawan RW, Agustiya RI, Letson GW, Vodicka E. Vaccine X. 2022 Jun 13;11:100179. doi: 10.1016/j.jvacx.2022.100179. eCollection 2022 Aug. PMID: 35782720

Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein.
Rappazzo CG, Hsieh CL, Rush SA, Esterman ES, Delgado T, Geoghegan JC, Wec AZ, Sakharkar M, Más V, McLellan JS, Walker LM. Immunity. 2022 Aug 3:S1074-7613(22)00336-3. doi: 10.1016/j.immuni.2022.07.003. Online ahead of print. PMID: 35944529

An ethics of anthropology-informed community engagement with COVID-19 clinical trials in Africa.
Edwards SJL, Silaigwana B, Asogun D, Mugwagwa J, Ntoumi F, Ansumana R, Bardosh K, Ambe J. Dev World Bioeth. 2022 Aug 9. doi: 10.1111/dewb.12367. Online ahead of print. PMID: 35944158

CAF08 adjuvant enables single dose protection against respiratory syncytial virus infection in murine newborns.
van Haren SD, Pedersen GK, Kumar A, Ruckwardt TJ, Moin S, Moore IN, Minai M, Liu M, Pak J, Borriello F, Doss-Gollin S, Beijnen EMS, Ahmed S, Helmel M, Andersen P, Graham BS, Steen H, Christensen D, Levy O. Nat Commun. 2022 Aug 2;13(1):4234. doi: 10.1038/s41467-022-31709-2. PMID: 35918315

Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study.
García-Pérez J, González-Pérez M, Castillo de la Osa M, Borobia AM, Castaño L, Bertrán MJ, Campins M, Portolés A, Lora D, Bermejo M, Conde P, Hernández-Gutierrez L, Carcas A, Arana-Arri E, Tortajada M, Fuentes I, Ascaso A, García-Morales MT, Erick de la Torre-Tarazona H, Arribas JR, Imaz-Ayo N, Mellado-Pau E, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Ochando J, Belda-Iniesta C, Frías J, Alcamí J, Pérez-Olmeda M; CombiVacS study Group. EClinicalMedicine. 2022 Jul 1;50:101529. doi: 10.1016/j.eclinm.2022.101529. eCollection 2022 Aug. PMID: 35795713

[Genetic characteristics of varicella zoster virus in Shandong province from 2020 to 2021].
Chen M, Wang ST, Liu Y, Xiong P, Tao ZX, Zhang L, Jia JL, Wang CY, Xu S. Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Aug 6;56(8):1080-1086. doi: 10.3760/cma.j.cn112150-20220105-00017. PMID: 35922235

Identifying novel tumor-related antigens and immune phenotypes for developing mRNA vaccines in lung adenocarcinoma.
Zhou B, Zang R, Zhang M, Song P, Liu L, Bie F, Peng Y, Bai G, Gao S. Int Immunopharmacol. 2022 Aug;109:108816. doi: 10.1016/j.intimp.2022.108816. Epub 2022 Apr 30. PMID: 35504200

An approach to p32/gC1qR/HABP1: a multifunctional protein with an essential role in cancer.
Egusquiza-Alvarez CA, Robles-Flores M. J Cancer Res Clin Oncol. 2022 Aug;148(8):1831-1854. doi: 10.1007/s00432-022-04001-5. Epub 2022 Apr 20. PMID: 35441886

Emerging roles for extracellular vesicles in Schistosoma infection.
Abou-El-Naga IF. Acta Trop. 2022 Aug;232:106467. doi: 10.1016/j.actatropica.2022.106467. Epub 2022 Apr 12. PMID: 35427535

Recent Advances in Modified Cap Analogs: Synthesis, Biochemical Properties, and mRNA Based Vaccines.
Shanmugasundaram M, Senthilvelan A, Kore AR. Chem Rec. 2022 Aug;22(8):e202200005. doi: 10.1002/tcr.202200005. Epub 2022 Apr 14. PMID: 35420257

Construction of a recombinant food-grade Lactococcus lactis expressing P23 protein of Cryptosporidium parvum.
Liu X, Deng L, Li W, Zhong Z, Zhou Z, Peng G. Folia Microbiol (Praha). 2022 Aug;67(4):625-631. doi: 10.1007/s12223-021-00923-8. Epub 2022 Mar 24. PMID: 35325408

Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings.
Ferreira VH, Solera JT, Hu Q, Hall VG, Arbol BG, Rod Hardy W, Samson R, Marinelli T, Ierullo M, Virk AK, Kurtesi A, Mavandadnejad F, Majchrzak-Kita B, Kulasingam V, Gingras AC, Kumar D, Humar A. Nat Commun. 2022 Aug 4;13(1):4489. doi: 10.1038/s41467-022-32235-x. PMID: 35927279

A structural vaccinology approach for in silico designing of a potential self-assembled nanovaccine against Leishmania infantum.
Vakili B, Nezafat N, Negahdaripour M, Ghasemi Y. Exp Parasitol. 2022 Aug;239:108295. doi: 10.1016/j.exppara.2022.108295. Epub 2022 Jun 14. PMID: 35709889

Dissolving microneedles: Applications and growing therapeutic potential.
Sartawi Z, Blackshields C, Faisal W. J Control Release. 2022 Aug;348:186-205. doi: 10.1016/j.jconrel.2022.05.045. Epub 2022 Jun 7. PMID: 35662577

COVID-19 and the cardiovascular system: an update.
Salabei JK, Asnake ZT, Ismail ZH, Charles K, Stanger GT, Abdullahi AH, Abraham AT, Okonoboh P. Am J Med Sci. 2022 Aug;364(2):139-147. doi: 10.1016/j.amjms.2022.01.022. Epub 2022 Feb 11. PMID: 35151635

Emerging immune-based technologies for high-grade gliomas.
Giotta Lucifero A, Luzzi S. Expert Rev Anticancer Ther. 2022 Aug 4. doi: 10.1080/14737140.2022.2110072. Online ahead of print. PMID: 35924820

Child Neurology: Initial Presentation of *PCDH19*-Related Epilepsy With New-Onset Refractory Status Epilepticus and Treatment With Anakinra.
Varughese RT, Karkare S, Poduri A, Kothare SV. Neurology. 2022 Aug 2;99(5):208-211. doi: 10.1212/WNL.0000000000200855. Epub 2022 Jun 3. PMID: 35914944

Dynamic of a two-strain COVID-19 model with vaccination.
Tchoumi SY, Rwezaura H, Tchuenche JM. Results Phys. 2022 Aug;39:105777. doi: 10.1016/j.rinp.2022.105777. Epub 2022 Jun 30. PMID: 35791392

Designing potential siRNA molecules for silencing the gene of the nucleocapsid protein of Nipah virus: A computational investigation.
Mahfuz A, Khan MA, Sajib EH, Deb A, Mahmud S, Hasan M, Saha O, Islam A, Rahaman MM. Infect Genet Evol. 2022 Aug;102:105310. doi: 10.1016/j.meegid.2022.105310. Epub 2022 May 28. PMID: 35636695

Meningococcal Disease and Immunization Activities in Hajj and Umrah Pilgrimage: a review.
Badur S, Khalaf M, Öztürk S, Al-Raddadi R, Amir A, Farahat F, Shibl A. Infect Dis Ther. 2022 Aug;11(4):1343-1369. doi: 10.1007/s40121-022-00620-0. Epub 2022 May 19. PMID: 35585384

Viral informatics: bioinformatics-based solution for managing viral infections.
Kumar S, Kumar GS, Maitra SS, Malý P, Bharadwaj S, Sharma P, Dwivedi VD. Brief Bioinform. 2022 Aug 10:bbac326. doi: 10.1093/bib/bbac326. Online ahead of print. PMID: 35947964

Third wave of COVID-19 pandemic in Africa: Challenges and recommendations.
Hemmeda L, Shabani MM, Kolawole BO, Muhammad SA, Fatima K, Siddiqui A, Rackimuthu S, Yaqoob S, Elechi KW, Abdallah Mohammed YI. Ann Med Surg (Lond). 2022 Aug 5:104314. doi: 10.1016/j.amsu.2022.104314. Online ahead of print. PMID: 35945972

Emerging Concepts in Congenital Cytomegalovirus.
Pesch MH, Schleiss MR. Pediatrics. 2022 Aug 1;150(2):e2021055896. doi: 10.1542/peds.2021-055896. PMID: 35909155

Association of Receipt of the Fourth BNT162b2 Dose With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care Facilities.
Muhsen K, Maimon N, Mizrahi AY, Boltyansky B, Bodenheimer O, Diamant ZH, Gaon L, Cohen D, Dagan R. JAMA Intern Med. 2022 Aug 1;182(8):859-867. doi: 10.1001/jamainternmed.2022.2658. PMID: 35737368

Effect of medium-chain fatty acids on growth, health, and immune response of dairy calves.
Klopp RN, Hernandez Franco JF, Hogenesch H, Dennis TS, Cowles KE, Boerman JP. J Dairy Sci. 2022 Aug 5:S0022-0302(22)00443-X. doi: 10.3168/jds.2021-21567. Online ahead of print. PMID: 35940917

Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants.
Bove R, Hellwig K, Pasquarelli N, Borriello F, Dobson R, Oreja-Guevara C, Lin CJ, Zecevic D, Craveiro L, McElrath T, Vukusic S. Mult Scler Relat Disord. 2022 Aug;64:103963. doi: 10.1016/j.msard.2022.103963. Epub 2022 Jun 11. PMID: 35753176

Production of single-cycle infectious SARS-CoV-2 through a trans-complemented replicon.
Cheung PH, Ye ZW, Lui WY, Ong CP, Chan P, Terence Lee TW, Tang TT, Yuen TL, Fung SY, Cheng Y, Chan CP, Chan CP, Jin DY. J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28057. Online ahead of print. PMID: 35941087

Germline IgM predicts T-cell immunity to Pneumocystis.
Noell K, Dai G, Pungan D, Ebacher A, McCombs JE, Landry SJ, Kolls JK. JCI Insight. 2022 Aug 2:e161450. doi: 10.1172/jci.insight.161450. Online ahead of print. PMID: 35917185

Phenotypic and genotypic analysis of Edwardsiella isolates from Taiwan indicates wide variation with a particular reference to Edwardsiella tarda and Edwardsiella anguillarum.
Rahmawaty A, Chen MY, Byadgi OV, Wang PC, Chen SC. J Fish Dis. 2022 Aug 2. doi: 10.1111/jfd.13688. Online ahead of print. PMID: 35916068

Genomic surveillance, evolution and global transmission of SARS-CoV-2 during 2019-2022.
Sharif N, Alzahrani KJ, Ahmed SN, Khan A, Banjer HJ, Alzahrani FM, Parvez AK, Dey SK. PLoS One. 2022 Aug 1;17(8):e0271074. doi: 10.1371/journal.pone.0271074. eCollection 2022. PMID: 35913920

Data-driven commentary on SARS-CoV-2 infection, vaccination, and fertility.
Klipstein S, Dionne JA, Feinberg EC, Kawwass JF, Pfeifer SM, Schlegel PN, Racowsky C. Fertil Steril. 2022 Aug;118(2):262-265. doi: 10.1016/j.fertnstert.2022.06.018. Epub 2022 Jun 29. PMID: 35779971

Norovirus outbreaks in China, 2000-2018: A systematic review.
Yu F, Jiang B, Guo X, Hou L, Tian Y, Zhang J, Li Q, Jia L, Yang P, Wang Q, Pang X, Gao Z. Rev Med Virol. 2022 Aug 10:e2382. doi: 10.1002/rmv.2382. Online ahead of print. PMID: 35946340

Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine.
Xia J, Miao Y, Wang X, Huang X, Dai J. Biomed Pharmacother. 2022 Aug;152:113250. doi: 10.1016/j.biopha.2022.113250. Epub 2022 Jun 13. PMID: 35700679

Evaluating the Role of Pharmacy Technician-Administered Vaccines.
Fuschetto KS, Amin KA, Gothard MD, Merico EM. J Pharm Pract. 2022 Aug 6:8971900221117893. doi: 10.1177/08971900221117893. Online ahead of print. PMID: 35938480

Infodemic and fake news - A comprehensive overview of its global magnitude during the COVID-19 pandemic in 2021: A scoping review.
Balakrishnan V, Ng WZ, Soo MC, Han GJ, Lee CJ. Int J Disaster Risk Reduct. 2022 Aug;78:103144. doi: 10.1016/j.ijdrr.2022.103144. Epub 2022 Jul 1. PMID: 35791376

Serological survey for maternal antibodies to Borreliella burgdorferi and Anaplasma phagocytophilum in dogs from endemic and non-endemic regions of the United States.
Stasiak KL, Cramer NA, Chambers GZ, Marconi RT. Vet Immunol Immunopathol. 2022 Aug 4;251:110471. doi: 10.1016/j.vetimm.2022.110471. Online ahead of print. PMID: 35940078

Spatiotemporal trends in norovirus outbreaks in the United States, 2009-2019.
Kambhampati AK, Calderwood L, Wikswo ME, Barclay L, Mattison CP, Balachandran N, Vinjé J, Hall AJ, Mirza SA. Clin Infect Dis. 2022 Aug 1:ciac627. doi: 10.1093/cid/ciac627. Online ahead of print. PMID: 35913377

Efficacy of high-throughput transthoracic ultrasonographic screening for on-farm detection of ovine pulmonary adenocarcinoma.

Cousens C, Ewing DA, McKendrick IJ, Todd H, Dagleish MP, Scott PR. Vet Rec. 2022 Aug;191(3):e1797. doi: 10.1002/vetr.1797. Epub 2022 Jul 5. PMID: 35788936

A tumor metastasis-associated molecule TWIST1 is a favorable target for cancer immunotherapy due to its immunogenicity.
Yajima Y, Kosaka A, Ishibashi K, Yasuda S, Komatsuda H, Nagato T, Oikawa K, Kitada M, Takekawa M, Kumai T, Ohara K, Ohkuri T, Kobayashi H. Cancer Sci. 2022 Aug;113(8):2526-2535. doi: 10.1111/cas.15429. Epub 2022 May 27. PMID: 35579200

Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope.
Dolton G, Rius C, Hasan MS, Wall A, Szomolay B, Behiry E, Whalley T, Southgate J, Fuller A; COVID-19 Genomics UK (COG-UK) consortium, Morin T, Topley K, Tan LR, Goulder PJR, Spiller OB, Rizkallah PJ, Jones LC, Connor TR, Sewell AK. Cell. 2022 Aug 4;185(16):2936-2951.e19. doi: 10.1016/j.cell.2022.07.002. Epub 2022 Jul 14. PMID: 35931021

Efficacy of Adjuvant Immune-cell Therapy Combined With Systemic Therapy for Solid Tumors.
Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E, Goto S. Anticancer Res. 2022 Aug;42(8):4179-4187. doi: 10.21873/anticanres.15918. PMID: 35896218

Modulating albumin-mediated transport of peptide-drug conjugates for antigen-specific Treg induction.
Lau CYJ, Benne N, Lou B, Zharkova O, Ting HJ, Ter Braake D, van Kronenburg N, Fens MH, Broere F, Hennink WE, Wang JW, Mastrobattista E. J Control Release. 2022 Aug;348:938-950. doi: 10.1016/j.jconrel.2022.06.025. Epub 2022 Jun 29. PMID: 35732251

IL-6 affects the severity of olfactory disorder: A cross-sectional survey of 148 patients who recovered from Omicron infection using the Sniffin' Sticks test in Tianjin, China.
Liang Y, Mao X, Kuang M, Zhi J, Zhang Z, Bo M, Zhang G, Lin P, Wang W, Shen Z. Int J Infect Dis. 2022 Aug 2:S1201-9712(22)00468-4. doi: 10.1016/j.ijid.2022.07.074. Online ahead of print. PMID: 35931372

EPIDEMIOLOGICAL ASSESSMENT OF SARS-COV-2 REINFECTION.
AlMadhi M, Alsayyad AS, Conroy R, Atkin S, Awadhi AA, Al-Tawfiq JA, AlQahtani M. Int J Infect Dis. 2022 Aug 2:S1201-9712(22)00470-2. doi: 10.1016/j.ijid.2022.07.075. Online ahead of print. PMID: 35931371

CWHM-12, an Antagonist of Integrin-Mediated Transforming Growth Factor-Beta Activation Confers Protection During Early *Mycobacterium tuberculosis* Infection in Mice.
Scott NR, Thirunavukkarasu S, Rangel-Moreno J, Griggs DW, Khader SA. J Interferon Cytokine Res. 2022 Aug 1. doi: 10.1089/jir.2022.0027. Online ahead of print. PMID: 35914102

Experiences of sharing results of community based serosurvey with participants in a district of Maharashtra, India.
Salvi N, Itta KC, Lachyan A, Hasan AZ, Prosperi C, Kumar MS, Wesley Vivian Thangaraj J, Kaduskar O, Bhatt V, Sapkal GN, Murhekar M, Gupta N, Mehendale S, Hayford K, Moss WJ, Chauhan S, Kulkarni R. PLoS One. 2022 Aug 4;17(8):e0271920. doi: 10.1371/journal.pone.0271920. eCollection 2022. PMID: 35925959

[Analysis on the epidemic characteristics and genetic characteristics of varicella in Beijing from 2019 to 2021].

Li AH, Zhao D, Wen XJ, Huang F, Lu L, Chen M, Gong C. Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Aug 6;56(8):1118-1122. doi: 10.3760/cma.j.cn112150-20220514-00479. PMID: 35922241

A novel clinic structure for exposure counseling during pregnancy.
Pressman K, Müller R, Krstić N, Običan S. Birth Defects Res. 2022 Aug 1. doi: 10.1002/bdr2.2069. Online ahead of print. PMID: 35912974

Two cases of acute respiratory failure following SARS-CoV-2 vaccination in post-COVID-19 pneumonia.
Bando T, Takei R, Mutoh Y, Sasano H, Yamano Y, Yokoyama T, Matsuda T, Kataoka K, Kimura T, Kondoh Y. Respirol Case Rep. 2022 Jul 4;10(8):e0995. doi: 10.1002/rcr2.995. eCollection 2022 Aug. PMID: 35814194

Molecular phylodynamics of infectious bursal disease viruses.
Agnihotri AA, Awandkar SP, Kulkarni MB, Chavhan SG, Kulkarni RC, Chavan VG. Virus Genes. 2022 Aug;58(4):350-360. doi: 10.1007/s11262-022-01905-9. Epub 2022 Apr 18. PMID: 35435635

The Impact of mRNA Technology in Regenerative Therapy: Lessons for Oral Tissue Regeneration.
Wisitrasameewong W, Champaiboon C, Surisaeng T, Sa-Ard-Iam N, Freire M, Pardi N, Pichyangkul S, Mahanonda R. J Dent Res. 2022 Aug;101(9):1015-1024. doi: 10.1177/00220345221084205. Epub 2022 Mar 23. PMID: 35319289

Promising inhibitors of nsp2 of CHIKV using molecular docking and temperature-dependent molecular dynamics simulations.
Meena MK, Kumar D, Kumari K, Kaushik NK, Kumar RV, Bahadur I, Vodwal L, Singh P. J Biomol Struct Dyn. 2022 Aug;40(13):5827-5835. doi: 10.1080/07391102.2021.1873863. Epub 2021 Jan 21. PMID: 33472563

Latent tuberculosis infection: Misperceptions among non-U.S.-born-populations from countries where tuberculosis is common.
Parmer J, Macario E, Tatum K, Brackett A, Allen L, Picard R, DeLuca N, Dowling M. Glob Public Health. 2022 Aug;17(8):1728-1742. doi: 10.1080/17441692.2021.1947342. Epub 2021 Jul 6. PMID: 34228584

Antibody response to an accelerated course of Hepatitis B vaccination.
Lian PCS, Morrish B. Occup Med (Lond). 2022 Aug 6:kqac054. doi: 10.1093/occmed/kqac054. Online ahead of print. PMID: 35932245

Generation and characterization of monoclonal antibodies against the hemagglutinin of H3N2 influenza A viruses.
Yang F, Zhu L, Liu F, Cheng L, Yao H, Wu N, Wu H, Li L. Virus Res. 2022 Aug;317:198815. doi: 10.1016/j.virusres.2022.198815. Epub 2022 May 18. PMID: 35595011

PLGA particle vaccination elicits resident memory CD8 T cells protecting from tumors and infection.
MacKerracher A, Sommershof A, Groettrup M. Eur J Pharm Sci. 2022 Aug 1;175:106209. doi: 10.1016/j.ejps.2022.106209. Epub 2022 May 15. PMID: 35580737

Comparative analysis of pre-Covid19 child immunization rates across 30 European countries and identification of underlying positive societal and system influences.

Cellini M, Pecoraro F, Rigby M, Luzi D. PLoS One. 2022 Aug 3;17(8):e0271290. doi: 10.1371/journal.pone.0271290. eCollection 2022. PMID: 35921275

De-isolation of vaccinated COVID-19 health care workers using rapid antigen detection test.
Alshukairi AN, Al-Omari A, Al Hroub MK, Al-Tawfiq JA, Qutub M, Shaikh S, Allali K, Saeedi MF, Alosaimi RS, Alamoudi E, Hefni LK, El-Saed A, Alhamlan FS, Dada A, Wali GY. J Infect Public Health. 2022 Aug;15(8):902-905. doi: 10.1016/j.jiph.2022.06.020. Epub 2022 Jul 7. PMID: 35868074

Efficient oral vaccination program against classical swine fever in wild boar population.
Ikeda T, Higashide D, Suzuki T, Asano M. Prev Vet Med. 2022 Aug;205:105700. doi: 10.1016/j.prevetmed.2022.105700. Epub 2022 Jun 21. PMID: 35772241

Characterization of aspartyl aminopeptidase from Schistosoma japonicum.
Shang Z, Guo Q, Zhou X, Yue Y, Zhou K, Tang L, Zhang Z, Fu Z, Liu J, Lin J, Xu B, Zhang M, Hong Y. Acta Trop. 2022 Aug;232:106519. doi: 10.1016/j.actatropica.2022.106519. Epub 2022 May 16. PMID: 35584779

Perceived Susceptibility and Severity of COVID-19 on Prevention Practices, Early in the Pandemic in the State of Florida.
DeDonno MA, Longo J, Levy X, Morris JD. J Community Health. 2022 Aug;47(4):627-634. doi: 10.1007/s10900-022-01090-8. Epub 2022 Apr 22. PMID: 35451692

An intranasal ASO therapeutic targeting SARS-CoV-2.
Zhu C, Lee JY, Woo JZ, Xu L, Nguyenla X, Yamashiro LH, Ji F, Biering SB, Van Dis E, Gonzalez F, Fox D, Wehri E, Rustagi A, Pinsky BA, Schaletzky J, Blish CA, Chiu C, Harris E, Sadreyev RI, Stanley S, Kauppinen S, Rouskin S, Näär AM. Nat Commun. 2022 Aug 3;13(1):4503. doi: 10.1038/s41467-022-32216-0. PMID: 35922434

Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of *Helicobacter pylori* Lipopolysaccharide for Antigenicity Evaluation with Human Serum.
Zou X, Hu J, Zhao M, Qin C, Zhu Y, Tian G, Cai J, Seeberger PH, Yin J. J Am Chem Soc. 2022 Aug 8. doi: 10.1021/jacs.2c03068. Online ahead of print. PMID: 35939326

Role of Differences in Respiratory Syncytial Virus F and G Glycoproteins on Susceptibility to Inactivation by Antimicrobial Peptides LL-37 and Human Beta-Defensins.
Latsko KN, Jacob AT, Junod NA, Haas CE, Castiglia KR, Kastelitz SR, Huffman ER, Trombley MP, Stobart CC. Viral Immunol. 2022 Aug 9. doi: 10.1089/vim.2022.0063. Online ahead of print. PMID: 35944261

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
Bellusci L, Grubbs G, Zahra FT, Forgacs D, Golding H, Ross TM, Khurana S. Nat Commun. 2022 Aug 8;13(1):4617. doi: 10.1038/s41467-022-32298-w. PMID: 35941152 Free PMC article.

Changes in serotype prevalence of Streptococcus pneumoniae in Southampton, UK between 2006 and 2018.
Cleary DW, Jones J, Gladstone RA, Osman KL, Devine VT, Jefferies JM, Bentley SD, Faust SN, Clarke SC. Sci Rep. 2022 Aug 3;12(1):13332. doi: 10.1038/s41598-022-17600-6. PMID: 35922536

Rapid displacement of SARS-CoV-2 variant Delta by Omicron revealed by allele-specific PCR in wastewater.
Lee WL, Armas F, Guarneri F, Gu X, Formenti N, Wu F, Chandra F, Parisio G, Chen H, Xiao A, Romeo C, Scali F, Tonni M, Leifels M, Chua FJD, Kwok GW, Tay JY, Pasquali P, Thompson J, Alborali GL, Alm EJ. Water Res. 2022 Aug 1;221:118809. doi: 10.1016/j.watres.2022.118809. Epub 2022 Jul 2. PMID: 35841797

The impact of genetic recombination on pathogenic Leptospira.
Mejía L, Prado B, Cárdenas P, Trueba G, González-Candelas F. Infect Genet Evol. 2022 Aug;102:105313. doi: 10.1016/j.meegid.2022.105313. Epub 2022 Jun 7. PMID: 35688386

Promising natural products against SARS-CoV-2: Structure, function, and clinical trials.
Zhao Y, Deng S, Bai Y, Guo J, Kai G, Huang X, Jia X. Phytother Res. 2022 Aug 5. doi: 10.1002/ptr.7580. Online ahead of print. PMID: 35932157

Structural basis of Omicron immune evasion: A comparative computational study.
Contractor D, Globisch C, Swaroop S, Jain A. Comput Biol Med. 2022 Aug;147:105758. doi: 10.1016/j.compbiomed.2022.105758. Epub 2022 Jun 20. PMID: 35763933

Re-Cellularised Kidney Scaffold for Chikungunya Virus Propagation: A Novel Approach.
Walawalkar S, Almelkar S. Tissue Eng Regen Med. 2022 Aug;19(4):769-779. doi: 10.1007/s13770-022-00449-1. Epub 2022 May 9. PMID: 35532737

Road to elimination of HCV: Clinical challenges in HCV management.
Hayes CN, Imamura M, Tanaka J, Chayama K. Liver Int. 2022 Aug;42(9):1935-1944. doi: 10.1111/liv.15150. Epub 2022 Jan 17. PMID: 34967486

Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 **Vaccine** at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months.
Low EV, Tok PSK, Husin M, Suah JL, Tng BH, Thevananthan T, Appannan MR, Yahaya H, Mohd Zin S, Muhamad Zin F, Sivasampu S, Peariasamy KM. JAMA Netw Open. 2022 Aug 1;5(8):e2226046. doi: 10.1001/jamanetworkopen.2022.26046. PMID: 35947381

Impact of adjuvants on the biophysical and functional characteristics of HIV **vaccine**-elicited antibodies in humans.
Xu S, Carpenter MC, Spreng RL, Neidich SD, Sarkar S, Tenney D, Goodman D, Sawant S, Jha S, Dunn B, Juliana McElrath M, Bekker V, Mudrak SV, Flinko R, Lewis GK, Ferrari G, Tomaras GD, Shen X, Ackerman ME. NPJ Vaccines. 2022 Aug 4;7(1):90. doi: 10.1038/s41541-022-00514-9. PMID: 35927399

In vitro antiviral activity of piperidine alkaloids from Senna spectabilis flowers on Chikungunya virus infection.
Freitas TR, Novais RM, Santos IA, Martins DOS, Danuello A, da Silva Bolzani V, Jardim ACG, Pivatto M. Pharmacol Rep. 2022 Aug;74(4):752-758. doi: 10.1007/s43440-022-00381-0. Epub 2022 Jul 27. PMID: 35882766

A Combination of MALDI-TOF MS Proteomics and Species-Unique Biomarkers' Discovery for Rapid Screening of Brucellosis.
Hamidi H, Bagheri Nejad R, Es-Haghi A, Ghassempour A. J Am Soc Mass Spectrom. 2022 Aug 3;33(8):1530-1540. doi: 10.1021/jasms.2c00110. Epub 2022 Jul 11. PMID: 35816556

Mecheliolide elicits ROS-mediated ERS driven immunogenic cell death in hepatocellular carcinoma.
Xu Z, Xu J, Sun S, Lin W, Li Y, Lu Q, Li F, Yang Z, Lu Y, Liu W. Redox Biol. 2022 Aug;54:102351. doi: 10.1016/j.redox.2022.102351. Epub 2022 May 28. PMID: 35671636

Humanizing plant-derived snakins and their encrypted antimicrobial peptides.
Ghanbarzadeh Z, Hemmati S, Mohagheghzadeh A. Biochimie. 2022 Aug;199:92-111. doi: 10.1016/j.biochi.2022.04.011. Epub 2022 Apr 26. PMID: 35472564

High viral loads: what drives fatal cases of COVID-19 in vaccinees? - an autopsy study.
Hirschbühl K, Schaller T, Märkl B, Claus R, Sipos E, Rentschler L, Maccagno A, Grosser B, Kling E, Neidig M, Kröncke T, Spring O, Braun G, Bösmüller H, Seidl M, Esposito I, Pablik J, Hilsenbeck J, Boor P, Beer M, Dintner S, Wylezich C. Mod Pathol. 2022 Aug;35(8):1013-1021. doi: 10.1038/s41379-022-01069-9. Epub 2022 Apr 1. PMID: 35365771

Factors influencing acceptance of influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease.
Saiphoklang N, Phadungwatthanachai J. Hum Vaccin Immunother. 2022 Aug 9:2102840. doi: 10.1080/21645515.2022.2102840. Online ahead of print. PMID: 35943223

Online cognitive behavioural therapy as a psychological **vaccine** against stress during the COVID-19 pandemic in pregnant women: A randomised controlled trial.
Puertas-Gonzalez JA, Mariño-Narvaez C, Romero-Gonzalez B, Sanchez-Perez GM, Peralta-Ramirez MI. J Psychiatr Res. 2022 Aug;152:397-405. doi: 10.1016/j.jpsychires.2022.07.016. Epub 2022 Jul 7. PMID: 35830754

Evaluation of Intervention Policies for the COVID-19 Epidemic in the Seoul/Gyeonggi Region through a Model Simulation.
Seok J, Lee Y, Choi JY, Choi JP, Seo H, Lee S, Lee J. Yonsei Med J. 2022 Aug;63(8):707-716. doi: 10.3349/ymj.2022.63.8.707. PMID: 35914752

Meaningful use of imaging resources to rule out cerebral venous sinus thrombosis after ChAdOx1 COVID-19 vaccination: Evaluation of the AHA diagnostic algorithm with a clinical cohort and a systematic data review.
Fervers P, Kottlors J, Persigehl T, Lennartz S, Maus V, Fischer S, Styczen H, Deuschl C, Schlamann M, Mpotsaris A, Zubel S, Schroeter M, Maintz D, Fink GR, Abdullayev N. J Clin Neurosci. 2022 Aug;102:5-12. doi: 10.1016/j.jocn.2022.05.031. Epub 2022 Jun 6. PMID: 35687921

Design and synthesis of harmiquins, harmine and chloroquine hybrids as potent antiplasmodial agents.
Poje G, Pessanha de Carvalho L, Held J, Moita D, Prudêncio M, Perković I, Tandarić T, Vianello R, Rajić Z. Eur J Med Chem. 2022 Aug 5;238:114408. doi: 10.1016/j.ejmech.2022.114408. Epub 2022 Apr 30. PMID: 35551033

CD4+ T-Cell Epitope Prediction by Combined Analysis of Antigen Conformational Flexibility and Peptide-MHCII Binding Affinity.
Charles T, Moss DL, Bhat P, Moore PW, Kummer NA, Bhattacharya A, Landry SJ, Mettu RR. Biochemistry. 2022 Aug 2;61(15):1585-1599. doi: 10.1021/acs.biochem.2c00237. Epub 2022 Jul 14. PMID: 35834502

TOLLIP Optimizes Dendritic Cell Maturation to Lipopolysaccharide and *Mycobacterium tuberculosis*.
Venkatasubramanian S, Pryor R, Plumlee C, Cohen SB, Simmons JD, Warr AJ, Graustein AD, Saha A, Hawn TR, Urdahl KB, Shah JA. J Immunol. 2022 Aug 1;209(3):435-445. doi: 10.4049/jimmunol.2200030. Epub 2022 Jul 8. PMID: 35803695

Pneumococcal pep27-mutant inhibits Wnt5a expression via the regulation of T helper cells to attenuate colitis.
Iqbal H, Kim GL, Kim JH, Ghosh P, Shah M, Lee W, Rhee DK. Int Immunopharmacol. 2022 Aug;109:108927. doi: 10.1016/j.intimp.2022.108927. Epub 2022 Jun 9. PMID: 35691272

The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on **vaccine** efficacy, its correlation to Delta variants: A computational approach.
Ranjan P, Neha, Devi C, Devar KA, Das P. Microb Pathog. 2022 Aug;169:105619. doi: 10.1016/j.micpath.2022.105619. Epub 2022 Jun 8. PMID: 35690234

One-year impact of COVID-19 pandemic on Italian dental professionals: a cross-sectional survey.
Paolone G, Mazzitelli C, Formiga S, Kaitsas F, Breschi L, Mazzoni A, Tete G, Polizzi E, Gherlone E, Cantatore G. Minerva Dent Oral Sci. 2022 Aug;71(4):212-222. doi: 10.23736/S2724-6329.21.04632-5. Epub 2021 Dec 1. PMID: 34851068

Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods.
Chandra A, Gurjar V, Ahmed MZ, Alqahtani AS, Qamar I, Singh N. J Biomol Struct Dyn. 2022 Aug;40(12):5507-5514. doi: 10.1080/07391102.2020.1871416. Epub 2021 Jan 25. PMID: 33491573

Tissue-adhesive hydrogel for multimodal drug release to immune cells in skin.
Day NB, Dalhuisen R, Loomis NE, Adzema SG, Prakash J, Shields Iv CW. Acta Biomater. 2022 Aug 1:S1742-7061(22)00455-X. doi: 10.1016/j.actbio.2022.07.053. Online ahead of print. PMID: 35921992

Molecular characterization of Infectious Bursal Disease Virus isolated in Chile reveals several mutations in VP2 coding region and a reassortment in its genome.
Guzmán M, Cádiz L, Guerrero-Moncayo A, Cáceres F, Vidal S, Lapierre L, Sáenz L, Hidalgo H. Vet Res Commun. 2022 Aug 3. doi: 10.1007/s11259-022-09956-x. Online ahead of print. PMID: 35918572

Piezoelectric point-of-care biosensor for the detection of SARS-COV-2 (COVID-19) antibodies.
Mandal D, Indaleeb MM, Younan A, Banerjee S. Sens Biosensing Res. 2022 Aug;37:100510. doi: 10.1016/j.sbsr.2022.100510. Epub 2022 Jul 14. PMID: 35855937

Generation of markerless and multiple-gene knockout in Glaesserella parasuis based on natural transformation and Flp recombinase.

Xiao J, Wang Q, Xiao K, Zhu W, Huang J, Cai X, Chen H, Xu X. Appl Microbiol Biotechnol. 2022 Aug;106(13-16):5167-5178. doi: 10.1007/s00253-022-11994-z. Epub 2022 Jul 19. PMID: 35851417

The role of immune modulation and anti-inflammatory agents in the management of prostate cancer: A case report of six patients.
Dalgleish AG, Liu WM. Oncol Lett. 2022 Jun 7;24(2):247. doi: 10.3892/ol.2022.13367. eCollection 2022 Aug. PMID: 35761946

No child left behind: Building a comprehensive sickle cell disease care oasis in the Lake County, Indiana care desert.
Brown LC, Hampton KC, Bloom EM, Lawson D, Cooper SH, Meier ER. Pediatr Blood Cancer. 2022 Aug;69(8):e29619. doi: 10.1002/pbc.29619. Epub 2022 Apr 20. PMID: 35441446

Interventions to Improve Adherence to Preventive Care in Inflammatory Bowel Disease: A Systematic Review.
Yu N, Basnayake C, Connell W, Ding NS, Wright E, Stanley A, Fry S, Wilson-O'Brien A, Niewiadomski O, Lust M, Schulberg J, Kamm MA. Inflamm Bowel Dis. 2022 Aug 1;28(8):1177-1188. doi: 10.1093/ibd/izab247. PMID: 34618007

Understandings and practices related to risk, immunity and vaccination during the Delta variant COVID-19 outbreak in Australia: An interview study.
Lupton D. Vaccine X. 2022 Aug;11:100183. doi: 10.1016/j.jvacx.2022.100183. Epub 2022 Jun 13. PMID: 35722522

Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases.
Petrone L, Picchianti-Diamanti A, Sebastiani GD, Aiello A, Laganà B, Cuzzi G, Vanini V, Gualano G, Grifoni A, Ferraioli M, Castilletti C, Meschi S, Vaia F, Nicastri E, Sette A, Goletti D. Int J Infect Dis. 2022 Aug;121:24-30. doi: 10.1016/j.ijid.2022.04.027. Epub 2022 Apr 22. PMID: 35462039

Exploration of Novel Lichen Compounds as Inhibitors of SARS-CoV-2 Mpro: Ligand-Based Design, Molecular Dynamics, and ADMET Analyses.
Gupta A, Sahu N, Singh AP, Singh VK, Singh SC, Upadhye VJ, Mathew AT, Kumar R, Sinha RP. Appl Biochem Biotechnol. 2022 Aug 3:1-21. doi: 10.1007/s12010-022-04103-3. Online ahead of print. PMID: 35921031

PEDOT:PSS in Solution Form Exhibits Strong Potential in Inhibiting SARS-CoV-2 Infection of the Host Cells by Targeting Viruses and Also the Host Cells.
Hung JN, Kha Vo DN, Thanh Ho HP, Tsai MH. Biomacromolecules. 2022 Aug 2:acs.biomac.2c00271. doi: 10.1021/acs.biomac.2c00271. Online ahead of print. PMID: 35918797

Incidence of SARS-CoV-2 over four epidemic waves in a low-resource community in Rio de Janeiro, Brazil: A prospective cohort study.
Carvalho MS, Bastos LS, Fuller T, Cruz OG, Damasceno L, Calvet G, Resende PC, Smith C, Whitworth J, Siqueira M, Brasil P. Lancet Reg Health Am. 2022 Aug;12:100283. doi: 10.1016/j.lana.2022.100283. Epub 2022 May 26. PMID: 35663637

Characterization of antibody response to an epitope spanning the haemagglutinin cleavage site of H7N9 subtype avian influenza virus for the differentiation of infected and vaccinated chickens.
Hu Z, Zhang Y, Hu J, Hu S, Liu X. Avian Pathol. 2022 Aug;51(4):330-338. doi: 10.1080/03079457.2022.2054308. Epub 2022 Apr 19. PMID: 35297704

Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates.
Hacioglu A, Borekci S, Melikoglu M, Ozguler Y, Esatoglu SN, Ugurlu S, Seyahi E, Fresko I, Hamuryudan V, Ozdogan H, Yurdakul S, Hatemi I, Celik AF, Ongen HG, Hatemi G. Rheumatol Int. 2022 Aug;42(8):1443-1451. doi: 10.1007/s00296-021-04926-z. Epub 2021 Jul 6. PMID: 34228162

Histidine acid phosphatase domain-containing protein from Haemonchus contortus is a stimulatory antigen for the Th1 immune response of goat PBMCs.
Wen Z, Zhang Z, Aimulajiang K, Aleem MT, Feng J, Liang M, Lu M, Xu L, Song X, Li X, Yan R. Parasit Vectors. 2022 Aug 6;15(1):282. doi: 10.1186/s13071-022-05411-7. PMID: 35933400

The burden of monkeypox virus amidst the Covid-19 pandemic in Africa: A double battle for Africa.
Uwishema O, Adekunbi O, Peñamante CA, Bekele BK, Khoury C, Mhanna M, Nicholas A, Adanur I, Dost B, Onyeaka H. Ann Med Surg (Lond). 2022 Aug;80:104197. doi: 10.1016/j.amsu.2022.104197. Epub 2022 Jul 14. PMID: 35855873

Reactive synovitis of the knee joint after COVID-19 vaccination: The first ultrastructural analysis of synovial fluid.
Vanaskova E, Kelbich P, Novotny T. Int J Rheum Dis. 2022 Aug 5. doi: 10.1111/1756-185X.14411. Online ahead of print. PMID: 35929362

Structural and Dynamic Insights into SARS-CoV-2 Spike-Protein-Montmorillonite Interactions.
Tiwari S, Adupa V, Das DS, Anki Reddy K, Bharat TV. Langmuir. 2022 Aug 2;38(30):9186-9194. doi: 10.1021/acs.langmuir.2c00837. Epub 2022 Jul 20. PMID: 35855632

All Public Health is Local: Lessons From Eagle County During the First 2 Years of the Coronavirus Disease-2019 Pandemic.
Knaus WA, Kehoe S, Lindley C. Med Care. 2022 Aug 1;60(8):596-601. doi: 10.1097/MLR.0000000000001736. Epub 2022 May 27. PMID: 35797458

PPSV-23 recommendation and vaccination coverage in China: a cross-sectional survey among healthcare workers, older adults and chronic disease patients.
Lai X, Lyu Y, Zhang H, Feng H, Fang H. Expert Rev Vaccines. 2022 Aug 10:1-11. doi: 10.1080/14760584.2022.2110074. Online ahead of print. PMID: 35924631

Trends in hospitalization and death rates among patients with head and neck cancer in Spain, 2009 to 2019.
Carazo-Casas C, Gil-Prieto R, Hernández-Barrera V, Gil de Miguel Á. Hum Vaccin Immunother. 2022 Aug 5:2082192. doi: 10.1080/21645515.2022.2082192. Online ahead of print. PMID: 35930449

Burden of pertussis among young infants in Malaysia: A hospital-based surveillance study.
Mohamed TJ, Fong SM, Nadarajaw T, Choo CM, Yusoff NKN, Nachiappan JP, Chan KC, Koh MT, Amran F, Hashim R, Jabar KA, Teh CSJ, Macina D, Ibrahim HM. Vaccine. 2022 Aug 1:S0264-410X(22)00894-5. doi: 10.1016/j.vaccine.2022.07.019. Online ahead of print. PMID: 35927133

COVID-19 Practices of Idaho Dental Hygienists.
Kanderis Lane CL, Gurenlian JR. J Dent Hyg. 2022 Aug;96(4):20-27. PMID: 35906077

Significance of digestive symptoms after COVID-19 vaccination: A retrospective single-center study.
Lee DS, Kim JW, Lee KL, Jung YJ, Kang HW. Am J Emerg Med. 2022 Aug;58:154-158. doi: 10.1016/j.ajem.2022.05.044. Epub 2022 May 28. PMID: 35691237

Evaluation of antibody response to BNT162b2 mRNA COVID-19 **vaccine** in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination.
Firinu D, Perra A, Campagna M, Littera R, Fenu G, Meloni F, Cipri S, Sedda F, Conti M, Miglianti M, Costanzo G, Secci M, Usai G, Carta MG, Cappai R, Orrù G, Del Giacco S, Coghe F, Chessa L. Clin Exp Med. 2022 Aug;22(3):477-485. doi: 10.1007/s10238-021-00771-3. Epub 2021 Nov 5. PMID: 34741188

Immunotherapy with anti-G_{D2} monoclonal antibody in infants with high-risk neuroblastoma.
Kushner BH, Modak S, Kramer K, Basu EM, Iglesias-Cardenas F, Roberts SS, Cheung NV. Int J Cancer. 2022 Aug 1. doi: 10.1002/ijc.34233. Online ahead of print. PMID: 35913764

Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2.
Newman J, Thakur N, Peacock TP, Bialy D, Elrefaey AME, Bogaardt C, Horton DL, Ho S, Kankeyan T, Carr C, Hoschler K, Barclay WS, Amirthalingam G, Brown KE, Charleston B, Bailey D. Nat Microbiol. 2022 Aug;7(8):1180-1188. doi: 10.1038/s41564-022-01163-3. Epub 2022 Jul 14. PMID: 35836002

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy.
Ntanasis-Stathopoulos I, Karalis V, Gavriatopoulou M, Malandrakis P, Sklirou AD, Eleutherakis-Papaiakovou E, Migkou M, Roussou M, Fotiou D, Alexopoulos H, Theodorakakou F, Kastritis E, Iconomidou VA, Trougakos IP, Dimopoulos MA, Terpos E. Hemasphere. 2022 Jul 29;6(8):e764. doi: 10.1097/HS9.0000000000000764. eCollection 2022 Aug. PMID: 35928542

B cell memory responses induced by foot-and-mouth disease virus-like particles in BALB/c mice.
Liu JH, Zhang JJ, Han WJ, Cui C, Li MZ, Tian ZY, Bai RM, Li LM. Vet Immunol Immunopathol. 2022 Aug;250:110458. doi: 10.1016/j.vetimm.2022.110458. Epub 2022 Jul 8. PMID: 35841772

Effect of BCG HSP70 Gene Transfection on Dendritic Cells Derived From Bone Marrow in Children With Acute Leukemia.
Wang J, Li X, Liu C, Wang S, Li J. J Pediatr Hematol Oncol. 2022 Aug 1;44(6):e939-e944. doi: 10.1097/MPH.0000000000002479. Epub 2022 May 11. PMID: 35622991

Molecular Characterization of *Eimeria* Species in Broiler Chickens, Ethiopia.
Chere MA, Melese K, Megerssa YC. Vet Med (Auckl). 2022 Aug 3;13:153-161. doi: 10.2147/VMRR.S357432. eCollection 2022. PMID: 35945979

A pre-**vaccine** exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population.
El-Ghitany EM, Farag S, Farghaly AG, Hashish MH, Hassaan MA, Omran EA. Trop Med Health. 2022 Aug 10;50(1):53. doi: 10.1186/s41182-022-00448-x. PMID: 35948951

Asia Pacific perspectives on the second year of the COVID-19 pandemic: A follow-up survey.
Pawankar R, Thong BY, Tiongco-Recto M, Wang JY, Latiff AHA, Leung TF, Li PH, Lobo RCM, Lucas M, Oh JW, Kamchaisatian W, Nagao M, Rengganis I, Udwadia ZF, Dhar R, Munkhbayarlakh S, Narantsetseg L, Pham DL, Zhang Y, Zhang L. Clin Exp Allergy. 2022 Aug;52(8):965-973. doi: 10.1111/cea.14191. PMID: 35906963

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.
Syed AM, Ciling A, Taha TY, Chen IP, Khalid MM, Sreekumar B, Chen PY, Kumar GR, Suryawanshi R, Silva I, Milbes B, Kojima N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Spraggon L, Tabata T, Ott M, Doudna JA. Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2200592119. doi: 10.1073/pnas.2200592119. Epub 2022 Jul 19. PMID: 35858386

Epidemiology of major entero-pathogenic viruses and genetic characterization of Group A rotaviruses among children (≤5 years) with acute gastroenteritis in eastern India, 2018-2020.
Mitra S, Lo M, Saha R, Deb AK, Debnath F, Miyoshi SI, Dutta S, Chawla-Sarkar M. J Appl Microbiol. 2022 Aug;133(2):758-783. doi: 10.1111/jam.15594. Epub 2022 May 12. PMID: 35462449

Childhood meningitis in rural Gambia: 10 years of population-based surveillance.
Ikumapayi UN, Hill PC, Hossain I, Olatunji Y, Ndiaye M, Badji H, Manjang A, Salaudeen R, Ceesay L, Adegbola RA, Greenwood BM, Mackenzie GA. PLoS One. 2022 Aug 10;17(8):e0265299. doi: 10.1371/journal.pone.0265299. eCollection 2022. PMID: 35947593

Seroepidemiological study of Japanese encephalitis virus in Chiang Mai: Immunity and susceptibility 28 years after introduction of a vaccination programme.
Sudjaritruk T, Kaewpoowat Q, Prasarakee C, Sarachai S, Taurel AF, Sricharoen N, Assawawongprom P, Saheng J, Harris R, Nealon J, Yoksan S. PLoS Negl Trop Dis. 2022 Aug 1;16(8):e0010674. doi: 10.1371/journal.pntd.0010674. Online ahead of print. PMID: 35913983

Characterization of *Mycobacterium tuberculosis*-Specific Th22 Cells and the Effect of Tuberculosis Disease and HIV Coinfection.
Makatsa MS, Omondi FMA, Bunjun R, Wilkinson RJ, Riou C, Burgers WA. J Immunol. 2022 Aug 1;209(3):446-455. doi: 10.4049/jimmunol.2200140. Epub 2022 Jul 1. PMID: 35777848

Estimating baseline rates of adverse perinatal and neonatal outcomes using a facility-based surveillance approach: A prospective observational study from the WHO Global **Vaccine** Safety Multi-Country Collaboration on safety in pregnancy.
Sharan A, Stuurman AL, Jahagirdar S, Elango V, Riera-Montes M, Kashyap NK, Biccler J, Poluru R, Arora NK, Mathai M, Mangtani P, Devlieger H, Anderson S, Whitaker B, Wong HL, Moran A, Maure CG; WHO Global Vaccine Safety Multi-Country Collaboration sites. EClinicalMedicine. 2022 Jun 17;50:101506. doi: 10.1016/j.eclinm.2022.101506. eCollection 2022 Aug. PMID: 35770255

T-cell recovery and evidence of persistent immune activation 12 months after severe COVID-19.
Taeschler P, Adamo S, Deng Y, Cervia C, Zurbuchen Y, Chevrier S, Raeber ME, Hasler S, Bächli E, Rudiger A, Stüssi-Helbling M, Huber LC, Bodenmiller B, Boyman O, Nilsson J. Allergy. 2022 Aug;77(8):2468-2481. doi: 10.1111/all.15372. Epub 2022 Jun 2. PMID: 35567391

Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer.
Liu M, Tayob N, Penter L, Sellars M, Tarren A, Chea V, Carulli I, Huang T, Li S, Cheng SC, Le P, Frackiewicz L, Fasse J, Qi C, Liu JF, Stover EH, Curtis J, Livak KJ, Neuberg D, Zhang G, Matulonis UA, Wu CJ, Keskin DB, Konstantinopoulos PA. Clin Cancer Res. 2022 Aug 2;28(15):3356-3366. doi: 10.1158/1078-0432.CCR-21-2834. PMID: 35443043

Assessment of COVID-19 risk and prevention effectiveness among spectators of mass gathering events.
Yasutaka T, Murakami M, Iwasaki Y, Naito W, Onishi M, Fujita T, Imoto S. Microb Risk Anal. 2022 Aug;21:100215. doi: 10.1016/j.mran.2022.100215. Epub 2022 Mar 31. PMID: 35382415

Which countries need COVID-19 vaccines the most? Development of a prioritisation tool.
Jain V, Atun R, Hansen P, Lorgelly P. BMC Public Health. 2022 Aug 10;22(1):1518. doi: 10.1186/s12889-022-13948-6. PMID: 35945545

Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) for COVID-19 among 1112 severely immunocompromised patients.
Nguyen Y, Flahault A, Chavarot N, Melenotte C, Cheminant M, Deschamps P, Carlier N, Lafont E, Thomas M, Flamarion E, Lebeaux D, Charlier C, Rachline A, Guérin C, Ratiney R, Touchard J, Péré H, Rozenberg F, Lanternier F, Arlet JB, Avouac J, Boussaud V, Guillemain R, Vignon M, Thervet E, Scemla A, Weiss L, Mouthon L; AP-HP-Centre Monoclonal Antibodies Working Group. Clin Microbiol Infect. 2022 Aug 1:S1198-743X(22)00383-4. doi: 10.1016/j.cmi.2022.07.015. Online ahead of print. PMID: 35926762

Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 Diabetes.
D'Addio F, Sabiu G, Usuelli V, Assi E, Abdelsalam A, Maestroni A, Seelam AJ, Ben Nasr M, Loretelli C, Mileto D, Rossi G, Pastore I, Montefusco L, Morpurgo PS, Plebani L, Rossi A, Chebat E, Bolla AM, Lunati ME, Mameli C, Macedoni M, Antinori S, Rusconi S, Gallieni M, Berra C, Folli F, Galli M, Gismondo MR, Zuccotti G, Fiorina P. Diabetes. 2022 Aug 1;71(8):1800-1806. doi: 10.2337/db22-0053. PMID: 35551366

Phylogenetic lineages of tuberculosis isolates and their association with patient demographics in Tanzania.
Mutayoba BK, Michael Hoelscher, Heinrich N, Joloba ML, Lyamuya E, Kilale AM, Range NS, Ngowi BJ, Ntinginya NE, Mfaume SM, Wilfred A, Doulla B, Lyimo J, Kisonga R, Kingalu A, Kabahita JM, Guido O, Kabugo J, Adam I, Luutu M, Namaganda MM, Namutebi J, Kasule GW, Nakato H, Byabajungu H, Lutaaya P, Musisi K, Oola D, Mboowa G, Pletschette M. BMC Genomics. 2022 Aug 5;23(1):561. doi: 10.1186/s12864-022-08791-3. PMID: 35931954

Immunization of preterm infants: current evidence and future strategies to individualized approaches.
Fortmann MI, Dirks J, Goedicke-Fritz S, Liese J, Zemlin M, Morbach H, Härtel C. Semin Immunopathol. 2022 Aug 3:1-18. doi: 10.1007/s00281-022-00957-1. Online ahead of print. PMID: 35922638

Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.

Hibino M, Uryu K, Takeda T, Kunimatsu Y, Shiotsu S, Uchino J, Hirai S, Yamada T, Okada A, Hasegawa Y, Hiranuma O, Chihara Y, Kamada R, Tobe S, Maeda K, Horiuchi S, Kondo T, Takayama K. J Thorac Oncol. 2022 Aug;17(8):1002-1013. doi: 10.1016/j.jtho.2022.05.015. Epub 2022 Jun 22. PMID: 35752437

Clinical and Immunological Defects and Outcomes in Patients with Chromosome 22q11.2 Deletion Syndrome.
Yu HH, Chien YH, Lu MY, Hu YC, Lee JH, Wang LC, Lin YT, Yang YH, Chiang BL. J Clin Immunol. 2022 Aug 4. doi: 10.1007/s10875-022-01340-3. Online ahead of print. PMID: 35925483

Contribution of child health interventions to under-five mortality decline in Ghana: A modeling study using lives saved and missed opportunity tools.
Kolekang A, Sarfo B, Danso-Appiah A, Dwomoh D, Akweongo P. PLoS One. 2022 Aug 1;17(8):e0267776. doi: 10.1371/journal.pone.0267776. eCollection 2022. PMID: 35913919

Diagnosis of brucellosis disease using data mining: A case study on patients of a hospital in Tehran.
Sebt MV, Jafari S, Khavaninzadeh M, Shavandi A. J Microbiol Methods. 2022 Aug;199:106530. doi: 10.1016/j.mimet.2022.106530. Epub 2022 Jun 28. PMID: 35777597

Effects of dietary bacitracin or Bacillus subtilis on the woody breast myopathy-associated gut microbiome of Eimeria spp. challenged and unchallenged broilers.
Jia L, Hsu CY, Zhang X, Li X, Schilling MW, Peebles ED, Kiess AS, Zhang L. Poult Sci. 2022 Aug;101(8):101960. doi: 10.1016/j.psj.2022.101960. Epub 2022 May 13. PMID: 35690000

An immunological glimpse of human virus peptides: Distance from self, MHC class I binding, proteasome cleveage, TAP transport and sequence composition entropy.
Santoni D, Felici G. Virus Res. 2022 Aug;317:198814. doi: 10.1016/j.virusres.2022.198814. Epub 2022 May 16. PMID: 35588940

SARS-CoV-2 Infection and Racial Disparities in Children: Protective Mechanisms and Severe Complications Related to MIS-C.
Kurup S, Burgess R, Tine F, Chahroudi A, Lee DL. J Racial Ethn Health Disparities. 2022 Aug;9(4):1536-1542. doi: 10.1007/s40615-021-01092-7. Epub 2021 Jul 13. PMID: 34255304

Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 - a computational modeling.
Noor H, Ikram A, Rathinavel T, Kumarasamy S, Nasir Iqbal M, Bashir Z. J Biomol Struct Dyn. 2022 Aug;40(13):5769-5784. doi: 10.1080/07391102.2021.1873190. Epub 2021 Jan 25. PMID: 33491580

Recent advances in natural products as potential inhibitors of dengue virus with a special emphasis on NS2b/NS3 protease.
Saqallah FG, Abbas MA, Wahab HA. Phytochemistry. 2022 Aug 7:113362. doi: 10.1016/j.phytochem.2022.113362. Online ahead of print. PMID: 35948138

Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
Yetmar ZA, Beam E, O'Horo JC, Seville MT, Brumble L, Ganesh R, Razonable RR. Transpl Infect Dis. 2022 Aug;24(4):e13901. doi: 10.1111/tid.13901. Epub 2022 Jul 25. PMID: 35848574

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kanji N, Libri V, Llewelyn MJ, McGregor AC, Maallah M, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Bawa T, Saralaya D, Sharma S, Sheridan R, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Lancet Infect Dis. 2022 Aug;22(8):1131-1141. doi: 10.1016/S1473-3099(22)00271-7. Epub 2022 May 9. PMID: 35550261

Comparison of Persistent Symptoms Following SARS-CoV-2 Infection by Antibody Status in Nonhospitalized Children and Adolescents.
Messiah SE, Hao T, DeSantis SM, Swartz MD, Talebi Y, Kohl HW 3rd, Zhang S, Valerio-Shewmaker M, Yaseen A, Kelder SH, Ross J, Gonzalez MO, Wu L, Padilla LN, Lopez KR, Lakey D, Shuford JA, Pont SJ, Boerwinkle E. Pediatr Infect Dis J. 2022 Aug 1:INF.0000000000003653. doi: 10.1097/INF.0000000000003653. Online ahead of print. PMID: 35939608

Immune Escape Adaptive Mutations in Hemagglutinin Are Responsible for the Antigenic Drift of Eurasian Avian-Like H1N1 Swine Influenza Viruses.
Xu C, Zhang N, Yang Y, Liang W, Zhang Y, Wang J, Suzuki Y, Wu Y, Chen Y, Yang H, Qiao C, Chen H. J Virol. 2022 Aug 2:e0097122. doi: 10.1128/jvi.00971-22. Online ahead of print. PMID: 35916512

US dental health care workers' mental health during the COVID-19 pandemic.
Eldridge LA, Estrich CG, Gurenlian JR, Battrell A, Lynch A, Vujicic M, Morrissey R, Dershewitz S, Geisinger ML, Araujo MWB. J Am Dent Assoc. 2022 Aug;153(8):740-749. doi: 10.1016/j.adaj.2022.02.011. PMID: 35902154

BCG lymphadenitis: a potential complication of immune reconstitution following haematopoietic stem cell transplant.
Tsilifis C, Schim van der Loeff I, Williams E, Owens S, Powell S, Gennery A, Slatter M. Arch Dis Child Educ Pract Ed. 2022 Aug;107(4):274-275. doi: 10.1136/archdischild-2020-320883. Epub 2020 Dec 18. PMID: 33355234

The long term **vaccine**-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade.
Geisen UM, Rose R, Neumann F, Ciripoi M, Vullriede L, Reid HM, Berner DK, Bertoglio F, Hoff P, Hust M, Longardt AC, Lorentz T, Martini GR, Saggau C, Schirmer JH, Schubert M, Sümbül M, Tran F, Voß M, Zeuner R, Morrison PJ, Bacher P, Fickenscher H, Gerdes S, Peipp M, Schreiber S, Krumbholz A, Hoyer BF. J Med Virol. 2022 Aug 9. doi: 10.1002/jmv.28063. Online ahead of print. PMID: 35945627

Global burden of SARS-CoV-2 infection, hospitalization and case fatality rate among COVID-19 vaccinated individuals and its associated factors: A systematic review and meta-analysis protocol.

Nka AD, Ka'e AC, Bouba Y, Ngoufack Jagni Semengue E, Tommo Tchouaket MC, Takou D, Pabo W, Fainguem N, Sosso SM, Colizzi V, Perno CF, Fokam J. PLoS One. 2022 Aug 9;17(8):e0272839. doi: 10.1371/journal.pone.0272839. eCollection 2022. PMID: 35943981

Longitudinal determination of BNT162b2 **vaccine** induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers.
Korodi M, Horváth I, Rákosi K, Jenei Z, Hudák G, Kákes M, Dallos-Fejér K, Simai E, Páll O, Staver N, Briciu V, Lupșe M, Flonta M, Almaș A, Birlutiu V, Daniela Lupu C, Magdalena Ghibu A, Pianoschi D, Terza LM, Fejer SN. Vaccine. 2022 Aug 1:S0264-410X(22)00936-7. doi: 10.1016/j.vaccine.2022.07.040. Online ahead of print. PMID: 35931634

DNAJC14-Independent Replication of the Atypical Porcine Pestivirus.
Reuscher CM, Seitz K, Schwarz L, Geranio F, Isken O, Raigel M, Huber T, Barth S, Riedel C, Netsch A, Zimmer K, Rümenapf T, Tautz N, Lamp B. J Virol. 2022 Aug 10;96(15):e0198021. doi: 10.1128/jvi.01980-21. Epub 2022 Jul 19. PMID: 35852352

United States Dental Health Care Workers' Mental Health During the COVID-19 Pandemic.
Eldridge LA, Estrich CG, Gurenlian JR, Battrell A, Lynch A, Vujicic M, Morrissey R, Dershewitz S, Geisinger ML, Araujo MWB. J Dent Hyg. 2022 Aug;96(4):9-11. PMID: 35906080

Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: A self-controlled case series study.
Chui CSL, Fan M, Wan EYF, Leung MTY, Cheung E, Yan VKC, Gao L, Ghebremichael-Weldeselassie Y, Man KKC, Lau KK, Lam ICH, Lai FTT, Li X, Wong CKH, Chan EW, Cheung CL, Sing CW, Lee CK, Hung IFN, Lau CS, Chan JYS, Lee MK, Mok VCT, Siu CW, Chan LST, Cheung T, Chan FLF, Leung AY, Cowling BJ, Leung GM, Wong ICK. EClinicalMedicine. 2022 Jun 25;50:101504. doi: 10.1016/j.eclinm.2022.101504. eCollection 2022 Aug. PMID: 35770253

Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study.
Yang LM, Costales C, Ramanathan M, Bulterys PL, Murugesan K, Schroers-Martin J, Alizadeh AA, Boyd SD, Brown JM, Nadeau KC, Nadimpalli SS, Wang AX, Busque S, Pinsky BA, Banaei N. J Clin Virol. 2022 Aug;153:105217. doi: 10.1016/j.jcv.2022.105217. Epub 2022 Jun 11. PMID: 35714462

Feline immunodeficiency virus (FIV) infection in domestic pet cats in Australia and New Zealand: Guidelines for diagnosis, prevention and management.
Westman ME, Coggins SJ, van Dorsselaer M, Norris JM, Squires RA, Thompson M, Malik R. Aust Vet J. 2022 Aug;100(8):345-359. doi: 10.1111/avj.13166. Epub 2022 May 16. PMID: 35578381

Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV.
Overton ET, Weir IR, Zanni MV, Fischinger S, MacArthur RD, Aberg JA, Fitch KV, Frank M, Albrecht H, Goodenough E, Rhame FS, Fichtenbaum CJ, Bloomfield GS, Malvestutto C, Supparatpinyo K, McCallum S, Douglas PS, Alter G, Ribaudo H, Grinspoon SK. J Acquir Immune Defic Syndr. 2022 Aug 1;90(4):377-381. doi: 10.1097/QAI.0000000000003000. PMID: 35413022

Comparative performance of COVID-19 serology testing.
Tran NK, May L, Cohen SH, Rodrigo J, Gong R, Liu Y, Conner P. Pract Lab Med. 2022 Aug;31:e00289. doi: 10.1016/j.plabm.2022.e00289. Epub 2022 Jul 6. PMID: 35818626

Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics.
Özüdoğru O, Acer Ö, Genç Bahçe Y. J Med Virol. 2022 Aug;94(8):3706-3713. doi: 10.1002/jmv.27778. Epub 2022 Apr 23. PMID: 35419851

Efficacy of vaccination against equine herpesvirus type 1 (EHV-1) infection: systematic review and meta-analysis of randomized controlled challenge trials.
Marenzoni ML, De Waure C, Timoney PJ. Equine Vet J. 2022 Aug 10. doi: 10.1111/evj.13870. Online ahead of print. PMID: 35946376

Impact of Epstein-Barr virus co-infection on natural acquired Plasmodium vivax antibody response.
Dias MHF, Guimarães LFF, Barcelos MG, Moreira EUM, do Nascimento MFA, de Souza TN, Pires CV, Monteiro TAF, Middeldorp JM, Soares IS, Fontes CJF, Ntumngia FB, Adams JH, Kano FS, Carvalho LH. PLoS Negl Trop Dis. 2022 Aug 3;16(8):e0010305. doi: 10.1371/journal.pntd.0010305. Online ahead of print. PMID: 35921373

Chitosan oligosaccharide improves the mucosal immunity of small intestine through activating SIgA production in mice: Proteomic analysis.
Wen J, Niu X, Chen S, Chen Z, Wu S, Wang X, Yong Y, Liu X, Yu Z, Ma X, Abd El-Aty AM, Ju X. Int Immunopharmacol. 2022 Aug;109:108826. doi: 10.1016/j.intimp.2022.108826. Epub 2022 May 12. PMID: 35569308

Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.
Steffanoni S, Calimeri T, Laurenge A, Fox CP, Soussain C, Grommes C, Tisi MC, Boot J, Crosbie N, Visco C, Arcaini L, Chaganti S, Sassone MC, Alencar A, Armiento D, Romano I, Dietrich J, Itchaki G, Bruna R, Fracchiolla NS, Arletti L, Venditti A, Booth S, Musto P, Hoang Xuan K, Batchelor TT, Cwynarski K, Ferreri AJM. Br J Haematol. 2022 Aug 9. doi: 10.1111/bjh.18396. Online ahead of print. PMID: 35945164

Characterization of Streptococcus pneumoniae Macrolide Resistance and Its Mechanism in Northeast China over a 20-Year Period.
Zhou X, Liu J, Zhang Z, Cui B, Wang Y, Zhang Y, Xu H, Cheng G, Liu Y, Qin X. Microbiol Spectr. 2022 Aug 8:e0054622. doi: 10.1128/spectrum.00546-22. Online ahead of print. PMID: 35938873

Perceptions and knowledge regarding the COVID-19 pandemic between U.S. and China: a mixed methods study.
Xiong Y, Weng X, Snyder B, Ma L, Cong M, Miller EL, Van Scoy LJ, Lennon RP. Global Health. 2022 Aug 8;18(1):76. doi: 10.1186/s12992-022-00864-y. PMID: 35941625

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.
Wu RL, Idris AH, Berkowitz NM, Happe M, Gaudinski MR, Buettner C, Strom L, Awan SF, Holman LA, Mendoza F, Gordon IJ, Hu Z, Campos Chagas A, Wang LT, Da Silva Pereira L, Francica JR, Kisalu NK, Flynn BJ, Shi W, Kong WP, O'Connell S, Plummer SH, Beck A, McDermott A, Narpala SR, Serebryannyy

L, Castro M, Silva R, Imam M, Pittman I, Hickman SP, McDougal AJ, Lukoskie AE, Murphy JR, Gall JG, Carlton K, Morgan P, Seo E, Stein JA, Vazquez S, Telscher S, Capparelli EV, Coates EE, Mascola JR, Ledgerwood JE, Dropulic LK, Seder RA; VRC 614 Study Team. N Engl J Med. 2022 Aug 4;387(5):397-407. doi: 10.1056/NEJMoa2203067. PMID: 35921449

High Incidence and Unique Features of Cerebral Venous Sinus Thrombosis in Hospitalized Patients With COVID-19 Infection.
McCullough-Hicks ME, Halterman DJ, Anderson D, Cohen K, Lakshminarayan K. Stroke. 2022 Aug 3:101161STROKEAHA122038955. doi: 10.1161/STROKEAHA.122.038955. Online ahead of print. PMID: 35920155

Is the Omicron variant truly less virulent in Solid Organ Transplant Recipients?
Anjan S, Khatri A, Viotti JB, Cheung T, Garcia LAC, Simkins J, Loebe M, Phancao A, O'Brien CB, Sinha N, Ciancio G, Vianna RM, Andrews D, Abbo LM, Guerra G, Natori Y. Transpl Infect Dis. 2022 Aug 1. doi: 10.1111/tid.13923. Online ahead of print. PMID: 35915957

The Population Genomics of Increased Virulence and Antibiotic Resistance in Human Commensal Escherichia coli over 30 Years in France.
Marin J, Clermont O, Royer G, Mercier-Darty M, Decousser JW, Tenaillon O, Denamur E, Blanquart F. Appl Environ Microbiol. 2022 Aug 9;88(15):e0066422. doi: 10.1128/aem.00664-22. Epub 2022 Jul 18. PMID: 35862685

Regional differences in human papillomavirus type 52 prevalence among Japanese women with cervical intraepithelial neoplasia†.
Kukimoto I, Onuki M, Yamamoto K, Yahata H, Aoki Y, Yokota H, Konnai K, Nio A, Takehara K, Kamiura S, Tsuda N, Takei Y, Shimada M, Nakai H, Yoshida H, Motohara T, Yamazaki H, Nakamura K, Okunomiya A, Tasaka N, Ishikawa M, Hirashima Y, Shimoji Y, Mori M, Iwata T, Takahashi F, Yoshikawa H, Yaegashi N, Matsumoto K; MINT Study Group. Jpn J Clin Oncol. 2022 Aug 6:hyac127. doi: 10.1093/jjco/hyac127. Online ahead of print. PMID: 35938523

Perception of canine rabies among pupils under 15 years in Kwara State, North Central Nigeria.
Al-Mustapha AI, Bamidele FO, Abubakar AT, Ibrahim A, Oyewo M, Abdulrahim I, Yakub JM, Olanrewaju IA, Elelu N, Gibson A, Mazeri S, Bolajoko MB. PLoS Negl Trop Dis. 2022 Aug 3;16(8):e0010614. doi: 10.1371/journal.pntd.0010614. eCollection 2022 Aug. PMID: 35921319

Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation.
Marcacci G, Coppola N, Madonna E, Becchimanzi C, De Pascalis S, D'Ovidio S, Crisci S, Maiolino P, De Filippi R, Pinto A. Infect Agent Cancer. 2022 Aug 3;17(1):41. doi: 10.1186/s13027-022-00454-y. PMID: 35922822

African Swine Fever Virus EP364R and C129R Target Cyclic GMP-AMP To Inhibit the cGAS-STING Signaling Pathway.
Dodantenna N, Ranathunga L, Chathuranga WAG, Weerawardhana A, Cha JW, Subasinghe A, Gamage N, Haluwana DK, Kim Y, Jheong W, Poo H, Lee JS. J Virol. 2022 Aug 10;96(15):e0102222. doi: 10.1128/jvi.01022-22. Epub 2022 Jul 21. PMID: 35861515

Occupation and SARS-CoV-2 infection risk among workers during the first pandemic wave in Germany: potential for bias.
Martie van Tongeren MVT, Rhodes S, Pearce N. Scand J Work Environ Health. 2022 Aug 8:4052. doi: 10.5271/sjweh.4052. Online ahead of print. PMID: 35938470

Factors Associated With Parental Acceptance of COVID-19 Vaccination: A Multicenter Pediatric Emergency Department Cross-Sectional Analysis.
Baumann BM, Rodriguez RM, DeLaroche AM, Rayburn D, Eucker SA, Nadeau NL, Drago LA, Cullen D, Meskill SD, Bialeck S, Gillman M. Ann Emerg Med. 2022 Aug;80(2):130-142. doi: 10.1016/j.annemergmed.2022.01.040. Epub 2022 Feb 1. PMID: 35525709

Long-term trajectories of SARS-CoV-2 neutralizing antibodies and predictive value of first dose vaccination-induced IgG-antibodies in hemodialysis patients.
Tillmann FP, Still H, von Landenberg P. Int Urol Nephrol. 2022 Aug;54(8):1939-1945. doi: 10.1007/s11255-021-03076-2. Epub 2021 Dec 3. PMID: 34860338

Evaluating the Biological Role of Lassa Viral Z Protein-Mediated RIG-I Inhibition Using a Replication-Competent Trisegmented Pichinde Virus System in an Inducible RIG-IN Expression Cell Line.
Di D, Huang Q, Ly H, Liang Y. J Virol. 2022 Aug 1:e0075422. doi: 10.1128/jvi.00754-22. Online ahead of print. PMID: 35913216

Sequelae at Hospital Discharge in 61 Children With Invasive Meningococcal Disease, Chile, 2009-2019.
Arteta-Acosta C, Villena Martínez R, Santolaya de Pablo ME. Pediatr Infect Dis J. 2022 Aug 1;41(8):607-613. doi: 10.1097/INF.0000000000003560. Epub 2022 Jul 13. PMID: 35421054

Risk factors for SARS-CoV-2 infection and transmission in households with children with asthma and allergy: A prospective surveillance study.
Seibold MA, Moore CM, Everman JL, Williams BJM, Nolin JD, Fairbanks-Mahnke A, Plender EG, Patel BB, Arbes SJ, Bacharier LB, Bendixsen CG, Calatroni A, Camargo CA Jr, Dupont WD, Furuta GT, Gebretsadik T, Gruchalla RS, Gupta RS, Khurana Hershey GK, Murrison LB, Jackson DJ, Johnson CC, Kattan M, Liu AH, Lussier SJ, O'Connor GT, Rivera-Spoljaric K, Phipatanakul W, Rothenberg ME, Seroogy CM, Teach SJ, Zoratti EM, Togias A, Fulkerson PC, Hartert TV; HEROS study team. J Allergy Clin Immunol. 2022 Aug;150(2):302-311. doi: 10.1016/j.jaci.2022.05.014. Epub 2022 Jun 1. PMID: 35660376

A comprehensive genomic study, mutation screening, phylogenetic and statistical analysis of SARS-CoV-2 and its variant omicron among different countries.
Ahmad SU, Hafeez Kiani B, Abrar M, Jan Z, Zafar I, Ali Y, Alanazi AM, Malik A, Rather MA, Ahmad A, Khan AA. J Infect Public Health. 2022 Aug;15(8):878-891. doi: 10.1016/j.jiph.2022.07.002. Epub 2022 Jul 8. PMID: 35839568

A time-course comparative clinical and immune response evaluation study between the human pathogenic Orientia tsutsugamushi strains: Karp and Gilliam in a rhesus macaque (Macaca mulatta) model.
Inthawong M, Sunyakumthorn P, Wongwairot S, Anantatat T, Dunachie SJ, Im-Erbsin R, Jones JW, Mason CJ, Lugo LA, Blacksell SD, Day NPJ, Sonthayanon P, Richards AL, Paris DH. PLoS Negl Trop Dis. 2022 Aug 4;16(8):e0010611. doi: 10.1371/journal.pntd.0010611. eCollection 2022 Aug. PMID: 35925895

Association of COVID-19 Vaccination During Pregnancy With Incidence of SARS-CoV-2 Infection in Infants.
Carlsen EØ, Magnus MC, Oakley L, Fell DB, Greve-Isdahl M, Kinge JM, Håberg SE. JAMA Intern Med. 2022 Aug 1;182(8):825-831. doi: 10.1001/jamainternmed.2022.2442. PMID: 35648413

Characteristics associated with the residual risk of severe COVID-19 after a complete vaccination schedule: A cohort study of 28 million people in France.
Semenzato L, Botton J, Drouin J, Baricault B, Bertrand M, Jabagi MJ, Cuenot F, Vu SL, Dray-Spira R, Weill A, Zureik M. Lancet Reg Health Eur. 2022 Aug;19:100441. doi: 10.1016/j.lanepe.2022.100441. Epub 2022 Jun 30. PMID: 35789881

Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial.
Segeral O, Dim B, Durier C, Nhoueng S, Chhim K, Sovann S, Yom S, Vong C, Yin S, Ros B, Ky V, Pech S, Nem B, Hout K, Guillebaud J, Ear E, Caroupaye-Caroupin L, Rekacewicz C, Fernandez L, Laurent D, Yay C, Kim R, Meyer L, Chhun S; Laurence Borand for the ANRS-MIE TA PROHM Study Group. Lancet Infect Dis. 2022 Aug;22(8):1181-1190. doi: 10.1016/S1473-3099(22)00206-7. Epub 2022 May 25. PMID: 35643089

Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
Kreuzberger N, Hirsch C, Andreas M, Böhm L, Bröckelmann PJ, Di Cristanziano V, Golinski M, Hausinger RI, Mellinghoff S, Lange B, Lischetzki T, Kappler V, Mikolajewska A, Monsef I, Park YS, Piechotta V, Schmaderer C, Stegemann M, Vanshylla K, Weber F, Weibel S, Stephani C, Skoetz N. Cochrane Database Syst Rev. 2022 Aug 9;8(8):CD015021. doi: 10.1002/14651858.CD015021. PMID: 35943061

Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial.
Cools F, Virdone S, Sawhney J, Lopes RD, Jacobson B, Arcelus JI, Hobbs FDR, Gibbs H, Himmelreich JCL, MacCallum P, Schellong S, Haas S, Turpie AGG, Ageno W, Rocha AT, Kayani G, Pieper K, Kakkar AK; ETHIC investigators. Lancet Haematol. 2022 Aug;9(8):e594-e604. doi: 10.1016/S2352-3026(22)00173-9. Epub 2022 Jun 30. PMID: 35779560

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20220801:20220811 as the publication date 44 records*

1.WO/2022/162205VACCINE COMPOSITION FOR BREAKING SELF-TOLERANCE
WO - 04.08.2022
Clasificación Internacional C07K 16/24 Nº de solicitud PCT/EP2022/052154 Solicitante BAYER ANIMAL HEALTH GMBH Inventor/a ILG, Thomas
The present invention relates to a vaccine composition for breaking self-tolerance against a self-protein of a host, in particular for breaking self-tolerance against endogenous cytokines, in particular against the endogenous IL-4, IL-5, IL-13, IL-31 and IL-33 proteins in an animal host. The vaccine composition of the

invention contains a polyprotein, a DNA encoding for the polyprotein and/or an RNA encoding for the polyprotein and one or more immunostimulatory oligonucleotides. The polyprotein comprises at least two self-protein segments of the host and one or more T-cell epitopes of non-host origin in between and/or adjacent to the at least two self-protein segments. The present invention further concerns the use of the vaccine composition for the prevention and/or treatment of diseases including the prevention and/or treatment of a pruritic condition and/or an allergic condition. In another aspect, the present invention provides a method for detecting the presence of autoantibodies against self-proteins that can be generated with the vaccine composition of the invention.

2.WO/2022/162204VACCINE COMPOSITION FOR BREAKING SELF-TOLERANCE
WO - 04.08.2022
Clasificación Internacional C07K 16/24 Nº de solicitud PCT/EP2022/052153 Solicitante BAYER ANIMAL HEALTH GMBH Inventor/a ILG, Thomas
The present invention relates to a vaccine composition for breaking self-tolerance against a self-protein of a host, in particular for breaking self-tolerance against endogenous cytokines in an animal host. The vaccine composition of the invention contains a polyprotein, a DNA encoding for the polyprotein and/or an RNA encoding for the polyprotein and one or more immunostimulatory oligonucleotides. The polyprotein comprises at least two self-protein segments of the host and one or more T-cell epitopes of non-host origin in between and/or adjacent to the at least two self-protein segments. The present invention further concerns the use of the vaccine composition for the prevention and/or treatment of diseases including the prevention and/or treatment of a pruritic condition and/or an allergic condition. In another aspect, the present invention provides a method for detecting the presence of autoantibodies against self-proteins that can be generated with the vaccine composition of the invention.

3.20220241390VACCINE COMPOSITION COMPRISING RECOMBINANT PROTEIN OF STAPHYLOCOCCUS AUREUS ATTENUATED ENTEROTOXIN AND CYTOTOXIN
US - 04.08.2022
Clasificación Internacional A61K 39/085 Nº de solicitud 17686606 Solicitante REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY) Inventor/a Dong Chan MOON
The present invention relates to a vaccine composition comprising a *Staphylococcus aureus* attenuated enterotoxin protein and cytotoxin protein, and more particularly to a *Staphylococcus aureus* enterotoxin protein, a *Staphylococcus aureus* cytotoxin protein, a vaccine composition for prevention of bovine mastitis, comprising the *Staphylococcus aureus* enterotoxin protein and *Staphylococcus aureus* cytotoxin protein and a method for preventing bovine mastitis comprising administering the vaccine composition to a bovine. The *Staphylococcus aureus* enterotoxin protein, the *Staphylococcus aureus* cytotoxin protein according to the present invention, and the vaccine composition comprising the proteins as an antigen can be used so that even vaccines comprising several antigens rather than all kinds of antigens show the excellent effects of prevention and treatment of bovine mastitis against all kinds of *Staphylococcus aureus* enterotoxin and cytotoxin having high incidence in Korea, thereby being more economically used for industrial purposes. Further, the vaccine composition for prevention of bovine mastitis, comprising the *Staphylococcus aureus* enterotoxin protein and *Staphylococcus aureus* cytotoxin protein according to the present invention has an excellent safety and bovine mastitis prevention and treatment effect even in the high CFU *Staphylococcus aureus* challenge test so that the composition can be variously utilized in *Staphylococcus aureus* vaccine and prevention related fields in future.

4.20220241409WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME
US - 04.08.2022
Clasificación Internacional A61K 39/39 Nº de solicitud 17600903 Solicitante Sumitomo Dainippon Pharma Co., Ltd. Inventor/a Hitoshi Ban

The present invention relates to a compound useful as a vaccine adjuvant for cancer vaccine, a preparation process thereof, a pharmaceutical composition comprising the compound, and use of the compound as a vaccine adjuvant for cancer vaccine.

5.WO/2022/162370ANTI-VIRAL THERAPEUTIC
WO - 04.08.2022
Clasificación Internacional C07K 16/08 Nº de solicitud PCT/GB2022/050217 Solicitante UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED Inventor/a STANTON, Richard
The invention relates to an anti-viral composition comprising at least one, and ideally a plurality of, monoclonal antibodies, or fragments thereof; an immunogenic agent, vaccine or pharmaceutical composition comprising the afore anti-viral composition; said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition for use in the treatment of or prevention of a viral infection; use of said anti-viral composition in the manufacture of a medicament to treat or prevent a viral infection; a combination therapeutic for use in the treatment or prevention of a viral infection comprising said anti-viral composition, immunogenic agent, vaccine or pharmaceutical composition in combination with at least one other therapeutic agent; and a method of treating or preventing a viral infection comprising administering said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition to an individual having, or suspected of having, a viral infection.

6.20220241389VACCINE FOR THE PREVENTION OF BREAST CANCER RELAPSE
US - 04.08.2022
Clasificación Internacional A61K 39/00 Nº de solicitud 17574178 Solicitante The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Inventor/a George E. PEOPLES
The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.

7.WO/2022/163902VACCINE COMPOSITION FOR PREVENTING HUMAN INFECTIOUS SARS CORONAVIRUS AND ALLEVIATING INFECTION SYMPTOMS
WO - 04.08.2022
Clasificación Internacional C12N 15/86 Nº de solicitud PCT/KR2021/003046 Solicitante LIBENTECH CO.,LTD. Inventor/a JANG, Hyun
The present invention relates to a vaccine composition for preventing human infectious SARS coronavirus (SARS-CoV-2, COVID-19) and alleviating infection symptoms. The vaccine composition, of the present invention, comprising a recombinant Newcastle disease virus, which expresses a SARS-CoV-2 RBD protein on the surface thereof, or an antigen purified therefrom induces immune responses that can fight COVID-19 infection, and thus can be effectively used as a vaccine for preventing and treating SARS-CoV-2 infection.

8.WO/2022/161969IMMUNOGENIC COMPOSITION AND VACCINE CONTAINING CHLAMYDIA SSP. SURFACE ANTIGENS AND ITS USE
WO - 04.08.2022
Clasificación Internacional A61K 39/118 Nº de solicitud PCT/EP2022/051669 Solicitante MEDIZINISCHE HOCHSCHULE HANNOVER Inventor/a KLOS, Andreas

The present invention relates in a first aspect to an immunogenic composition comprising at least three Chlamydia ssp. surface antigens selected from the group of PmpA, PmpD, PmpG, PmpH and antigen Ctad1. Further, the present invention relates to the immunogenic composition comprising CDN as adjuvant, in particular, c-diAMP. Moreover, a pharmaceutical composition comprising the immunogenic composition according to the present invention is provided as well as a vaccine comprising said immunogenic composition. The vaccine is particularly useful in eliciting an immune response against Chlamydia ssp. in an animal, including a human, in particular, for use in treating or preventing the infection by Chlamydia ssp. The vaccine, pharmaceutical composition or immunogenic composition may be administered mucosally, preferably is administered at least three times.

9.20220241395INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS
US - 04.08.2022
Clasificación Internacional A61K 39/145 Nº de solicitud 17497810 Solicitante Najít Technologies, Inc. Inventor/a Ian J. Amanna
Provided are surprisingly effective methods for inactivating pathogens, and for producing highly immunogenic vaccine compositions containing an inactivated pathogen rendered noninfectious by exposure to a Fenton reagent, or by exposure to a Fenton reagent or a component thereof in combination with a methisazone reagent selected from the group consisting of methisazone, methisazone analogs, functional group(s)/substructure(s) of methisazone, and combinations thereof. The methods efficiently inactivate pathogens, while substantially retaining pathogen antigenicity and/or immunogenicity, and are suitable for inactivating pathogens, or for the preparation of vaccines for a wide variety of pathogens with genomes comprising RNA or DNA, including viruses and bacteria. Also provided are highly immunogenic inactivated vaccine compositions prepared by using any of the disclosed methods, and methods for eliciting an immune response in a subject by administering such vaccine compositions.

10.WO/2022/162177CHLAMYDIA TRACHOMATIS ANTIGENIC POLYPEPTIDES AND USES THEREOF FOR VACCINE PURPOSES
WO - 04.08.2022
Clasificación Internacional C07K 16/28 Nº de solicitud PCT/EP2022/052104 Solicitante INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor/a LEVY, Yves
Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors have set up candidate vaccines against Chlamydia trachomatis. In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to in silico analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope). Finally, the inventors have generated some specific CD40 or Langerin antibodies comprising one or more identified epitope(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to Chlamydia trachomatis (Ct) antigenic polypeptides and uses thereof for vaccine purposes.

11.WO/2022/163647ORAL CORONAVIRUS INFECTION VACCINE
WO - 04.08.2022
Clasificación Internacional C12N 1/21 Nº de solicitud PCT/JP2022/002677 Solicitante NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY Inventor/a SHIRAKAWA, Toshiro
Provided is a vaccine that can be administered orally against coronavirus infection. A vaccine that can be administered orally against coronavirus infection can be provided by transformed bifidobacteria designed so as to present some or all of the proteins that constitute the coronavirus on the bifidobacterium surface layer. Transformed bifidobacteria designed so as to present some or all of the proteins that constitute the

coronavirus on the bifidobacterium surface layer induce humoral immunity and cellular immunity by oral administration and can suppress any increase in severity of pneumonia, etc., even after viral infection.

12.4036226ABGESCHWÄCHTES AFRIKANISCHES SCHWEINEPESTVIRUS UND SEINE VERWENDUNG ALS IMPFSTOFF
EP - 03.08.2022
Clasificación Internacional C12N 7/00 Nº de solicitud 21305138 Solicitante AGENCE NAT CHARGEE DE LA SECURITE SANITAIRE DE LALIMENTATION DE LENVIRONNEMENT ET DU TRAVAIL Inventor/a BLOT LE POTIER MARIE-FRÉDÉRIQUE
The present invention relates to an attenuated African Swine Fever (ASF) virus, wherein :• genes MGF 360-12L, 360-13L, 360-14L, 505-2R, 505-3R are deleted or are interrupted or mutated such that the genes are not transcribed and/or translated,• ORF of ASFV_G_ACD_00520 is deleted or is interrupted or mutated such that it is not transcribed and/or translated, and• genes MGF 505-1R et 505-4R are truncated,compared to the genome of the corresponding unattenuated virus.The present invention also refers to a vaccine comprising the attenuated ASF virus, and its use in preventing African Swine Fever in a subject.The present invention also relates to an in-vitro method for obtaining the attenuated ASF virus, which comprises at least one step of thermal-attenuation of a virulent ASFV virus strain selected among Georgia 2007/1, Pig/HLJ/2018, a strain of ASF virus of genotype II or a genetically close ASF virus strain, and amplification by inoculation of Specific-Pathogen-Free pigs and selecting said attenuated ASF virus.The present invention refers to an in vitro method for the differential detection of the attenuated ASF virus and of the corresponding non-attenuated ASF virus as well.

13.4034148BIOMATERIALBASIERTER ANTIGENFREIER IMPFSTOFF UND VERWENDUNG DAVON
EP - 03.08.2022
Clasificación Internacional A61K 38/19 Nº de solicitud 20868441 Solicitante HARVARD COLLEGE Inventor/a NAJIBI ALEXANDER J
Disclosed herein are vaccine compositions and method to use the same. The compositions and methods disclosed herein provide means to prevent and/or treat a variety of cancers.

14.4034158BIOLOGISCH ABBAUBARE NANOKOMPLEX-IMPFSTOFFE, VERFAHREN ZUR UNTERDRÜCKUNG DER HEPAPITIS-B-VIRUS-REPLIKATION UND DER HEPAPITIS-B-VIRUS-OBERFLÄCHENANTIGENSEKRETION
EP - 03.08.2022
Clasificación Internacional A61K 39/29 Nº de solicitud 20868095 Solicitante ASCENDO BIOTECHNOLOGY INC Inventor/a HUANG PING-YEN
A hepatitis B virus (HBV) vaccine includes an HBV core antigen (HBcAg) and/or HBV surface antigen (HBsAg) formulated in nanocomplexes. The nanocomplexes contain chitosan and g-PGA. These nanocomplexes containing HBc/sAg, chitosan, and g-PGA can induce more balanced T helper cells (Th1 and Th2) polarization than can a conventional vaccine with an alum adjuvant. HBc/s-NC of the invention can elicit high levels of antibodies against HBsAg, a rapid elimination of HBsAg, and a slow decrease of HBeAg, indicating a phenomenon of HBsAg seroconversion. Thus, HBc/s-NC can overcome immune tolerance caused by chronic HBV infection to re-establish host immunity leading a functional cure.

15.2603362Immunogenic compositions against enteric diseases and methods for its preparation thereof
GB - 03.08.2022
Clasificación Internacional A61K 39/112 Nº de solicitud 202204276 Solicitante SERUM INSTITUTE OF INDIA PVT LTD Inventor/a RAJEEV MHALASAKANT DHERE
The present disclosure relates to novel immunogenic monovalent and multivalent polysaccharide-protein conjugate vaccine compositions comprising a polysaccharide selected from Salmonella serovar strains S. typhi; S. paratyphi A; S. typhimurium and S. enteritidis and alternative improved methods of

polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation. The present disclosure further relates to methods for inducing an immune response in subjects against Salmonella typhi and non-typhi related diseases and/or for reducing or preventing Salmonella typhi and non-typhi related diseases in subjects using the compositions disclosed herein. The vaccine elicits bactericidal antibodies and is useful for prevention of gastroenteritis, enteric and typhoid fever.

16.4035676IMPFSTOFFZUSAMMENSETZUNGEN
EP - 03.08.2022
Clasificación Internacional A61K 39/12 Nº de solicitud 21386011 Solicitante UNIV OXFORD INNOVATION LTD Inventor/a
The invention describes vaccine compositions containing particles having a polypeptide shell and a water-immiscible core. The polypeptide shell may comprise one or more pathogenic antigen proteins and/or one or more adjuvant polypeptides. Administration of the composition generates an immune response to the polypeptide contained in the shell. Adjuvant may be comprised in the water-immiscible core of the particle. The particles are therefore useful in methods of vaccination.

17.WO/2022/162398VACCINE COMPOSITIONS
WO - 04.08.2022
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/GB2022/050253 Solicitante OXFORD UNIVERSITY INNOVATION LIMITED Inventor/a CARLISLE, Robert
The invention describes vaccine compositions containing particles having a polypeptide shell and a water-immiscible core. The polypeptide shell may comprise one or more pathogenic antigen proteins and/or one or more adjuvant polypeptides. Administration of the composition generates an immune response to the polypeptide contained in the shell. Adjuvant may be comprised in the water-immiscible core of the particle. The particles are therefore useful in methods of vaccination.

18.20220241421REDUCED FOAMING VACCINE COMPOSITIONS
US - 04.08.2022
Clasificación Internacional A61K 47/26 Nº de solicitud 17580896 Solicitante Abic Biological Laboratories Ltd. Inventor/a Noel Yves Henri Jean Genin
The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

19.4034153MODIFIZIERTES VESIKULÄRES STOMATITIS-VIRUS-GLYCOPROTEIN UND VERWENDUNGEN DAVON ZUR BEHANDLUNG VON HIRNTUMOREN
EP - 03.08.2022
Clasificación Internacional A61K 39/00 Nº de solicitud 20775645 Solicitante UNIV LOUVAIN Inventor/a VANDERMEULEN GAËLLE
The present invention relates to a vaccine for treating and/or preventing a brain tumor. More particularly, the invention relates to a modified vesicular stomatitis virus glycoprotein (VSV-G) comprising at least one tumor antigen, or a fragment thereof, for use in preventing and/or treating a brain tumor in an individual in need thereof, when administered before a surgery intended to remove all or part of the tumor, such as, a tumor resection. The inventors have shown that vaccination of individual with a brain tumor with a vaccine comprising a nucleic acid sequence encoding a modified VSV-G according to the invention may be combined to a tumor resection in order to ameliorate the prognostic of said individuals.

20.20220241387HORN FLY PROTEIN AS ACTIVE ANTIGEN IN ANTI-HORN FLY VACCINE FOR PROTECTION OF BOVINES AGAINST HORN FLY INFESTATIONS
US - 04.08.2022

Clasificación Internacional A61K 39/00 Nº de solicitud 17166433 Solicitante The United States of America, as represented by the Secretary of Agriculture Inventor/a FELICITO GUERRERO
Antigenic polypeptides derived from a naturally occurring horn fly protein, and nucleic acid molecules encoding the polypeptides, are described. The polypeptides elicit an immune response which, in turn, produces detrimental effects in horn flies feeding on vaccinated cattle. Thus, the present disclosure provides a novel horn fly vaccine.

21.WO/2022/161495RECOMBINANT SARS-COV-2 VACCINE
WO - 04.08.2022
Clasificación Internacional C12N 15/50 Nº de solicitud PCT/CN2022/075134 Solicitante GENESAIL BIOTECH (SHANGHAI) CO., LTD. Inventor/a LIANG, Min
Provided are SARS-CoV-2 vaccines useful for treating or protecting a subject from infection by SARS-CoV-2. The SARS-CoV-2 vaccines contain nucleic acids encoding at least one type of S protein variant, and other factors useful for treating or protecting a subject from infection by SARS-CoV-2, or expression vectors or viruses containing such nucleic acids, or host cells containing such nucleic acids or expression vectors.

22.WO/2022/162539AN IMMUNOGEN
WO - 04.08.2022
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/IB2022/050661 Solicitante UNIVERSITY OF PRETORIA Inventor/a MILLAR, Robert Peter
This invention relates to an immunogen comprising a gonadotropin releasing hormone (GnRH) peptide sequence, a kisspeptin peptide sequence and a stimulant of raising an immune response, such an immunogen for use in a method to regulate the release of hormones in a vertebrate including modulation of reproductive hormones, to reduce fertility in a vertebrate and to treat hormone-dependent diseases including hormone-dependent tumours including prostate tumours, breast, ovary and endometrial tumours, benign hyperplasia including benign prostatic hyperplasia and uterine fibroids, endometriosis, polycystic ovarian disease, infertility, sexual dysfunction and any disorder that would benefit from an increased or decreased GnRH-dependent activity and a vaccine formulation comprising the immunogen. The invention also relates to the use of the immunogen in the preparation of a medicament for use in a method to regulate the release of hormones in a vertebrate.

23.4034550IMPFTHERAPIE FÜR RAN-PROTEINERKRANKUNGEN
EP - 03.08.2022
Clasificación Internacional C07K 14/47 Nº de solicitud 20869039 Solicitante UNIV FLORIDA Inventor/a RANUM LAURA
Aspects of the disclosure relate to compositions and methods for eliciting (or enhancing) anti-repeat-associated non-ATG (RAN) protein antibody expression or production in a subject. Administration of the compositions according to the methods of the present disclosure may in some embodiments result in decreased levels of RAN protein expression and/or aggregation. Such compositions and methods may therefore be useful for the treatment of diseases and disorders known to be associated with RAN proteins.

24.4035673TRANSDERMALER IMPFSTOFF
EP - 03.08.2022
Clasificación Internacional A61K 39/00 Nº de solicitud 21386013 Solicitante UNIV OXFORD INNOVATION LTD Inventor/a
The invention describes transdermal vaccines which contain ultrasound responsive particles comprising a polypeptide shell. The surface of the particle has one or more indentations which are generally able to entrap a gas bubble. The particles are capable of generating inertial cavitation on exposure to ultrasound.

The particles can be delivered transdermally, and can comprise antigen protein and/or adjuvant within the particle structure. The particles are therefore useful in methods of vaccination using transdermal delivery routes.

25.WO/2022/162397TRANSDERMAL VACCINE
WO - 04.08.2022
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/GB2022/050252 Solicitante OXFORD UNIVERSITY INNOVATION LIMITED Inventor/a HETTINGA, Johanna
The invention describes transdermal vaccines which contain ultrasound responsive particles comprising a polypeptide shell. The surface of the particle has one or more indentations which are generally able to entrap a gas bubble. The particles are capable of generating inertial cavitation on exposure to ultrasound. The particles can be delivered transdermally, and can comprise antigen protein and/or adjuvant within the particle structure. The particles are therefore useful in methods of vaccination using transdermal delivery routes.

26.20220241393PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE VIRUS
US - 04.08.2022
Clasificación Internacional A61K 39/12 Nº de solicitud 17618625 Solicitante Elanco US, Inc. Inventor/a Stephen Qitu WU
The present invention relates to modified, live Porcine Reproductive and Respiratory Syndrome viruses. Viruses were genetically analyzed and selected based on phylogenetic grouping for modification by repeated passage in tissue culture. The modified, live viruses were assessed for the ability to provide protective immunity to heterologous viruses. The modified, live viruses are useful in vaccines, particularly in vaccines which can treat infection of swine by multiple heterologous viruses.

27.4035677FALTUNGSPROMOTOREN UND IHRE VERWENDUNG ZUR HERSTELLUNG UND STABILISIERUNG VON POLYPEPTIDEN
EP - 03.08.2022
Clasificación Internacional A61K 39/215 Nº de solicitud 21154077 Solicitante MAX PLANCK GESELLSCHAFT Inventor/a
The present invention relates to the recombinant production of a protein of interest in a prokaryotic host cell wherein the protein of interest is obtained in a correctly folded and stable form. The protein of interest may be a difficult-to-make polypeptide for use as a vaccine or a pharmaceutical. The protein of interest is co-expressed with or fused to a 'fold promoter', which may be a VHH antibody recognizing the said protein.

28.WO/2022/162165FOLD PROMOTERS AND THEIR USE FOR THE PRODUCTION AND STABILIZATION OF POLYPEPTIDES
WO - 04.08.2022
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/EP2022/052087 Solicitante MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER Inventor/a GÖRLICH, Dirk
The present invention relates to the recombinant production of a protein of interest in a prokaryotic host cell or eukaryotic host cell wherein the protein of interest is obtained in a correctly folded and stable form. The protein of interest may be a difficult-to-make polypeptide for use as a vaccine or a pharmaceutical. The protein of interest is co- expressed with or fused to a 'fold promoter', which may be a VHH antibody recognizing the said protein.

29.WO/2022/165340UNIVERSAL VACCINES AGAINST IMMUNOGENS OF PATHOGENIC ORGANISMS THAT PROVIDE ORGANISM-SPECIFIC AND CROSS-GROUP PROTECTION
WO - 04.08.2022

Clasificación Internacional A61K 35/76 Nº de solicitud PCT/US2022/014572 Solicitante AEGLE BIOTECH Inventor/a LUBIT, Beverly, W.
The present disclosure provides, in part, a priming and boosting vector-based platform to develop vaccines against viral pathogens that is tailored to elicit a broad T cell response targeting conserved viral epitopes while including helper T cell (TH) epitopes and an adjuvant to achieve a balanced immune response consisting of both cellular immunity, coupled with a broad neutralizing antibody response in the design of a candidate universal vaccine to HIV or a human coronavims, e.g., SARS-CoV-2. The universal vaccines are prepared against an immunogen of an infectious pathogenic virus comprising at least one nucleic acid polynucleotide comprising an open reading frame encoding at least one polypeptide antigen or an immunogenic fragment thereof, wherein the polypeptide antigen, or the immunogenic fragment thereof, comprises a conserved internal protein that is enriched in T cell recognition antigens. The effectiveness of the priming and boosting platform is tested in humanized mouse models: a transgenic mouse model that expresses the hACE2 gene uder the control of the human cytokeratin 18 promoter and a humanized mouse model comprising a fully functional human immune system.

30.20220241398LYSSAVIRUS ANTIGEN CONSTRUCTS
US - 04.08.2022
Clasificación Internacional A61K 39/205 Nº de solicitud 17591421 Solicitante GLAXOSMITHKLINE BIOLOGICALS SA Inventor/a KATHRYN HASHEY
Nucleic acid based vaccine constructs encoding Lyssaviral antigens are useful in preventing and treating diseases. Self-amplifying RNA molecules encoding Lyssaviral antigens provide potent and long-lasting immunity.

31.20220242867NOVEL IMIDAZOPYRIMIDINE COMPOUNDS AND USES THEREOF
US - 04.08.2022
Clasificación Internacional C07D 487/04 Nº de solicitud 16764171 Solicitante Dana-Farber Cancer Institute, Inc. Inventor/a Ofer Levy
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers and/or modifiers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease), or as stand alone anti-infective or immune response modifying agents. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

32.20220242925NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST SMALL CELL LUNG CANCER AND OTHER CANCERS
US - 04.08.2022
Clasificación Internacional C07K 14/47 Nº de solicitud 17716026 Solicitante Immatics Biotechnologies GmbH Inventor/a Andrea MAHR
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

33.20220241410VACCINE ADJUVANTS BASED ON TLR RECEPTOR LIGANDS

US - 04.08.2022
Clasificación Internacional A61K 39/39 Nº de solicitud 17613414 Solicitante THE UNIVERSITY OF MONTANA Inventor/a Helene Bazin-Lee
Lipidated oxoadenines of formula (I) are TLR7/8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic application in the treatment of cancer, infectious diseases, allergy, or autoimmnune disorders.

34.20220241403Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV Core Antigen
US - 04.08.2022
Clasificación Internacional A61K 39/29 Nº de solicitud 17721554 Solicitante UNIVERSITY OF WASHINGTON Inventor/a Edward A. CLARK
Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.

35.20220241391METHODS OF BLOCKING ASFV INFECTION THROUGH INTERRUPTION OF CELLULAR AND VIRAL RECEPTOR INTERACTIONS
US - 04.08.2022
Clasificación Internacional A61K 39/12 Nº de solicitud 17535545 Solicitante Dalu CHEN Inventor/a Dalu CHEN
A method of preventing and treating viral infections in animals (and preferably ASFV in porcine), by inhibiting viral ligand interactions with critical cellular receptors that are involved either directly (endocytosis and/or macropinocytosis) or indirectly (phagocytosis of RBCs that have been aggregated by viral interactions) with cellular entry in an animal, and preventing and treating the viral infection in the animal. A method of treating a viral infection in an individual with a virus that is both lysogenic and lytic. A composition for treating a viral infection in an individual with a virus that is both lysogenic and lytic. A vaccine for preventing viral infection, including whole and/or partial domains of proteins of both a lysogenic and lytic phase of a virus.

36.4034548CORONAVIRUSIMPFSTOFFE UND VERWENDUNGEN DAVON
EP - 03.08.2022
Clasificación Internacional C07K 14/165 Nº de solicitud 20923712 Solicitante GUANGZHOU ARGORNA BIOPHARMACEUTICALS CO LTD Inventor/a ZHANG BILL BILIANG
This disclosure relates to coronavirus vaccines and uses thereof. In one aspect, the disclosure provides a nucleic acid vaccine, comprising a sequence encoding a spike protein or fragment thereof derived from a coronavirus.

37.4034253ZUSAMMENSETZUNGEN UND VERFAHREN ZUR ERHÖHUNG DER WIRKSAMKEIT VON IMMUNTHERAPIEN UND IMPFSTOFFEN
EP - 03.08.2022
Clasificación Internacional A61P 35/00 Nº de solicitud 20869832 Solicitante UNIV MICHIGAN REGENTS Inventor/a MOON JAMES J
This invention relates generally to compositions and methods for increasing the efficacy of immunotherapies and vaccines. In particular, the present invention relates to elevating the richness and diversity of a subject's gut microbiome through administration of an agent (e.g., fiber containing prebiotic agent (e.g., epigallocatechin gallate (EGCG), fucoidan, potato starch, oligofructose and inulin)) (e.g., melatonin) with an immunotherapy or vaccine. Such compositions and methods are useful for treating cancer, infectious pathogens, autoimmune diseases, neurological disorders, and/or obesity.

38.4034159NEOGLYCOKONJUGATE ALS IMPFSTOFFE UND THERAPEUTISCHE WERKZEUGE

EP - 03.08.2022
Clasificación Internacional A61K 39/385 Nº de solicitud 20867004 Solicitante KORANEX CAPITAL Inventor/a SHIAO TZE CHIEH
Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thio ether bond and the second end comprising a functional group reactable with a free amine group. Following coupling, the carbohydrate antigen becomes covalently bound to the carrier material via an amide, a carbamate, a sulfonamide, a urea, or a thiourea bond, thereby producing the neoglycoconjugate. Applications of the neoglycoconjugates as antigens, immunogens, vaccines, and in diagnostics are also described. Specifically, the use of (neo)glycoconjugates as vaccine candidates and other therapeutic tools against cancers, viruses such as SARS-CoV-2, and other diseases characterized by expression of aberrant glycosylation are also described.

39.4035675NEUARTIGE PEPTIDE UND KOMBINATION AUS PEPTIDEN ZUR VERWENDUNG IN DER IMMUNTHERAPIE GEGEN OVARIALKARZINOM UND ANDERE KARZINOME
EP - 03.08.2022
Clasificación Internacional A61K 39/00 Nº de solicitud 22151693 Solicitante IMMATICS BIOTECHNOLOGIES GMBH Inventor/a SCHUSTER HEIKO
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

40.20220241401VACCINES AGAINST GENITAL HERPES SIMPLEX INFECTIONS
US - 04.08.2022
Clasificación Internacional A61K 39/245 Nº de solicitud 17550272 Solicitante Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Inventor/a Konstantin G. Kousoulas
The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.

41.2920140Anticuerpos neutralizantes del virus de la inmunodeficiencia humana (VIH)
ES - 01.08.2022
Clasificación Internacional A61K 39/00 Nº de solicitud 19156884 Solicitante Theraclone Sciences, Inc. Inventor/a Chan-Hui, Po-ying

42.2022205209Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
AU - 04.08.2022
Clasificación Internacional C07K 14/47 Nº de solicitud 2022205209 Solicitante Immatics Biotechnologies GmbH Inventor/a Fritsche, Jens
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor associated T-cell peptide epitopes, alone or in combination with other tumor associated peptides that can for example serve as active pharmaceutical ingredients of

vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

43.WO/2022/160017SARS-COV-2 VACCINE ANTIGENS
WO - 04.08.2022
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/AU2022/050050 Solicitante GRIFFITH UNIVERSITY Inventor/a GOOD, Michael
The present disclosure provides immunogenic compositions and methods of inducing an immune response and/or preventing, treating or ameliorating an infection, disease or condition associated with SARS-CoV-2 in a subject with such immunogenic compositions.

44.WO/2022/162312PEPTIDES AND USES THEREOF
WO - 04.08.2022
Clasificación Internacional A61K 8/64 Nº de solicitud PCT/FR2022/050145 Solicitante SCHWEIGHOFFER, Fabien Inventor/a SCHWEIGHOFFER, Fabien
The present application relates to compounds and their use in health or cosmetics. The application more particularly relates to peptides that can be used in vaccine strategy as well as for the cosmetic or therapeutic treatment of any tissue or organ. The invention covers peptides as well as compositions containing same, the preparation and uses thereof, in particular in humans.

Patentes registradas en la United States Patent and Trademark Office (USPTO)

Results Search in US Patent Collection db for: (ABST/vaccine AND ISD/20220801->20220811), 21 records.

PAT. NO.	Title	
1	11,407,829	LAG3 binding peptides
2	11,407,819	Compositions and use of a fibrinogen binding motif present in EFB and COA for therapeutics and vaccines against Staphylococcus aureus
3	11,407,810	Peptides and combination of peptides for use in immunotherapy against various tumors
4	11,407,809	Peptides and combination of peptides for use in immunotherapy against various tumors
5	11,407,808	Peptides and combination of peptides for use in immunotherapy against various tumors
6	11,407,807	Peptides and combination of peptides for use in immunotherapy against various tumors
7	11,407,798	Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
8	11,406,706	Lipid nanoparticle vaccine adjuvants and antigen delivery systems
9	11,406,701	Vaccination of immunocompromised subjects

10	11,406,698	Vaccine compositions
11	11,406,697	Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
12	11,406,691	AMH-INH-GNIH tri-expression gene vaccine of improving fecundity of animals, preparation method and application
13	11,401,319	Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
14	11,401,310	Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
15	11,401,267	Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
16	11,400,170	Methods for treating cancers
17	11,400,151	Methods for improving immunological response in vaccinated animals
18	11,400,149	Ebola virus and Marburg virus glycoprotein mucin-like domain replacement expression system used as new vaccine approaches
19	11,400,147	Pneumococcal capsular saccharide conjugate vaccine
20	11,400,108	Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
21	11,400,094	2H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Ma. Victoria Guzmán Sánchez mguzman@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu
Rolando Ochoa Azze ochoa@finlay.edu.cu

FINLAY EDICIONES